








Investigating  the  utility  of  exome  sequencing  for  kidney  disease    
  
Emily  Eve  Groopman  
  
Submitted  in  partial  fulfillment  of  the    
requirements  for  the  degree  of    
Doctor  of  Philosophy  
under  the  Executive  Committee  of  the    

































Emily  Eve  Groopman  
All  rights  reserved  
ABSTRACT  
Investigating  the  utility  of  exome  sequencing  for  kidney  disease  
Emily  Groopman    
  
Exome  sequencing  (ES)  has  empowered  genetic  diagnosis  and  novel  gene  discovery,  and  is  increasingly  
applied  as  a  first-­line  test  for  a  variety  of  disorders.  Chronic  kidney  disease  (CKD)  affects  more  than  in  1  
in  10  persons  worldwide,  resulting  in  high  morbidity,  mortality,  and  healthcare  costs.  As  CKD  displays  
substantial  genetic  and  phenotypic  heterogeneity,  the  unbiased  approach  of  ES  can  help  to  pinpoint  a  
specific  etiology  and  thereby  support  personalized  care.  However,  the  broader  utility  of  ES  for  
nephropathy  and  challenges  associated  with  such  expanded  implementation  have  yet  to  be  
systematically  assessed.  Here,  we  investigate  these  questions  through  integrating  ES  and  phenotype  
data  from  large  CKD  case  and  control  cohorts.  First,  we  survey  the  genetic  and  clinical  disease  spectrum  
of  Mendelian  forms  of  kidney  and  genitourinary  disease,  and  generate  a  comprehensive  curated  list  of  
gene-­disease  pairs.  We  then  use  ES  data  from  7,974  self-­declared  healthy  adults  to  evaluate  the  
population  prevalence  of  candidate  pathogenic  variants  for  Mendelian  nephropathy  under  different  
analytic  filtering  pipelines.  We  observe  an  appreciable  frequency  of  putatively  diagnostic  variants  for  
these  conditions  using  stringent  as  well  as  standard  filters,  resulting  in  a  considerable  burden  for  both  
variant  interpretation  and  clinical  follow-­up.  Next,  we  perform  ES  and  diagnostic  analysis  in  a  combined  
cohort  of  3,315  all-­cause  CKD  cases.  We  find  diagnostic  variants  among  patients  spanning  clinical  
disease  categories,  and  that  both  the  primary  and  secondary  genetic  findings  resulting  from  ES  have  
meaningful  implications  for  medical  management.  We  conclude  by  discussing  the  greater  insights  
regarding  the  value  of  ES  for  kidney  disease  emerging  from  our  investigations,  and  promising  avenues  for  
subsequent  studies.    
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Exome  sequencing  (ES)  has  revolutionized  both  genetic  diagnosis  and  novel  gene  discovery  and  
is  increasingly  deployed  as  a  first-­line  test  in  clinical  medicine(1,  2).  ES  has  been  successfully  utilized  for  
a  wide  range  of  disorders;;  leading  indications  currently  include  critically  ill  neonates  with  suspected  
monogenic  disorders(3,  4),  neurometabolic  disorders  and  developmental  delay(5,  6),  and  in  both  
pediatrics  and  adults,  cancer(7,  8).  Importantly,  the  yield  of  ES  varies  substantially  by  indication(9,  10),  
necessitating  disease-­specific  investigation,  within  each  medical  subspecialty.    
   Affecting  more  than  1  in  10  individuals  globally(11),  chronic  kidney  disease  (CKD)  represents  a  
promising  field  for  the  use  of  ES.  CKD  can  result  from  a  variety  of  etiologies,  and  confers  substantial  
morbidity  and  mortality(11,  12).  Moreover,  as  early  stage  (stages  1-­3)  CKD  can  be  asymptomatic(13),  
patients  can  go  unrecognized  until  they  reach  end-­stage  renal  disease  (ESRD),  at  which  point  traditional  
diagnostics  such  as  imaging  and  renal  biopsy  may  be  unrevealing,  or  contraindicated  altogether(14,  15).  
Thus,  in  more  than  1  in  10  incident  adult  ESRD  patients,  the  clinical  diagnosis  is  “other”  or  “unknown”(16-­
18).  Such  etiologic  uncertainty  impedes  precise  diagnosis  and  development  of  targeted  therapies(11,  19).    
   Approximately  25%  of  CKD  patients  report  a  positive  family  history(20,  21),  and  monogenic  
causes  are  estimated  to  account  for  10%  of  adults  with  end-­stage  renal  disease(22,  23)  and  are  a  leading  
cause  of  pediatric  nephropathy(24,  25).  Importantly,  clinical  prognosis,  course,  and  indicated  
management  can  differ  not  only  between  inherited  and  acquired  forms  of  CKD,  but  between  different  
monogenic  causes  of  CKD  as  well(26-­28).  Thus,  in  many  cases,  achieving  a  genetic  diagnosis  can  
empower  targeted  care  (Table  1).  However,  as  monogenic  kidney  diseases  display  high  genetic  and  
phenotypic  heterogeneity,  identification  of  a  specific  molecular  etiology  can  be  difficult  based  on  
traditional  diagnostic  modalities  alone(19,  26,  29),    
  
Table  1.  Examples  of  the  clinical  utility  of  genetic  diagnoses  in  nephrology  
Indication   Genetic  
finding  









Nephrotic  syndrome  1    
(OMIM  256300)  
Increased  risk  of  post-­transplant  
disease  recurrence   (30,  31)  
  3  
   COQ2  
mutation  
CoQ10  deficiency  1    
(OMIM  607426)  
CoQ10  supplementation  can  attenuate  
proteinuria  and  extra-­renal  









Distinguish  between  autosomal  
(COL4A3  or  COL4A4)  versus  X-­linked  
(COL4A5)  inheritance,  informing  family  
counselling  
  
Loss  of  function  mutations  are  
associated  with  more  severe  disease  
and  faster  progression  to  ESRD  versus  
missense  mutations  
  
Avoid  immunosuppression,  a  







Renal  cysts  and  
diabetes  syndrome    
(OMIM  137920)  
Multisystem  work-­up  for  associated  
extrarenal  complications,  including  
testing  for  diabetes,  exocrine  
pancreatic  insufficiency,  hepatic  
function,  structural  neurological  
anomalies,  and  neurocognitive  
impairment  
(37,  38)  
Nephrolithiasis     ARPT  mutation  
ARPT  deficiency    
(OMIM  614723)  
Xanthine  dehydrogenase  inhibition  to  











(PGL1;;  OMIM  168000)  
Imaging  studies  to  screen  for  additional  
tumors  
  
Catecholamine  antagonists  and/or  
surgical  tumor  resection  
  
Knowledge  of  parent-­of-­origin  effect  
due  to  maternal  imprinting  informs  
genetic  counselling    
  
Lower  risk  of  malignancy  relative  to  











disease  Ia  (OMIM  
232200)  
Dietary  therapy  (frequent  meals,  
nasogastric  tube,  and/or  raw  starch  to  
prevent  hypoglycaemia;;  oral  
bicarbonate  and  fructose/glucose  
avoidance  to  prevent  acidosis)  
  
Surveillance  for  hepatic  adenoma;;  liver  
transplant  may  be  needed    
(43,  44)  
  
Adopted  from  Groopman  et  al.(27).  17q12  deletion,  deletion  at  the  hepatocyte  nuclear  factor  1  (HNF1B)  locus;;  APRT,  
adenine  phosphoribosyltransferase  gene;;  COL4A3-­5,  type  IV  collagen  alpha-­3  (COL4A3),  alpha-­4  (COL4A4),  and  
alpha-­5  (COL4A5)  genes;;  COQ2,  parahydroxybenzoate-­polyprenyltransferase  gene;;  CoQ10,  Coenzyme  Q10;;  G6PC,  
glucose-­6-­phosphatase  gene;;  NPHS1,  nephrin  gene;;  SDHD,  succinate  dehydrogenase  complex,  subunit  D  gene;;  
TBMD,  thin  basement  membrane  disease  
  
ES  has  been  successfully  used  for  genetic  diagnosis  and  novel  gene  discovery  for  a  range  of  
CKD  subtypes,  including  congenital  anomalies  of  the  kidney  and  urinary  tract(45-­47),  cystic  renal  
  4  
diseases(48,  49),  and  focal  segmental  glomerulosclerosis(50-­52).  Moreover,  in  the  context  of  the  
aforementioned  high  genetic  and  phenotypic  heterogeneity  of  many  monogenic  nephropathies,  the  
expanded  genetic  search  space  provided  by  ES  can  increase  diagnostic  sensitivity  relative  to  single-­gene  
testing  or  targeted  phenotype-­driven  gene  panels.  For  example,  nephronophthisis-­related  ciliopathies  can  
result  from  variants  in  at  least  90  genes(53).  Accordingly,  60-­70%  yield  has  been  observed  with  ES(48,  
54),  over  3-­5-­fold  higher  than  the  rates  reported  with  gene  panels(55,  56).  Similarly,  ES  studies  of  
pediatric  patients  with  steroid-­resistant  nephrotic  syndrome  (SRNS)  identified  diagnostic  variants  in  
approximately  25%(50,  51);;  importantly,  13%  of  positive  cases  harbored  mutations  in  genes  not  
classically  associated  with  SRNS,  such  that  they  could  have  gone  unresolved  using  a  narrower,  
phenotype-­driven  panel.  Case  reports(57,  58)  and  small  pilot  studies(59)  also  support  use  of  ES  for  
patients  with  undiagnosed  nephropathy  “of  unknown  etiology,”  albeit  in  the  context  of  those  pre-­selected  
for  early-­onset  and/or  familial  disease.  
   Thus,  the  broader  utility  of  ES  for  the  general  CKD  population,  which  largely  consists  of  
unselected  adults,  has  yet  to  be  systematically  assessed.  Furthermore,  successful  implementation  of  ES  
in  nephrology  requires  investigation  of  the  many  questions  accompanying  its  more  widespread  usage.  
What  is  the  general  population  prevalence  of  candidate  pathogenic  variants  for  monogenic  CKD,  and  
what  challenges  does  this  pose  for  clinical  sequence  interpretation  and  medical  follow-­up?  What  is  the  
diagnostic  yield  of  ES  across  different  CKD  subtypes,  and  what  are  the  implications  of  the  genetic  
findings  for  clinical  management?  What  is  the  prevalence  of  medically  actionable  secondary  findings  in  
the  CKD  population,  and  what  are  their  implications  for  nephrologic  as  well  as  non-­nephrologic  care?  
   The  present  work  will  utilize  ES  and  phenotype  data  from  large  CKD  case  and  control  cohorts  to  
investigate  these  questions.  In  Chapter  I,  we  assess  the  prevalence  of  candidate  pathogenic  variants  for  
monogenic  kidney  and  genitourinary  disorders  in  ES  data  from  7,974  self-­declared  healthy  adults,  and  the  
associated  burden  of  variant  interpretation  and  clinical  follow-­up.  In  Chapter  II,  we  conduct  ES  and  
diagnostic  analysis  of  3,315  CKD  patients  drawn  from  two  independent  cohorts,  and  examine  the  
implications  of  the  genetic  findings  for  clinical  management.  Finally,  we  conclude  with  a  general  
discussion  of  the  insights  regarding  the  utility  of  ES  for  kidney  disease  that  have  been  gained  through  
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ES  is  increasingly  applied  across  clinical  medicine(3,  5-­7,  9),  including  for  the  diagnostic  workup  
of  suspected  hereditary  nephropathies(47,  48,  50).  In  addition  to  providing  increased  diagnostic  
sensitivity,  the  genome-­wide  scope  of  ES  results  in  the  capacity  to  reveal  findings  for  other  genetic  
conditions  unrelated  to  the  primary  indication  for  testing.  At  present,  the  American  College  of  Medical  
Genetics  and  Genomics  (ACMG)  has  recommended  the  return  of  such  secondary  findings  in  59  genes  as  
medically  actionable  findings  to  all  patients  undergoing  ES(60).  However,  the  studies  to  date  report  that  
the  majority  of  individuals  undergoing  genomic  sequencing  would  like  to  receive  all  findings  potentially  
relevant  to  their  health(61,  62).  Similarly,  many  clinicians  have  voiced  enthusiasm  regarding  the  
opportunity  to  discover  medically  actionable  information  provided  through  expanded  analysis  of  
secondary  findings(63,  64).  Accordingly,  many  clinical  laboratories  have  already  begun  to  assess  and  
return  a  broader  scope  of  secondary  findings(65),  and  large  sequencing  consortia  are  investigating  the  
clinical  impact  of  testing  for  a  range  of  medically  actionable  conditions  in  large  populations  of  ethnically  
diverse,  unselected  adults(66,  67).    
   Kidney  disease  encompasses  a  wide  range  of  etiologies  and  affects  10-­15%  of  adults  worldwide,  
resulting  in  a  high  burden  in  morbidity,  mortality,  and  healthcare  costs(11,  12).  As  early-­stage  kidney  
disease  can  be  clinically  silent,  affected  individuals  can  go  unrecognized  until  they  have  advanced  
nephropathy,  requiring  dialysis  or  renal  transplantation(13,  68,  69).  Moreover,  although  inherited  kidney  
diseases  can  be  nonspecific  and/or  heterogeneous  in  their  manifestations,  the  clinical  prognosis,  course,  
and  indicated  management  frequently  differ  between  hereditary  and  acquired  forms  of  disease,  as  well  as  
between  different  monogenic  etiologies(19,  26-­28).  Thus,  genome-­wide  approaches  such  as  ES  hold  the  
potential  to  enable  early  and  targeted  interventions  (see  Introduction,  Table  1)  in  the  context  of  both  
primary  (diagnostic)  and  secondary  findings,  favoring  their  broader  deployment.  However,  such  expanded  
use  also  carries  the  challenge  of  distinguishing  truly  disease  causal  variants  in  the  context  of  the  
abundance  of  putatively  deleterious  variation  present  in  each  human  genome(70,  71).    
   Current  clinical  sequence  interpretation  guidelines  advise  evaluating  candidate  pathogenic  
variants  based  on  a  framework  that  examines  their  rarity  (as  reflected  by  minor  allele  frequency;;  MAF),  
reported  occurrences  in  disease  cases,  and  impact  on  the  function  of  the  encoded  protein(72,  73).  Thus,  
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disease  causality  is  strongly  considered  for  rare  variants  previously  reported  as  pathogenic  and/or  
predicted  to  cause  loss  of  function  of  the  encoded  protein  due  to  premature  truncation(72,  73).  Housing  
over  325,000  variants  in  more  than  4,800  genes,  the  Human  Gene  Mutation  Database  (HGMD)  and  
ClinVar  are  two  eminent  clinical  variant  databases  which  function  as  key  resources  in  the  identification  
and  clinical  interpretation  of  previously  reported  pathogenic  variants(74,  75).  However,  both  HGMD  and  
ClinVar  include  many  variants  first  deemed  disease  causal  prior  to  the  advent  of  large  population  genetic  
datasets(76,  77).  Analyses  using  these  datasets  have  revealed  that  a  substantial  proportion  of  these  
variants  are  present  at  population  frequencies  incompatible  with  causality  for  the  associated  diseases(78-­
81).  Although  this  new  knowledge  has  enabled  reclassification  of  many  of  these  previously  reported  
pathogenic  variants  to  variants  of  uncertain  significance  (VUS),  likely  benign,  or  benign,  many  remain  
listed  as  “pathogenic,”  augmenting  the  already  considerable  burden  of  diagnostic  sequence  
interpretation(76,  78).    
   Prior  studies  have  leveraged  such  large  population  genetic  datasets  to  examine  the  prevalence  of  
purportedly  pathogenic  variants  for  the  ACMG  59  medically  actionable  genes  and  selected  monogenic  
diseases(78,  82-­84).  Within  nephrology,  external  control  population  datasets  have  been  successfully  
used  to  gain  further  insight  regarding  the  prevalence  of  specific  monogenic  forms  of  kidney  disease  such  
as  steroid  resistant  nephrotic  syndrome(85)  and  autosomal  dominant  polycystic  kidney  disease(86).  
However,  the  prevalence  of  candidate  pathogenic  variants  for  monogenic  nephropathy  requires  broader  
assessment,  across  different  disease  subtypes.  Moreover,  the  practical  consequences  of  these  findings,  
for  both  clinical  sequence  interpretation  and  workup,  have  yet  to  be  systematically  examined.       
To  this  aim,  we  utilized  a  large  cohort  of  7,974  self-­reported  healthy  adults  to  evaluate  the  
prevalence  of  candidate  pathogenic  variants  in  genes  associated  with  kidney  and  genitourinary  disorders.    
We  examined  the  prevalence  of  candidate  pathogenic  variants  and  the  resultant  burden  for  diagnostic  
sequence  interpretation  and  clinical  follow-­up.    
  
METHODS    
Identification  of  Mendelian  Kidney  and  Genitourinary  Disorder-­Associated  Genes  
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We  used  the  Online  Mendelian  Inheritance  in  Man  (OMIM)(87)  and  the  Orpha.net(88)  databases  to  
identify  genes  associated  with  Mendelian  kidney  and  genitourinary  disorders,  which  we  then  curated  to  
generate  a  final  gene  list.  The  gene  curation  pipeline  is  shown  in  Figure  1,  and  detailed  in  further  depth  
below.    




Schematic  of  the  pipeline  used  to  generate  the  list  of  Mendelian  kidney  and  genitourinary-­associated  disease  genes.  
OMIM:  Online  Mendelian  Inheritance  in  Man.    
  
Briefly,  we  took  the  union  of  the  genes  resulting  from  searching  these  databases  for  Human  Phenotype  
Ontology(89)  sub-­terms  under  the  broad  category  “abnormality  of  the  urinary  tract,’  (HP:  0000079)’,  which  
includes  anomalies  of  the  bladder,  kidneys,  ureters  and  urethra.  A  multidisciplinary  panel  including  
clinicians  and  geneticists  specialized  in  inherited  kidney  and  genitourinary  disorders  then  manually  
























phenotype  and/or  display  non-­Mendelian  inheritance  (i.e.,  “risk  factors”,  such  as  the  apolipoprotein  1  
(APOL1)  gene(90,  91))  were  removed.  The  panel  also  identified  an  additional  51  genes  absent  from  the  
OMIM  and  Orpha.net  searches,  which  were  added  following  consensus  approval.  Genes  were  then  
characterized  according  to  their  molecular  genetic  features,  including  inheritance  mode,  functional  type  of  
variants  previously  reported  causal,  clinical  category  of  the  associated  disease,  and  constraint  against  
protein-­truncating  (“loss-­of-­function”;;  LOF)  and  missense  variants.  Genic  constraint  again  protein-­
truncating  and  missense  variants  was  respectively  assessed  using  the  pLI  and  missense  z-­scores  
developed  by  the  Exome  Aggregation  Consortium  (ExAC)(77).  Genes  associated  with  dominant  kidney  
and  genitourinary  disorders  for  which  there  was  at  least  one  pathogenic  protein-­truncating  variant  in  
ClinVar,  were  deemed  “LOF-­associated”  genes.  The  genes  are  listed  in  Supplementary  Appendix  I,  




We  analyzed  ES  data  from  7,974  self-­identified  healthy  adults  who  consented  to  have  their  anonymized  
sequence  data  available  for  secondary  genetic  analysis  (Table  2).  Of  these  individuals,  47.2%  were  
recruited  as  healthy  controls  (not  otherwise  specified)  for  genetic  studies  and  50.2%  as  healthy  family  
members  of  probands  with  suspected  genetic  diseases  other  than  a  kidney  and  genitourinary  disorder;;  
the  remaining  2.6%  were  HIV-­infected  individuals  who  were  otherwise  healthy.  At  least  41%  of  individuals  
were  aged  >65  years  at  the  time  of  recruitment;;  50.6%  self-­identified  as  of  European  ancestry  and  56.4%  
were  female.  Samples  were  sequenced  using  13  different  next-­generation  sequencing  (NGS)  methods,  
with  the  majority  (78%)  on  Roche  kits.  We  used  KING(93)  to  remove  related  individuals  (kinship  
coefficient  >  0.1,  i.e.,  relatedness  of  second  degree  or  closer),  yielding  a  final  cohort  of  7,974  unrelated  
adults.  
  




No.  of  individuals   Proportion  of  cohort  (%)  





European  (Non-­Hispanic  white)   4036   50.6  
Hispanic   1883   24.1  
  
Black  or  African  American   1059   13.1  
  
Asian   190   2.3  
  
Other   568   7.1  
  
Unknown   335   3.3  
Phenotype   Healthy  control   3761   47.2  
Healthy  family  member   4004   50.2  
HIV-­infected  individuala   209   2.6  
Sequencing    
modality  
Whole  genomeb   459   5.8  
Exome     7515   94.2  
Exome  Capture  Kit        
      Roche   6222   78.0  
      65MB   872   10.9  
      50MB   205   2.6  
      AgilentV5UTR   69   0.9  
      37MB   42   0.5  
      AgilentV4UTR   30   0.4  
      RocheV2   26   0.3  
      Agilentv5   18   0.2  
      VCRome2_1   17   0.2  
      AgilentV4   7   0.1  
      MedExome   5   0.1  
      AgilentCRE   2   <0.1  
  
a  HIV:  Human  Immunodeficiency  Virus;;  105  individuals  were  HIV-­controllers  
b  For  the  individuals  who  underwent  whole  genome  sequencing,  only  exome  sequence  data  was  assessed.  
  
Sequence  Analysis  and  Variant  Annotation    
Sequence  data  was  annotated  using  the  Analysis  Tool  for  Annotated  Variants(94)  and  ANNOVAR(95).  To  
increase  analytical  specificity,  we  applied  stringent  quality  filters  (Supplementary  Appendix  I,  Section  
S1),  and  removed  potential  technical  false  positive  insertion  and  deletion  variants  (indels)  using  a  
previously  validated  method(96).  We  used  HGMD(75)  and  ClinVar(74)  to  identify  previously  reported  
pathogenic  variants;;  only  those  classified  pathogenic  at  least  one  of  the  databases  (i.e.,  “DM”  in  HGMD  
and/or  “Pathogenic”  in  ClinVar)  were  included.  As  protein-­truncating  variants,  including  those  not  
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previously  reported  as  pathogenic,  are  highly  prioritized  under  current  clinical  sequence  interpretation  
guidelines(72,  73),  we  also  annotated  sequence  data  for  protein-­truncating  variants  not  previously  
reported  in  HGMD  and/or  ClinVar.    
  
In-­silico  Variant  Interpretation    
For  all  analyses,  only  individuals  with  genotypes  consistent  with  the  reported  inheritance  mode  of  the  
associated  disorder  were  assessed.    
Standard  Filtering  Pipeline  
Current  diagnostic  sequence  interpretation  guidelines(72,  73)  advise  analyzing  “rare”  variants,  typically  
defined  as  those  with  minor  allele  frequency  (MAF)  less  than  1%(73,  97).  Conservatively,  we  defined  
“rare”  variants  as  those  with  a  MAF  <  1%  within  any  of  the  Exome  Aggregation  Consortium  (ExAC)  ethnic  
subpopulations  as  well  as  the  aggregate  (Global)  population.  Moreover,  we  required  variants  meet  this  
cutoff  with  respect  to  both  their  MAF  within  any  of  the  ExAC  ethnic  subpopulations  (“popmax  MAF”)(77)  
and  within  our  cohort  (“internal  MAF”)(98).  To  replicate  a  diagnostic  sequence  interpretation  workflow,  we  
defined  candidate  pathogenic  variants  as  any  rare,  previously  reported  pathogenic  variant  or  any  rare,  
protein-­truncating  variant  not  previously  reported  in  HGMD  and/or  ClinVar.      
Stringent  Filtering  Pipeline  
Because  the  standard  pipeline  yielded  an  implausibly  high  number  of  candidate  pathogenic  variants,  we  
subsequently  applied  a  more  stringent  in-­silico  annotation  pipeline.  The  analyses  conducted  to  develop  
this  pipeline  are  detailed  in  Supplementary  Appendix  I,  Section  S2;;  briefly,  we  assessed  the  yield  of  
candidate  pathogenic  variants  using  various  MAF  cutoffs  (Supplementary  Appendix  I,  Table  S2)  and  in-­
silico  deleteriousness  predictors  (Supplementary  Appendix  I,  Table  S3).  In  addition,  hypothesizing  that  
under-­transmission  from  parent  to  offspring  could  correspond  to  artefactual  variants,  we  evaluated  the  
transmission  rate  of  SNVs  and  indel  variants  in  genes  associated  with  dominant  forms  of  disease  
(Supplementary  Appendix  I,  Table  S4).  The  resultant  stringent  pipeline  consisted  of  applying  a  MAF  
cutoff  of  <0.01%  and  <0.1%  for  dominant  and  recessive  disorders,  respectively,  and  removing  indels  due  




Manual  variant  and  clinical  data  review    
In  practice,  diagnostic  sequence  interpretation  requires  manually  reviewing  the  evidence  for  a  variant’s  
causality  for  the  associated  disease,  as  well  as  the  concordance  between  the  patient’s  known  clinical  
features  and  the  candidate  genetic  diagnosis(73,  99).  If  the  evidence  for  either  insufficient,  additional  
clinical  follow-­up  is  advised  to  clarify  the  significance  of  the  genetic  findings(73).  Thus,  we  manually  
classified  a  subset  of  candidate  pathogenic  variants  (Supplementary  Appendix  I,  Table  S7)  and  
evaluated  the  phenotypic  concordance  for  the  individuals  for  whom  clinical  data  was  available  
(Supplementary  Appendix  I,  Table  S8).  Variant  classification  was  done  per  ACMG  guidelines(73),  
incorporating  multiple  lines  of  evidence  including  number  of  reported  cases,  familial  segregation,  
experimental  assays  supporting  altered  protein  function,  and  the  observed  MAF  versus  the  known  
prevalence  of  the  associated  disorder.  In  addition,  to  examine  the  potential  burden  of  clinical  follow-­up,  for  
each  variant  manually  classified  as  non-­benign  (i.e.,  Pathogenic,  Likely  Pathogenic,  or  VUS)  we  noted  the  
clinical  evaluations  needed  to  validate  or  refute  the  candidate  genetic  diagnosis  (in  addition  to  review  of  
an  individual’s  known  clinical  features)  and  the  implications  of  confirming  the  genetic  diagnosis  for  clinical  
management  (Supplementary  Appendix  I,  Table  S8).      
  
Statistical  Analysis  
We  compared  genic  constraint  (pLI  and  missense  Z)  scores  using  Tukey’s  honest  significance  test  
(Supplementary  Appendix  I,  Table  S5).    Parent-­offspring  transmission  rate  was  calculated  using  the  
individuals  recruited  as  healthy  family  members  with  offspring  sequencing  data  available;;  we  applied  an  
Exact  Binomial  test  to  assess  whether  transmission  rates  differed  from  Mendelian  expectations  (50%  
transmission).  All  statistical  analyses  were  conducted  in  R  Statistical  Software  (version  3.4.1).  
  
RESULTS    
Identification  and  Characterization  of  625  Mendelian  Kidney  and  Genitourinary  Disease-­
Associated  Genes    
We  generated  a  list  of  625  genes  associated  with  Mendelian  forms  of  kidney  and  genitourinary  disorders  
(Table  3;;  Figure  1;;  Supplementary  Appendix  I,  Table  S1).  Altogether,  the  list  consisted  of  172  genes  
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associated  exclusively  with  dominant  disorders  (161  autosomal  and  11  X-­linked),  409  with  recessive  
disorders  (382  autosomal  and  27  X-­linked),  and  44  with  disorders  reported  to  show  both  dominant  and  
recessive  inheritance  (40  autosomal  and  4  X-­linked)  (Table  3).  The  majority  of  the  genes  were  associated  
with  disorders  primarily  characterized  by  renal  involvement,  such  as  congenital  anomalies  of  the  kidney  
and  urinary  tract,  tubulointerstitial  diseases,  and  glomerulopathies.  The  remaining  genes  were  associated  
with  renal  cancers,  multisystem  disorders  with  secondary  renal  involvement,  or  genital  anomalies.  
Nineteen  of  the  625  genes  also  are  included  in  the  59  genes  recommended  by  the  ACMG  for  return  as  
medically  actionable  incidental  findings.  
   After  assigning  mode  of  inheritance  for  each  disease-­gene  pair,  we  assessed  genic  constraint  
against  protein-­truncating  variants  and  missense  variation,  as  respectively  indexed  by  the  pLI  and  
missense  Z-­scores(77).  Consistent  with  previous  analyses(77),  the  172  exclusively  dominant  genes  were  
highly  constrained  against  heterozygous  protein-­truncating  variants  and  missense  variants  versus  the  409  
exclusively  recessive  genes  or  the  44  genes  for  which  both  dominant  and  recessive  inheritance  has  been  
reported  (Figure  2;;  Supplementary  Appendix  I,  Table  S5).  Thus,  for  subsequent  analyses  we  grouped  









































































































































































Figure  2.  Genic  intolerance  to  (A)  loss  of  function  and  (B)  missense  variation  
  
Genes  associated  with  dominant  Mendelian  kidney  and  genitourinary  disorders  displayed  significantly  
higher  intolerance  to  (A)  loss  of  function  (LOF)  variants  based  on  ExAC  pLI  score  and  (B)  missense  
variation  based  on  ExAC  missense  Z-­score  than  those  associated  with  Mendelian  kidney  and  
genitourinary  disorders  displaying  recessive  inheritance,  or  those  for  which  both  dominant  and  recessive  
inheritance  has  been  reported.    
ExAC:  Exome  Aggregation  Consortium;;  pLI:  the  probability  of  being  intolerant  to  protein-­truncating  
variants;;  missense  Z-­score:  the  probability  of  being  missense  intolerant(77).  *P  <  0.01;;  **P  <  1x10-­9  
























































































Assessment  of  the  Prevalence  of  Candidate  Pathogenic  Variants  
We  next  investigated  the  prevalence  of  candidate  pathogenic  variants  in  these  625  Mendelian  kidney  and  
genitourinary  disorder-­associated  genes  in  7,974  self-­reported  healthy  adults  under  both  the  standard  
and  stringent  filtering  pipelines,  and  the  associated  burden  for  manual  variant  interpretation  and  clinical  
follow-­up  (Figure  3;;  Figure  4).    
  
Figure  3.  Assessment  of  the  burden  of  candidate  pathogenic  variants  for  kidney  and  genitourinary  




Boxes  describe  the  results  of  analysis  of  whole-­exome  sequence  data  from  7,974  self-­declared  healthy  individuals  for  
candidate  pathogenic  variants  in  625  kidney  and  genitourinary  disorder-­associated  genes,  using  standard  and  
stringent  filtering  procedures  (detailed  in  the  Methods),  followed  by  manual  variant  classification  and  case-­level  
clinical  data  review.    
⍙Stringent  and  standard  filtering  procedures  are  as  defined  in  the  Methods.  †Of  these  individuals,  one  had  clinical  
data  available.  ††Of  these  individuals,  one  had  clinical  data  available,  but  the  variant  found  would  not  merit  return  
under  current  guidelines,  and  thus  also  would  not  warrant  further  clinical  follow-­up.  ⍬This  individual  already  had  the  
clinical  diagnosis  corresponding  to  the  genetic  disease  detected;;  thus,  no  further  clinical  evaluation  would  be  needed.    
Abbreviations:  n=  number  of  individuals;;  v=  number  of  unique  candidate  pathogenic  variants  identified;;  Stringent  P:  
Passed  stringent  filtering;;  Stringent  F:  Failed  stringent  filtering;;  MAF:  Minor  Allele  Frequency,  with  the  MAF  cutoff  with  



















































Standard  Filtering  Pipeline  
Altogether,  we  detected  705  candidate  pathogenic  variants  in  6,461  of  the  7,974  individuals  (81%).  
Considering  only  “rare”  variants  (MAF<1%),  the  standard  filtering  pipeline  detected  522  candidate  
pathogenic  variants  in  23.3%  of  self-­declared  healthy  adults  (Figure  3;;  Supplementary  Appendix  I,  
Table  S2).  The  majority  of  variants  were  previously  reported  pathogenic  (385  variants,  73.7%)  and/or  in  
genes  associated  with  dominant  disorders  (377  variants,  72.2%)  (Supplementary  Appendix  I,  Table  
S2).  These  522  variants  were  in  genes  associated  with  155  distinct  monogenic  disorders,  which  
collectively  spanned  all  categories  of  kidney  and  genitourinary  disease  (Figure  4).    
Notably,  variants  in  one  tenth  (17/172)  of  all  dominant  genes  accounted  for  45.3%  of  rare  
previously  reported  pathogenic  variants  and  variants  in  one  tenth  (11/107)  of  the  dominant  LOF-­
associated  genes  accounted  for  the  52.2%  of  rare,  previously  unreported  protein-­truncating  variants  
(Table  4;;  Supplementary  Appendix  I,  Table  S6).  The  genes  found  to  bear  the  highest  burden  of  
candidate  pathogenic  variants  were  discovered  prior  to  the  release  of  the  large  population  genetic  
database  ExAC  (2016),  and  altogether  accounted  for  67.7%  of  individuals  carrying  candidate  pathogenic  
variants.  
  
Stringent  Filtering  Pipeline  
As  kidney  disease  affects  approximately  10-­15%  of  adults(11,  12)  and  Mendelian  kidney  and  
genitourinary  disorders  are  estimated  to  account  for  approximately  10%  of  adult  ESRD  cases(22,  23),  we  
found  the  23.3%  yield  of  candidate  pathogenic  variants  in  a  cohort  of  self-­declared  adults  to  be  
implausibly  high.  Therefore,  we  next  applied  a  stringent  filtering  pipeline,  consisting  of  removing  indels  
and  applying  more  stringent  MAF  cutoffs  of  <0.01%  and  <0.1%  for  dominant  and  recessive  disorders,  
respectively;;  see  Methods).  Nonetheless,  under  this  stringent  filtering  left  1.4%  of  individuals  with  112  
candidate  pathogenic  variants  potentially  qualifying  for  clinical  return  (Figure  3).  Of  these  112  variants,  82  
(73%)  were  previously  reported  pathogenic  variants  and  30  (27%)  were  previously  unreported  protein-­


























































































































Constraint   MAF  <1%   MAF  <0.1%  
pLI   Z   N   %   N   %  
PRP   1   PKD1   1994   14138   1   -­0.68   21(0)   207   2.6   16   0.2  
PRP   2   GLI3   1997   8208   1   1.52   4  (0)   147   1.84   4   0.05  
PRP   3   PROKR2   2006   1155   0   0.23   13  (1)   131   1.64   27   0.34  
PRP   4   CHD7   2004   11568   1   1.92   8  (1)   98   1.23   7   0.09  
PRP   5   KMT2D   2010   19419   1   3.1   12  (3)   64   0.8   9   0.11  
PRP   6   JAG1   1997   6048   1   4.05   7  (0)   60   0.75   8   0.1  
PRP   7   GDNF   1996   3810   0.7   1.37   3  (0)   55   0.69   3   0.04  
PRP   8   PTEN   1997   9027   0.98   3.71   4  (0)   52   0.65   6   0.08  
PRP   9   TSC2   1996   6156   1   0.89   12  (1)   52   0.65   15   0.19  
PRP   10   NOTCH3   1997   8666   0.21   4.79   12  (0)   50   0.63   19   0.24  
PRP   11   NF1   1990   12425   1   6.22   14  (0)   49   0.61   13   0.16  
PRP   12   ARMC5   2013   4844   0.05   3.32   3  (0)   43   0.54   2   0.03  
PRP   13   CREBBP   1995   10803   1   5.58   3  (0)   38   0.48   2   0.03  
PRP   14   HNF1B   1997   2977   1   2.32   7  (0)   38   0.48   6   0.08  
PRP   15   MYH9   2000   7501   1   5.59   3  (0)   36   0.45   1   0.01  
PRP   16   CFHR5   2006   2810   0   -­2.31   1  (1)   34   0.43   0   0  
PRP   17   DSTYK   2013   7874   0.15   1.73   3  (0)   29   0.36   4   0.05  
PTV   1   MAPRE2   2015   4323   0.97   3.34   1  (1)   34   0.43   0   0  
PTV   2   SETBP1   2010   9899   1   1.9   2  (1)   19   0.24   4   0.05  
PTV   3   CACNA1S   1994   6166   0   -­0.97   9  (2)   15   0.19   10   0.13  
PTV   4   TSC2   1996   6156   1   0.89   4  (2)   13   0.16   13   0.16  
PTV   5   CFHR5   2006   2810   0   -­2.31   9  (4)   11   0.14   8   0.1  
PTV   6   ASXL1   2010   7038   0   0.08   5  (2)   9   0.11   9   0.11  
PTV   7   GNAS   1989   4029   1   4.34   5  (3)   6   0.08   6   0.08  
PTV   8   SALL1   1999   5253   0.99   0.48   3  (2)   6   0.08   6   0.08  
PTV   9   NR3C2   1998   5893   0.93   1.84   2  (2)   5   0.06   5   0.06  
PTV   10   ARID1A   2012   8577   1   4.1   1  (0)   4   0.05   4   0.05  
PTV   11   CREBBP   1995   10803   1   5.58   1  (1)   4   0.05   0   0  
  
PRP:  previously  reported  pathogenic  variants;;  PTV:  Protein-­Truncating  Variants  unreported  in  ClinVar  or  HGMD;;  
MAF:  minor  allele  frequency;;  the  internal  MAF  and  ExAC  popmax  MAF  were  used  to  determine  the  MAF  for  each  
variant;;  N:  Number;;  aRanked  based  on  the  observed  prevalence  of  individuals  assessed  with  PRPs  or  PTVs  in  the  
gene;;  bYear  identified,  per  OMIM  entry;;  c  Largest  transcript,  per  Ensembl  database;;  d  Number  of  insertion  or  deletions  


































































































































































































































































































































































































































































































































































































































































































Clinical  Interpretation  of  Candidate  Pathogenic  Variants  
  
Manual  Variant  Classification    
Using  the  ACMG  guidelines(73),  we  manually  classified  the  112  variants  which  passed  the  stringent  
filtering  pipeline.  Of  these,  29  (25.9%)  were  deemed  Pathogenic  or  Likely  Pathogenic,  71  (63.4%)  VUS,  
and  13  Benign  or  Likely  Benign  (Figure  3;;  Supplementary  Appendix  I,  Table  S7).  Thus,  89.2%  of  
variants  could  not  be  ruled  out  as  benign,  leaving  1.2%  of  self-­reported  healthy  adults  with  a  candidate  
pathogenic  variant.    
While  these  stringent  filtering  procedures  efficiently  reduced  the  number  of  individuals  with  
candidate  pathogenic  variants,  they  potentially  excluded  relevant  variants  (i.e.,  indels),  or  pathogenic  
variants  with  higher  MAFs.  Thus,  we  manually  reviewed  62  variants  in  dominant  genes  excluded  by  
stringent  filtering  but  passing  the  standard  filtering,  such  as  previously  unreported  indels  or  variants  with  
MAFs  which  met  the  traditional  1%  cutoff  for  rarity,  but  exceeded  the  0.01%  MAF  cutoff  applied  on  
stringent  filtering  (Figure  3).  Of  these  62  variants,  only  10  (16.1%)  were  deemed  Benign,  Likely  Benign,  
or  likely  somatic  or  technical  false  positives  (Figure  3;;  Supplementary  Appendix  I,  Table  S7);;  the  
remainder  were  classified  as  VUS  (27/62;;  43.5%)  and  Pathogenic  or  Likely  Pathogenic  (25/62;;  40.3%).  
The  25  Pathogenic  or  Likely  Pathogenic  variants  were  present  in  31  individuals  and  spanned  18  different  
genes;;  they  comprised  24  previously  unreported  protein-­truncating  variants  and  one  previously  reported  
pathogenic  missense  variant  in  the  COL4A5  gene.  Hence,  while  reducing  the  burden  of  variant  
interpretation,  applying  highly  stringent  MAF  cutoffs  and  omitting  indels  may  also  have  discarded  
potentially  causal  variants.      
  
Assessment  of  the  Potential  Burden  of  Clinical  Follow-­up  
Manual  variant  classification  revealed  that  altogether  176/213  (82.6%)  individuals  harbored  variants  
which  could  merit  clinical  follow-­up  (Table  6;;  Supplementary  Appendix  I,  Table  S8).  In  addition  to  
requiring  detailed  assessment  for  consistent  personal  features  and/or  family  history,  these  follow-­ups  
could  involve  referrals  to  one  or  more  of  10  subspecialties,  reflecting  that  many  of  the  associated  
disorders  can  have  multi-­organ  involvement  (Supplementary  Appendix  I,  Table  S8).  For  example,  we  
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identified  3  self-­declared  healthy  adults  with  Pathogenic  and  Likely  Pathogenic  variants  in  HNF1B,  
associated  with  renal  cysts  and  diabetes  syndrome.  These  findings  could  prompt  targeted  work-­up  and  
surveillance  for  the  associated  complications,  including  screening  for  congenital  kidney  and  urinary  tract  
anomalies,  electrolyte  anomalies,  and  renal  disease;;  genital  anomalies  in  women;;  and  glucose  tolerance  
and  liver  function  tests.  Similarly,  we  identified  3  self-­declared  healthy  adults  with  Likely  Pathogenic  
variants  in  TSC2.  These  would  at  the  very  least  prompt  detailed  chart  review  for  features  of  the  
corresponding  disease,  tuberous  sclerosis.  Assuming  a  clinical  diagnosis  was  not  found  on  chart  review,  
these  individuals  could  undergo  considerable  work-­up,  including  neurologic,  cardiac,  and  abdominal  
imaging  studies  for  the  associated  tumors.  If  confirmed,  the  genetic  diagnosis  would  prompt  further  
evaluation  and  monitoring,  including  comprehensive  neurodevelopmental,  dermatologic,  ophthalmologic,  
cardiac,  pulmonary,  nephrologic,  and  dental  examinations.  As  diagnostic  laboratories  generally  report  
non-­benign  variants  if  related  to  manifesting  symptoms,  and  some  also  report  VUS  for  secondary  
findings(100,  101),  many  individuals  undergoing  genomic  sequencing  could  potentially  have  a  variant  
returned  and  undergo  considerable  clinical  work-­up.  
  
Clinical  Data  Review  
To  further  reproduce  a  diagnostic  sequence  interpretation  workflow,  we  not  only  manually  classified  the  
candidate  pathogenic  variants,  but  also  attempted  to  review  the  clinical  data  for  the  individuals  harboring  
them.  Clinical  data  was  unavailable  for  150  (85.2%)  of  the  176  individuals  with  non-­benign  variants;;  thus,  
at  the  very  least,  the  genetic  findings  would  necessitate  obtaining  and  reviewing  this  information  (Figure  
3;;  Supplementary  Appendix  I,  Table  S8).    
De-­identified  billing  and  diagnostic  codes  from  electronic  health  records  were  available  for  28  
individuals;;  the  corresponding  variants  spanned  both  the  stringent  and  standard  filtering  pipelines  and  all  
manual  variant  classification  categories.  These  included  2  individuals  carrying  variants  which  would  not  
merit  return  under  current  guidelines:  IID  4  harbored  a  variant  deemed  likely  somatic  in  the  ASXL1  
gene(102)  and  IID  66  harbored  a  previously  unreported  protein-­truncating  variant  in  CACNA1S,  a  gene  
for  which  return  of  only  previously  reported  pathogenic  variants  is  advised  under  current  guidelines  for  
secondary  findings(60)  (Figure  3;;  Supplementary  Appendix  I,  Table  S8).  Only  one  case  could  be  
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resolved  upon  clinical  data  review  alone:  IID  86,  with  a  previously  reported  pathogenic  variant  in  the  NF1  
gene,  had  a  clinical  diagnosis  of  neurofibromatosis;;  this  person  was  recruited  as  a  healthy  family  member  
of  a  child  with  microcephaly.    
For  the  remaining  25/28  (89%)  individuals,  their  known  clinical  features  were  not  sufficiently  
specific  to  confirm  or  refute  the  candidate  genetic  diagnosis,  such  that  additional  clinical  evaluation  would  
be  required.  These  included  individuals  who  had  multiple  features  consistent  with  the  candidate  genetic  
diagnosis,  but  which  could  also  result  from  other  causes.  For  example,  one  individual  aged  77  years  old,  
a  self-­declared  healthy  control  recruited  for  a  population  health  study  of  adults  aged  65  years  and  older,  
harbored  a  rare  protein-­truncating  variant  in  the  CHD7  gene  manually  classified  as  Likely  Pathogenic.  
While  not  clinically  recognized  to  have  CHARGE  syndrome,  he  was  noted  to  have  the  potentially  
compatible  features  of  “psychiatric  problems,”  “cardiac  dysrhythmia,”  and  “abdominal  and  skeletal  
anomalies.”  Similarly,  another  individual,  also  recruited  for  such  studies  of  self-­declared  healthy  older  
adults,  had  a  rare  previously  reported  pathogenic  variant  in  the  FLCN  gene  deemed  Pathogenic  on  
manual  classification.  This  individual  was  noted  to  have  a  history  of  “spontaneous  pneumothorax,”  
“abnormal  lung  imaging”  with  “pulmonary  blebs,”  and  “thyroid  neoplasm,”  consistent  with  the  associated  
disorder,  Birt-­Hogg  Dubé  syndrome.  While  supportive,  such  features  alone  would  not  be  diagnostic  and  
support  additional  clinical  evaluation,  such  as  screening  for  the  characteristic  skin  lesions  and  renal  
tumors.  
  








Clinical  evaluations  needed  to  refute  or  
confirm  the  candidate  genetic  diagnosis  







Likely  Pathogenic   Yes  
Detailed  history,  physical  exam  and/or  family  
history;;  subspecialty  evaluation;;  and/or  
additional  testing  





Detailed  history,  physical  exam  and/or  family  
history;;  subspecialty  evaluation;;  and/or  
additional  testing  
91  (83.5%)   118  




benign,  or  likely  
technical  false  
positive  
No   None  based  on  internal  classification  or  current  ACMG  guidelines   22  (63.6%)   28  
  




ES  holds  the  potential  to  enable  specific  diagnosis  and  targeted  care  for  a  broad  range  of  etiologically  
heterogeneous  conditions,  including  kidney  and  genitourinary  disorders.  However,  realizing  this  promise  
requires  distinguishing  truly  disease-­causal  variants  from  the  abundance  of  presumptively  deleterious  
variation  found  in  each  human  genome(70,  71).  Here,  we  generated  a  comprehensive  list  of  genes  
associated  with  Mendelian  kidney  and  genitourinary  disorders,  spanning  the  major  clinical  categories  of  
nephropathy,  and  evaluated  the  burden  of  candidate  pathogenic  variants  in  these  genes  in  a  large  cohort  
of  self-­declared  healthy  adults.    
We  found  a  strikingly  high  frequency  of  candidate  pathogenic  variants  using  standard  filtering  
pipelines,  with  some  observed  at  frequencies  over  20-­fold  higher  than  the  estimated  aggregate  
prevalence  of  Mendelian  kidney  and  genitourinary  disorders.  While  applying  stringent  automated  filters  
reduced  the  burden,  at  least  1.4%  of  self-­declared  healthy  adults  remained  with  candidate  pathogenic  
variants  requiring  manual  review.  On  subsequent  manual  sequence  interpretation,  the  majority  of  these  
variants  were  classified  as  non-­benign  (i.e.,  Pathogenic,  Likely  Pathogenic  or  VUS),  such  that  they  could  
generate  medical  record  review,  additional  diagnostic  studies,  and  subspecialty  referrals  to  clarify  their  
clinical  significance,  particularly  when  detected  as  a  secondary  genetic  finding  in  a  self-­declared  healthy  
adult.  These  results  highlight  the  potential  of  ES  to  initiate  new  “diagnostic  odysseys,”  rather  than  
alleviate  the  burden  of  multiple  medical  referrals  for  patients  and  their  families(103,  104).  Our  findings  
thus  highlight  the  need  for  systematic  investigation  of  the  burden  of  candidate  pathogenic  variants  and  
detailed  gene-­  and  variant-­level  curation  within  each  medical  discipline(105).    
   We  found  that  rare  previously  reported  pathogenic  variants  accounted  for  the  majority  of  the  
candidate  pathogenic  variant  burden,  demanding  time-­intensive  manual  curation  of  the  supporting  
primary  literature(82).  These  results  reinforce  the  need  for  continuous  review  of  clinical  variant  
databases(78),  particularly  for  variants  in  genes  identified  prior  to  the  release  of  large  population  genetic  
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datasets,  such  as  the  17  dominant  genes  which  contributed  most  to  the  burden  of  previously  reported  
pathogenic  variants.  In  addition,  we  observed  a  substantial  number  of  previously  unreported  protein-­
truncating  variants  in  a  number  of  LOF-­associated  genes,  even  when  excluding  indels,  indicating  that  this  
did  not  simply  reflect  next-­generation  sequencing-­related  artifacts.  Assuming  full  penetrance,  these  
observations  support  more  cautious  interpretation  of  protein-­truncating  variants  for  the  associated  
disorders.  Moreover,  our  findings  reinforce  the  need  for  routine  reassessment  of  both  the  case-­level  
evidence  for  variant  pathogenicity  and  the  reported  mechanisms  of  disease.    
   We  note  that  our  study  likely  underestimates  the  follow-­up  burden  of  candidate  pathogenic  
variants  from  ES  because  we  applied  highly  stringent  MAF  cutoffs.  While  the  majority  of  Mendelian  
disease-­causal  variants  are  ultra-­rare,  founder  mutations  and  incompletely  penetrant  variants  may  be  
present  at  frequencies  exceeding  stringent  MAF  cutoffs,  or  even  the  standard  1%  threshold(106,  107).  
The  p.G624D  missense  variant  in  the  COL4A5  gene,  a  founder  variant  conferring  a  milder  form  of  Alport  
syndrome,  illustrates  this  point(108,  109).  Hence,  some  of  the  non-­benign  candidate  pathogenic  variants  
observed  may  represent  cases  with  unrecognized  Mendelian  nephropathy,  reinforcing  the  need  to  
incorporate  disease-­specific  subtleties  when  applying  automated  filters.  Our  stringent  filtering  pipeline  
also  likely  underestimates  the  prevalence  of  candidate  pathogenic  variants  due  to  the  omission  of  indels  
and  novel  missense  variants,  each  of  which  can  be  disease-­causal  but  respectively  pose  a  greater  
interpretative  burden  due  to  lower  analytical  specificity  and  ambiguity  regarding  their  effect  on  the  
encoded  protein.  Technical  advances  in  next-­generation  sequencing(110),  novel  pathogenicity  prediction  
tools(111-­113)  and  development  of  high-­throughput  functional  assays(114,  115)  will  help  to  address  
these  challenges.  Ongoing  efforts  to  refine  existing  clinical  sequence  interpretation  guidelines(116)  
likewise  promises  to  increase  both  the  efficiency  and  accuracy  of  diagnostic  variant  analysis.    
   Limitations  of  this  study  include  limited  information  about  age  at  recruitment  and  the  inability  to  
review  the  medical  records  of  all  participants  with  rare  candidate  pathogenic  variants  to  evaluate  
phenotypic  concordance  with  the  candidate  genetic  diagnosis.  Such  limited  access  to  clinical  information  
impedes  accurate  sequence  interpretation;;  moreover,  due  to  the  genome-­wide  search  space  provided  by  
ES,  even  with  clinical  data  available,  additional  workup  is  often  needed  to  ascertain  the  significance  of  the  
genetic  findings.  The  fact  that  early-­stage  kidney  disease  is  often  clinically  silent  and  affected  individuals  
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are  unaware  of  their  condition(13,  68,  69)  can  further  contribute  to  this  ambiguity,  but  also  favors  broader  
use  of  genetic  testing  as  a  means  of  presymptomatic  diagnosis.  Balancing  the  benefit  of  detecting  
unrecognized  genetic  disorders  in  a  few  individuals  with  the  risk  of  initiating  unneeded  clinical  workup  in  
many  healthy  persons  has  already  shaped  selection  of  genes  for  return  as  medically  actionable  
secondary  findings(117),  and  will  be  particularly  complex  for  kidney  and  genitourinary  disorders  and  other  
such  common,  etiologically  heterogeneous  constitutional  conditions.  The  above  issues  reinforce  the  need  
for  detailed,  longitudinal  phenotypic  as  well  as  genetic  data  for  both  disease  and  control  cohorts  in  order  
to  effectively  apply  genomics  in  medicine  (118).    
   Altogether,  the  high  prevalence  of  purportedly  “pathogenic”  variants  in  a  large  cohort  of  self-­
reported  healthy  adults  reveals  the  challenges  of  variant  interpretation  and  the  growing  potential  of  ES  to  
initiate  as  well  as  to  resolve  the  “diagnostic  odyssey”  in  the  context  of  broadening  utilization  and  analytic  
scope  of  genome-­wide  assessment.  Moreover,  our  results  illustrate  key  issues  emerging  from  the  
expanding  use  of  genomic  sequencing,  including  the  limitations  of  self-­reported  health  status  and  the  
difficulties  of  assessing  variant  pathogenicity  without  additional  clinical  follow-­up.  Systematic  curation  of  
clinical  variant  databases  for  each  medical  subspecialty  and  large,  longitudinal  studies  incorporating  
comprehensive  health  data  will  help  to  characterize  the  pathogenicity  and  penetrance  of  the  many  rare  



















Chapter  II:    




















In  Chapter  I,  we  identified  and  characterized  a  comprehensive  set  of  genes  associated  with  Mendelian  
kidney  and  genitourinary  disorders.  We  leveraged  a  large,  ethnically  diverse  ES  dataset  from  7,974  self-­
declared  healthy  adults  to  evaluate  the  prevalence  of  candidate  pathogenic  variants  in  these  genes  using  
standard  and  more  stringent  clinical  sequence  interpretation  workflows,  and  examined  associated  burden  
of  clinical  follow-­up.  Altogether,  this  investigation  offers  insight  into  the  molecular  features  of  Mendelian  
kidney  and  genitourinary  disease-­associated  genes,  as  well  as  the  challenges  arising  from  broader  use  of  
ES  to  detect  putatively  pathogenic  variants  in  them.  
   Here,  we  utilize  a  combined  cohort  totaling  3,315  ethnically  diverse  CKD  cases  to  assess  the  
utility  of  ES  for  the  broader,  all-­cause  CKD  population.  As  noted  in  the  Introduction,  ES  has  been  
successfully  used  to  identify  a  genetic  cause  of  nephropathy  amongst  cases  clinically  diagnosed  with  
presumed  hereditary  etiologies  of  CKD  and/or  with  other  supportive  clinical  features,  such  as  early-­onset  
and/or  familial  disease.  While  these  studies  highlight  the  promise  of  ES  in  clinical  nephrology,  their  
assessment  of  such  pre-­selected  patient  populations  limits  their  generalizability  to  the  broader  CKD  
population,  which  largely  consists  of  unselected  adults  clinically  diagnosed  with  a  variety  of  etiologies,  
including  those  with  CKD  presumed  secondary  to  acquired  causes  such  as  diabetic  or  hypertensive  
nephropathy(16-­18).    
   To  our  knowledge,  the  present  work  represents  the  first  large-­scale  diagnostic  ES  study  of  all-­
cause  CKD.  Thus,  it  provides  the  unique  opportunity  to  investigate  the  many  questions  needed  to  inform  
subsequent  use  of  ES  in  clinical  nephrologic  practice.  What  is  prevalence  of  Mendelian  forms  of  
nephropathy  in  the  general  all-­cause  CKD  population,  and  the  associated  genetic  and  clinical  diagnostic  
spectrum  represented?  How  does  yield  vary  across  different  patient  subpopulations,  and  which  clinical  
features  are  strong  predictors  of  achieving  a  genetic  diagnosis?  How  does  the  yield  of  ES  compare  with  
that  of  more  targeted  genetic  testing,  and  in  how  many  cases  are  putatively  deleterious  variants  found  
that  require  additional  follow-­up  to  ascertain  their  clinical  significance?  How  might  the  clinical  insight  
resulting  from  a  genetic  diagnosis  guide  management  in  different  clinical  contexts,  and  what  are  the  
broader  implications,  across  different  medical  subspecialties?  How  many  cases  harbor  pathogenic  
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variants  in  genes  currently  recommended  for  return  as  medically  actionable  secondary  findings(60),  and  
what  are  the  broader  implications  of  these  secondary  findings  for  management?    
   To  address  these  questions,  we  performed  ES  in  two  independent  chronic  kidney  disease  
cohorts,  totaling  3,315  patients  representing  the  broad  clinical  subcategories  of  nephropathy(16-­18).  We  
assessed  the  yield  of  diagnostic  and  otherwise  clinically  relevant  findings,  and,  among  the  cases  with  
more  detailed  clinical  data  available,  examined  the  implications  of  these  findings  for  both  nephrologic  and  




We  conducted  proband-­only  exome  sequencing  in  3,315  patients  with  kidney  disease  (Table  7):  1,128  
from  the  AURORA  study,  a  clinical  trial  involving  2,773  ESRD  patients  aged  50  to  80  years  from  280  
medical  centers  across  25  nations(119-­121)  and  2,187  from  the  Columbia  University  Medical  Center  
(CUMC)  Genetic  Studies  of  Chronic  Kidney  Disease,  a  genetic  research  and  biobanking  protocol  
recruiting  patients  seen  by  the  CUMC  Nephrology  Division  for  the  evaluation  and  management  of  
nephropathy  (Supplementary  Appendix  II,  Section  S1;;  Tables  S1,  S2,  and  S3).  The  clinical  diagnosis  
was  classified  by  broad  etiologic  category.  For  AURORA  patients,  only  these  broad  categories  and  
diagnostic  codes  for  their  major  clinical  features  were  available;;  for  CUMC  patients,  more  detailed  clinical  
information  was  available  from  patients’  electronic  health  records.  All  patients  or  guardians  provided  
informed  consent.  The  study  was  approved  by  the  Columbia  University  Institutional  Review  Board  and  
local  ethics  committees  and  performed  in  accordance  with  the  policy  on  bioethics  and  human  biologic  
samples  of  the  AURORA  study  sponsor,  AstraZeneca.      
  
Exome  sequencing  and  bioinformatics  processing    
Genomic  DNA  was  isolated  from  patient  samples  using  standard  protocols,  and  sequenced  at  the  
Columbia  Institute  for  Genomic  Medicine  (IGM).  Peripheral  blood  samples  were  provided  for  the  majority  
of  patients,  although  other  sources  of  DNA  were  accepted.  Sequence  capture  was  performed  using  either  
the  Roche  NimbleGen  SeqCap  Exome  EZ  v3.0  kit  or  the  IDT  xGen  Exome  Research  Panel  v1.0  kit.    
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Paired-­end  sequencing  was  performed  on  the  Illumina  2500  HiSeq  platform  or  the  Illumina  NovaSeq  
6000  platform,  using  125bp  and  150bp  reads,  respectively.  Mean  sequence  coverage  was  111x,  with  on  
average  97%  of  the  target  bases  in  a  given  sample  achieving  at  least  10x  coverage.  
   Exome  sequence  data  was  processed  as  previously  described(122).  Briefly,  reads  were  aligned  
to  the  reference  genome  (Genome  Reference  Consortium  build  37,  human  genome  19)  using  Burrows-­
Wheeler  Alignment  Tool  (BWA),  followed  by  duplicate  removal  using  Picard  tools.  Variant  and  genotype  
calling  were  performed  using  GATK  v3.6  best  practices(123).    
  
Variant  annotation  
Variants  were  annotated  using  the  Analysis  Tool  for  Annotated  Variants(94)  
(https://redmine.igm.cumc.columbia.edu/projects/atav)  and  ANNOVAR(95).    
Key  resources  used  for  variant  annotation  are  listed  in  Supplementary  Appendix  II,  Table  S4.      
   In  addition,  to  facilitate  identification  of  variants  potentially  causal  for  nephropathy  we  utilized  a  
manually  curated  list  of  625  genes  associated  with  Mendelian  forms  of  genitourinary  disease.  This  list  is  
described  in  depth  in  Chapter  I;;  briefly,  it  was  generated  by  our  research  group  in  May  2016  by  querying  
the  Online  Mendelian  Inheritance  in  Man  (OMIM)(87)  and  Orpha.net(88)  databases  for  genes  associated  
with  Mendelian  forms  of  genitourinary  disease,  followed  by  manual  review  of  the  primary  literature  to  
assess  the  strength  of  evidence  supporting  each  gene-­disease  association  and  characterize  the  relevant  
molecular  genetic  and  clinical  attributes  of  the  gene-­disease  pairs.    
The  list  is  provided  in  Supplementary  Appendix  I,  Table  S1  and  is  publicly  available  via  our  
research  group’s  website(92);;  the  genes  and  number  of  exons  uncaptured  by  the  exome  sequencing  
capture  kits  used  in  this  study  are  given  in  Supplementary  Appendix  II,  Table  S5.  
  
Variant  interpretation    
Variants  resulting  from  the  following  analyses  are  listed  in  Supplementary  Appendix  II,  Tables  S7,  S8,  
S15,  and  S18  and  have  been  submitted  to  the  National  Center  for  Biotechnology  Information  ClinVar  




Primary  findings  for  Mendelian  forms  of  nephropathy  
We  prioritized  rare  (global  MAF  ≤1%  in  the  Genome  Aggregation  Database  (gnomAD))  nonsynonymous  
variants  and  canonical  splice  site  variants  occurring  in  the  above  625  nephropathy-­associated  genes  
(Supplementary  Appendix  I,  Table  S1),  and  also  evaluated  such  rare,  predicted  deleterious  variants  in  
other  genes  associated  with  Mendelian  disorders  using  the  OMIM  database(87).  In  addition,  we  analyzed  
sequence  data  for  more  common  (MAF  >1%)  Mendelian  nephropathy-­associated  alleles,  such  as  the  
NPHS2  p.R229Q  allele.  The  NPHS2  p.R229Q  allele  is  known  to  be  causal  for  steroid-­resistant  nephrotic  
syndrome  when  found  in  trans  with  certain  variants  in  the  more  distal  exons(124,  125);;  thus,  for  the  
purposes  of  diagnostic  analysis,  we  noted  only  the  patients  who  harbored  it  with  another  such  pathogenic  
allele  (see  Supplementary  Appendix  II,  Table  S8).    
To  identify  diagnostic  variants,  we  assessed  1)  the  pathogenicity  of  the  variant  per  American  
College  of  Medical  Genetics  (ACMG)  guidelines  for  diagnostic  sequence  interpretation(73)  and  2)  
whether  it  was  explicative  for  the  individual’s  renal  disease,  based  on  the  clinical  information  available.  
The  methods  for  each  of  these  are  detailed  in  the  “Variant-­level  assessment”  and  “Case-­level  
assessment”  sections,  below.  Only  alleles  that  both  were  classified  as  Pathogenic  or  Likely  Pathogenic  
per  ACMG  criteria  and  were  judged  to  be  explicative  for  the  individual’s  renal  disease  were  deemed  
diagnostic.  Diagnostic  variants  were  manually  reviewed  using  the  Integrative  Genomics  Viewer(126);;  
those  which  were  also  suspect  of  being  artefactual  variant  calls  based  on  variant  type  (e.g.,  small  indels)  
or  sequencing  quality  metrics  (single  nucleotide  variants  with  a  genotype  quality  score  ≤30)  were  
confirmed  by  Sanger  sequencing.  
  
Variant-­level  assessment    
As  noted  above,  we  classified  variants  according  to  the  ACMG  guidelines  for  diagnostic  sequence  
interpretation(73).  Supporting  criteria  for  alleles  classified  as  Pathogenic  or  Likely  Pathogenic  at  the  
variant  level  are  provided  in  the  relevant  tables  (Supplementary  Appendix  II,  Table  S8  and  Table  S15).    
Per  this  framework,  variants  for  which  1)  not  all  criteria  were  met  to  qualify  as  Pathogenic  or  Likely  
Pathogenic  or  2)  the  criteria  for  benign  and  pathogenic  were  contradictory  were  classified  as  variants  of  
uncertain  significance  (VUS).  We  then  applied  stringent  filtering  criteria  to  the  observed  VUS  to  assess  
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the  minimal  burden  of  these  variants.  We  considered  individuals  with  heterozygous  genotypes  under  a  
dominant  model  and  those  with  biallelic  (i.e.,  hemizygous,  homozygous,  and  compound  heterozygous)  
genotypes  under  a  recessive  model.  Filtering  criteria  for  each  model  are  summarized  below;;  the  resultant  
variants  are  listed  in  Supplementary  Appendix  II,  Table  S7.    
Model   Dominant   Recessive  
Genotypes   Heterozygous   Biallelic  (homozygous,  hemizygous,    or  compound  heterozygous)  
Population  allele  
frequency  cutoff  a   Zero  (absent)   ≤  0.05%  and  zero  homozygotes    
Variant  types   Nonsense,  frameshift,  splice-­site,  in-­frame  insertion/deletion,  missense  
Predicted  
deleteriousness  
CADD(127)  ≥  20b;;  Missense  variants  –  predicted  damaging  by  3  out  of  3  
missense  meta-­predictors:  MetaSVM(128),  M-­CAP(129),  and  REVEL(130)  
a  Population  allele  frequency  cutoff  was  evaluated  using  the  global  frequency  in  the  Genome  Aggregation  Database  
(gnomAD),  a  database  including  exome  sequence  data  from  123,136  unrelated  population  controls.  The  0.05%  
frequency  cutoff  was  calculated  using  a  previously  published  formula  to  derive  frequencies  for  causal  variants  for  
monogenic  disorders(131),  using  the  following  parameters:  prevalence  ≤  1/10,000,  corresponding  to  the  maximal  
estimated  prevalence  of  common  recessive  monogenic  renal  disorders(132);;  full  penetrance;;  and  each  causal  variant  
accounting  for  no  more  than  5%  of  disease  cases.    
bCADD  ≥  20:  top  1%  deleteriousness  percentile  of  variants,  relative  to  all  possible  single-­nucleotide  substitutions  of  
the  human  genome  (not  applicable  for  insertion/deletion  variants).  Missense  score  cutoffs  were:  MetaSVM  –  D  
(Damaging);;  M-­CAP  –  D  (Damaging);;  REVEL  ≥  0.7  (corresponding  to  exclusion  of  95%  of  benign  variants).  
  
Case-­level  assessment    
Following  identification  of  putatively  pathogenic  variants  (classified  as  Pathogenic  or  Likely  Pathogenic  
per  ACMG  guidelines  (73)),  we  assessed  whether  the  genetic  findings  were  explicative  for  the  individual’s  
renal  disease  via  reviewing  their  available  clinical  data.  For  CUMC  patients,  we  had  access  to  individuals’  
electronic  health  records,  which  we  manually  reviewed  to  assess  whether  the  genetic  findings  were  
explicative  for  the  patient’s  observed  clinical  presentation.  For  AURORA  cases,  we  had  more  limited  
information,  which  included  the  primary  cause  of  renal  disease,  as  classified  by  broad  etiologic  subtype,  
and  the  major  medical  problems,  given  as  clinical  diagnostic  codes,  for  each  individual.  The  individuals  
for  which  the  variants  found  were  explicative  of  their  known  clinical  presentation  were  deemed  diagnostic  
cases  (Supplementary  Appendix  II,  Table  S8).  
For  an  additional  30  patients  (Supplementary  Appendix  II,  Table  S15),  the  putatively  
pathogenic  variants  found  remained  inexplicative  of  their  known  clinical  presentation  following  review.  
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These  alleles  may  in  fact  be  contributory,  but  nonetheless  were  not  deemed  diagnostic  due  to  insufficient  
phenotypic  concordance  based  on  the  clinical  information  available.    
  
Additional  findings  of  renal  relevance  
In  addition  to  assessing  sequence  data  for  variants  in  genes  associated  with  Mendelian  forms  of  
nephropathy,  we  annotated  for  the  APOL1  risk  genotypes  (two  copies  of  the  APOL1  G1  (rs73885139  and  
rs60910145)  and  G2  (rs71785313)  risk  alleles;;  i.e.,  G1/G1,  G1/G2,  or  G2/G2),  as  they  have  been  
reported  to  influence  disease  risk,  prognosis,  and  transplant  outcomes  across  different  forms  of  
nephropathy  (90,  91).  However,  the  presence  of  the  APOL1  risk  genotype  was  considered  independently  
of  the  findings  diagnostic  for  Mendelian  forms  of  nephropathy,  and  thus  not  counted  towards  the  yield  of  
such  diagnostic  variants.      
  
Secondary  findings  
We  assessed  CUMC  patients’  sequence  data  for  pathogenic  variants  in  the  59  genes  recommended  by  
the  ACMG  for  return  as  medically  actionable  secondary  findings  for  individuals  undergoing  genome-­wide  
sequencing(60).  As  the  AURORA  study  protocol  and  consent  did  not  permit  analysis  of  the  cohort  for  
secondary  findings,  we  did  not  perform  this  analysis  for  AURORA  patients.  Per  ACMG  recommendations  
for  analysis  of  secondary  findings(60),  we  noted  only  variants  classified  as  known  pathogenic  (KP)  or  
expected  pathogenic  (EP).    
EP  variants  were  noted  only  among  the  genes  for  which  reporting  EP  as  well  as  KP  variants  has  
been  recommended(60)  and,  per  current  ACMG  recommendations  for  secondary  findings(60),  were  
limited  to  previously  unreported  loss-­of-­function  variants  (LOFs;;  defined  as  nonsense,  frameshift,  and  
canonical  splice  site)  occurring  in  genes  for  which  LOF  is  a  known  mechanism  of  disease.  To  identify  
(KP)  missense  variants,  we  rigorously  curated  missense  variants  previously  reported  pathogenic  (i.e.,  
classified  as  “Pathogenic”  or  “Likely  Pathogenic”  in  ClinVar  and/or  “Disease  Mutation  (DM)”  in  the  Human  
Gene  Mutation  Database).  The  missense  variants  included  here  thus  represent  variants  meeting  the  
criteria  to  be  classified  as  Known  Pathogenic,  which  include  multiple  independent  case  occurrences,  with  
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segregation  amongst  the  families  assessed  and  experimental  evidence  using  well-­established  assays  
supporting  that  the  variant  impairs  the  function  of  the  gene  or  encoded  protein.  
  
Comparison  of  the  diagnostic  yield  of  exome  sequencing  versus  that  using  more  targeted  genetic  
testing    
  
To  further  examine  the  diagnostic  utility  of  exome  sequencing  for  patients  with  kidney  disease,  we  
evaluated  the  diagnostic  yield  found  in  our  study  to  the  yield  which  may  result  from  applying  more  
targeted  approaches.  To  this  aim,  we  compared  the  diagnostic  yield  observed  using  exome  sequencing  in  
the  combined  AURORA-­CUMC  cohort  to  that  potentially  obtained  used  the  more  targeted  modality  of  
phenotype-­driven  gene  panels.    
Given  that  clinicians  may  vary  in  how  they  classify  patients’  phenotypes  and  which  gene  panels  
they  choose  to  order  for  that  phenotype,  we  evaluated  the  yield  of  targeted  panels  for  congenital  or  cystic  
renal  disease,  glomerulopathy  (including  the  subtypes  of  Alport  syndrome  and  thin  basement  membrane  
disease  and  focal  segmental  glomerulosclerosis),  and  tubulointerstitial  disease  across  major  clinical  
diagnostic  categories  of  kidney  disease,  represented  in  the  AURORA-­CUMC  cohort  (see  Table  7).  The  
phenotypes  targeted  by  these  panels  are  among  the  leading  indications  for  genetic  testing  among  
patients  suspected  to  have  monogenic  forms  of  nephropathy(19,  133).  Moreover,  these  panels  include  
the  most  prevalent  monogenic  forms  of  nephropathy  detected  in  our  cohort  (see  Figure  5):  autosomal  
dominant  polycystic  kidney  disease  due  to  mutations  in  PKD1  and  PKD2  (cystic  renal  disease  panels);;  
glomerulopathy  due  to  mutations  in  COL4A3,  COL4A4,  and  COL4A5  (glomerulopathy  panels);;  and  
UMOD-­associated  tubulointerstitial  disease  (tubulointerstitial  disease  panels).  
As  the  panels  for  these  phenotypes  can  also  vary  between  different  genetic  testing  providers,  we  
assessed  offerings  from  three  different  clinical  laboratories.  When  evaluating  diagnostic  yield  of  targeted  
testing  for  each  phenotype,  we  conservatively  used  the  union  of  the  panels  from  the  three  different  clinical  
genetic  testing  providers  assessed  –  i.e.,  we  defined  positive  cases  as  those  for  which  the  causal  gene  
detected  via  exome  sequencing  was  included  on  any  of  the  three  targeted  panels  included  for  the  given  
phenotype.  Similarly,  for  the  comparison,  we  assumed  equivalent  technical  sensitivity  and  specificity  for  
each  testing  modality,  although  these  may  likewise  vary  in  practice.  Gene  panels  were  identified  via  
querying  the  National  Institutes  of  Health  Genetic  Testing  Registry  (GTR;;  see  
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https://www.ncbi.nlm.nih.gov/gtr/)  for  gene  panels  associated  with  each  of  the  above  broad  kidney  
disease  phenotypes.    
The  panels  used,  along  with  the  provider,  number  of  genes  tested,  and  GTR  test  identification  number,  
are  provided  in  Supplementary  Appendix  II,  Table  S6.  The  results  of  the  comparison  are  shown  in  
Table  10.  
  
Statistical  analysis    
Diagnostic  yield  was  calculated  using  counts  of  Pathogenic  and  Likely  Pathogenic  variants.  We  assessed  
the  yield  for  each  clinical  diagnostic  category  using  logistic  regression  model  (R  function  GLM),  with  
diabetic  nephropathy,  where  yield  was  lowest,  as  reference.  In  addition,  we  ran  models  adjusting  for  
cohort,  sex,  age  at  time  of  study  entry,  and  self-­identified  non-­European  ancestry.  Pairwise  comparisons  




Cohort  characteristics    
The  characteristics  of  the  3,315  patients  sequenced  are  shown  in  Table  7.  The  cohort  was  predominantly  
adult  (3,037  (91.6%)  cases  aged  over  21y);;  1,179  (35.6%)  patients  were  of  self-­identified  non-­European  
ancestry.  The  patients  represented  all  major  categories  of  nephropathy(16-­18),  including  281  (8.5%)  with  
nephropathy  “of  unknown  etiology.”  Altogether,  2,144  (64.7%)  patients  had  reached  ESRD:  all  1,128  
AURORA  patients  and  1,016  (46.5%)  of  the  2,187  CUMC  patients.  Family  history,  available  only  for  
CUMC  patients,  was  positive  for  kidney  disease  in  28.3%  (619/2,187)  cases,  a  similar  proportion  as  




Table  7.  Clinical  characteristics  of  the  3,315  patients  sequenced  
Cohort   AURORA   CUMC   AURORA-­CUMC  
No.  of  patients   1,128   2,187   3,315  
Characteristic   N   %   N   %   N   %  
Age  at  time  of  study  entry  (yr)  
0-­21     0   0   278   12.7   278   8.4  
22-­44     0   0   713   32.6   713   21.5  
45-­64     560   49.6   800   36.6   1360   41.0  
65+     568   50.4   396   18.1   964   29.1  
Sex  
Female   427   37.9   945   43.2   1372   41.4  
Male   701   62.1   1242   56.8   1943   58.6  
Race/Ethnicity  
White  European   1023   90.7   1113   50.9   2136   64.4  
Hispanic   50   4.4   435   19.9   485   14.6  
Black/African  American   18   1.6   330   15.1   348   10.5  
Asian   20   1.8   224   10.2   244   7.4  
Other/Unspecified   17   1.5   85   3.9   102   3.1  
Clinical  diagnosis  
Congenital  or  cystic  renal  disease   159   14.1   372   17.0   531   16.0  
Glomerulopathy   231   20.5   1180   54.0   1411   42.6  
Diabetic  nephropathy   184   16.3   186   8.5   370   11.2  
Hypertensive  nephropathy   193   17.1   126   5.8   319   9.6  
Tubulointerstitial  disease   212   18.8   32   1.5   244   7.4  
Other   50   4.4   109   5.0   159   4.8  
Nephropathy  "of  unknown  etiology"     99   8.8   182   8.3   281   8.5  
Reached  ESRDa   1128   100.0   1016   46.5   2144   64.7  
Positive  family  history  for  kidney  diseaseb   -­   -­   619   28.3   -­   -­  
  
aESRD:  End-­stage  renal  disease.    
Per  the  AURORA  study  design,  all  patients  had  reached  ESRD  at  the  time  of  study  entry.    
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Genetic  findings  and  diagnostic  yield    
We  detected  diagnostic  variants  in  307  of  the  3,315  (9.3%)  probands,  encompassing  66  distinct  
monogenic  disorders  (Table  8;;  Supplementary  Appendix  II,  Table  S8  and  Table  S9).  Of  these  patients,  
206  (67%)  had  an  autosomal  dominant  disease,  42  (14%)  an  autosomal  recessive  disease,  and  54  (18%)  
an  X-­linked  disease  (Supplementary  Appendix  II,  Table  S10).  The  remaining  5  positive  cases  (2%)  had  
dual  molecular  diagnoses  (Supplementary  Appendix  II,  Table  S11).  The  343  diagnostic  variants  
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detected  encompassed  167  protein-­truncating  variants  and  176  non-­truncating  variants;;  202  variants  
(59%)  had  been  previously  reported  as  pathogenic  and  141  variants  (41%)  had  not  at  the  time  of  analysis  
(Supplementary  Appendix  II,  Table  S10).  The  majority  (228/343;;  66%)  of  diagnostic  variants  were  
absent  from  population  control  databases  (Supplementary  Appendix  II,  Figure  S1).    
   Of  the  66  distinct  monogenic  disorders  detected,  six  accounted  for  198  (63%)  of  the  312  genetic  
diagnoses  (Figure  5,  Panel  A):  autosomal  dominant  polycystic  kidney  disease  (ADPKD)  due  to  mutations  
in  PKD1  (N=75)  and  PKD2  (N=22),  glomerulopathy  due  to  mutations  in  COL4A3  (N=27),  COL4A4  
(N=21),  and  COL4A5  (N=44),  and  UMOD-­associated  tubulointerstitial  disease  (N=9).  However,  the  
majority  of  genetic  disorders  (39/66;;  59%)  identified  were  unique  to  a  single  patient  (Table  8).  Moreover,  
for  21  genes,  diagnostic  variants  were  detected  in  patients  from  different  clinical  categories  (Figure  5,  
Panel  B;;  Table  8;;  Supplementary  Appendix  II,  Table  S9;;  Table  S12).  For  example,  only  35  (38%)  of  
the  91  patients  with  diagnostic  variants  in  COL4A3,  COL4A4,  or  COL4A5  were  clinically  diagnosed  with  
the  associated  disorder,  Alport  syndrome  or  thin  basement  membrane  disease;;  the  remaining  70  patients  
clinically  diagnosed  with  focal  segmental  glomerulosclerosis  (FSGS;;  N=15  (16%)),  unspecified  
“glomerulopathy”  (N=20  (22%))  or  “congenital  renal  disease”  (N=4  (4%)),  hypertensive  nephropathy  (N=3  
(3%)),  and  nephropathy  “of  unknown  etiology”  (N=14  (15%))  (Figure  6).     
Diagnostic  yield  (Table  8)  was  highest  among  patients  with  a  clinical  diagnosis  of  congenital  or  
cystic  renal  disease  (127/531  (23.9%))  and  patient  with  nephropathy  “of  unknown  etiology”  (48/281  
(17.1%)).  Diagnostic  variants  were  found  in  94  of  the  619  CUMC  (15.2%)  patients  with  a  positive  family  
history  vs.  in  75  of  the  1,568  (4.7%)  patients  without  one.  Diagnostic  yield  was  7.2%  (101/1411)  for  
patients  clinically  diagnosed  with  glomerulopathy,  4.5%  (11/244)  for  patients  with  tubulointerstitial  
disease,  2.5%  (8/319)  for  patients  with  hypertensive  nephropathy,  1.6%  (6/370)  for  patients  with  diabetic  
nephropathy,  and  3.8%  (6/159)  for  those  with  nephropathy  attributed  to  other  causes.  Diagnostic  yield  
was  higher  in  the  AURORA  cohort,  reflecting  an  enrichment  for  autosomal  dominant  polycystic  kidney  
disease  patients;;  excluding  these  cases,  yield  did  not  differ  significantly  between  cohorts  
(Supplementary  Appendix  II,  Table  S13).  Altogether,  a  positive  family  history  and  the  clinical  diagnoses  
of  congenital  or  cystic  renal  disease  and  nephropathy  “of  unknown  etiology”  were  independent  predictors  





























































































































































Figure  6.  Clinical  diagnostic  spectrum  of  patients  with  diagnostic  variants  in  COL4A3-­5  
  
  
     
  
The  clinical  diagnostic  spectrum  of  the  patients  with  diagnostic  variants  in  the  COL4A3,  COL4A4,  and  
COL4A5  genes  is  shown  above.  In  total,  variants  in  these  genes  accounted  for  92  genetic  diagnoses  in  
91  patients:  as  a  single  trait  in  90  patients  and  as  a  dual  molecular  diagnosis  in  one  patient,  who  had  
diagnostic  variants  in  both  COL4A4  and  COL4A5  (see  Supplementary  Appendix  II,  Table  S11).  Clinical  
diagnoses  are  abbreviated  as  follows:  GN:  glomerulopathy;;  AS  or  TBMD:  Alport  syndrome  or  thin  
basement  membrane  disease,  a  subtype  of  glomerulopathy;;  FSGS:  focal  segmental  glomerulosclerosis,  
a  subtype  of  glomerulopathy;;  HTN:  hypertensive  nephropathy;;  NOS:  not  otherwise  specified;;  Unknown:  
nephropathy  “of  unknown  etiology.  
AS/TBMD Congenital renal disease, NOS
FSGS GN, Other or U specified





















































































































































































































































Variants  of  uncertain  significance  (VUS)  
Variant-­level  VUS  
We  identified  on  average  6.6  VUS  per  individual  (range  3-­8),  with  85.9%  of  individuals  having  at  least  one  
VUS.  Novel,  rare  missense  variants  in  autosomal  dominant  nephropathy-­associated  genes  accounted  for  
the  majority  of  these  cases,  with  77.6%  of  individuals  with  VUS  harboring  at  least  one  such  variant.  The  
majority  of  recurrent  VUS  were  previously  reported  variants  listed  as  disease  causal  in  clinical  variant  
databases  (i.e.,  classified  as  “Pathogenic”  or  “Likely  Pathogenic”  in  ClinVar  and/or  “Disease  Mutation  
(DM)”  in  the  Human  Gene  Mutation  Database)  whose  allele  frequencies  exceeded  that  expected  for  the  
associated  disorder,  based  on  known  disease  prevalence  and  allelic  heterogeneity.  We  then  applied  
stringent  filtering  criteria  (see  Methods)  to  the  variants  observed  to  estimate  the  minimal  burden  of  VUS.  
This  yielded  1,088  heterozygous  genotypes  and  29  biallelic  genotypes;;  altogether,  927  (28.0%)  of  the  
3,315  individuals  in  the  AURORA-­CUMC  cohort  harbored  at  least  one  such  stringently  filtered  VUS  
(Supplementary  Appendix  II,  Table  S7).    
Case-­level  VUS    
In  an  additional  30  (0.9%)  persons,  we  detected  putatively  diagnostic  variants  for  renal  disorders  
inexplicable  for  the  patient's  known  clinical  phenotype  (Supplementary  Appendix,  Table  S15).  These  
cases  involved  dual  genetic  diagnoses  that  may  contribute  to  a  complex  clinical  presentation  or  represent  
potential  phenotypic  expansions  or  clinical  misclassification  of  nephropathy,  such  as  with  the  putatively  
pathogenic  COL4A3  and  COL4A4  variants  detected  in  seven  AURORA  patients  reported  to  have  
tubulointerstitial  disease.  These  cases  would  require  additional  clinical  follow-­up  to  reconcile  the  genetic  
findings  with  the  reported  phenotype.  
  
Comparison  of  the  diagnostic  yield  of  exome  sequencing  versus  targeted  panel  testing  
To  further  assessed  the  diagnostic  utility  of  exome  sequencing  for  patients  with  kidney  disease,  we  
compared  the  diagnostic  yield  observed  using  exome  sequencing  in  the  combined  AURORA-­CUMC  
cohort  versus  that  potentially  obtained  using  more  targeted  testing.  The  methodology  for  this  analysis  is  












































































































































































































































Other  findings  of  renal  relevance    
We  observed  the  APOL1  risk  genotypes(134,  135)  in  100  of  the  348  (29%)  African  American  and  36  of  
the  485  (7%)  Hispanic  cases  versus  in  173  of  1219  (14%)  African  American  and  14  of  511  (3%)  Hispanic  
controls  (Fisher  exact  test:  African  American:  OR=2.4  [1.8,  3.3],  P=1.9x10-­9;;  Hispanic:  OR=2.8  [1.5,  5.8],  
P=7.5x10-­4).  The  APOL1  risk  genotypes  were  frequently  observed  amongst  patients  clinically  diagnosed  
with  glomerulopathy  (79/363  (22%)),  particularly  FSGS  (56/116  (48%)),  hypertensive  nephropathy  (19/81  
(23%)),  and  nephropathy  “of  unknown  etiology”  (19/78  (24%))  (Supplementary  Appendix  II,  Table  S16).  
Six  of  the  136  (4.4%)  cases  with  the  APOL1  risk  genotypes  also  had  diagnostic  variants  for  a  Mendelian  
etiology  of  kidney  disease  (Supplementary  Appendix  II,  Table  S17).    
  
Clinical  implications  of  genetic  diagnoses  in  the  CUMC  cases    
For  the  167  CUMC  patients  with  a  genetic  diagnosis,  we  utilized  the  more  detailed  clinical  data  available  
to  assess  the  diagnostic  utility  and  potential  implications  for  clinical  management  (Table  11;;  
Supplementary  Appendix  II,  Table  S8).    
In  the  majority  of  cases  (122;;  73%),  the  genetic  diagnosis  gave  novel  clinical  insight.  For  65  
patients,  it  identified  a  specific  etiology  within  the  broader  category  of  clinically  suspected  disease,  such  
as  pinpointing  the  precise  genetic  subtype  of  FSGS  or  cystic  disease.  In  18  patients,  the  genetic  findings  
reclassified  the  disease,  e.g.,  reclassified  FSGS  to  COL4A3-­5-­associated  nephropathy.  Finally,  exome  
sequencing  identified  a  molecular  etiology  for  the  patient’s  nephropathy  in  39  patients  referred  with  
nephropathy  “of  unknown  etiology.”  The  22  different  monogenic  disorders  detected  in  this  group  spanned  
the  major  categories  of  renal  disease,  and  the  majority  (11  of  22;;  50%)  were  singleton  cases  (Table  11;;  
Supplementary  Appendix  II,  Table  S8).  Patients  with  nephropathy  “of  unknown  etiology”  accounted  for  
3  of  the  5  dual  molecular  diagnoses  observed  in  the  whole  cohort,  consistent  with  previous  observations  
that  dual  molecular  diagnoses  cause  ambiguous  and  complex  phenotypes  (Supplementary  Appendix  II,  
Table  S11)(136).      
In  the  remaining  45  (27%)  positive  cases,  the  genetic  findings  confirmed  the  clinical  diagnoses,  
encompassing  12  different  monogenic  nephropathies,  including  COL4A3-­5-­associated  nephropathy  and  
ADPKD.  Nonetheless,  for  34  (76%)  cases,  the  genotype-­level  knowledge  provided  additional  clinical  
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insight,  including  estimating  the  risk  of  nephropathy  progression  and/or  guiding  family  counseling  and  
donor  selection  for  transplantation  (Table  11;;  Supplementary  Appendix  II,  Table  S8).    
For  88  (53%)  of  the  167  patients,  the  genetic  diagnosis  would  initiate  subspecialty  referral  and  
evaluation  for  previously  unrecognized  extra-­renal  features  of  the  associated  disease,  spanning  15  
different  medical  specialties  (Supplementary  Appendix  II,  Table  S8).  For  84  patients  (50%),  the  genetic  
diagnosis  would  inform  therapy,  such  as  disfavoring  immunosuppression  among  patients  found  to  have  
monogenic  forms  of  FSGS,  referral  for  clinical  trials  targeted  to  the  genetic  disorder  identified,  or  
institution  of  tailored  therapies,  such  as  thiazide  diuretics  and  a  high  citrate  diet  for  patients  with  Dent  
disease.  
  
Table  11.  Diagnostic  utility  and  clinical  implications  of  genetic  findings  in  the  167  positive  CUMC  
cases  
  













No.  (%)  of  patients  
where  the  genetic  
diagnosis  had  
implications  for  clinical  
managementa  
Confirm  suspected  hereditary  
etiology   45   12   5   34  (76)  
Discern  specific  sub-­etiology  
within  broader  clinical  disease  
category  
65   36   24   58  (89)  
Reclassify  disease   18   11   7   18  (100)  
Identify  molecular  etiology  for  
undiagnosed  case   39   22   11   39  (100)  
Total   167   55b   35b   149  (89)  
  
a  Implications  for  clinical  management  included:  informing  prognosis  (e.g.,  regarding  disease  severity  and/or  
transplantation),  initiating  referral  for  subspecialty  care,  and/or  advising  choice  of  therapy,  such  as  use  or  avoidance  
of  agents  and/or  referral  to  clinical  trials  for  therapies  targeted  to  the  underlying  genetic  disease.  




We  detected  pathogenic  variants  in  16  of  the  59  ACMG  medically  actionable  genes  in  34  of  the  2,187  
(1.5%)  CUMC  patients  (Supplementary  Appendix  II,  Table  S18).  Review  of  the  electronic  health  
records  of  these  persons  revealed  that  26  (76%)  of  them  had  a  personal  and/or  family  history  of  clinical  
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features  consistent  with  the  associated  ACMG  59  disorder  (Table  12;;  Supplementary  Appendix  II,  
Table  S18).    
  
Table  12.  Clinical  concordance  among  cases  with  ACMG  59  genetic  findings    
  
Concordance  of  Known  Clinical  Features    
with  ACMG  59  Genetic  Diagnosis  
No.  of  
individuals   Rate  (%)  
Consistent  personal  features   19   56  
            Highly  specific  clinical  diagnosis   5   15  
            Suggestive  clinical  features   14   41  
            Consistent  clinical  features  and  positive  family  history   6   32a  
Positive  family  history  only   7   21  
Consistent  personal  features  and/or  family  history   26   76  
No  known  supportive  clinical  features   8   24  
Total   34   -­  
a  Percentage  with  respect  to  the  total  number  of  individuals  with  consistent  personal  features,  N=19.  
  
We  found  5  of  the  34  (14.7%)  individuals  had  diagnoses  that  were  highly  specific  for  the  
associated  ACMG  59  genetic  diagnosis  (e.g.,  early-­onset  colon  and  endometrial  cancer  in  the  context  of  
an  MSH2  variant;;  familial  hypercholesterolemia  with  LDLR  mutation)  and  14  (41%)  had  suggestive  
clinical  features  potentially  consistent  with  the  associated  ACMG  59  diagnosis  (e.g.,  prolonged  QT  
interval  in  the  context  of  an  SCN5A  mutation;;  prostate  cancer  in  a  male  with  a  BRCA2  mutation).  Of  these  
19  individuals,  6  (31%)  had  a  concordant  family  history.    
As  many  of  the  ACMG  59  disorders  have  late  onset  and  may  not  have  yet  manifested  in  the  
proband,  we  also  checked  for  a  compatible  family  history  of  disease.  An  additional  7  (21%)  individuals  
who  did  not  personally  manifest  signs  of  the  associated  ACMG  59  gene  condition  had  a  positive  family  
history  (e.g.,  multiple  relatives  with  early-­onset  breast  cancer  in  the  context  of  a  BRCA2  mutation).  All  of  
these  7  individuals  had  variants  in  genes  associated  with  hereditary  cancer  predisposition  (BRCA2:  N=4;;  
PMS2:  N=2;;  MSH6:  N=1);;  importantly,  6  of  these  7  individuals  were  aged  40y  or  under,  such  that  the  
associated  disease  may  still  manifest.  The  remaining  8  (24%)  of  individuals  had  no  documented  clinical  
features  supportive  of  the  ACMG  59  condition;;  however,  4  of  these  8  individuals  had  not  undergone  the  
relevant  diagnostic  studies  (e.g.,  no  record  of  cardiac  ECG  and/or  echocardiography  in  the  context  of  
mutations  for  hereditary  cardiomyopathy).  
 
  46  
   These  secondary  findings  would  require  targeted  subspecialty  referral  and  workup,  such  as  
oncologic  evaluation  and  mammography  for  patients  with  BRCA2  mutations  detected.  Remarkably,  for  
each  patient,  the  ACMG  59  findings  also  had  implications  for  nephrological  care,  such  as  informing  use  of  
immunosuppression  in  patients  with  findings  for  hereditary  cancers,  or  influencing  dialysis  and/or  diuretic  
prescriptions  in  patients  found  to  have  a  genetic  predisposition  to  cardiac  arrhythmias  (Supplementary  
Appendix  II,  Table  S18).    
  
DISCUSSION  
In  the  present  ES  study  of  an  ethnically  diverse,  largely  adult  combined  cohort  of  3,315  chronic  kidney  
disease  cases,  we  detected  diagnostic  variants  in  307  (9.3%)  persons.  This  yield  is  comparable  to  that  
observed  for  cancer,  where  genomic  diagnostics  are  routinely  used(7,  8,  137).  We  identified  66  distinct  
monogenic  disorders,  with  a  high  rate  of  singleton  genetic  diagnoses  and,  within  single  genetic  
diagnoses,  patients  spanning  a  range  of  clinical  categories.  Moreover,  we  noted  diagnostic  variants  in  48  
(17.1%)  of  the  281  patients  with  nephropathy  “of  unknown  etiology,”  a  patient  population  who  may  
comprise  up  to  15%  of  incident  end-­stage  renal  disease  population(16-­18)  and  for  whom  traditional  
diagnostics  are  often  unrevealing  and/or  contraindicated.    
   Overall,  these  findings  emphasize  the  high  genetic  and  phenotypic  heterogeneity  of  hereditary  
nephropathies,  and  demonstrate  the  extent  to  which  genetic  testing  can  help  to  resolve  clinical  diagnostic  
challenges.  For  57  of  the  167  (34%)  cases  reviewed,  the  genetic  findings  reclassified  disease  or  provided  
an  etiology  for  undiagnosed  nephropathy,  emphasizing  the  utility  of  the  “agnostic”  approach  of  exome  
sequencing,  which  assesses  genes  that  otherwise  may  have  gone  unevaluated  using  single-­gene  or  
phenotype-­driven  panel  testing.  We  also  found  that  these  more  targeted  approaches  would  constitute  an  
effective  first-­line  alternative  for  the  patients  with  relatively  specific  clinical  presentations,  such  as  ADPKD.  
Nonetheless,  as  demonstrated  by  the  three  patients  clinically  diagnosed  with  nephropathy  “of  unknown  
etiology”  with  diagnostic  PKD1  variants,  broader  genetic  testing  can  help  resolve  atypical  cases  
(Supplementary  Appendix  II,  Section  S2).  Moreover,  analysis  of  all  307  patients  diagnosed  using  




   Detailed  case-­level  review  showed  that  for  the  majority  of  patients,  the  genetic  diagnoses  
provided  novel  clinical  insight.  Moreover,  our  results  highlight  the  potential  of  genetic  findings  to  alter  
medical  management  through  initiating  multidisciplinary  care  and/or  advising  choice  of  therapy.  For  
example,  56  (62%)  of  the  91  patients  with  mutations  in  COL4A3,  COL4A4,  COL4A5  were  not  clinically  
diagnosed  with  the  classically  associated  nephropathies,  Alport  syndrome  or  thin  basement  membrane  
disease.  For  these  patients,  the  genetic  diagnosis  would  indicate  ophthalmologic  and  otolaryngologic  
referral,  and,  among  the  15  (16%)  cases  clinically  diagnosed  with  FSGS,  disfavor  immunosuppressive  
therapy.  Conversely,  negative  exome  sequencing  results  can  also  inform  clinical  management.  For  
example,  among  patients  with  FSGS,  the  absence  of  genetic  mutations  in  structural  components  of  the  
glomerular  basement  membrane  would  support  an  acquired,  immunologic  etiology  and  use  of  
immunosuppression(138).  
   We  detected  known  or  expected  pathogenic  variants  in  the  ACMG  59  medically  actionable  genes  
in  34  (1.5%)  of  the  2,187  cases  assessed,  consistent  with  prior  studies  of  unselected  adults(82,  139).  
While  classically  viewed  as  secondary  findings,  the  ACMG  59  genetic  findings  had  implications  for  renal  
care  in  all  cases.  Conversely,  patients’  nephropathy  could  also  modify  the  management  of  these  genetic  
diseases,  e.g.,  influencing  choice  of  chemotherapeutic  agent  for  patients  with  hereditary  cancers.  These  
results  highlight  both  the  value  and  challenges  of  genome-­wide  assessment,  where  one  may  detect  
genetic  variants  unrelated  to  the  disorder  under  evaluation,  which  nonetheless  can  shape  its  
management.  As  the  majority  of  patients  undergoing  diagnostic  genomic  sequencing  opt  to  receive  
findings  in  genes  unrelated  to  the  primary  test  indication(140),  our  data  reinforce  the  growing  need  for  
multidisciplinary  collaborations  to  address  such  “secondary”  findings.    
   Known  limitations  of  exome  sequencing  include  suboptimal  coverage  of  some  clinically  relevant  
regions,  such  as  the  mitochondrial  genome  or  the  duplicated  regions  of  the  PKD1  gene(141).  The  inability  
to  detect  intronic  and  copy  number  variants  represent  additional  limitations(142).  Consequently,  our  study  
probably  underestimates  the  overall  burden  of  genetic  disorders  among  patients  with  nephropathy.    
Beyond  such  technical  limitations,  our  study  illustrates  the  broader  challenges  of  implementing  exome  
sequencing  among  ethnically  diverse  adults,  where  biosamples  from  family  members  and  antecedent  
health  records  are  often  unavailable.  Familial  testing  can  increase  diagnostic  yield  relative  to  proband-­
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only  exome  sequencing(143).  Moreover,  as  illustrated  in  30  cases,  putatively  pathogenic  variants  were  
detected  but  either  did  not  explain  the  patient’s  known  renal  phenotype  or  could  not  be  fully  adjudicated  
due  to  lack  of  additional  clinical  information  and/or  supporting  familial  studies.  Such  variants  may  
represent  coexistent  genetic  diseases  unrelated  to  the  condition  evaluated,  novel  phenotypic  expansions,  
or  simple  clinical  misclassifications.  We  anticipate  their  interpretation  –  and  resultant  need  for  deeper  
phenotyping,  including  associated  subspecialty  referrals  –  will  challenge  geneticists  and  medical  
specialists.    
   Recent  publications  have  highlighted  the  need  to  “reconsider  disease  ontology  on  the  basis  of  
molecular  classifiers”  to  support  precision  medicine  and  augment  clinical  trials  in  nephrology(144,  145).  
Our  findings  support  the  diagnostic  utility  of  ES  across  different  clinical  categories  of  kidney  disease,  and  
point  to  the  novel  utility  of  genomic  sequencing  to  identify  otherwise  medically  actionable  findings  which  
can  also  inform  clinical  care.  These  results  highlight  the  potential  of  genetic  testing  to  accurately  direct  
patients  to  relevant  clinical  trials  and  targeted  therapies,  encouraging  similar  investigations  across  other  
subspecialties.  







In  the  prior  chapters,  we  evaluated  the  utility  of  exome  sequencing  (ES)  for  kidney  disease  and  the  
challenges  accompanying  its  broader  use.  We  first  generated  a  manually  curated  list  of  genes  associated  
with  Mendelian  kidney  and  genitourinary  diseases,  spanning  the  major  clinical  categories  of  nephropathy.  
We  then  evaluated  the  prevalence  of  candidate  pathogenic  variants  in  these  genes  using  different  
analytic  pipelines,  and  the  associated  burden  for  variant  interpretation  and  clinical  follow  up.  We  then  
went  on  to  investigate  the  broader  value  of  ES  in  nephrology  through  performing  ES  and  diagnostic  
analysis  of  a  large,  all-­cause  CKD  cohort.  We  assessed  the  implications  of  diagnostic  and  otherwise  
clinically  relevant  findings  for  both  nephrologic  and  non-­nephrologic  management,  as  well  as  the  merits  of  
applying  ES  versus  more  targeted  testing  approaches.  These  investigations  highlighted  both  the  value  of  
and  challenges  associated  with  using  ES  as  a  first-­line  genetic  testing  modality  in  nephrology.  Here,  we  
discuss  the  major  conclusions  emerging  from  these  analyses  and  avenues  for  future  investigation.    
  
Characterizing  the  genetic  and  phenotypic  heterogeneity  of  kidney  diseases  through  ES    
Our  generation  of  a  nephropathy-­associated  gene  list  and  subsequent  diagnostic  analyses  each  
illustrate  the  substantial  genetic  heterogeneity  of  Mendelian  kidney  and  genitourinary  diseases.  On  review  
of  gene-­disease  databases  and  the  primary  literature,  we  identified  625  genes  associated  with  these  
disorders,  with  each  clinical  disease  category  housing  a  diverse  range  of  single-­gene  etiologies,  each  of  
which  in  turn  displayed  its  own  distinct  molecular  genetic  features.  Similarly,  in  our  diagnostic  analysis  of  
a  large,  ethnically  diverse  all-­cause  CKD  cohort,  we  detected  66  different  monogenic  disorders  in  the  307  
positive  cases.  Strikingly,  the  majority  of  the  disorders  detected  were  unique  to  a  single  patient,  and  the  
majority  of  recurrent  genetic  diagnoses  spanned  patients  belonging  to  different  clinical  diagnostic  
categories.  Accordingly,  we  found  that  the  majority  of  positive  cases  on  ES  would  be  left  undiagnosed  by  
targeted  phenotype-­driven  gene  panel  testing,  regardless  of  which  panel  was  selected.  These  findings  
highlight  the  diagnostic  advantages  of  ES  in  the  context  of  an  etiologically  complex  and  clinically  
heterogeneous  disorder,  especially  for  cases  with  ambiguous  and/or  nondiagnostic  phenotypes,  as  
illustrated  by  the  high  diagnostic  yield  observed  among  patients  with  nephropathy  “of  unknown  etiology.”  
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However,  this  genetic  and  phenotypic  heterogeneity  can  also  impede  achieving  a  genetic  
diagnosis  via  ES.  The  CKD  cases  assessed  included  those  with  clinical  presentations  highly  specific  for  
well-­characterized  single-­gene  etiologies  of  nephropathy,  but  no  diagnostic  variants  in  the  known  
disease-­associated  genes  on  ES  analysis  (e.g.,  a  proband  with  early-­onset  hematuria  and  hearing  loss  
and  glomerular  basement  lamellation  on  renal  biopsy,  strongly  supportive  of  a  diagnosis  of  Alport  
syndrome(34),  but  with  no  compelling  variants  in  COL4A3-­5  found  on  ES).  Beyond  the  possibility  of  
variants  missed  due  to  technical  limitations  of  ES(146,  147),  these  null  findings  may  reflect  the  fact  that  
the  causal  variant  lies  in  a  yet-­undiscovered  gene.  ES  has  shown  that  many  Mendelian  nephropathies  are  
in  fact  more  genetically  heterogeneous  than  originally  thought.  For  example,  while  autosomal  dominant  
polycystic  kidney  disease  has  long  been  thought  to  result  solely  from  mutations  in  two  genes,  PKD1  and  
PKD2,  recent  ES  studies  have  revealed  additional  causal  loci,  such  as  GANAB(49)  and  DNAJB11(148),  
resolving  initially  null  cases.  Thus,  while  the  sensitivity  of  diagnostic  ES  analysis  is  limited  by  current  
knowledge,  the  genome-­wide  of  sequencing  itself  facilitates  reanalysis  for  such  newly  discovered  genes,  
an  advantage  relative  to  more  targeted  genetic  testing  approaches.    
   Conversely,  the  unbiased  approach  of  ES  can  result  in  putatively  pathogenic  variants  in  
nephropathy-­associated  genes  being  found  in  a  proband  with  a  wholly  disparate  renal  disease  phenotype  
or  in  a  self-­declared  healthy  individual.  In  some  instances,  these  cases  can  be  resolved  through  clinical  
follow-­up  as  representing  instances  of  initial  misphenotyping.  As  demonstrated  in  Chapter  II,  the  limited  
capacity  of  traditional  diagnostics  to  distinguish  between  distinct  molecular  etiologies  can  lead  to  ES  
reclassifying  patients’  disease,  e.g.,  patients  presumed  to  have  glomerulopathy  instead  found  to  have  the  
renal  tubulopathy  of  Dent  disease,  reflecting  that  proteinuria  and  glomerulosclerosis  can  be  seen  in  both  
disorders(149,  150).  Similarly,  in  Chapter  I,  we  found  on  review  of  the  electronic  health  record  of  a  self-­
declared  “healthy  control”  with  a  NF1  variant  manually  classified  as  Pathogenic  that  this  person  in  fact  
was  clinically  diagnosed  with  the  associated  disease,  Neurofibromatosis  1.    
   However,  in  many  cases,  clinical  follow-­up  reveals  features  that  are  potentially  consistent  but  
insufficiently  specific,  or  does  not  unearth  any  consistent  clinical  features  whatsoever.  Thus,  in  Chapter  I,  
we  found  self-­declared  healthy  adults  with  variants  classified  as  Pathogenic  or  Likely  Pathogenic  for  
early-­onset,  syndromic  Mendelian  nephropathies  who  on  electronic  health  record  review  harbored  
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multiple  features  compatible  with  the  associated  disorder,  but  which  could  also  result  from  other  causes,  
thereby  necessitating  additional  clinical  evaluation.  Similarly,  in  Chapter  II,  we  found  individuals  with  
Pathogenic  or  Likely  Pathogenic  for  disorders  inexplicative  of  their  known  renal  disease,  which  remained  
unreconciled  upon  case-­level  review.  When  found  in  a  kidney  disease  case,  such  findings  could  be  
interpreted  as  novel  phenotypic  expansions  of  the  given  monogenic  nephropathy,  but  would  require  
additional  case  occurrences  to  definitively  establish  the  association.  Their  presence  in  an  apparently  
unaffected  individual  poses  a  perhaps  even  greater  interpretative  challenge.  Under  current  diagnostic  
sequence  interpretation  guidelines(73),  observation  of  a  variant  in  a  healthy  adult  is  considered  strong  
evidence  against  its  pathogenicity.  However,  for  many  Mendelian  kidney  disorders,  penetrance  and  
expressivity  are  poorly  characterized;;  moreover,  individuals  with  renal  disease  can  display  subtle  
symptoms  or  be  altogether  clinically  silent,  such  that  ascertaining  true  affectation  status  can  be  
challenging.  Thus,  it  can  difficult  to  confidently  ascertain  whether  the  genetic  variant  in  question  is  benign  
or  instead  reflects  a  more  complex  genetic  disease  model.  These  complexities  point  to  the  need  for  large  
studies  integrating  genetic  and  detailed,  longitudinal  phenotypic  data  from  both  disease  cases  and  
controls  to  help  elucidate  the  genetic  architecture  and  phenotypic  spectrum  of  monogenic  nephropathies.    
  
Challenges  of  diagnostic  sequence  interpretation  in  the  context  of  broadening  ES  use    
As  discussed  above,  the  genome-­wide  scope  of  ES  increases  diagnostic  sensitivity,  especially  
the  context  of  the  high  genetic  and  phenotypic  heterogeneity  displayed  by  many  Mendelian  renal  
disorders.  However,  this  greater  detection  potential  also  confers  a  considerable  interpretative  burden  in  
the  context  of  the  many  putatively  pathogenic  variants  present  in  each  human  genome(70,  76,  77).  
Advances  in  sequencing  technology  have  drastically  reduced  the  costs  associated  with  ES(110),  but  the  
process  of  sequence  interpretation  has  yet  to  be  streamlined(71,  151).  Thus,  data  interpretation,  rather  
than  data  generation,  represents  a  key  bottleneck  in  the  clinical  deployment  of  ES.    
Currently,  diagnostic  sequence  interpretation  involves  manually  reviewing  various  lines  of  
evidence,  including  minor  allele  frequency,  prior  disease  case  reports,  and  impact  on  the  function  of  the  
encoded  protein,  to  arrive  at  an  overall  classification(73).  Importantly,  this  requires  time-­intensive  curation  
of  the  primary  supporting  literature  by  individuals  with  the  needed  domain-­specific  expertise.  While  an  
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initial  MAF  filter  may  be  applied  (e.g.,  MAF  <5%  or  MAF  <1%)(5,  73),  given  the  many  rare  variants  
present  in  the  human  genome,  there  nonetheless  remains  a  large  burden  of  variants  for  manual  curation.  
Moreover,  under  current  guidelines,  variants  for  which  there  is  insufficient  or  conflicting  evidence  are  
deemed  variants  of  uncertain  significance  (VUS)(73).  Accordingly,  47%  of  the  variants  currently  listed  in  
ClinVar  are  classified  as  VUS  by  at  least  one  submitter,  and  for  22,819  (5.2%)  of  variants,  reflecting  20%  
of  all  those  with  multiple  submitters,  submitters  disagree  meaningfully  regarding  their  pathogenicity  
(i.e.,  whether  they  should  be  classified  as  Pathogenic/Likely  Pathogenic,  VUS,  or  Benign/Likely  Benign),  
such  that  they  too  could  qualify  as  VUS(152).    
Our  findings  reinforce  the  substantial  VUS  burden  resulting  from  diagnostic  ES  analysis  and    
through  highlighting  major  contributing  factors,  identify  key  priorities  in  addressing  this  issue.  In  Chapter  I,  
we  classified  98  of  the  174  (56%)  candidate  pathogenic  variants  reviewed  as  VUS;;  similarly,  in  Chapter  II,  
we  found  that  85.9%  (2,815/3,315)  of  the  CKD  cases  harbored  at  least  one  VUS  in  a  nephropathy-­
associated  gene,  with  on  average  6.6  such  VUS  detected  per  individual.  Previously  reported  pathogenic  
variants  with  appreciable  control  population  allele  frequencies  overwhelmingly  accounted  for  the  recurrent  
VUS,  and  thereby  the  cohort-­level  burden  of  these  variants.  In  addition  to  emphasizing  the  importance  of  
regular  review  of  the  alleles  listed  in  clinical  variant  databases,  this  observation,  along  with  the  fact  that  
majority  of  variants  we  classified  Pathogenic  or  Likely  Pathogenic  were  absent  from  population  
databases,  supports  the  utility  of  more  stringent  MAF  cutoffs  in  decreasing  the  interpretative  labor  of  
diagnostic  sequence  interpretation.  Nonetheless,  as  evinced  by  the  substantial  number  of  VUS  remaining  
in  the  both  the  CKD  case  (Chapter  II)  and  population  control  (Chapter  I)  cohorts  following  application  of  
stringent  MAF  cutoffs,  using  rarity  alone  cannot  wholly  eliminate  the  VUS  burden.  Moreover,  we  observed  
that  certain  well-­established  disease  causal  variants  would  be  removed  by  such  stringent  MAF  cutoffs  
(e.g.,  the  COL4A5  p.G624D  allele,  a  European  founder  variant  associated  with  a  milder  form  of  Alport  
syndrome(108,  109)),  or  even  more  liberal  ones  (e.g.,  the  NPHS2  p.R229Q  allele,  associated  with  
Nephrotic  syndrome  type  2(124,  125),  with  a  global  MAF  of  3%  in  gnomAD,  and  as  high  as  7%  in  certain  
ethnic  subpopulations).  Altogether,  these  emphasize  the  importance  of  burgeoning  efforts  to  develop  and  
implement  disease-­specific  MAF  cutoffs  in  clinical  sequence  interpretation  pipelines,  which  will  help  to  
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adjudicate  the  classification  of  previously  reported  variants,  and  effectively  balance  sensitivity  and  
specificity  when  assessing  novel  ones(131,  153).    
We  found  that  ultra-­rare  previously  unreported  non-­protein  truncating  variants  contributed  the  
majority  of  unique  VUS  in  nephropathy-­associated  genes.  At  present,  ascertaining  the  pathogenicity  of  
such  variants  is  difficult,  reflecting  the  uncertainty  regarding  their  impact  on  the  function  of  the  encoded  
protein.  A  plethora  of  in-­silico  predictors  are  available  for  this  purpose;;  however,  at  present  no  specific  
guidelines  exist  regarding  which  and/or  how  many  to  use.  Moreover,  as  others  have  also  observed,  we  
found  that  they  varied  widely  in  their  pathogenicity  predictions  and  altogether  had  limited  ability  to  reduce  
the  candidate  pathogenic  variant  burden(154,  155).  These  findings  highlight  the  need  for  the  development  
and  wider  implementation  of  methodologically  robust,  high-­throughput  experimental  assays  to  clarify  the  
functional  significance  of  these  variants,  as  has  been  successfully  applied  for  other  disorders(114,  115).  
However,  this  represents  a  considerable  challenge  in  in  the  context  of  the  substantial  cellular  complexity  
of  the  kidney,  which  contains  at  least  thirteen  distinct  epithelial  cell  types  alone(156,  157).  Emerging  
techniques  such  as  massively  parallel  single-­cell  RNA  sequencing(158)  and  renal  organoids(159)  will  
help  to  create  appropriate  model  systems,  supporting  both  accurate  assessment  of  variants’  in  vivo  
consequences  and  identification  of  potential  cellular  targets  for  disease-­specific  therapies.    
  
Potential  clinical  value  of  primary  and  secondary  genetic  findings  and  challenges  of  effective  
implementation  
  
In  Chapter  I,  we  observed  on  manual  review  that  the  majority  of  putatively  diagnostic  variants  
detected  could  prompt  considerable  clinical  workup  for  the  self-­declared  healthy  individuals  in  whom  they  
were  detected,  reflecting  the  systemic  nature  of  many  Mendelian  kidney  diseases.  Moreover,  if  confirmed,  
these  genetic  findings  would  meaningfully  shape  subsequent  medical  management,  including  initiating  
long-­term  subspecialty  monitoring,  dietary  and/or  lifestyle  modifications,  and  even  preemptive  surgical  
and/or  pharmacologic  interventions.  Similarly,  in  Chapter  II,  we  observed  that  in  the  majority  of  CKD  
cases  with  diagnostic  variants  for  their  nephropathy,  the  genetic  findings  provided  novel  insight,  which  
had  the  potential  to  inform  disease  prognosis,  initiate  subspecialty  workup,  and/or  advise  therapy.    
Together,  these  results  illustrate  the  capacity  of  ES  to  shape  clinical  care,  whether  the  genetic  
results  are  detected  as  primary  diagnostic  or  secondary  findings.  Importantly,  in  both  contexts,  the  
 
  55  
genetic  findings  provide  potentially  valuable  clinical  information,  but  at  the  same  time  can  result  in  new  
“diagnostic  odysseys”  as  individuals  undergo  the  oftentimes  considerable  clinical  workup  prompted  by  
their  detection.  Thus,  our  findings  highlight  the  question  of  how  to  best  balance  the  opportunity  to  identify  
potentially  valuable  clinical  information  with  the  potential  for  psychosocial  stress  and  increased  healthcare  
costs  that  this  considerable  clinical  workup  can  confer(160,  161).  Furthermore,  given  that  many  of  the  
associated  disorders  can  be  highly  variable  in  their  manifestations,  they  point  to  the  question  of  the  extent  
of  workup  which  should  be  initiated  following  detection,  supporting  the  need  for  additional  study  to  help  
ascertain  the  true  prevalence  of  different  features  and  thereby  enable  more  targeted  workup.    
Currently,  the  ACMG  recommends  return  of  known  and  expected  pathogenic  variants  in  59  genes  
as  medically  actionable  secondary  findings  to  patients  undergoing  genomic  sequencing(60).  In  Chapter  II,  
we  found  that  the  secondary  findings  emerging  from  analysis  of  these  genes  had  meaningful  implications  
for  nephrologic  as  well  as  non-­nephrologic  care.  Conversely,  in  many  cases,  the  presence  of  CKD  could  
also  inform  management  of  the  ACMG  59  secondary  disorder  detected.  Importantly,  surveys  of  patient  
preferences  and  current  clinical  laboratory  practices  for  secondary  findings  in  genomic  sequencing  show  
that  a  wide  range  of  secondary  findings,  including  for  adult-­onset  Mendelian  disorders,  hereditary  cancer  
predisposition,  carrier  status  for  severe  monogenic  conditions,  and  pharmacogenomic  variants,  are  
requested,  assessed,  and  already  in  many  cases,  returned(62,  65,  107,  162).  Thus,  the  ACMG  59  genes  
arguably  represent  the  “floor”  of  secondary  findings  from  genomic  sequencing,  and  the  scope  of  
secondary  findings  analyzed  and  returned  to  patients  with  CKD  undergoing  ES  will  likely  continue  to  
expand.  Our  findings  therefore  point  to  the  need  to  assess  the  opportunities  and  challenges  resulting  from  
these  additional  categories  of  secondary  findings,  which  hold  similar  potential  to  both  shape  renal  care  
and  have  their  management  shaped  by  patients’  renal  disease.    
In  addition  to  reinforcing  the  importance  of  collaboration  across  medical  specialties,  our  results  for  
both  primary  diagnostic  and  secondary  findings  emphasize  the  importance  of  ongoing  efforts  to  develop  
effective  workflows  for  their  return  and  implementation,  and  assess  the  practical  consequences  of  these  
processes(67,  163).  Many  healthcare  providers  may  have  scant  knowledge  of  genetics  and  thus  may  feel  
ill-­prepared  to  return  and  implement  genetic  results,  particularly  those  for  disorders  outside  of  their  
medical  subspecialty(164,  165).  Increasing  access  to  pre-­  and  post-­test  genetic  counseling  services  will  
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support  patients  and  providers  in  navigating  and  acting  upon  these  results;;  clinical  decision  support  tools  
will  likewise  help  to  address  the  genetic  knowledge  gap  among  healthcare  providers  and  ensure  
appropriate  management  of  the  genetic  disorders  detected(166,  167).  Given  the  current  paucity  of  data  
regarding  the  long-­term  impact  of  genetic  findings  on  healthcare  utilization  and  clinical  outcomes,  
longitudinal  studies  involving  multiple  large  healthcare  systems  will  help  to  inform  usage  of  ES  and  create  
best  practice  guidelines  for  return  and  implementation  of  genetic  results(67,  163).  
  
Future  Directions  
In  addition  to  the  follow  up  studies  described  in  the  prior  chapters,  our  studies  point  to  several  key  
avenues  for  future  research.  Here,  we  assessed  the  diagnostic  yield  of  ES  for  the  detection  of  monogenic  
etiologies  of  kidney  disease.  As  this  approach  did  not  include  certain  types  of  variants,  such  as  noncoding  
variants  and  copy  number  variants  (CNVs),  both  of  which  have  been  implicated  across  a  variety  of  
monogenic  nephropathies(142,  168-­172),  the  detection  rate  observed  using  ES  alone  likely  
underestimates  the  true  diagnostic  yield  of  genetic  testing  for  patients  with  this  condition.  While  
microarrays  are  currently  the  gold  standard  for  CNV  detection,  a  number  of  tools  for  CNV-­calling  from  ES  
data  have  arisen,  reflecting  the  desire  for  an  “all-­in-­one”  genetic  test(173,  174).  Whole  genome  
sequencing  (WGS)  can  detect  causal  noncoding  variants  and  CNVs,  and  generally  has  higher  technical  
accuracy  versus  ES(147,  175),  and  given  declining  sequencing  costs  and  development  of  new  annotation  
tools  to  help  facilitate  noncoding  variant  interpretation,  has  been  predicted  to  overtake  ES  as  the  favored  
genome-­wide  testing  modality(110,  176).  However,  to  our  knowledge,  the  diagnostic  yield,  associated  
analytic  burden,  and  cost  of  ES  versus  WGS  have  yet  to  be  compared  in  a  large,  all-­cause  CKD  cohort.  
Such  future  investigation  will  enable  assessment  of  both  the  broader  contribution  of  noncoding  variants  
and  CNVs  and  the  relative  merits  of  WGS  versus  ES  across  different  clinical  disease  categories,  
informing  creation  of  evidence-­based  guidelines  for  deployment  of  genetic  testing  in  nephrology.  
   Our  studies  revealed  that  ACMG  59  medically  actionable  gene  findings  had  meaningful  
implications  for  nephrologic  as  well  as  non-­nephrologic  care  revealed  a  novel  capacity  for  “secondary”  
findings  to  inform  management  of  a  patient’s  primary  disease.  Moreover,  on  case-­level  review  we  found  a  
high  rate  of  phenotypic  concordance  between  patient’s  known  clinical  features  and  the  associated  ACMG  
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59  disorder,  supporting  that  these  findings  may  in  fact  represent  medically  actionable  conditions  that  
could  have  otherwise  gone  undetected,  further  highlighting  the  value  of  secondary  findings  analysis.  
Given  the  aforementioned  expansion  in  both  use  of  genomic  diagnostics  in  nephrology  and  scope  of  
secondary  findings  assessed,  subsequent  investigations  should  examine  the  yield  of  different  categories  
of  secondary  findings  (e.g.,  hereditary  cancers,  other  monogenic  disorders,  pharmacogenomic  variants)  
using  large,  ethnically  and  etiologically  diverse  CKD  cohorts.  Moreover,  as  CKD  patients  frequently  have  
other  comorbidities,  future  studies  should  take  a  global  approach  and  evaluate  the  implications  of  the  
secondary  genetic  disorders  detected  for  these  comorbidities  as  well.    
   Currently,  clinical  trials  for  diagnostic  and/or  screening  services  are  underrepresented  among  
clinical  trials  in  nephrology  and  targeted  therapies  are  likewise  scant,  reflecting  the  limitations  of  
traditional  diagnostics  in  detecting  individuals  at  risk  and  distinguishing  between  molecularly  distinct  
etiologies(145,  177).  Our  findings  that  ES  can  provide  a  specific  diagnosis  which  frequency  has  
meaningful  implications  for  disease  prognosis,  workup,  and/or  therapy  points  to  its  potential  to  support  
both  presymptomatic  diagnosis  and  accurate  patient  stratification,  facilitating  personalized  care  for  kidney  
disease.  However,  realizing  this  promise  requires  conducting  large-­scale  clinical  trials  which  integrate  
genetic  information  with  the  given  interventions  and  involve  longitudinal  assessment  of  outcomes.  In  
addition  to  investigating  the  efficacy  of  experimental  drugs  on  patients  with  a  given  monogenic  
nephropathy,  future  studies  should  include  those  assessing  the  predictive  value  of  genotype-­level  
knowledge  on  disease  severity  and  response  to  therapy,  which  can  then  be  applied  to  design  more  
tailored  agents.  Genome-­wide  sequencing  will  also  enable  identification  of  clinically  relevant  secondary  
findings  for  disorders  which  could  impact  the  primary  outcome  of  interest  (e.g.,  detection  of  a  hereditary  
predisposition  to  cardiac  arrhythmia  in  the  context  of  a  clinical  trial  for  a  new  diuretic  agent).  Pragmatic  
approaches(144),  involving  diverse  patient  populations  and  utilizing  existing  clinical  infrastructure,  will  
support  such  studies  and  yield  more  broadly  generalizable  conclusions.    
   Altogether,  the  future  studies  described  above  can  help  to  inform  the  broader  application  of  ES  in  
nephrology,  supporting  the  creation  of  evidence-­based  practice  guidelines  and  the  development  of  
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the  genes  accounting  for  the  majority  of  the  burden  of  rare  unreported  
protein-­truncating  variants  
107  
Table  S7   Manual  classification  of  174  candidate  pathogenic  variants     108  







Section  S1.  Bioinformatics  processing  and  variant  annotation  of  sequence  data    
  
Sequencing  data  was  processed  as  previously  described(122).  Reads  were  aligned  to  the  reference  
genome  (Genome  Reference  Consortium  build  37,  human  genome  19)  using  Burrows-­Wheeler  Alignment  
Tool  (BWA),  followed  by  duplicate  removal  using  Picard  tools.  Variant  and  genotype  calling  were  
performed  using  GATK  v3.6.  best  practices(123).    
All  analyses  were  performed  using  Analysis  Tool  for  Annotated  Variants  (ATAV),  a  variant  analysis  
tool  developed  by  the  Columbia  Institute  for  Genomic  Medicine  (IGM)(94).  Sequence  data  was  retrieved  
from  AnnoDB,  the  IGM’s  in-­house  database,  and  annotated  using  ATAV(94)  and  ANNOVAR(95).  To  
support  identification  of  high  quality  variants,  we  used  the  following  parameters,  which  are  described  in  
further  depth  at  https://redmine.igm.cumc.columbia.edu/projects/atav/wiki:  
1.   Variant  quality  status  “pass”  
2.   Coverage  ≥10x,  qual  ≥  50,  quality  per  depth  (QD)  ≥2,  genotype  quality  ≥  20,  rms  mapping  quality  
(MQ)  ≥40  
3.   Exclude  heterozygous  variants  with  alternate  read  frequency  less  than  25%  
Exclude  variants  failing  quality  cutoffs  in  the  Exome  Variant  Server  (EVS)  and/or  those  identified  as  




Section  S2.  Development  of  a  stringent  in-­silico  annotation  pipeline  
We  first  filtered  sequence  data  using  a  framework  broadly  representative  of  standard  diagnostic  analysis  
workflows.  This  standard  filtering  pipeline  consisted  of  filtering  for  variants  with  minor  allele  frequency  
(MAF)  <1%  in  the  Exome  Aggregation  Consortium  (ExAC)  database  and  within  the  cohort  that  had  either:  
1)  been  previously  reported  pathogenic  in  the  Human  Gene  Mutation  Database  (HGMD)  and/or  ClinVar;;  
or  2)  were  protein-­truncating  variants  not  previously  reported  in  these  databases  occurring  in  genes  at  
least  one  protein-­truncating  variant  had  been  previously  reported  pathogenic  (see  Chapter  I,  Methods).    
Under  this  standard  filtering  pipeline,  522  distinct  candidate  pathogenic  variants  for  Mendelian  
kidney  and  genitourinary  disorders  were  found  in  1,856  (23.3%)  of  the  7,974  self-­declared  health  adults  
assessed.  Given  that  kidney  disease  affects  approximately  10-­15%  of  adults(11,  12)  and  Mendelian  
kidney  and  genitourinary  disorders  account  for  an  estimated  10%  of  adult  ESRD  cases(22,  23),  we  found  
the  23.3%  yield  of  candidate  pathogenic  variants  in  a  cohort  of  self-­declared  adults  to  be  implausibly  high.  
Thus,  we  developed  and  applied  a  more  stringent  filtering  pipeline,  consisting  of  implementing  
stricter  MAF  cutoffs  and  removing  indels;;  the  rationale  and  associated  analyses  are  described  below.    
  
MAF  cutoffs  
We  used  a  previously  published  method,  known  as  the  Maximum  Credible  Population  Allele  
Frequency(131),  to  calculate  expected  MAF  cutoffs  based  on  the  known  allelic  heterogeneity,  
penetrance,  and  prevalence  for  Mendelian  kidney  and  genitourinary  disorders,  as  ascertained  through  the  
literature  review  conducted  to  construct  the  gene  list.  Conservatively,  we  utilized  the  prevalence  of  the  
most  common  forms  of  these  disorders.  The  resultant  MAF  thresholds  represent  the  estimated  MAF  
cutoffs  for  disease-­causal  variants.  
Inheritance   Prevalence  (%)   Allelic  heterogeneity   Penetrance   MAF  cutoff  (%)  
Dominant   0.1a   0.1   Full   0.01  
Recessive   0.01b   0.1   Full   0.1  
  
a  Corresponding  to  the  known  prevalence  of  most  common  dominant  form  of  Mendelian  kidney  and  genitourinary  
disease,  autosomal  dominant  polycystic  kidney  disease  (ADPKD)(178).  
b  Corresponding  to  the  estimated  prevalence  of  common  forms  of  recessive  kidney  and  genitourinary  disease  such  as  





As  expected,  increasingly  stringent  MAF  cutoffs  reduced  the  number  of  individuals  carrying  candidate  
pathogenic  variants.  Applying  the  respective  MAF  cutoffs  of  <0.01%  and  <0.1%  for  dominant  and  
recessive  disorders,  2.1%  of  individuals  harbored  a  candidate  pathogenic  variant:  1.4%  for  dominant  
disorders  and  0.7%  for  recessive  disorders  (Table  S2).    
  
In-­silico  predictors  of  variant  deleteriousness    
Current  guidelines  recommend  using  multiple  in-­silico  algorithms  to  help  ascertain  variant  
pathogenicity(73),  and  there  is  vast  array  available(71).  However,  at  present  which  algorithms  that  should  
be  used,  nor  how  they  should  be  weighted,  is  not  well-­specified.  We  evaluated  the  yield  of  candidate  
pathogenic  variants  using  various  combinations  of  the  following  seven  in-­silico  predictors:  GERP(180),  
CADD(127),  Polyphen(181),  SIFT(182),  MutationTaster(183),  MetaSVM(128),  and  dbscSNV  ADA  
score(184).  Of  the  predictors  assessed,  a  composite  score,  MetaSVM(128)  removed  the  greatest  number  
of  variants.    Nonetheless,  filtering  using  MetaSVM  nonetheless  left  5.8%  of  the  cohort  with  rare,  
previously  reported  pathogenic  variants  in  dominant  genes  (Table  S3),  supporting  the  limitations  of  
filtering  on  in-­silico  variant  predictors  alone.  Therefore,  we  did  not  include  in-­silico  variant  deleteriousness  
prediction  algorithms  in  the  stringent  filtering  pipeline.    
  
Transmission  Rate  Analysis  
As  global  assessment  of  pathogenicity,  we  examined  the  parent-­child  transmission  rate  of  different  
classes  of  variants  for  dominant  disorders,  hypothesizing  that  under-­transmission  from  parent  to  offspring  
would  support  deleteriousness  or,  potentially,  next-­generation  sequencing-­associated  errors.    Amongst  all  
individuals  with  candidate  pathogenic  variants,  we  identified  those  recruited  as  healthy  family  members  
for  whom  we  had  access  to  sequencing  data  for  their  offspring  using  KING(93).  We  then  identified  the  
offspring  with  candidate  pathogenic  variants  and  used  this  to  calculate  the  proportion  of  transmitted  
variants.  We  performed  an  Exact  Binomial  test  to  analyze  whether  the  observed  transmission  rates  
differed  significantly  from  the  Mendelian  expectation  of  50%  transmission.      
Transmission  rates  did  not  significantly  deviate  from  Mendelian  expectations  for  previously  
reported  pathogenic  variants  and  previously  unreported  single  nucleotide  protein-­truncating  variants  
 
  79  
(Table  S4).  However,  there  was  significant  evidence  of  under-­transmission  for  previously  unreported  indel  
protein-­truncating  variants.  As  both  single  nucleotide  and  indel  protein-­truncating  variants  should  have  
similar  functional  effects  (i.e.,  premature  protein  truncation),  the  under-­transmission  observed  for  indels  is  
consistent  with  the  previously  noted  higher  error  rate  using  next-­generation  sequencing  methods(110),  
reinforcing  the  analytical  as  well  as  interpretative  challenge  these  variants  pose.  To  reduce  the  
contribution  of  technical  false-­positives  to  the  burden  of  candidate  pathogenic  variants,  we  therefore  








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table  S3.  Parent-­child  transmission  of  candidate  pathogenic  variants  from  standard  filtering  
pipeline  
  





















pathogenic  variants   All   593   546   621   291   47%   0.127  
Protein-­truncating  
variants  b   All   96   79   82   29   35%   0.020  
   SNVs   34   25   26   9   35%   0.169  
   Indels   68   56   56   20   36%   0.044  
  
All  parent-­child  sets,  not  including  variants  present  in  both  parents,  and  variants  for  which  one  of  the  parents  is  
homozygous;;  includes  both  complete  trios  and  duos  (child  and  one  of  the  parents).  
SNVs:  Single-­Nucleotide  Variant;;  indels:  insertions  and  deletions;;    
aNumber  of  inherited  variants  in  children;;  b  protein-­truncating  variants  unreported  in  ClinVar  or  HGMD  occurring  in  
genes  in  which  protein-­truncating  variants  have  been  reported  as  pathogenic  in  ClinVar.
 
  105  
Table  S4.  Effect  of  filtering  using  in-­silico  algorithms  on  the  burden  of  previously  reported  
pathogenic  variants    
  











<1%   None      1571   20%   287   80  
<1%   GERP   >2   1249   16%   243   72  
<1%   CADD   >15   1153   14%   224   68  
<1%   PolyPhen  HumDiv   D  or  P   964   12%   182   66  
<1%   SIFT   D   803   10%   144   60  
<1%   MutationTaster   A  or  D   801   10%   143   59  
<1%   dbscSNV  ADA  
score  
>0.9   9   <1%   6   6  




variant  to  be  
deleterious  
1185   15%   234   67  
<1%   MetaSVMc   D   459   5.8%   109   45  
<0.1%   MetaSVM  c   D   154   1.9%   80   38  
<0.01%   MetaSVM  c   D   46   0.6%   46   24  
MAF:  minor  allele  frequency,  internal  and  ExAC  popmax  minor  allele  frequency;;    
Variants  annotated  with  ANNOVAR,  using  version  dbNSFP33a.    
b  Including  individuals  with  multiple  previously  reported  pathogenic  variants;;  c  Polyphen(181),  SIFT(182),  
MutationTaster(183)  and  MetaSVM(128)  annotate  only  missense  variants;;  d  dbscSNV  ADA  Score(184)  only  
annotates  splice-­site  variants.  
 
  106  
Table  S5.  Comparison  of  the  differential  constraint  of  genes  associated  with  each  inheritance  
mode  
  
Mode  of  inheritance  


















   2.1x10-­4   4.4x10-­10  
Dominant/  Recessive  
(median=1.12)  
3.3x10-­4      5.8x10-­5  
Recessive  
(median=0.25)  
4.4x10-­10   8.4x10-­3     
  
Comparison  performed  using  Tukey’s  honest  significance  test  (see  Methods).  Mis-­Z:  missense  Z-­score;;  pLI:  







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table  S8.  Clinical  implications  of  the  174  candidate  pathogenic  variants    
  
  
EHR information Clinical Management
Row 
Number















































Clinical Workup Needed to Validate Or 
Refute the Candidate Genetic Diagnosis
Known Clinical 
Features Potentially 
Consistent With the 
Candidate Genetic 
Diagnosis 
Implications of Confirming Genetic Diagnosis for Clinical 
Management
1 ID_1 ARID1B Heterozygote Stringent No Congenital.or.developmental c.3026-1G>A 2.98E-05 1 . . . . VUS Coffin-Siris syndrome 1 135900 Dominant No
Digital anomalies (fifth digit hypoplasia or 
aplasia, +/- additional digits)
Developmental delay
Dysmorphic facies
Abnormal hair growth (hirsutism/hypertrichosis, 
sparse scalp hair)
CNS anomalies, hypotonia, seizures




Feeding difficulties, poor growth
Recurrent infections 
Structural cardiac anomalies
Renal and genitourinary anomalies 
Yes
Detailed history and physical exam to 
assess for key features of fifth digit 
hypoplasia/aplasia, characteristic facies, 
hirsuitism/hypertrichosis and sparse scalp 
hair, hypotonia, and developmental delay
No access to clinical 
information
Detailed neurodevelopmental assessment, +/- neuroimaging and EEG
Opthalmologic exam
Audiology evaluation 
Gastroenterological evaluation; nutritional therapy if needed
Cardiac exam and imaging
Renal function tests and imaging
2 ID_2 ASXL1 Heterozygote Stringent No Congenital.or.developmental p.Q396X 0.00E+00 1 . . . . Likely somatic Bohring-Opitz syndrome 605039 Dominant No
Craniofacial anomalies 
Developmental delay, seizures; CNS anomalies
Joint, digitial, and postural anomalies; hypotonia 
Opthamologic and optic nerve anomalies
Cardiac anomalies




No None based on internal classification
No access to clinical 
information
None based on internal classification
3 ID_3 ASXL1 Heterozygote Stringent No Congenital.or.developmental p.Q491X 0.00E+00 1 . . . . Likely somatic Bohring-Opitz syndrome 605039 Dominant No
Craniofacial anomalies 
Developmental delay, seizures; CNS anomalies
Joint, digitial, and postural anomalies; hypotonia 
Opthamologic and optic nerve anomalies
Cardiac anomalies




No None based on internal classification
No access to clinical 
information
None based on internal classification
4 ID_4 ASXL1 Heterozygote Stringent No Congenital.or.developmental p.E705X 0.00E+00 1 . . . . Likely somatic Bohring-Opitz syndrome 605039 Dominant No
Craniofacial anomalies 
Developmental delay, seizures; CNS anomalies
Joint, digitial, and postural anomalies; hypotonia 
Opthamologic and optic nerve anomalies
Cardiac anomalies




No None based on internal classification
Passed away at the age 
of 88 years old, Cardiac 
anomalies, CAKUT, GI 
(nausea and vomiting, 
gallstones - 
occasionally reported in 
individuals)
None based on internal classification
5 ID_5 BMP4 Heterozygote Stringent No Congenital.or.developmental p.W171X 0.00E+00 1 . . . .
VUS (recent 
annotation as VUS 
in ClinVar)





Ocular anomalies (anopthalmia or 
microopthalmia, retinal dystrophy, myopia)
Craniofacial anomalies, including cleft palate
CNS anomalies, psychomotor retardation, 
developmental delay
Endocrine anomalies (hypopituitarism, adrenal 
hypoplasia)
Musculoskeletal anomalies (vertebral, digital) 
Renal and genital anomalies 
Yes
Detailed physical exam to evaluate for 
characteristic craniofacial anomalies 
Opthalmologic exam to assess for 
characteristic ocular anomalies
Brain and orbit imaging (CT or MRI) to 
assess for CNS and optic nerve anomalies
No access to clinical 
information
Detailed neurodevelopmental assessment
Endocrinological asessment, including pituitary and adrenal hormone 
studies and imaging
Orthopedic evaulation for musculoskeletal anomalies
Renal function tests and imaging
6 ID_6 BMP4 Heterozygote Stringent Yes Congenital.or.developmental p.N150K 3.00E-05 1 DM 18305125 . . VUS





Ocular anomalies (anopthalmia or 
microopthalmia, retinal dystrophy, myopia)
Craniofacial anomalies, including cleft palate
CNS anomalies, psychomotor retardation, 
developmental delay
Endocrine anomalies (hypopituitarism, adrenal 
hypoplasia)
Musculoskeletal anomalies (vertebral, digital) 
Renal and genital anomalies 
Yes
Detailed physical exam to evaluate for 
characteristic craniofacial anomalies 
Opthalmologic exam to assess for 
characteristic ocular anomalies
Brain and orbit imaging (CT or MRI) to 
assess for CNS and optic nerve anomalies
No access to clinical 
information
Detailed neurodevelopmental assessment
Endocrinological asessment, including pituitary and adrenal hormone 
studies and imaging
Orthopedic evaulation for musculoskeletal anomalies
Renal function tests and imaging
7 ID_7 CDC5L Heterozygote Stringent Yes Congenital.or.developmental p.P672S 4.00E-05 1 DM 24429398 . . VUS
Congenital anomalies of the 
kidney and urinary tract
NA Dominant No
Congenital kidney and/or genitourinary 
anomalies
Yes
Detailed history and physical exam, and 
renal imaging
No access to clinical 
information
Nephrologic evaluation; monitor renal function (blood, urine studies)
Consider ACE-i/ARB therapy to delay renal disease progression













Choanal atresia or stenosis





Genitourinary anomalies (renal and/or genital)
Endocrine dysfunction (growth hormone 
deficiency, parathyroid hypoplasia, 
hypogonadism, hypothyroidism) 
Tracheoesophageal fistula 
Craniofacial anomalies (dysmorphic facies, 
orofacial clefting)
Thymic hypoplasia or aplasia, immunodeficiency
Musculoskeletal anomalies (hand, vertebral)
Yes
Detailed family history and physical exam, 
Opthalmologic exam
Gastrointestinal evaluation and imaging
Detailed neurologic exam, including cranial 
nerve function testing
Detailed physical exam to assess for 
characteristic cranofacial and ear anomalies 
and other associated dysmorphologies
No access to clinical 
information
Regular opthalmologic evaluation to monitor visual function
Cardiac exam and imaging 
Otolaryngologic evaluation, including CT of temporal bones to detect 
middle and inner ear anomalies; routine audiologic function testing 
Abdominal ultrasound, renal function tests 
Detailed neurodevelopmental assessment 
Endocrinological evaluation, including hormone testing
Immunologic evaluation, including CBC and thymic imaging
Orthopedic evaluation and imaging
Cautious use of anesthesia and increased surveillance for airway 
management during surgery
9 ID_9 DSTYK Heterozygote Stringent Yes Congenital.or.developmental p.S843L 1.80E-05 1 DM 23862974 . . VUS
Congenital anomalies of the 
kidney and urinary tract 1
610805 Dominant No
Congenital kidney and/or genitourinary 
anomalies
Yes
Detailed family history and physical exam, , 
Renal imaging
No access to clinical 
information
Nephrologic evaluation; monitor renal function (blood, urine studies)
Consider ACE-i/ARB therapy to delay renal disease progression
10 ID_10 HNF1B Heterozygote Stringent Yes Congenital.or.developmental p.Q136X 0.00E+00 1 DM 16249435 . . Pathogenic
Renal Cysts and Diabetes 
Syndrome
 137920 Dominant No
Renal anomalies, tubulointerstitial renal disease, 
CKD
Hyperuricemia, gout
Abnormal liver function tests 
Diabetes mellitus 
Pancreatic hypoplasia, exocrine pancreatic 
dysfunction
Genital tract anomalies (uterine, vaginal) 
Neuropsychiatric disease, intellectual disability, 
CNS anomalies
Yes
Detailed history and physical exam to 
assess for personal and/or family history of 
characteristic disease manifestions
No access to clinical 
information
Nephrologic evaluation, including renal function tests (BUN, 
creatinine, electrolytes) and imaging 
Fasting glucose and glucose tolerance tests
Gastrointestinal and hepatologic evaluation, including liver function 
tests 
Gynecological evaluation
Neurodevelopmental assessment; consider neuroimaging and EEG





Renal Cysts and Diabetes 
Syndrome
 137920 Dominant No
Renal anomalies, tubulointerstitial renal disease, 
CKD
Hyperuricemia, gout
Abnormal liver function tests 
Diabetes mellitus 
Pancreatic hypoplasia, exocrine pancreatic 
dysfunction
Genital tract anomalies (uterine, vaginal) 
Neuropsychiatric disease, intellectual disability, 
CNS anomalies
Yes
Detailed history and physical exam to 
assess for personal and/or family history of 
characteristic disease manifestions
No access to clinical 
information
Nephrologic evaluation, including renal function tests (BUN, 
creatinine, electrolytes) and imaging 
Fasting glucose and glucose tolerance tests
Gastrointestinal and hepatologic evaluation, including liver function 
tests 
Gynecological evaluation
Neurodevelopmental assessment; consider neuroimaging and EEG
12 ID_12 KAL1 Hemizygote Stringent Yes Congenital.or.developmental p.G567S 6.53E-04 1 DM 26141714 . . VUS Kallmann syndrome 1 308700 X-linked No
Hypogonadotrophic hypogonadism
Anosmia or hyposmia
CNS anomalies (olfactory bulb 
aplasia/hypoplasia)




Detailed history and physical exam to 
assess for personal and/or family history of 
characteristic disease manifestions, Detailed 
endocrinology workup, including Tanner 
staging and measurement of LH, FSH, and 
sex steroid hormones
Olfactory function testing
No access to clinical 
information
Renal function tests and imaging
Evaluation for bone disease (calcium, PTH, Vitamin D levels; DEXA 
scan) and routine monitoring of bone density; consider calcium and 
Vitamin D supplementation
Neurologic evaluation, including neuroimaging
Hormone replacement therapy if patient desires fertility
13 ID_13 KAL1 Hemizygote Stringent Yes Congenital.or.developmental p.K185N 4.99E-04 1 DM 20696889 . . Likely Benign Kallmann syndrome 1 308700 X-linked No
Hypogonadotrophic hypogonadism
Anosmia or hyposmia
CNS anomalies (olfactory bulb 
aplasia/hypoplasia)
Digital synkinesia (hand mirror movements)
Renal anomalies 
Palatal anomalies
No None based on internal classification
No access to clinical 
information
None based on internal classification







 615278 Dominant No
Structural cardiac anomalies
Craniofacial anomalies
Cutaneous anomalies (skin, hair, nails)
Gastrointestinal dysfunction, GI tract anomalies 
Neurodevelopmental delay, intellectual 
disability, CNS anomalies, seizures
Ocular anomalies, visual impairment
Otolaryngologic anomalies, recurrent otitis 
media
Bleeding diathesis
Renal and genitourinary tract anomalies
Musculoskeletal anomalies, hypotonia
Yes
Detailed physical exam to evaluate for 
characteristic craniofacial and cutaneous 
anomalies
Cardiac exam and imaging
Passed away at the age 
of 86 years old, 
Seizures (Generalized 
convulsive epilepsy)
Neurodevelopmental evaluation +/- neuroimaging and EEG
GI evaluation +/- imaging to detect GI tract anomalies
Endocrine evaluation for growth hormone deficiency
Opthalmologic evaluation
Otolaryngologic evaluation
Hematologic evaluation, including coagulation studies; avoidance of 
aspirin 
Renal function tests, abdominal imaging
Orthopedic evaluation and imaging
Routine cardiologic monitoring for later-onset cardiac disease











Retinitis pigmentosa, retinal dystrophy
Renal and genitourinary tract anomalies
Digital anomalies (polydactyly, syndactly)
Neurodevelopmental delay, intellectual disability
No None based on internal classification
No access to clinical 
information
None based on internal classification
16 ID_16 MYCN Heterozygote Stringent Yes Congenital.or.developmental p.R111X 0.00E+00 1 DM 15821734 . . Likely Pathogenic Feingold syndrome 164280 Dominant No
Digital anomalies (brachymesophalangy, 
syndactyly, thumb hypoplasia)
Craniofacial anomalies (microcephaly, short 
palpebral fissures, micrognathia)
Gastrointestinal atresias (esophageal, intestinal, 
and/or anal)
Intellectual disability 
Impaired growth, short stature
Structural cardiac anomalies
Hearing loss 
Kidney and genitourinary tract anomalies
Yes
Detailed physical exam to assess for digital 
and craniofacial anomalies
Gastrointestinal evaluation and imaging to 
assess for gastrointestinal tract atresias
No access to clinical 
information
Neurodevelopmental evaluation 
Endocrine evaluation for growth impairment
Cardiac exam and imaging 
Otolaryngologic evaluation, including hearing tests
Nephrologic evaluation, including renal function tests and imaging 
17 ID_17 NOTCH3 Heterozygote Stringent No Congenital.or.developmental p.S968X 0.00E+00 1 . . . . Likely Pathogenic Lateral meningocele syndrome 130720 Dominant No





Developmental delay, intellectual disability
Musculoskeletal anomalies (hypotonia, 
hyperextensibility, scoliosis, vertebral fusion)
Structural cardiac anomalies




Detailed physical exam to assess for 
craniofacial anomalies 
Neurologic evaluation, including imaging 
(spine MRI) for spinal meningoceles 
Passed away at the age 
of 66 years old, Joint 
anomalies, degenerative 




Neurodevelopmental assessment, with neuroimaging to assess for 
CNS anomalies; neurosurgical intervention if indicated
Opthalmologic exam 
Otolaryngologic evaluation, including hearing tests
Orthopedic exam and imaging 
Cardiac exam and imaging 
Gastrointestinal evaluation and imaging 
Nephrologic/urologic evaluation, including imaging to assess for 
genitourinary tract anomalies 
18 ID_18 NOTCH3 Heterozygote Stringent Yes Congenital.or.developmental p.R728C 1.86E-05 1 DM 9388399 . . VUS Lateral meningocele syndrome 130720 Dominant No





Developmental delay, intellectual disability
Musculoskeletal anomalies (hypotonia, 
hyperextensibility, scoliosis, vertebral fusion)
Structural cardiac anomalies




Detailed physical exam to assess for 
craniofacial anomalies 
Neurologic evaluation, including imaging 
(spine MRI) for spinal meningoceles 
No access to clinical 
information
Neurodevelopmental assessment, with neuroimaging to assess for 
CNS anomalies; neurosurgical intervention if indicated
Opthalmologic exam 
Otolaryngologic evaluation, including hearing tests
Orthopedic exam and imaging 
Cardiac exam and imaging 
Gastrointestinal evaluation and imaging 
Nephrologic/urologic evaluation, including imaging to assess for 
genitourinary tract anomalies 
19 ID_19 NOTCH3 Heterozygote Stringent Yes Congenital.or.developmental p.D80G 0.00E+00 1 DM 25604251 . . Pathogenic Lateral meningocele syndrome 130720 Dominant No





Developmental delay, intellectual disability
Musculoskeletal anomalies (hypotonia, 
hyperextensibility, scoliosis, vertebral fusion)
Structural cardiac anomalies




Detailed physical exam to assess for 
craniofacial anomalies 
Neurologic evaluation, including imaging 
(spine MRI) for spinal meningoceles 
No access to clinical 
information
Neurodevelopmental assessment, with neuroimaging to assess for 
CNS anomalies; neurosurgical intervention if indicated
Opthalmologic exam 
Otolaryngologic evaluation, including hearing tests
Orthopedic exam and imaging 
Cardiac exam and imaging 
Gastrointestinal evaluation and imaging 
Nephrologic/urologic evaluation, including imaging to assess for 
genitourinary tract anomalies 
20 ID_20 NSD1 Heterozygote Stringent No Congenital.or.developmental p.S2631X 0.00E+00 1 . . . . VUS Sotos syndrome 1  117550 Dominant No
Craniofacial anomalies 
Developmental delay, intellectual disability
Overgrowth (macrocephaly, height)





Musculoskeletal anomalies (joint laxity, pes 
planus, scoliosis)
Kidney and genitourinary anomalies 
Malignancies, including acute lymphoblastic 
leukemia (rare)
Yes
Detailed physical exam to assess for 
craniofacial anomalies and signs of 
overgrowth
No access to clinical 
information
Neurodevelopmental evaluation, with neuroimaging and EEG if 
indicated
Otolaryngologic evaluation, including hearing function tests
Cardiac exam and imaging 
Orthopedic exam and imaging
Nephrologic evaluation, including renal function tests (serum BUN 





Stringent No Congenital.or.developmental p.R55X 3.48E-04 4 . . . . Likely Pathogenic
Multiple congenital anomalies-
hypotonia-seizures syndrome 1





Musculoskeletal anomalies (including 
brachdactyly, deep plantar grooves)
Neurologic dysfunction (seizures, tremors), CNS 
anomalies
Structural cardiac anomalies
Kidney and genitourinary tract anomalies
Yes
Detailed physical exam, including 
neurologic testing
Parental testing to confirm compound 
heterozygosity
No access to clinical 
information
Neurodevelopmental assessment, with neuroimaging and EEG
Opthalmologic exam
Otolaryngologic evaluation
Cardiac exam and imaging
Nephrologic evaluation, including renal function tests (serum BUN 
and creatinine, urinanalysis) and imaging
















Musculoskeletal anomalies (including 
brachdactyly, deep plantar grooves)
Neurologic dysfunction (seizures, tremors), CNS 
anomalies
Structural cardiac anomalies
Kidney and genitourinary tract anomalies
Yes
Detailed physical exam, including 
neurologic testing
Parental testing to confirm compound 
heterozygosity
No access to clinical 
information
Neurodevelopmental assessment, with neuroimaging and EEG
Opthalmologic exam
Otolaryngologic evaluation
Cardiac exam and imaging
Nephrologic evaluation, including renal function tests (serum BUN 
and creatinine, urinanalysis) and imaging
23 ID_22 PIK3CA Heterozygote Stringent Yes Congenital.or.developmental p.R382K 0.00E+00 1 DM 23246288
Pathogeni
c
5.9E+08 VUS Cowden syndrome 5 615108 Dominant No
Multiple hamartomas 
Tumor predisposition (including thyroid, breast, 
endometrium, gastrointestinal, renal cell 
carcinoma)
Craniofacial anomalies (including macrocephaly)
Mucocutaneous anomalies (trichilemmomas, 





History and physical exam to assess for 
personal and/or family history of cutaneous 
anomalies, macrocephaly, and cancer
No access to clinical 
information
Dermatologic evaluation for mucocutaneous lesions, with regular 
follow-up to screen for malignancy; use of topical agents to relieve 
associated discomfort, excision if maligant
Oncologic evaluation for associated cancers; routine screening, 
including mammography, thyroid ultrasound, endometrial biopsy or 
transvaginal ultrasound, colonoscopy, and renal CT/MRI
24 ID_23 PKD1 Heterozygote Stringent No Congenital.or.developmental
c.10403-
2A>C
0.00E+00 1 . . . . Likely Pathogenic Polycystic kidney disease 1 173900 Dominant No
Bilaterally enlarged, cystic kidneys, 
hypertension, progressive CKD
Cysts in other organs (liver, pancreas, seminal 
vesicles, arachnoid membrane)
Cerebrovascular disease (esp. intracranial 
aneurysm)
Cardiac valvular disease (aortic root dilation, 




Detailed history and physical exam to 
assess for personal and/or family history of 
characteristic disease manifestions, 
Nephrologic evaluation, including 
abdominal ultrasound to detect cysts and 
assessment for positive family history for 
cystic renal disease
No access to clinical 
information
Tight blood pressure management, consider ACE-i/ARB therapy; 
routine renal function tests (serum BUN and creatinine, urinalysis) and 
abdominal imaging to monitor cystic disease progression
Neurologic evaluation, with neuroimaging 
Cardiac exam and imaging
Gastrointestinal evaluation
Hepatological evaluation 
Avoidance of nephrotoxic agents, caffeine, and estrogens (if liver 
involvment)
Consider enrollment into trials for novel therapies (e.g., Tolvaptan) 
25 ID_24 PKD1 Heterozygote Stringent No Congenital.or.developmental
c.10218-
2A>G
0.00E+00 1 . . . . Likely Pathogenic Polycystic kidney disease 1 173900 Dominant No
Bilaterally enlarged, cystic kidneys, 
hypertension, progressive CKD
Cysts in other organs (liver, pancreas, seminal 
vesicles, arachnoid membrane)
Cerebrovascular disease (esp. intracranial 
aneurysm)
Cardiac valvular disease (aortic root dilation, 




Detailed history and physical exam to 
assess for personal and/or family history of 
characteristic disease manifestions, 
Nephrologic evaluation, including 
abdominal ultrasound to detect cysts and 




Tight blood pressure management, consider ACE-i/ARB therapy; 
routine renal function tests (serum BUN and creatinine, urinalysis) and 
abdominal imaging to monitor cystic disease progression
Neurologic evaluation, with neuroimaging 
Cardiac exam and imaging
Gastrointestinal evaluation
Hepatological evaluation 
Avoidance of nephrotoxic agents, caffeine, and estrogens (if liver 
involvment)
Consider enrollment into trials for novel therapies (e.g., Tolvaptan) 
26 ID_25 PKD1 Heterozygote Stringent Yes Congenital.or.developmental p.R3646Q 6.00E-05 1 DM 24611717 . . VUS Polycystic kidney disease 1 173900 Dominant No
Bilaterally enlarged, cystic kidneys, 
hypertension, progressive CKD
Cysts in other organs (liver, pancreas, seminal 
vesicles, arachnoid membrane)
Cerebrovascular disease (esp. intracranial 
aneurysm)
Cardiac valvular disease (aortic root dilation, 




Detailed history and physical exam to 
assess for personal and/or family history of 
characteristic disease manifestions, 
Nephrologic evaluation, including 
abdominal ultrasound to detect cysts and 
assessment for positive family history for 
cystic renal disease
No access to clinical 
information
Tight blood pressure management, consider ACE-i/ARB therapy; 
routine renal function tests (serum BUN and creatinine, urinalysis) and 
abdominal imaging to monitor cystic disease progression
Neurologic evaluation, with neuroimaging 
Cardiac exam and imaging
Gastrointestinal evaluation
Hepatological evaluation 
Avoidance of nephrotoxic agents, caffeine, and estrogens (if liver 
involvment)





Stringent Yes Congenital.or.developmental p.P805L 1.17E-04 1 DM 12846734 . . VUS
autosomal recessive polycystic 
kidney disease, Polycystic and 
hepatic disease
 263200 Recessive No




Lung hypoplasia, oligohydraminos (severe cases)
Yes
Detailed history and physical exam to 
assess for personal and/or family history of 
characteristic disease manifestions, 
Abdominal imaging for hepato-renal 
anomalies 
Family testing to confirm compound 
heterozygosity
No access to clinical 
information
Nephrologic evaluation, including renal function tests (serum BUN, 
creatinine, electrolytes); tight monitoring of blood pressure and 
electrolytes
Hepatologic evaluation, including laboratory and imaging studies to 
assess liver and biliary function
Immunization +/- prophylactic antibiotics against encapsulated 
bacteria to decrease risk of infection
Combined kidney-liver transplant if resistant portal hypertension or 





Stringent Yes Congenital.or.developmental p.I3177T 1.17E-04 1 DM 12846734 . . VUS
autosomal recessive polycystic 
kidney disease, Polycystic and 
hepatic disease
 263200 Recessive No




Lung hypoplasia, oligohydraminos (severe cases)
Yes
Detailed history and physical exam to 
assess for personal and/or family history of 
characteristic disease manifestions, 
Abdominal imaging for hepato-renal 
anomalies 
Family testing to confirm compound 
heterozygosity
No access to clinical 
information
Nephrologic evaluation, including renal function tests (serum BUN, 
creatinine, electrolytes); tight monitoring of blood pressure and 
electrolytes
Hepatologic evaluation, including laboratory and imaging studies to 
assess liver and biliary function
Immunization +/- prophylactic antibiotics against encapsulated 
bacteria to decrease risk of infection
Combined kidney-liver transplant if resistant portal hypertension or 
severe renal and hepatobiliary disease
29 ID_27 PTEN Heterozygote Stringent Yes Congenital.or.developmental p.I50T 0.00E+00 1 DM 24375884 . . Likely Pathogenic






Tumor predisposition (including thyroid, breast, 
endometrium, gastrointestinal, renal cell 
carcinoma)
Craniofacial anomalies (including macrocephaly)
Mucocutaneous anomalies (trichilemmomas, 





Detailed history and physical exam to 
assess for personal and/or family history of 
cutaneous anomalies, macrocephaly, and 
cancer
34 years old, 
immunodeficiency 
symptoms 
Dermatologic evaluation for mucocutaneous lesions, with regular 
follow-up to screen for malignancy; use of topical agents to relieve 
associated discomfort, excision if maligant
Oncologic evaluation for associated cancers; routine screening, 
including mammography, thyroid ultrasound, endometrial biopsy or 
transvaginal ultrasound, colonoscopy, and renal CT/MRI











Tumor predisposition (including thyroid, breast, 
endometrium, gastrointestinal, renal cell 
carcinoma)
Craniofacial anomalies (including macrocephaly)
Mucocutaneous anomalies (trichilemmomas, 





Detailed history and physical exam to 
assess for personal and/or family history of 
cutaneous anomalies, macrocephaly, and 
cancer
No access to clinical 
information
Dermatologic evaluation for mucocutaneous lesions, with regular 
follow-up to screen for malignancy; use of topical agents to relieve 
associated discomfort, excision if maligant
Oncologic evaluation for associated cancers; routine screening, 
including mammography, thyroid ultrasound, endometrial biopsy or 
transvaginal ultrasound, colonoscopy, and renal CT/MRI




Noonan syndrome with multiple 




Cutaneous lesions (lentigines, café au lait 
macules)
Structural cardiac anomalies, cardiomyopathy, 
conduction anomalies
Dysmorphic facies (including hypertelorism and 
ptosis)
Hearing impairment
Short stature, growth impairment
Musculoskeletal anomalies (including pectus 
excavatum or pectus carinum)
Developmental delay, intellectual disability
CNS anomalies
Kidney and genitourinary tract anomalies
Yes
Detailed physical exam to assess for 
lentigines, pectus anomalies, and 
dysmorphic facies
Cardiac exam and imaging for 
cardiomyopathy
Endocrinologic evaluation for short stature
High-risk pregnancies 
(missing age)
Neurodevelopmental assessment with neuroimaging
Cardiac exam with echocardiography and electrocardiography; 
monitor cardiac function during pregancy (increased risk of heart 
failure)
Opthalmologic evaluation
Otolaryngologic evaluation with hearing function testing 
Orthopedic evaluation and imaging
Nephrologic evaluation with renal function tests (serum BUN and 
creatinine, urinalysis) and imaging 




Noonan syndrome with multiple 




Cutaneous lesions (lentigines, café au lait 
macules)
Structural cardiac anomalies, cardiomyopathy, 
conduction anomalies
Dysmorphic facies (including hypertelorism and 
ptosis)
Hearing impairment
Short stature, growth impairment
Musculoskeletal anomalies (including pectus 
excavatum or pectus carinum)
Developmental delay, intellectual disability
CNS anomalies
Kidney and genitourinary tract anomalies
Yes
Detailed physical exam to assess for 
lentigines, pectus anomalies, and 
dysmorphic facies
Cardiac exam and imaging for 
cardiomyopathy
Endocrinologic evaluation for short stature
No access to clinical 
information
Neurodevelopmental assessment with neuroimaging
Cardiac exam with echocardiography and electrocardiography; 
monitor cardiac function during pregancy (increased risk of heart 
failure)
Opthalmologic evaluation
Otolaryngologic evaluation with hearing function testing 
Orthopedic evaluation and imaging
Nephrologic evaluation with renal function tests (serum BUN and 
















Detailed history and physical exam to 
assess for personal and/or family history of 
characteristic disease manifestions, 
Nephrologic evaluation with renal imaging
Family testing to confirm compound 
heterozygosity
No access to clinical 
information
Routine nephrologic evaluation to monitor renal function (blood 
pressure, serum BUN and creatinine, urinanalysis); consider ACE-
















Detailed history and physical exam to 
assess for personal and/or family history of 
characteristic disease manifestions, 
Nephrologic evaluation with renal imaging
Family testing to confirm compound 
heterozygosity
No access to clinical 
information
Routine nephrologic evaluation to monitor renal function (blood 
pressure, serum BUN and creatinine, urinanalysis); consider ACE-
i/ARB therapy to slow renal disease progression
35 ID_32 RPS24 Heterozygote Stringent No Congenital.or.developmental c.391-2A>T 1.92E-05 1 . . . . VUS Blackfan-Diamond anemia 3  610629 Dominant No
Normochromic, macroytic anemia 
Craniofacial and neck anomalies 
Ocular anomalies (glaucoma, cataract, 
strabismus)
Upper limb and hand anomalies
Structural cardiac anomalies
Growth retardation, developmental delay
Malignancy predisposition (including acute 
myelogenous leukemia and myelodsyplastic 
syndrome)
Kidney and genitourinary tract anomalies
Yes
Detailed history and physical exam to 
assess for personal and/or family history of 
characteristic disease manifestions, 
Hematologic evaluation, including CBC 
with reticulocyte count, measurement of 
erythrocyte adenosine deaminase activity 
and fetal hemoglobin, and bone marrow 
aspiration and biopsy
Passed away at the age 
of 82 years old, None* 
(*blood coagulation 
anomaly noted, but at 
same time as 
cerebrovascular event, 




Cardiac exam and imaging
Neurodevelopmental assessment 
Nephrologic evaluation, with renal function tests and imaging 
Oncologic evaluation for malignancy, routine monitoring for evidence 
hematologic malignancy
Routine hematologic monitoring, including CBC and bone marrow 
aspirate/biopsy; use of corticosteroids to manage anemia (red blood 
cell transfusion if corticosteroid-resistant)
Consider hematopoietic stem cell transplantation (curative)
36 ID_33 RPS24 Heterozygote Stringent No Congenital.or.developmental p.E274X 0.00E+00 1 . . . . VUS Blackfan-Diamond anemia 3  610629 Dominant No
Normochromic, macroytic anemia 
Craniofacial and neck anomalies 
Ocular anomalies (glaucoma, cataract, 
strabismus)
Upper limb and hand anomalies
Structural cardiac anomalies
Growth retardation, developmental delay
Malignancy predisposition (including acute 
myelogenous leukemia and myelodsyplastic 
syndrome)
Kidney and genitourinary tract anomalies
Yes
Detailed history and physical exam to 
assess for personal and/or family history of 
characteristic disease manifestions, 
Hematologic evaluation, including CBC 
with reticulocyte count, measurement of 
erythrocyte adenosine deaminase activity 
and fetal hemoglobin, and bone marrow 
aspiration and biopsy




Cardiac exam and imaging
Neurodevelopmental assessment 
Nephrologic evaluation, with renal function tests and imaging 
Oncologic evaluation for malignancy, routine monitoring for evidence 
hematologic malignancy
Routine hematologic monitoring, including CBC and bone marrow 
aspirate/biopsy; use of corticosteroids to manage anemia (red blood 
cell transfusion if corticosteroid-resistant)
Consider hematopoietic stem cell transplantation (curative)
37 ID_34 RPS26 Heterozygote Stringent No Congenital.or.developmental c.-101C>T 0.00E+00 1 . . . . VUS Diamond-Blackfan anemia 10  613309 Dominant No
Normochromic, macroytic anemia 
Craniofacial and neck anomalies 
Ocular anomalies (glaucoma, cataract, 
strabismus)
Upper limb and hand anomalies
Structural cardiac anomalies
Growth retardation, developmental delay
Malignancy predisposition (including acute 
myelogenous leukemia and myelodsyplastic 
syndrome)
Kidney and genitourinary tract anomalies
Yes
Detailed history and physical exam to 
assess for personal and/or family history of 
characteristic disease manifestions, 
Hematologic evaluation, including CBC 
with reticulocyte count, measurement of 
erythrocyte adenosine deaminase activity 
and fetal hemoglobin, and bone marrow 
aspiration and biopsy




Cardiac exam and imaging
Neurodevelopmental assessment 
Nephrologic evaluation, with renal function tests and imaging 
Oncologic evaluation for malignancy, routine monitoring for evidence 
hematologic malignancy
Routine hematologic monitoring, including CBC and bone marrow 
aspirate/biopsy; use of corticosteroids to manage anemia (red blood 
cell transfusion if corticosteroid-resistant)
Consider hematopoietic stem cell transplantation (curative)




 107480 Dominant No
Imperforate anus
Ear anomalies, hearing impairment
Thumb anomalies
Kidney and genitourinary anomalies
Structural cardiac anomalies 
Foot anomalies
Developmental delay, intellectual disability
CNS anomalies (cranial nerve dysfunction, 
Duane anomaly, brain malformations)
Skeletal anomalies (ribs, vertebrae)
Ocular anomalies 
Growth retardation, congenital hypothyroidism
Yes
Detailed physical exam to assess for 
characteristic triad of imperforate anus, ear 
anomalies, and thumb anomalies
35 years old, no 
relevant clinical 
features
Otolaryngologic evaluation, including hearing tests; routine 
monitoring of hearing function
Nephrologic evaluation, including renal function tests (serum BUN 
and creatinine, urinalysis) and imaging; routine monitoring of renal 
function
Cardiac exam and imaging
Neurodevelopmental evaluation +/- neuroimaging 
Orthopedic evaluation and imaging
Opthalmologic exam
Endocrine evaluation, with hormone studies if indicated
Avoidance of oto- and/or nephrotoxic agents
39 ID_36 SALL4 Heterozygote Stringent No Congenital.or.developmental p.K634X 0.00E+00 1 . . . . Likely Pathogenic
Acro-renal-ocular syndrome; 





Radial ray anomalies (thenar and/or radii 
hypoplasia; forearm shortening and radial 
deviation; thumb anomalies)
Kidney and genitourinary anomalies 
Opthalmologic anomalies (coboloma, Duane 
anomaly)
Ear anomalies, hearing loss
Structural cardiac anomalies
Anal stenosis, imperforate anus
Dysmorphic facies
Orthopedic anomalies (spine, lower extremities)
Endocrine anomalies (GH deficiency, pituitary 
hypoplasia)
Hematologic anomalies (thrombocytopenia, 
leukocytosis)
Yes
Detailed physical exam to assess for radial 
ray anomalies
Opthalmologic exam to assess for 
opthalmologic anomalies 
Nephrologic evaluation, including imaging 
for kidney and genitourinary anomalies
26 years old, history of 
dysuria and UTI 
Routine nephrologic evaluation
Opthalmologic evaluation, corrective surgery if indicated 
Otolaryngologic exam with hearing function tests
Cardiac exam and imaging
Endocrine evaluation
CBC to evaluate for hematologic anomalies 







Craniofacial anomalies (including high 
protruding forehead, coarse facies, midface 
retraction, and hypertrichosis)
CNS anomalies, seizures, developmental 
delay/intellectual disability




Kidney and genitourinary tract anomalies 
(including hydronephrosis and vesicourethral 
reflux and hypoplastic genitalia)
Yes
Detailed physical exam to assess for 
characteristic craniofacial anomalies 
Neurodevelopmental evaluation for 
developmental delay/intellectual disability
Orthopedic exam and imaging for skeletal 
anomalies
Nephrologic/urologic evaluation, including 
imaging, for hydronephrosis
No access to clinical 
information
Neurologic evaluation, with imaging
Cardiac exam and imaging
Oncologic evaluation




7.6E+08 VUS Peutz-Jeghers syndrome  175200 Dominant Yes
Gastrointestinal polyps 
Extraintestinal polyps (genitourinary tract, 
gallbladder, bronchus, nasal passages)
Mucocutaneous macules
Malignancy predisposition (colorectal, gastric, 
pancreatic, breast, ovarian, gonadal)
Yes
Detailed history to assess for positive 
family history of disease manifestations, 
Gastrointestinal evaluation with 
histopathological analysis for intestinal 
polyps
Detailed physical exam for mucocutaneous 
lesions 
No access to clinical 
information
Routine gastroenterologic screening, including endoscopy and 
colonoscopy
Oncologic evaluation and routine screening for associated extra-
intestinal malignancies; prophylactic surgery (e.g., masectomy, 








5.9E+08 VUS Peutz-Jeghers syndrome  175200 Dominant Yes
Gastrointestinal polyps 
Extraintestinal polyps (genitourinary tract, 
gallbladder, bronchus, nasal passages)
Mucocutaneous macules
Malignancy predisposition (colorectal, gastric, 
pancreatic, breast, ovarian, gonadal)
Yes
Detailed history to assess for positive 
family history of disease manifestations; 
Gastrointestinal evaluation with 
histopathological analysis for intestinal 
polyps
Detailed physical exam for mucocutaneous 
lesions 
No access to clinical 
information
Routine gastroenterologic screening, including endoscopy and 
colonoscopy
Oncologic evaluation and routine screening for associated extra-
intestinal malignancies; prophylactic surgery (e.g., masectomy, 
hysterectomy) may be considered 




1.2E+08 VUS Peutz-Jeghers syndrome  175200 Dominant Yes
Gastrointestinal polyps 
Extraintestinal polyps (genitourinary tract, 
gallbladder, bronchus, nasal passages)
Mucocutaneous macules
Malignancy predisposition (colorectal, gastric, 
pancreatic, breast, ovarian, gonadal)
Yes
Detailed history to assess for positive 
family history of disease manifestations; 
Gastrointestinal evaluation with 
histopathological analysis for intestinal 
polyps
Detailed physical exam for mucocutaneous 
lesions 
No access to clinical 
information
Routine gastroenterologic screening, including endoscopy and 
colonoscopy
Oncologic evaluation and routine screening for associated extra-
intestinal malignancies; prophylactic surgery (e.g., masectomy, 
hysterectomy) may be considered 
44 ID_41 TBX18 Heterozygote Stringent No Congenital.or.developmental p.Y438X 0.00E+00 1 . . . . Likely Pathogenic
Congenital hydronephrosis, 
Congenital anomalies of Kidney 
and Urinary Tract 2
 143400 Dominant No
Congenital kidney and/or genitourinary 
anomalies
Yes
Detailed history to assess for positive 
family history of disease manifestations, 
Renal imaging
No access to clinical 
information
Nephrologic evaluation; monitor renal function (blood, urine studies)
Consider ACE-i/ARB therapy to delay renal disease progression
45 ID_42 VANGL1 Heterozygote Stringent Yes Congenital.or.developmental p.R272Q 4.48E-05 1 DM 17409324 Other 1.2E+08 VUS Caudal regression syndrome  600145 Dominant No
Lumbosacral vertebral anomalies (sacral 
meningocele, sacral agenesis, coccygeal 
anomalies, tethered cord)





Kidney and genitourinary anomalies
Yes
Detailed history to assess for positive 
family history of disease manifestations; 
Orthopedic exam and imaging
No access to clinical 
information
Neurodevelopmental assessment with neuroimaging
Gastrointestinal evaluation; dietary and/or pharmacotherapeutic 
intervention for constipation if indicated
Nephrologic evaluation, including renal function tests and imaging
46 ID_43 WFS1 Homozygote Stringent Yes Congenital.or.developmental p.R457S 6.56E-04 12 DM 15605410 . . VUS Wolfram syndrome type 1  222300 Recessive No
Diabetes mellitus
Optic atrophy +/- other opthalmologic anomalies
Hearing loss
Neurologic anomalies (ataxia, peripheral 
neuropathy, dementia, neuropsychiatric disease)
Urinary and bladder dysfunction (hydroureter, 
incontinence, recurrent UTIs)
Cardiomyopathy, structural heart anomalies
Endocrine anomalies (diabetes insipidus, 
hypogonadism, hypothyroidism)
Gastrointestinal dysfunction (dysmotility, celiac 
disease)
Yes
Detailed history to assess for positive 
family history of disease manifestations; 
Fasting glucose and glucose tolerance tests
Opthalmologic exam
No access to clinical 
information
Routine opthalmologic evaluation
Regular glucose tolerance testing; glycemic control (via diet/lifestyle 
and pharmacologic agents) to prevent diabetes-related complications
Otolarynogologic evaluation with hearing function tests
Neurodevelopmental evaluation and neuroimaging
Nephrologic/urologic evaluation, with abdominal imaging and voiding 
cystourethrogram 
Endocrine evaluation, including hormonal studies and water restriction 
testing if indicated 
Gastroenterological evaluation 
47 ID_44 AGXT Homozygote Stringent Yes Electrolytes_Metabolic p.F152I 1.74E-04 1 DM 8101040
Pathogeni
c
1.2E+08 Pathogenic Hyperoxaluria primary type 1 259900 Recessive No
Ocular anomalies (optic atrophy, retinopathy) 
and visual impairment
Dental anomalies (root resorption, 
hypermobility)
Heart block, cardiomyopathy; vasospasm and 
peripheral vascular disease
Calcium oxalate nephrolithiasis; nephrocalcinois; 
ESRD






Urine studies (oxalate, glycolate, and L-
glycerate); plasma oxalate 




Cardiac exam and imaging 
Detailed nephrologic assessment, including renal function tests and 






Pyroxidine therapy trial; combined liver-kidney transplant may be 
ultimately needed
48 ID_45 CLCN5 Hemizygote Stringent Yes Electrolytes_Metabolic p.R648X 0.00E+00 1 DM 8559248
Pathogeni
c
1.5E+08 Pathogenic Dent disease 1 300009 X-linked No
Proximal renal tubulopathy, with low molecular 
weight proteinuria and hypercalciuria
Hypophosphatemia 
Nephrolithiasis, nephrolithiasis, CKD 
Skeletal anomalies (rickets or osteomalacia, 
growth restriction, short stature) 
Yes Nephrologic evaluation, with urinalysis
No access to clinical 
information
Routine nephrologic evaluation to monitor renal function; imaging to 
assess for nephrolithiasis and nephrocalcinosis
Consider thiazide diuretics to minimize hypercalciuria and ACE-
i/ARB therapy to slow renal disease progression
Musculoskeletal imaging; workup and routinely monitor for bone 
disease (DEXA, serum calcium, phosphorus, PTH, and Vitamin D 
levels) 
49 ID_46 CUL3 Heterozygote Stringent No Electrolytes_Metabolic c.1708-1G>A 0.00E+00 1 . . . . Likely Pathogenic
Pseudohypoaldosteronism, type 
IIE
 614496 Dominant No
Hypertension
Electrolyte anomalies (hyperchloremia, 
hyperkalemia, metabolic acidosis)
Yes
Nephrologic evaluation, including 
measurement of blood pressure and serum 
electrolytes
No access to clinical 
information
Thiazide diuretics for blood pressure and electrolyte management 
Regular nephrologic follow-up to monitor blood pressure and 
electrolytes
50 ID_47 HNF4A Heterozygote Stringent Yes Electrolytes_Metabolic p.Y286C 2.69E-05 1 DM 21105491 . . VUS
Fanconi renotubular syndrome 
4, with maturity-onset diabetes 
of the young; Maturity onset 




Early-onset hyperinsulinism, diabetes mellitus
Hepatomegaly, abnormal liver function tests
Renal Fanconi syndrome; nephrocalcinosis
Short stature, rickets
Yes
Detailed clinical history to assess for 
history of early-onset diabetes
Endocrine/metabolic studies (including 
glucose, insulin, ketones) to screen for 
hyperinsulinism and diabetes
Serum electrolytes and urinalysis to assess 
for Renal Fanconi syndrome 
No access to clinical 
information
Endocrinologic evaluation and monitoring for diabetes; diazoxide to 
manage hyperinsulinism
Nephrologic evaluation, including renal function tests and imaging; 
oral bicarbonate and potassium supplementation if chronic electrolyte 
imbalances





Stringent Yes Electrolytes_Metabolic p.S833T 6.54E-04 10 DM 22009145 . . VUS Gitelman syndrome  263800 Recessive No
Renal tubulopathy, electrolyte imbalances 
(hypokalemia, metabolic alkalosis, 
hypomagnesemia, hypocalciuria), polyuria
Muscle weakness and cramping, tetany




Family testing to confirm compound 
heterozygosity Nephrologic evaluation, 
including blood pressure measurement and 
serum and urine electrolyte studies, and 
exclusion of secondary causes of electrolyte 
imbalance.
No access to clinical 
information
Potassium-sparing diuretics, NSAIDs, potassium and magnesium 
supplementation for electrolyte imbalances; encourage liberal salt 
intake
Regular nephrologic evaluation, including blood pressure and 
electrolytes
Skeletal studies if chondrocalcinosis suspected
Opthalmologic exam






Stringent Yes Electrolytes_Metabolic p.C994Y 9.12E-04 3 DM 12112667 . .
Pathogenic, but 
other variant 
identified in this 
individual is a 
VUS
Gitelman syndrome  263800 Recessive No
Renal tubulopathy, electrolyte imbalances 
(hypokalemia, metabolic alkalosis, 
hypomagnesemia, hypocalciuria), polyuria
Muscle weakness and cramping, tetany




Family testing to confirm compound 
heterozygosity Nephrologic evaluation, 
including blood pressure measurement and 
serum and urine electrolyte studies, and 
exclusion of secondary causes of electrolyte 
imbalance
No access to clinical 
information
Potassium-sparing diuretics, NSAIDs, potassium and magnesium 
supplementation for electrolyte imbalances; encourage liberal salt 
intake
Regular nephrologic evaluation, including blood pressure and 
electrolytes
Skeletal studies if chondrocalcinosis suspected
Opthalmologic exam






Stringent Yes Electrolytes_Metabolic p.G429R 6.38E-04 1 DM 9042911
Pathogeni
c
1.2E+08 Likely Benign Hereditary orotic aciduria  258900 Recessive No
High urinary orotic acid excretion, orotic acid 
crystalluria 
Megaloblastic anemia
Developmental delay, intellectual disability
Cardiac anomalies
Immunodeficiency
No None based on internal classification
No access to clinical 
information





Stringent Yes Electrolytes_Metabolic p.R96G 2.90E-04 1 DM 9042911
Pathogeni
c
1.2E+08 Likely Benign Hereditary orotic aciduria  258900 Recessive No
High urinary orotic acid excretion, orotic acid 
crystalluria 
Megaloblastic anemia
Developmental delay, intellectual disability
Cardiac anomalies
Immunodeficiency
No None based on internal classification
No access to clinical 
information
None based on internal classification











Detailed history and physical exam to 
assess for personal and/or family history of 
epistaxis, telangiectasias, and AVMs
No access to clinical 
information
Comprehensive imaging (contrast echocardiography, head MRI, abd 
US/CT) to screen for visceral AVMs
Avoidance of nasal trauma/straining; severe epistaxis may require 
hemostatic agents and/or surgery
CBC to screen for anemia and polycythemia
Hepatologic evaluation, incuding liver function tests





Stringent Yes Glomerular p.R478L 4.48E-05 1 DM 20595690 . NA VUS
C3 deficiency; Atypical 










Drusen, increased risk of age-related macular 
degeneration
Yes
Determine cis or trans and clinical 
correlation, then potential Renal biopsy, 
with immunofluorescence and electron 
microscopy
No access to clinical 
information
Laboratory studies for complement factors/function
Serology to measure complement-associated autoantibodies
Renal function tests; regular nephrologic monitoring; consider ACE-
i/ARB and lipid-lowering therapy to help delay renal disease 
progression
Opthalmologic examination, surveillance for AMD/visual impairment
Consider anti-complement inhibitor therapy (e.g., Eculizumab)





Stringent Yes Glomerular p.T1383N 4.47E-04 4 DM 20595690 . NA VUS
C3 deficiency; Atypical 










Drusen, increased risk of age-related macular 
degeneration
Yes
Determine cis or trans and clinical 
correlation, then potential Renal biopsy, 
with immunofluorescence and electron 
microscopy
No access to clinical 
information
Laboratory studies for complement factors/function
Serology to measure complement-associated autoantibodies
Renal function tests; regular nephrologic monitoring; consider ACE-
i/ARB and lipid-lowering therapy to help delay renal disease 
progression
Opthalmologic examination, surveillance for AMD/visual impairment
Consider anti-complement inhibitor therapy (e.g., Eculizumab)
High risk of recurrence and allograft failure post-renal transplant
58 ID_52 CFHR5 Heterozygote Stringent No Glomerular p.S186X 2.69E-05 1 . . . . VUS
Nephropathy due to CFHR5 
deficiency
 614809 Dominant No
Glomerulonephritis, ESRD
Hypocomplementemia (low CFHR5 levels)
Yes
Detailed family history and physical exam, 
Renal biopsy, with immunofluorescence 
and electron microscopy
No access to clinical 
information
Laboratory studies for complement factors/function
Serology to measure complement-associated autoantibodies
Renal function tests; regular nephrologic monitoring; consider ACE-
i/ARB and lipid-lowering therapy to help delay renal disease 
progression
Consider anti-complement inhibitor therapy (e.g., Eculizumab)
High risk of recurrence and allograft failure post-renal transplant
59 ID_53 CFHR5 Heterozygote Stringent No Glomerular p.R435X 3.25E-05 1 . . . . VUS
Nephropathy due to CFHR5 
deficiency
 614809 Dominant No
Glomerulonephritis, ESRD
Hypocomplementemia (low CFHR5 levels)
Yes
Detailed family history and physical exam, 
Renal biopsy, with immunofluorescence 
and electron microscopy
No access to clinical 
information
Laboratory studies for complement factors/function
Serology to measure complement-associated autoantibodies
Renal function tests; regular nephrologic monitoring; consider ACE-
i/ARB and lipid-lowering therapy to help delay renal disease 
progression
Consider anti-complement inhibitor therapy (e.g., Eculizumab)
High risk of recurrence and allograft failure post-renal transplant
60 ID_54 FOXC2 Heterozygote Stringent Yes Glomerular p.L487P 2.99E-05 1 DM 22768468 . . VUS
Lymphedema-distichiasis 










Renal and genitourinary tract anomalies; CKD
Diabetes mellitus
Yes
Detailed family history and physical exam 
to assess for primary lymphedema and 
distichiasis
No access to clinical 
information
Opthalmologic evaluation, including slit lamp exam, to assess extent 
of distichiasis and for other ocular anomalies
Lymphoscintiagraphy to detect underlying vascular anomalies
Cardiac exam and imaging
Abdominal ultrasound and imaging 
Neurologic evaluation, including imaging, to screen for spinal cysts
Orthopedic evaluation for scoliosis 
Compression therapy (hosiery, bandaging) for lymphedema; 
heightened surveillance for cellulitis, with antibiotic prophylaxis if 
recurrent episodes
Fasting glucose, glucose tolerance tests







Focal segmental glomerulosclerosis, ESRD
Peripheral motor and sensory neuropathy 
Foot and hand anomalies
Yes Nephrologic evaluation, with urinalysis 
No access to clinical 
information
Nephrologic evaluation and monitoring of renal function; ACE-i/ARB 
therapy to slow renal disease progression
Favorable renal transplant prognosis, if ESRD is reached
Neurologic evaluation +/- neuromuscular studies (nerve conduction 
velocity, EMG)
Orthopedic evaluation and imaging
62 ID_56 KANK4 Homozygote Stringent No Glomerular p.R448X 1.96E-04 3 . . . . VUS Nephrotic syndrome NA Recessive No
Focal segmental glomerulosclerosis, ESRD




Detailed history and physical exam to 
assess for personal and/or family history of 
characteristic disease manifestions, 
Nephrologic evaluation, with urinalysis 
No access to clinical 
information
Nephrologic evaluation and monitoring of renal function; ACE-i/ARB 
therapy to slow renal disease progression
Cardiac exam and imaging
Neurodevelopmental evaluation
63 ID_57 LMX1B Heterozygote Stringent Yes Glomerular p.C118Y 0.00E+00 1 DM 10571942
Pathogeni
c
1.2E+08 Likely Pathogenic Nail-patella syndrome 161200 Dominant No
Nail dysplasia
Musculoskeletal anomalies (arthopathy, 
osteoporosis) 
Proteinuria and CKD 
Glaucoma and opthalmologic anomalies  
GI dysfunction (constipation, IBS) 
Peripheral neuropathy, epilepsy 
Vasomotor dysfunction 
Dental anomalies (increased fragility, enamel 
hypoplasia)
Yes
Detailed musculoskeletal exam and imaging 
to detect nail and orthopedic anomalies
No access to clinical 
information
Routine DEXAs for bone mineral density; analagesiacs, physical 
therapy, and/or surgery for orthopedic anomalies
Renal function tests; consider ACE-i/ARB therapy 
Opthalmologic exam; regular glaucoma screening, with 
medication/surgical intervention if indicated 
GI screening for digestive issues 
Neurologic exam and EEG 
Dental screening and heightened surveillance for tooth damage, decay, 
and trauma
64 ID_58 LMX1B Heterozygote Stringent Yes Glomerular p.R223Q 0.00E+00 1 DM 9837817
Pathogeni
c
1.2E+08 Pathogenic Nail-patella syndrome 161200 Dominant No
Nail dysplasia
Musculoskeletal anomalies (arthopathy, 
osteoporosis) 
Proteinuria and CKD 
Glaucoma and opthalmologic anomalies  
GI dysfunction (constipation, IBS) 
Peripheral neuropathy, epilepsy 
Vasomotor dysfunction 
Dental anomalies (increased fragility, enamel 
hypoplasia)
Yes
Detailed musculoskeletal exam and imaging 
to detect nail and orthopedic anomalies





Routine DEXAs for bone mineral density; analagesiacs, physical 
therapy, and/or surgery for orthopedic anomalies
Renal function tests; consider ACE-i/ARB therapy 
Opthalmologic exam; regular glaucoma screening, with 
medication/surgical intervention if indicated 
GI screening for digestive issues 
Neurologic exam and EEG 
Dental screening and heightened surveillance for tooth damage, decay, 
and trauma
65 ID_59 MYH9 Heterozygote Stringent Yes Glomerular p.R1877Q 2.72E-05 1 DM 25077172 . . VUS






Elevated liver enzymes (AST and/or ALT)
Glomerulopathy, ESRD
Yes
Detailed history and physical exam to 
assess for personal and/or family history of 
characteristic disease manifestions, 
Hematologic evaluation, including CBC 
and peripheral blood smear with 
microscopic and immunofluorescence 
analysis
No access to clinical 
information
Routine hematologic evaluation, monitor for thrombocytopenia and 
anemia (secondary to bleeding diathesis)
Otolaryngologic evaluation, including hearing tests
Opthalmologic exam
Hepatologic evaluation, including liver function tests 
Nephrologic evaluation, including renal function tests (serum BUN 
and creatinine, urinalysis); consider ACE-i/ARB therapy to slow renal 
disease progression
Heightened surveillance to prevent bleeding secondary to surgical 
procedures, with prophalyctic agents (e.g., platelet transfusion, 
despromessin)
Avoid anti-platelet and anti-coagulant agents (e.g., aspirin) and high-
risk activities (e.g., contact sports)
Cautious use of ototoxic, hepatotoxic and/or nephrotoxic agents







Episodic inflammatory episodies, with skin rash, 
arthralgias, leukocytosis, fever, and 




Detailed history and physical exam to 
assess for personal and/or family history of 
characteristic disease manifestions, 
Rheumatologic evaluation for personal 









Otolaryngologic evaluation, including hearing tests
Nephrologic evaluation, including renal function tests (serum BUN 
and creatinine, urinalysis) and renal biopsy to assess for amyloidosis
Consider anti-inflammatory agents (NSAIDs and/or corticosteroids to 
reduce joint pain; anti-IL1 agents for longer-term therapy)







Episodic inflammatory episodies, with skin rash, 
arthralgias, leukocytosis, fever, and 




Detailed history and physical exam to 
assess for personal and/or family history of 
characteristic disease manifestions, 
Rheumatologic evaluation for personal 
and/or family history of inflammatory 
episodes
No access to clinical 
information
Otolaryngologic evaluation, including hearing tests
Nephrologic evaluation, including renal function tests (serum BUN 
and creatinine, urinalysis) and renal biopsy to assess for amyloidosis
Consider anti-inflammatory agents (NSAIDs and/or corticosteroids to 




68 ID_62 PDSS1 Homozygote Stringent No Glomerular c.130-1G>C 0.00E+00 1 . . . . Likely Pathogenic
Coenzyme Q10 deficiency, 
primary, 2
 614651 Recessive No
Obesity
Early-onset hearing loss, deafness
Optic atrophy




Elevated serum lactate 
Steroid-resistance nephrotic syndrome* 
Yes
Detailed history and physical exam to 
assess for personal and/or family history of 
characteristic disease manifestions, 
Biochemical testing (skeletal muscle 
CoQ10 levels, reduced muscle 
mitochondrial respiratory chain compelex 
I+III and II+III activity)
No access to clinical 
information
Neurologic evaluation, with imaging
Cardiac exam and imaging
Opthalmologic evaluation
Otolaryngologic evaluation, including hearing function tests
Nephrologic evaluation, including renal function tests (serum BUN 
and creatinine, urinanalysis); consider ACE-i/ARB therapy (in 
conjunction with CoQ10 supplementation) to slow renal disease 
progression
CoQ10 supplementation
69 ID_63 TRPC6 Heterozygote Stringent Yes Glomerular p.R360H 6.00E-05 1 DM 22732337 . . VUS
Focal Segmental 
Glomerulosclerosis 2
603965 Dominant No Focal segmental glomerulosclerosis, ESRD Yes
Detailed history to assess for positive 
family history of disease manifestations, 
Nephrologic evaluation, with urinalysis 
No access to clinical 
information
Nephrologic evaluation and monitoring of renal function; ACE-i/ARB 
therapy to slow renal disease progression
Favorable renal transplant prognosis, if ESRD is reached











Neuropsychiatric dysfunction (depression, 
cognitive alterations)
Yes
Detailed endocrinology workup, including 
measurement of plasma cortisol and ACTH
Abdominal imaging to screen for adrenal 
tumors
No access to clinical 
information
Adrenalectomy; interim use of steroidogenesis inhibitors or other G-
protein coupled receptor-blocking agents
Routine endocrinologic monitoring
71 ID_65 CACNA1S Heterozygote Stringent No Secondary.Renal
c.4113+1G>
A
0.00E+00 1 . . . . VUS
Hypokalemic periodic paralysis 
type 1; Malignant hyperthermia 
susceptibility 5, Thyrotoxic 











Episodic attacks of muscular weakness and 
paralysis, accompanied by hypokalemia
Myopathy (variable, generally later-onset)
Malignant hyperthermia (increased 
susceptibility)
No None based on current ACMG59 guidelines
No access to clinical 
information
None based on current ACMG59 guidelines
72 ID_66 CACNA1S Heterozygote Stringent No Secondary.Renal c.2491-1G>T 0.00E+00 1 . . . . VUS
Hypokalemic periodic paralysis 
type 1; Malignant hyperthermia 
susceptibility 5, Thyrotoxic 











Episodic attacks of muscular weakness and 
paralysis, accompanied by hypokalemia
Myopathy (variable, generally later-onset)
Malignant hyperthermia (increased 
susceptibility)
No None based on current ACMG59 guidelines
Passed away at the age 
of 80 years old, None
None based on current ACMG59 guidelines
73 ID_67 CACNA1S Heterozygote Stringent No Secondary.Renal p.R757X 6.27E-05 1 . . . . VUS
Hypokalemic periodic paralysis 
type 1; Malignant hyperthermia 
susceptibility 5, Thyrotoxic 











Episodic attacks of muscular weakness and 
paralysis, accompanied by hypokalemia
Myopathy (variable, generally later-onset)
Malignant hyperthermia (increased 
susceptibility)
No None based on current ACMG59 guidelines
No access to clinical 
information
None based on current ACMG59 guidelines
74 ID_68 CACNA1S Heterozygote Stringent No Secondary.Renal
c.1948+1G>
A
8.97E-05 1 . . . .
VUS (recent 
annotation as VUS 
in ClinVar)
Hypokalemic periodic paralysis 
type 1; Malignant hyperthermia 
susceptibility 5, Thyrotoxic 











Episodic attacks of muscular weakness and 
paralysis, accompanied by hypokalemia
Myopathy (variable, generally later-onset)
Malignant hyperthermia (increased 
susceptibility)
No None based on current ACMG59 guidelines
No access to clinical 
information
None based on current ACMG59 guidelines
75 ID_69 CACNA1S Heterozygote Stringent No Secondary.Renal p.W369X 0.00E+00 1 . . . . VUS
Hypokalemic periodic paralysis 
type 1; Malignant hyperthermia 
susceptibility 5, Thyrotoxic 











Episodic attacks of muscular weakness and 
paralysis, accompanied by hypokalemia
Myopathy (variable, generally later-onset)
Malignant hyperthermia (increased 
susceptibility)
No None based on current ACMG59 guidelines
No access to clinical 
information
None based on current ACMG59 guidelines
76 ID_70 CACNA1S Heterozygote Stringent Yes Secondary.Renal p.Q1265H 8.96E-06 1 DM 26247046 . . VUS
Hypokalemic periodic paralysis 
type 1; Malignant hyperthermia 
susceptibility 5, Thyrotoxic 











Episodic attacks of muscular weakness and 
paralysis, accompanied by hypokalemia
Myopathy (variable, generally later-onset)
Malignant hyperthermia (increased 
susceptibility)
Yes
Detailed history for personal and/or family 
history of muscle weakness with 
hypokalemia, without other causes; physical 
exam to detect decreased muscle tone 
Potassium studies 
No access to clinical 
information
Neurologic exam to assess muscle strength in lower extremities
Thyroid function tests
CT scan of muscles to evaluate myopathy (if fixed muscle weakness)
Avoidance of potential triggers of muscle attacks (e.g., strenuous 
exertion, prolonged immobility, carbohydrate-rich diet), associated 
dietary/lifestyle counseling
Consider use of anti-hypokalemic agents (e.g., potassium 
supplementation, acetazolamide) to prevent attacks
Cautious use of anesthesia (with heightened pre- and post-operative 
surveillance), corticosteroids, and alpha- and beta-adrenergics










Opthalmologic anomalies (corneal, lenticular 
opacities)
Cardiac disease (ischemia, hypertrophic 
cardiomyopathy, mitral valvular disease, 
congestive heart failure)
Cerebrovascular disease
Renal azotemia and progressive CKD 
Gastrointestinal dysfunction, diverticulosis 
Obstructive lung disease
Lower extremity edema 
Vestibulo-cochlear dysfunction
Neuropsychiatric dysfunction (depression, 
anxiety, severe fatigue)
Yes
Detailed history and physical exam to 
assess for personal and/or family history of 
characteristic disease manifestions
Measurement of alpha-galactosidase A 
enzyme activity
No access to clinical 
information
Dermatologic exam for angiokeratomas
Neurologic evaluation; use of anti-neuropathic agents for 
acroparesthesias; routine neuroimaging (MRI/MRA)
Opthalmologic evaluation
Cardiac exam and imaging
Nephrologic evaluation, including renal function tests (serum BUN, 
creatinine, urinalysis)
Gastrointestinal evaluation, with follow-up imaging if indicated
Pulmonary function testing
Psychiatric evaluation
Enzyme replacement therapy; consider enrolling into clinical trials for 
newer therapies (e.g., chaperone therapy)
Renovascular, cardiovascular, and cerebrovascular disease prophylaxis 
(ACE-i/ARBs, lipid-lowering agents, aspirin/other anti-platelet agents)
78 ID_72 GLA Hemizygote Stringent Yes Secondary.Renal p.R363H 3.13E-04 1 DM HGOL
Pathogeni
c




Opthalmologic anomalies (corneal, lenticular 
opacities)
Cardiac disease (ischemia, hypertrophic 
cardiomyopathy, mitral valvular disease, 
congestive heart failure)
Cerebrovascular disease
Renal azotemia and progressive CKD 
Gastrointestinal dysfunction, diverticulosis 
Obstructive lung disease
Lower extremity edema 
Vestibulo-cochlear dysfunction
Neuropsychiatric dysfunction (depression, 
anxiety, severe fatigue)
Yes
Detailed history and physical exam to 
assess for personal and/or family history of 
characteristic disease manifestions
Measurement of alpha-galactosidase A 
enzyme activity
76 years old, None
Dermatologic exam for angiokeratomas
Neurologic evaluation; use of anti-neuropathic agents for 
acroparesthesias; routine neuroimaging (MRI/MRA)
Opthalmologic evaluation
Cardiac exam and imaging
Nephrologic evaluation, including renal function tests (serum BUN, 
creatinine, urinalysis)
Gastrointestinal evaluation, with follow-up imaging if indicated
Pulmonary function testing
Psychiatric evaluation
Enzyme replacement therapy; consider enrolling into clinical trials for 
newer therapies (e.g., chaperone therapy)
Renovascular, cardiovascular, and cerebrovascular disease prophylaxis 
(ACE-i/ARBs, lipid-lowering agents, aspirin/other anti-platelet agents)










Opthalmologic anomalies (corneal, lenticular 
opacities)
Cardiac disease (ischemia, hypertrophic 
cardiomyopathy, mitral valvular disease, 
congestive heart failure)
Cerebrovascular disease
Renal azotemia and progressive CKD 
Gastrointestinal dysfunction, diverticulosis 
Obstructive lung disease
Lower extremity edema 
Vestibulo-cochlear dysfunction
Neuropsychiatric dysfunction (depression, 
anxiety, severe fatigue)
Yes
Detailed history and physical exam to 
assess for personal and/or family history of 
characteristic disease manifestions
Measurement of alpha-galactosidase A 
enzyme activity
No access to clinical 
information
Dermatologic exam for angiokeratomas
Neurologic evaluation; use of anti-neuropathic agents for 
acroparesthesias; routine neuroimaging (MRI/MRA)
Opthalmologic evaluation
Cardiac exam and imaging
Nephrologic evaluation, including renal function tests (serum BUN, 
creatinine, urinalysis)
Gastrointestinal evaluation, with follow-up imaging if indicated
Pulmonary function testing
Psychiatric evaluation
Enzyme replacement therapy; consider enrolling into clinical trials for 
newer therapies (e.g., chaperone therapy)
Renovascular, cardiovascular, and cerebrovascular disease prophylaxis 















Opthalmologic anomalies (corneal, lenticular 
opacities)
Cardiac disease (ischemia, hypertrophic 
cardiomyopathy, mitral valvular disease, 
congestive heart failure)
Cerebrovascular disease
Renal azotemia and progressive CKD 
Gastrointestinal dysfunction, diverticulosis 
Obstructive lung disease
Lower extremity edema 
Vestibulo-cochlear dysfunction
Neuropsychiatric dysfunction (depression, 
anxiety, severe fatigue)
Yes
Detailed history and physical exam to 
assess for personal and/or family history of 
characteristic disease manifestions
Measurement of alpha-galactosidase A 
enzyme activity
No access to clinical 
information
Dermatologic exam for angiokeratomas
Neurologic evaluation; use of anti-neuropathic agents for 
acroparesthesias; routine neuroimaging (MRI/MRA)
Opthalmologic evaluation
Cardiac exam and imaging
Nephrologic evaluation, including renal function tests (serum BUN, 
creatinine, urinalysis)
Gastrointestinal evaluation, with follow-up imaging if indicated
Pulmonary function testing
Psychiatric evaluation
Enzyme replacement therapy; consider enrolling into clinical trials for 
newer therapies (e.g., chaperone therapy)
Renovascular, cardiovascular, and cerebrovascular disease prophylaxis 
(ACE-i/ARBs, lipid-lowering agents, aspirin/other anti-platelet agents)










Opthalmologic anomalies (corneal, lenticular 
opacities)
Cardiac disease (ischemia, hypertrophic 
cardiomyopathy, mitral valvular disease, 
congestive heart failure)
Cerebrovascular disease
Renal azotemia and progressive CKD 
Gastrointestinal dysfunction, diverticulosis 
Obstructive lung disease
Lower extremity edema 
Vestibulo-cochlear dysfunction
Neuropsychiatric dysfunction (depression, 
anxiety, severe fatigue)
No None based on internal classification
No access to clinical 
information
None based on internal classification
82 ID_76 SCN4A Heterozygote Stringent Yes Secondary.Renal p.R1460Q 8.97E-06 1 DM 21752396 . . VUS
Hypokalemic periodic paralysis 
type 2
613345 Dominant No
Episodic attacks of muscular weakness and 
paralysis, accompanied by hypokalemia
Myopathy (variable)
Yes
Detailed history for personal and/or family 
history of muscle weakness with 
hypokalemia, without other causes; physical 
exam to detect decreased muscle tone 
Potassium studies 
No access to clinical 
information
Neurologic exam to assess muscle strength in lower extremities
CT scan of muscles to evaluate myopathy (if fixed muscle weakness)
Avoidance of potential triggers of muscle attacks (e.g., strenuous 
exertion, prolonged immobility, carbohydrate-rich diet), associated 
dietary/lifestyle counseling
Guide choice of therapy for attacks (potassium favored over 
acetazolamide)
83 ID_77 SCN4A Heterozygote Stringent Yes Secondary.Renal p.R1135C 1.80E-05 1 DM 24549961 . .





Hypokalemic periodic paralysis 
type 2
613345 Dominant No
Episodic attacks of muscular weakness and 
paralysis, accompanied by hypokalemia
Myopathy (variable)
No None based on internal classification
No access to clinical 
information
None based on internal classification










Hypokalemic periodic paralysis 
type 2
613345 Dominant No
Episodic attacks of muscular weakness and 
paralysis, accompanied by hypokalemia
Myopathy (variable)
No None based on internal classification
No access to clinical 
information
None based on internal classification
85 ID_79 PROKR2 Heterozygote Stringent Yes Genital p.M111R 8.95E-06 1 DM 20696889 . . VUS
Kallmann syndrome 3 
(Hypogonadotropic 






Detailed endocrinology workup, including 
Tanner staging and measurement of LH, 
FSH, and sex steroid hormones
Olfactory function testing
No access to clinical 
information
Evaluation for bone disease (calcium, PTH, Vitamin D levels; DEXA 
scan) and routine monitoring of bone density; consider calcium and 
Vitamin D supplementation
Hormone replacement therapy if patient desires fertility
86 ID_80 CDKN1B Heterozygote Stringent No Cancer p.R5X 4.53E-05 1 . . . . VUS




Neuroendocrine tumors (pituitary adenoma, 
parathyroid adenoma; carcinoid tumors; papillary 
thyroid carcinoma; cervical carcinoma; 
pancreatic neoplasms)




Detailed family history and physical exam, 
Detailed endocrinology workup, including 
parathyroid function studies and imaging 
for tumors
No access to clinical 
information
Regular endocrine evaluation, including monitoring parathyroid 
function and bone density; parathyroidectomy may be needed
Routine screening for tumors








Neuroendocrine tumors (pituitary adenoma, 
parathyroid adenoma; carcinoid tumors; papillary 
thyroid carcinoma; cervical carcinoma; 
pancreatic neoplasms)




Detailed family history and physical exam, 
Detailed endocrinology workup, including 
parathyroid function studies and imaging 
for tumors
44 years old, GI 
neoplasm, NOS
Regular endocrine evaluation, including monitoring parathyroid 
function and bone density; parathyroidectomy may be needed
Routine screening for tumors
88 ID_82 CDKN1B Heterozygote Stringent Yes Cancer p.G9R 6.50E-05 1 DM 21289244 . . VUS




Neuroendocrine tumors (pituitary adenoma, 
parathyroid adenoma; carcinoid tumors; papillary 
thyroid carcinoma; cervical carcinoma; 
pancreatic neoplasms)




Detailed family history and physical exam, 
Detailed endocrinology workup, including 
parathyroid function studies and imaging 
for tumors
No access to clinical 
information
Regular endocrine evaluation, including monitoring parathyroid 
function and bone density; parathyroidectomy may be needed
Routine screening for tumors
89 ID_83 FLCN Heterozygote Stringent Yes Cancer c.250-2A>G 8.97E-06 1 DM 18234728
Pathogeni
c
4E+08 Pathogenic Birt-Hogg-Dube Syndrome  135150 Dominant No
Fibrofolliculomas and/or other cutaneous lesions
Lung cysts, spontaneous pneumothorax
Renal tumors
Other malignancies (e.g., parotid oncoytoma)
Yes
Dermatologic evaluation for cutaneous 
lesions
Chest CT scan to detect lung cyts
Abdominal imaging for renal tumors 
Passed away at the age 




abnormal lung imaging; 
thyroid neoplasm
Detailed examination, including biopsy, of suspected cutaneous 
lesions
Routine screening for renal tumors, including annual renal imaging
Avoid carcinogenic agents (e.g., smoking, radiation) due to 
malignancy predisposition and high ambient pressures (may 
precipitate spontaneous pneumothorax)
90 ID_109 FLCN Heterozygote Stringent Yes Cancer p.Y463X 0.00E+00 1 DM 12204536
Pathogeni
c
1.4E+08 Pathogenic Birt-Hogg-Dube Syndrome  135150 Dominant No
Fibrofolliculomas and/or other cutaneous lesions
Lung cysts, spontaneous pneumothorax
Renal tumors
Other malignancies (e.g., parotid oncoytoma)
Yes
Dermatologic evaluation for cutaneous 
lesions
Chest CT scan to detect lung cyts
Abdominal imaging for renal tumors 
No access to clinical 
information
Detailed examination, including biopsy, of suspected cutaneous 
lesions
Routine screening for renal tumors, including annual renal imaging
Avoid carcinogenic agents (e.g., smoking, radiation) due to 













Sebaceous gland neoplasms 
Visceral malignancies, including colorectal, 
endometrial, gastric, and genitourinary tumors
Yes
Oncologic evaluation, including assessment 
for a positive personal and/or family history 
for the associated malignancies and 
microsatellite instability testing of tumors 
detected
No access to clinical 
information
Heightened surveillance for associated malignancies, including regular 
colonoscopies with removal of any polyps detected
Consider chemoprevention to reduce risk of associated malignancies 
(aspirin for colorectal cancer, oral contraceptives for endometrial 
cancer) and prophylactic surgery for gynecological malignancies (e.g., 
hysterectomy for endometrial cancer)






3.7E+08 VUS Neurofibromatosis, type 1 162200 Dominant No
Cutaneous lesions (Café au lait macules, axillary 
or inguinal freckles)
Neurofibromas
Opthalmologic tumors (optic glioma, Lisch 
nodules (iris hamartomas))
Osseous lesions
Intellectual disability, neuropsychiatric disease
Neurologic dysfunction (polyneuropathy, 
seizures), cerebrovascular disease
Musculoskeletal anomalies (osteopenia, long-
bone dysplasia, scoliosis)
Hypertension, renovascular disease
Structural cardiac anomalies, pulmonary 
hypertension
Leukemia and myelodysplastic syndrome 
predisposition
Yes
Detailed history and physical exam to 
assess for positive family history and 
presence of cutaneous lesions, ocular 
anomalies, and osseous lesions
No access to clinical 
information
Opthalmologic evaluation, including slit lamp exam and infrared 
reflectance imaging or optical CT scan scan of fundus
Neurodevelopmental assessment, including neuroimaging and EEG
Cardiac exam and imaging 
Orthopedic evaluation and imaging 
Nephrologic evaluation, including renal imaging, to assess for 
hypertension and renovascular disease 
Hematologic evaluation; heightened surveillance for malignancy
93 ID_86 NF1 Heterozygote Stringent Yes Cancer p.R461X 0.00E+00 1 DM 10712197
Pathogeni
c
8.8E+08 Pathogenic Neurofibromatosis, type 1 162200 Dominant No
Cutaneous lesions (Café au lait macules, axillary 
or inguinal freckles)
Neurofibromas
Opthalmologic tumors (optic glioma, Lisch 
nodules (iris hamartomas))
Osseous lesions
Intellectual disability, neuropsychiatric disease
Neurologic dysfunction (polyneuropathy, 
seizures), cerebrovascular disease
Musculoskeletal anomalies (osteopenia, long-
bone dysplasia, scoliosis)
Hypertension, renovascular disease
Structural cardiac anomalies, pulmonary 
hypertension
Leukemia and myelodysplastic syndrome 
predisposition
Yes
Detailed history and physical exam to 
assess for positive family history and 
presence of cutaneous lesions, ocular 









5.9E+08 VUS Neurofibromatosis, type 1 162200 Dominant No
Cutaneous lesions (Café au lait macules, axillary 
or inguinal freckles)
Neurofibromas
Opthalmologic tumors (optic glioma, Lisch 
nodules (iris hamartomas))
Osseous lesions
Intellectual disability, neuropsychiatric disease
Neurologic dysfunction (polyneuropathy, 
seizures), cerebrovascular disease
Musculoskeletal anomalies (osteopenia, long-
bone dysplasia, scoliosis)
Hypertension, renovascular disease
Structural cardiac anomalies, pulmonary 
hypertension
Leukemia and myelodysplastic syndrome 
predisposition
Yes
Detailed history and physical exam to 
assess for positive family history and 
presence of cutaneous lesions, ocular 
anomalies, and osseous lesions
No access to clinical 
information
Opthalmologic evaluation, including slit lamp exam and infrared 
reflectance imaging or optical CT scan scan of fundus
Neurodevelopmental assessment, including neuroimaging and EEG
Cardiac exam and imaging 
Orthopedic evaluation and imaging 
Nephrologic evaluation, including renal imaging, to assess for 
hypertension and renovascular disease 
Hematologic evaluation; heightened surveillance for malignancy
95 ID_88 NF1 Heterozygote Stringent Yes Cancer p.R440X 5.80E-05 1 DM 7655472
Pathogeni
c
7.8E+08 Pathogenic Neurofibromatosis, type 1 162200 Dominant No
Cutaneous lesions (Café au lait macules, axillary 
or inguinal freckles)
Neurofibromas
Opthalmologic tumors (optic glioma, Lisch 
nodules (iris hamartomas))
Osseous lesions
Intellectual disability, neuropsychiatric disease
Neurologic dysfunction (polyneuropathy, 
seizures), cerebrovascular disease
Musculoskeletal anomalies (osteopenia, long-
bone dysplasia, scoliosis)
Hypertension, renovascular disease
Structural cardiac anomalies, pulmonary 
hypertension
Leukemia and myelodysplastic syndrome 
predisposition
Yes
Detailed history and physical exam to 
assess for positive family history and 
presence of cutaneous lesions, ocular 
anomalies, and osseous lesions
No access to clinical 
information
Opthalmologic evaluation, including slit lamp exam and infrared 
reflectance imaging or optical CT scan scan of fundus
Neurodevelopmental assessment, including neuroimaging and EEG
Cardiac exam and imaging 
Orthopedic evaluation and imaging 
Nephrologic evaluation, including renal imaging, to assess for 
hypertension and renovascular disease 
Hematologic evaluation; heightened surveillance for malignancy
96 ID_89 NF1 Heterozygote Stringent Yes Cancer p.M1073V 2.81E-05 1 DM 15060124
Not 
Provided
2E+08 VUS Neurofibromatosis, type 1 162200 Dominant No
Cutaneous lesions (Café au lait macules, axillary 
or inguinal freckles)
Neurofibromas
Opthalmologic tumors (optic glioma, Lisch 
nodules (iris hamartomas))
Osseous lesions
Intellectual disability, neuropsychiatric disease
Neurologic dysfunction (polyneuropathy, 
seizures), cerebrovascular disease
Musculoskeletal anomalies (osteopenia, long-
bone dysplasia, scoliosis)
Hypertension, renovascular disease
Structural cardiac anomalies, pulmonary 
hypertension
Leukemia and myelodysplastic syndrome 
predisposition
Yes
Detailed history and physical exam to 
assess for positive family history and 
presence of cutaneous lesions, ocular 
anomalies, and osseous lesions
No access to clinical 
information
Opthalmologic evaluation, including slit lamp exam and infrared 
reflectance imaging or optical CT scan scan of fundus
Neurodevelopmental assessment, including neuroimaging and EEG
Cardiac exam and imaging 
Orthopedic evaluation and imaging 
Nephrologic evaluation, including renal imaging, to assess for 
hypertension and renovascular disease 
Hematologic evaluation; heightened surveillance for malignancy




5.4E+08 VUS Neurofibromatosis, type 1 162200 Dominant No
Cutaneous lesions (Café au lait macules, axillary 
or inguinal freckles)
Neurofibromas
Opthalmologic tumors (optic glioma, Lisch 
nodules (iris hamartomas))
Osseous lesions
Intellectual disability, neuropsychiatric disease
Neurologic dysfunction (polyneuropathy, 
seizures), cerebrovascular disease
Musculoskeletal anomalies (osteopenia, long-
bone dysplasia, scoliosis)
Hypertension, renovascular disease
Structural cardiac anomalies, pulmonary 
hypertension
Leukemia and myelodysplastic syndrome 
predisposition
Yes
Detailed history and physical exam to 
assess for positive family history and 
presence of cutaneous lesions, ocular 
anomalies, and osseous lesions
No access to clinical 
information
Opthalmologic evaluation, including slit lamp exam and infrared 
reflectance imaging or optical CT scan scan of fundus
Neurodevelopmental assessment, including neuroimaging and EEG
Cardiac exam and imaging 
Orthopedic evaluation and imaging 
Nephrologic evaluation, including renal imaging, to assess for 
hypertension and renovascular disease 
Hematologic evaluation; heightened surveillance for malignancy






2E+08 VUS Neurofibromatosis, type 1 162200 Dominant No
Cutaneous lesions (Café au lait macules, axillary 
or inguinal freckles)
Neurofibromas
Opthalmologic tumors (optic glioma, Lisch 
nodules (iris hamartomas))
Osseous lesions
Intellectual disability, neuropsychiatric disease
Neurologic dysfunction (polyneuropathy, 
seizures), cerebrovascular disease
Musculoskeletal anomalies (osteopenia, long-
bone dysplasia, scoliosis)
Hypertension, renovascular disease
Structural cardiac anomalies, pulmonary 
hypertension
Leukemia and myelodysplastic syndrome 
predisposition
Yes
Detailed history and physical exam to 
assess for positive family history and 
presence of cutaneous lesions, ocular 
anomalies, and osseous lesions
No access to clinical 
information
Opthalmologic evaluation, including slit lamp exam and infrared 
reflectance imaging or optical CT scan scan of fundus
Neurodevelopmental assessment, including neuroimaging and EEG
Cardiac exam and imaging 
Orthopedic evaluation and imaging 
Nephrologic evaluation, including renal imaging, to assess for 
hypertension and renovascular disease 
Hematologic evaluation; heightened surveillance for malignancy




8.8E+08 VUS Neurofibromatosis, type 1 162200 Dominant No
Cutaneous lesions (Café au lait macules, axillary 
or inguinal freckles)
Neurofibromas
Opthalmologic tumors (optic glioma, Lisch 
nodules (iris hamartomas))
Osseous lesions
Intellectual disability, neuropsychiatric disease
Neurologic dysfunction (polyneuropathy, 
seizures), cerebrovascular disease
Musculoskeletal anomalies (osteopenia, long-
bone dysplasia, scoliosis)
Hypertension, renovascular disease
Structural cardiac anomalies, pulmonary 
hypertension
Leukemia and myelodysplastic syndrome 
predisposition
Yes
Detailed history and physical exam to 
assess for positive family history and 
presence of cutaneous lesions, ocular 
anomalies, and osseous lesions
No access to clinical 
information
Opthalmologic evaluation, including slit lamp exam and infrared 
reflectance imaging or optical CT scan scan of fundus
Neurodevelopmental assessment, including neuroimaging and EEG
Cardiac exam and imaging 
Orthopedic evaluation and imaging 
Nephrologic evaluation, including renal imaging, to assess for 
hypertension and renovascular disease 
Hematologic evaluation; heightened surveillance for malignancy




7.9E+08 VUS Neurofibromatosis, type 1 162200 Dominant No
Cutaneous lesions (Café au lait macules, axillary 
or inguinal freckles)
Neurofibromas
Opthalmologic tumors (optic glioma, Lisch 
nodules (iris hamartomas))
Osseous lesions
Intellectual disability, neuropsychiatric disease
Neurologic dysfunction (polyneuropathy, 
seizures), cerebrovascular disease
Musculoskeletal anomalies (osteopenia, long-
bone dysplasia, scoliosis)
Hypertension, renovascular disease
Structural cardiac anomalies, pulmonary 
hypertension
Leukemia and myelodysplastic syndrome 
predisposition
Yes
Detailed history and physical exam to 
assess for positive family history and 
presence of cutaneous lesions, ocular 
anomalies, and osseous lesions
No access to clinical 
information
Opthalmologic evaluation, including slit lamp exam and infrared 
reflectance imaging or optical CT scan scan of fundus
Neurodevelopmental assessment, including neuroimaging and EEG
Cardiac exam and imaging 
Orthopedic evaluation and imaging 
Nephrologic evaluation, including renal imaging, to assess for 
hypertension and renovascular disease 
Hematologic evaluation; heightened surveillance for malignancy






  612359; 
115310
Dominant Yes
Multiple paragangliomas (parasympathetic - 
carotid body, vagus nerve, jugulotympanic 
region; sympathetic - thorax, abdomen, pelvis)
Pheochromocytomas (adrenal or extra-adrenal)
Other tumors (gastrointestinal stromal, renal cell 
carcinoma, papillary thyroid carcinoma)
Yes
Detailed history to assess for personal 
and/or family history of symptoms 
consistent with catecholamine excess and 
associated tumors
Physical exam, including blood pressure 
measurement and detailed skull and neck 
examination
Imaging for tumors (CT/MRI), urinary 
catecholamine studies
No access to clinical 
information
Follow-up imaging to assess full tumor burden, with surgical resection 
of tumors detected due to high risk of metastasis
Oncologic screening for renal cell carcinoma
Routine biochemical and clinical surveillance for paraganglioma and 
pheochromocytoma, including imaging, urinary catecholamine studies
Evaluation for gastrointestinal tumors
Avoidance of hypoxic environments (e.g., high altitudes)







  612359; 
115310
Dominant Yes
Multiple paragangliomas (parasympathetic - 
carotid body, vagus nerve, jugulotympanic 
region; sympathetic - thorax, abdomen, pelvis)
Pheochromocytomas (adrenal or extra-adrenal)
Other tumors (gastrointestinal stromal, renal cell 
carcinoma, papillary thyroid carcinoma)
Yes
Detailed history to assess for personal 
and/or family history of symptoms 
consistent with catecholamine excess and 
associated tumors
Physical exam, including blood pressure 
measurement and detailed skull and neck 
examination
Imaging for tumors (CT/MRI), urinary 
catecholamine studies
No access to clinical 
information
Follow-up imaging to assess full tumor burden, with surgical resection 
of tumors detected due to high risk of metastasis
Oncologic screening for renal cell carcinoma
Routine biochemical and clinical surveillance for paraganglioma and 
pheochromocytoma, including imaging, urinary catecholamine studies
Evaluation for gastrointestinal tumors
Avoidance of hypoxic environments (e.g., high altitudes)






  612359; 
115310
Dominant Yes
Multiple paragangliomas (parasympathetic - 
carotid body, vagus nerve, jugulotympanic 
region; sympathetic - thorax, abdomen, pelvis)
Pheochromocytomas (adrenal or extra-adrenal)
Other tumors (gastrointestinal stromal, renal cell 
carcinoma, papillary thyroid carcinoma)
Yes
Detailed history to assess for personal 
and/or family history of symptoms 
consistent with catecholamine excess and 
associated tumors
Physical exam, including blood pressure 
measurement and detailed skull and neck 
examination
Imaging for tumors (CT/MRI), urinary 
catecholamine studies
No access to clinical 
information
Follow-up imaging to assess full tumor burden, with surgical resection 
of tumors detected due to high risk of metastasis
Oncologic screening for renal cell carcinoma
Routine biochemical and clinical surveillance for paraganglioma and 
pheochromocytoma, including imaging, urinary catecholamine studies
Evaluation for gastrointestinal tumors
Avoidance of hypoxic environments (e.g., high altitudes)







  612359; 
115310
Dominant Yes
Multiple paragangliomas (parasympathetic - 
carotid body, vagus nerve, jugulotympanic 
region; sympathetic - thorax, abdomen, pelvis)
Pheochromocytomas (adrenal or extra-adrenal)
Other tumors (gastrointestinal stromal, renal cell 
carcinoma, papillary thyroid carcinoma)
Yes
Detailed history to assess for personal 
and/or family history of symptoms 
consistent with catecholamine excess and 
associated tumors
Physical exam, including blood pressure 
measurement and detailed skull and neck 
examination
Imaging for tumors (CT/MRI), urinary 
catecholamine studies
No access to clinical 
information
Follow-up imaging to assess full tumor burden, with surgical resection 
of tumors detected due to high risk of metastasis
Oncologic screening for renal cell carcinoma
Routine biochemical and clinical surveillance for paraganglioma and 
pheochromocytoma, including imaging, urinary catecholamine studies
Evaluation for gastrointestinal tumors
Avoidance of hypoxic environments (e.g., high altitudes)






  612359; 
115310
Dominant Yes
Multiple paragangliomas (parasympathetic - 
carotid body, vagus nerve, jugulotympanic 
region; sympathetic - thorax, abdomen, pelvis)
Pheochromocytomas (adrenal or extra-adrenal)
Other tumors (gastrointestinal stromal, renal cell 
carcinoma, papillary thyroid carcinoma)
Yes
Detailed history to assess for personal 
and/or family history of symptoms 
consistent with catecholamine excess and 
associated tumors
Physical exam, including blood pressure 
measurement and detailed skull and neck 
examination
Imaging for tumors (CT/MRI), urinary 
catecholamine studies
No access to clinical 
information
Follow-up imaging to assess full tumor burden, with surgical resection 
of tumors detected due to high risk of metastasis
Oncologic screening for renal cell carcinoma
Routine biochemical and clinical surveillance for paraganglioma and 
pheochromocytoma, including imaging, urinary catecholamine studies
Evaluation for gastrointestinal tumors
Avoidance of hypoxic environments (e.g., high altitudes)




7.7E+08 VUS Tuberous sclerosis-1  191100 Dominant Yes
Skin lesions (hypomelanotic macules, facial 
angiofibromas, shagreen patches, cephalic 
plaques, ungual fibromas)
CNS tumors (cortical dysplasias, subependymal 
nodules, and subependymal giant cell 
astrocytomas)
Seizures, developmental delay and intellectual 
disability, neuropsychiatric disease
Cardiac rhabdomyomas, cardiac arrhythmias
Lymphangioleiomyomatosis
Renal angiomyolipomas, renal cysts, renal cell 
carcinoma
Retinal hamartomas





Detailed history to assess for positive 
family history of disease manifestations, 
Detailed physical exam to assess for 
characteristic skin lesions
CNS, cardiac, and abdominal imaging for 
tumors
No access to clinical 
information
Neurodevelopmental evaluation, with neuroimaging and EEG
Dermatologic evaluation
Opthalmologic exam
Cardiac exam and imaging
Pulmonary function testing
Nephrologic evaluation, including renal function tests (serum BUN 





107 ID_100 TSC1 Heterozygote Stringent Yes Cancer p.V82I 6.50E-05 1 DM 19747374
Not 
Provided
1.2E+08 Benign Tuberous Sclerosis-1  191100 Dominant Yes
Skin lesions (hypomelanotic macules, facial 
angiofibromas, shagreen patches, cephalic 
plaques, ungual fibromas)
CNS tumors (cortical dysplasias, subependymal 
nodules, and subependymal giant cell 
astrocytomas)
Seizures, developmental delay and intellectual 
disability, neuropsychiatric disease
Cardiac rhabdomyomas, cardiac arrhythmias
Lymphangioleiomyomatosis
Renal angiomyolipomas, renal cysts, renal cell 
carcinoma
Retinal hamartomas




No None based on internal classification
No access to clinical 
information
None based on internal classification
108 ID_101 TSC2 Heterozygote Stringent No Cancer c.2967-1G>T 0.00E+00 1 . . . . Likely Pathogenic Tuberous sclerosis-2  613254 Dominant Yes
Skin lesions (hypomelanotic macules, facial 
angiofibromas, shagreen patches, cephalic 
plaques, ungual fibromas)
CNS tumors (cortical dysplasias, subependymal 
nodules, and subependymal giant cell 
astrocytomas)
Seizures, developmental delay and intellectual 
disability, neuropsychiatric disease
Cardiac rhabdomyomas, cardiac arrhythmias
Lymphangioleiomyomatosis
Renal angiomyolipomas, renal cysts, renal cell 
carcinoma
Retinal hamartomas





Detailed history to assess for positive 
family history of disease manifestations; 
Detailed physical exam to assess for 
characteristic skin lesions
CNS, cardiac, and abdominal imaging for 
tumors
No access to clinical 
information
Neurodevelopmental evaluation, with neuroimaging and EEG
Dermatologic evaluation
Opthalmologic exam
Cardiac exam and imaging
Pulmonary function testing
Nephrologic evaluation, including renal function tests (serum BUN 
and creatinine, urinalysis) and imaging
Dental exam




8E+08 VUS Tuberous sclerosis-2  613254 Dominant Yes
Skin lesions (hypomelanotic macules, facial 
angiofibromas, shagreen patches, cephalic 
plaques, ungual fibromas)
CNS tumors (cortical dysplasias, subependymal 
nodules, and subependymal giant cell 
astrocytomas)
Seizures, developmental delay and intellectual 
disability, neuropsychiatric disease
Cardiac rhabdomyomas, cardiac arrhythmias
Lymphangioleiomyomatosis
Renal angiomyolipomas, renal cysts, renal cell 
carcinoma
Retinal hamartomas





Detailed history to assess for positive 
family history of disease manifestations; 
Detailed physical exam to assess for 
characteristic skin lesions
CNS, cardiac, and abdominal imaging for 
tumors
No access to clinical 
information
Neurodevelopmental evaluation, with neuroimaging and EEG
Dermatologic evaluation
Opthalmologic exam
Cardiac exam and imaging
Pulmonary function testing
Nephrologic evaluation, including renal function tests (serum BUN 
and creatinine, urinalysis) and imaging
Dental exam




1.4E+08 VUS Tuberous sclerosis-2  613254 Dominant Yes
Skin lesions (hypomelanotic macules, facial 
angiofibromas, shagreen patches, cephalic 
plaques, ungual fibromas)
CNS tumors (cortical dysplasias, subependymal 
nodules, and subependymal giant cell 
astrocytomas)
Seizures, developmental delay and intellectual 
disability, neuropsychiatric disease
Cardiac rhabdomyomas, cardiac arrhythmias
Lymphangioleiomyomatosis
Renal angiomyolipomas, renal cysts, renal cell 
carcinoma
Retinal hamartomas





Detailed history to assess for positive 
family history of disease manifestations; 
Detailed physical exam to assess for 
characteristic skin lesions
CNS, cardiac, and abdominal imaging for 
tumors
No access to clinical 
information
Neurodevelopmental evaluation, with neuroimaging and EEG
Dermatologic evaluation
Opthalmologic exam
Cardiac exam and imaging
Pulmonary function testing
Nephrologic evaluation, including renal function tests (serum BUN 




















CNS hemangioblastomas (spinal, cerebellar)
Adrenal or extra-adrenal pheochromocytoma
Renal cysts; renal cell carcinoma
Pancreatic cysts; pancreatic neuroendocrine 
tumors
Endolymphatic sac tumors
Epididymal and broad ligament cystadenomas
No None based on internal classification
No access to clinical 
information














CNS hemangioblastomas (spinal, cerebellar)
Adrenal or extra-adrenal pheochromocytoma
Renal cysts; renal cell carcinoma
Pancreatic cysts; pancreatic neuroendocrine 
tumors
Endolymphatic sac tumors
Epididymal and broad ligament cystadenomas
Yes
Imaging studies (brain, spinal cord, 
abdomen) to detect associated tumors 
and/or blood and urinary catecholamine 
studies (to screen for pheochromocytomas)
Opthalmologic exam, with fundoscopy, for 
retinal angiomas
Detailed clinical history to assess for 
personal and/or family history of disease 
manifestations
No access to clinical 
information
Regular neurologic evaluation, with neuroimaging 
Regular opthalmologic exams 
Nephrologic evaluation, including blood pressure monitoring, 















 107480 Dominant No
Imperforate anus
Ear anomalies, hearing impairment
Thumb anomalies
Kidney and genitourinary anomalies
Structural cardiac anomalies 
Foot anomalies
Developmental delay, intellectual disability
CNS anomalies (cranial nerve dysfunction, 
Duane anomaly, brain malformations)
Skeletal anomalies (ribs, vertebrae)
Ocular anomalies 
Growth retardation, congenital hypothyroidism
Yes
Detailed history to assess for positive 
family history of disease manifestations; 
Detailed physical exam to assess for 
characteristic triad of imperforate anus, ear 
anomalies, and thumb anomalies
54 years old, 
Congenital heart 
disease (ASD, VSD)
Otolaryngologic evaluation, including hearing tests; routine 
monitoring of hearing function
Nephrologic evaluation, including renal function tests (serum BUN 
and creatinine, urinalysis) and imaging; routine monitoring of renal 
function
Cardiac exam and imaging
Neurodevelopmental evaluation +/- neuroimaging 
Orthopedic evaluation and imaging
Opthalmologic exam
Endocrine evaluation, with hormone studies if indicated




ARID1A Heterozygote Standard No Congenital.or.developmental p.Q1584R 6.00E-04 4 NA NA NA NA Likely Pathogenic Coffin-Siris syndrome 2 614607 Dominant No
Digital anomalies (fifth digit hypoplasia or 
aplasia, +/- additional digits)
Developmental delay
Dysmorphic facies
Abnormal hair growth (hirsutism/hypertrichosis, 
sparse scalp hair)
CNS anomalies, hypotonia, seizures




Feeding difficulties, poor growth
Recurrent infections 
Structural cardiac anomalies
Renal and genitourinary anomalies 
Yes
Detailed history and physical exam to 
assess for key features of fifth digit 
hypoplasia/aplasia, characteristic facies, 
hirsuitism/hypertrichosis and sparse scalp 
hair, hypotonia, and developmental delay
information for 1/4 
individuals with the 
variant: 39 years old, 
No relevant clinical 
features
Detailed neurodevelopmental assessment, +/- neuroimaging and EEG
Opthalmologic exam
Audiology evaluation 
Gastroenterological evaluation; nutritional therapy if needed
Cardiac exam and imaging
Renal function tests and imaging
115 ID_112 ASXL1 Heterozygote
Standard 
(indel)
No Congenital.or.developmental p.H674Pfs*3 0.00E+00 1 NA NA NA NA Likely somatic Bohring-Opitz syndrome 605039 Dominant No
Craniofacial anomalies 
Developmental delay, seizures; CNS anomalies
Joint, digitial, and postural anomalies; hypotonia 
Opthamologic and optic nerve anomalies
Cardiac anomalies




No None based on internal classification
No access to clinical 
information
None based on internal classification






0.00E+00 1 NA NA NA NA Likely Pathogenic Coffin-Siris syndrome 1 135900 Dominant No
Digital anomalies (fifth digit hypoplasia or 
aplasia, +/- additional digits)
Developmental delay
Dysmorphic facies
Abnormal hair growth (hirsutism/hypertrichosis, 
sparse scalp hair)
CNS anomalies, hypotonia, seizures




Feeding difficulties, poor growth
Recurrent infections 
Structural cardiac anomalies
Renal and genitourinary anomalies 
Yes
Detailed history to assess for positive 
family history of disease manifestations; 
Detailed history and physical exam to 
assess for key features of fifth digit 
hypoplasia/aplasia, characteristic facies, 
hirsuitism/hypertrichosis and sparse scalp 
hair, hypotonia, and developmental delay
No access to clinical 
information
Detailed neurodevelopmental assessment, +/- neuroimaging and EEG
Opthalmologic exam
Audiology evaluation 
Gastroenterological evaluation; nutritional therapy if needed
Cardiac exam and imaging
Renal function tests and imaging







3.25E-05 1 NA NA NA NA Likely Pathogenic
CHARGE syndrome; 
Hypogonadotropic 






Choanal atresia or stenosis





Genitourinary anomalies (renal and/or genital)
Endocrine dysfunction (growth hormone 
deficiency, parathyroid hypoplasia, 
hypogonadism, hypothyroidism) 
Tracheoesophageal fistula 
Craniofacial anomalies (dysmorphic facies, 
orofacial clefting)
Thymic hypoplasia or aplasia, immunodeficiency
Musculoskeletal anomalies (hand, vertebral)
Yes
Detailed history to assess for positive 
family history of disease manifestations; 
Opthalmologic exam
Gastrointestinal evaluation and imaging
Detailed neurologic exam, including cranial 
nerve function testing
Detailed physical exam to assess for 
characteristic cranofacial and ear anomalies 
and other associated dysmorphologies
No access to clinical 
information
Regular opthalmologic evaluation to monitor visual function
Cardiac exam and imaging 
Otolaryngologic evaluation, including CT of temporal bones to detect 
middle and inner ear anomalies; routine audiologic function testing 
Abdominal ultrasound, renal function tests 
Detailed neurodevelopmental assessment 
Endocrinological evaluation, including hormone testing
Immunologic evaluation, including CBC and thymic imaging
Orthopedic evaluation and imaging





CHD7 Heterozygote Standard No Congenital.or.developmental p.E2185X 2.00E-04 2 NA NA NA NA Likely Pathogenic
CHARGE syndrome; 
Hypogonadotropic 






Choanal atresia or stenosis





Genitourinary anomalies (renal and/or genital)
Endocrine dysfunction (growth hormone 
deficiency, parathyroid hypoplasia, 
hypogonadism, hypothyroidism) 
Tracheoesophageal fistula 
Craniofacial anomalies (dysmorphic facies, 
orofacial clefting)
Thymic hypoplasia or aplasia, immunodeficiency
Musculoskeletal anomalies (hand, vertebral)
Yes
Detailed history to assess for positive 
family history of disease manifestations; 
Opthalmologic exam
Gastrointestinal evaluation and imaging
Detailed neurologic exam, including cranial 
nerve function testing
Detailed physical exam to assess for 
characteristic cranofacial and ear anomalies 
and other associated dysmorphologies
Information for 1/2 









anomalies (mitral valve 
disorder)
Regular opthalmologic evaluation to monitor visual function
Cardiac exam and imaging 
Otolaryngologic evaluation, including CT of temporal bones to detect 
middle and inner ear anomalies; routine audiologic function testing 
Abdominal ultrasound, renal function tests 
Detailed neurodevelopmental assessment 
Endocrinological evaluation, including hormone testing
Immunologic evaluation, including CBC and thymic imaging
Orthopedic evaluation and imaging
Cautious use of anesthesia and increased surveillance for airway 
management during surgery












with higher MAF 
in the cohort
Costello.syndrome 218040 Dominant No
Failure to thrive
Short stature
Craniofacial anomalies (including coarse facies, 
full lips, large mouth) 
Curly or sparse, fine hair
Skin anomalies (laxity, hyperpigmentation, 
palmar and plantar creasing, papillomatomata, 
premature aging)
Musculoskeletal anomalies (hypotonia, joint 
laxity, ulnar deviation of wrists and fingers; hip, 
foot, pectoral, rib, and foot anomalies)
Cardiac anomalies (hypertrophy, congenital heart 
defects, arrhythmias)
Neurologic dysfunction (CNS anomalies, 
seizures), develompental delay, intellectual 
disability
Malignancy predisposition
No None based on internal classification
No access to clinical 
information
None based on internal classification
164 ID_161 COL4A5 Heterozygote Standard Yes Glomerular p.G624D 2.00E-04 1 DM 9848783
Pathogeni
c
1E+08 Pathogenic Alport syndrome 301050 Dominant No
Glomerulonephritis, with microscopic hematuria; 
ESRD
Hearing loss
Opthalmologic anomalies (anterior lenticonus, 
maculopathy, corneal dystrophy)
Aortic aneuryms (males, rare)
Yes
Nephrological evaluation, including 
assessment for personal and/or family 
history of disease manifestation and 
urinalysis +/- renal biopsy
No access to clinical 
information
Audiologic evaluation, with hearing function testing
Opthalmologic exam
Cardiac evaluation and imaging (males, to screen for aortic aneurysm)
Nephrologic evaluation and monitoring of renal function; ACE-i/ARB 
therapy to slow renal disease progression
171 ID_167 DLX4 Heterozygote Standard No Genital p.C6X 1.25E-04 1 NA NA NA NA Likely Pathogenic Orofacial cleft 15 616788 Dominant No
Dysmorphic facies 
Opthalmologic anomalies
Cleft lip and cleft palate
Dental anomalies 
Hyponasal speech
Bilateral inguinal hernia 
Genitourinary tract anomalies
Yes
Detailed physical exam to assess for 
characteristic craniofacial and 
opthalmologic anomalies




Physical exam +/- imaging for hernias, with surgical intervention if 
indicated
Nephrologic/urologic evaluation
Consider surgical intervention for cleft lip/palate
172 ID_168 DLX4 Heterozygote
Standard 
(indel)
No Genital p.G10Afs*18 5.56E-05 1 NA NA NA NA Likely Pathogenic Orofacial cleft 15  616788 Dominant No
Dysmorphic facies 
Opthalmologic anomalies
Cleft lip and cleft palate
Dental anomalies 
Hyponasal speech
Bilateral inguinal hernia 
Genitourinary tract anomalies
Yes
Detailed physical exam to assess for 
characteristic craniofacial and 
opthalmologic anomalies




Physical exam +/- imaging for hernias, with surgical intervention if 
indicated
Nephrologic/urologic evaluation










0.00E+00 1 NA NA NA NA Likely Pathogenic
Cardiac valvular dysplasia X-
linked, Congenital short bowel 
syndrome, FG syndrome 2, 


















Craniofacial anomalies (proptosis, full cheeks, 
asymmetric facies, micrognathia)
Musculoskeletal anomalies (thorax, ribs, 
vertebrae, long bones; scoliosis, digital 
elongation, joint bowing or subluxation)
Hearing impairment
Cardiac anomalies
Kidney and genitourinary tract anomalies
Subglottic stenosis 
Hirsuitism 





Detailed physical exam to assess for 
characteristic craniofacial anomalies 
Orthopedic exam and imaging for skeletal 
anomalies
No access to clinical 
information
Comprehensive skeletal imaging
Otolaryngologic evaluation, with hearing function tests
Comprehensive neurodevelopmental assessment, with imaging
Cardiac exam and imaging 
Nephrologic evaluation, with renal function tests and imaging




















Endocrinologic anomalies (hyperparathyroidism, 
hypothyroidism, growth hormone deficiency, 
hypogonadotropic hypogonadism)
Facial anomalies (round face, full cheeks, short 
neck, low nasal bridge)
Opthalmologic anomalies (cataract, nystagmus)
Dental anomalies 
Obesity
Intellectual disability, developmental delay 
Musculoskeletal anomalies (subcutaneous 
ossifications, brachydactyly) 
Yes
Endocrine evaluation, with parathyroid 
hormone and calcium studies +/- Gsα 
protein functional assays
Musculoskeletal exam +/- imaging
No access to clinical 
information
Comprehensive endocrinologic evaluation and monitoring, including 
of parathyroid hormone, serum and urine calcium, phosphate, thryoid 
hormone, and Vitamin D levels
Calcium and vitamin D supplementation to maintain high-normal 




Regular musculoskeletal exams and imaging to monitor height and 
ossifications; surgical removal of ossifications if indicated
Nutritional and lifestyle counseling if obesity 
150 ID_147 GNAS Heterozygote
Standard 
(indel)














Endocrinologic anomalies (hyperparathyroidism, 
hypothyroidism, growth hormone deficiency, 
hypogonadotropic hypogonadism)
Facial anomalies (round face, full cheeks, short 
neck, low nasal bridge)
Opthalmologic anomalies (cataract, nystagmus)
Dental anomalies 
Obesity
Intellectual disability, developmental delay 
Musculoskeletal anomalies (subcutaneous 
ossifications, brachydactyly) 
Yes
Endocrine evaluation, with parathyroid 
hormone and calcium studies +/- Gsα 
protein functional assays
Musculoskeletal exam +/- imaging
No access to clinical 
information
Comprehensive endocrinologic evaluation and monitoring, including 
of parathyroid hormone, serum and urine calcium, phosphate, thryoid 
hormone, and Vitamin D levels
Calcium and vitamin D supplementation to maintain high-normal 




Regular musculoskeletal exams and imaging to monitor height and 
ossifications; surgical removal of ossifications if indicated




CHD7 Heterozygote Standard Yes Congenital.or.developmental p.G1845R 5.20E-04 2 DM 25472840 . . VUS
CHARGE syndrome; 
Hypogonadotropic 






Choanal atresia or stenosis





Genitourinary anomalies (renal and/or genital)
Endocrine dysfunction (growth hormone 
deficiency, parathyroid hypoplasia, 
hypogonadism, hypothyroidism) 
Tracheoesophageal fistula 
Craniofacial anomalies (dysmorphic facies, 
orofacial clefting)
Thymic hypoplasia or aplasia, immunodeficiency
Musculoskeletal anomalies (hand, vertebral)
Yes
Detailed history to assess for positive 
family history of disease manifestations; 
Opthalmologic exam
Gastrointestinal evaluation and imaging
Detailed neurologic exam, including cranial 
nerve function testing
Detailed physical exam to assess for 
characteristic cranofacial and ear anomalies 
and other associated dysmorphologies
No access to clinical 
information
Regular opthalmologic evaluation to monitor visual function
Cardiac exam and imaging 
Otolaryngologic evaluation, including CT of temporal bones to detect 
middle and inner ear anomalies; routine audiologic function testing 
Abdominal ultrasound, renal function tests 
Detailed neurodevelopmental assessment 
Endocrinological evaluation, including hormone testing
Immunologic evaluation, including CBC and thymic imaging
Orthopedic evaluation and imaging
Cautious use of anesthesia and increased surveillance for airway 
management during surgery













Choanal atresia or stenosis





Genitourinary anomalies (renal and/or genital)
Endocrine dysfunction (growth hormone 
deficiency, parathyroid hypoplasia, 
hypogonadism, hypothyroidism) 
Tracheoesophageal fistula 
Craniofacial anomalies (dysmorphic facies, 
orofacial clefting)
Thymic hypoplasia or aplasia, immunodeficiency
Musculoskeletal anomalies (hand, vertebral)
Yes
Detailed history to assess for positive 
family history of disease manifestations, 
Opthalmologic exam
Gastrointestinal evaluation and imaging
Detailed neurologic exam, including cranial 
nerve function testing
Detailed physical exam to assess for 
characteristic cranofacial and ear anomalies 
and other associated dysmorphologies
42 years old,  no 
relevant clinical 
features
Regular opthalmologic evaluation to monitor visual function
Cardiac exam and imaging 
Otolaryngologic evaluation, including CT of temporal bones to detect 
middle and inner ear anomalies; routine audiologic function testing 
Abdominal ultrasound, renal function tests 
Detailed neurodevelopmental assessment 
Endocrinological evaluation, including hormone testing
Immunologic evaluation, including CBC and thymic imaging
Orthopedic evaluation and imaging
Cautious use of anesthesia and increased surveillance for airway 
management during surgery
128 ID_125 EYA1 Heterozygote Standard Yes Congenital.or.developmental p.D256Y 3.70E-04 1 DM 23552953 . . VUS
Branchio-oto-renal syndrome, 




Ear anomalies and hearing impairment
Branchial cleft anomalies (fistulae, cysts)
Congenital kidney and genitourinary tract 
anomalies
Lacrimal duct aplasia
Craniofacial anomalies (cleft palate, 
retrognathia)
Euthyroid goiter
Neurologic anomalies (facial nerve palsy, 
gustatory lacrimation)
Yes
Detailed physical exam to assess for 
presence of branchial arch and ear 
anomalies and/or hearing impairment
Renal imaging to screen for congenital 
kidney and genitourinary tract anomalies
No access to clinical 
information
Detailed examination of cervical region for fistulae; neck CT scan for 
masses
Audiologic evaluation and CT scan of temporal bone for hearing 
impairment; routine audiologic testing to monitor hearing function
Routine nephrologic evaluation, with renal function testing
Endocrinologic evaluation if evidence of euthyroid goiter
















Limb anomalies (polydactyly, syndactyly)
Facial anomalies (macrocephaly, widely spaced 
eyes, wide nasal bridge)
Hypothalamic hamartoma
Bifid epiglottis
Kidney and genitourinary tract anomalies 
Intellectual disability, neuropsychiatric disease
Pulmonary anomalies (bilateral bilobed lungs)
No None based on internal classification
No access to clinical 
information









Renal Cysts and Diabetes 
Syndrome
 137920 Dominant No
Renal anomalies, tubulointerstitial renal disease, 
CKD
Hyperuricemia, gout
Abnormal liver function tests 
Diabetes mellitus 
Pancreatic hypoplasia, exocrine pancreatic 
dysfunction
Genital tract anomalies (uterine, vaginal) 
Neuropsychiatric disease, intellectual disability, 
CNS anomalies
No None based on internal classification
No access to clinical 
information




JAG1 Heterozygote Standard Yes Congenital.or.developmental p.R1213Q 1.80E-04 3 DM 12297837 . . VUS





Hepatobiliary anomalies (bile duct paucity, 
cholestasis, progressive liver disease)
Cardiac anomalies (e.g., pulmonic stenosis, 
tetralogy of Fallot)
Opthalmologic anomalies (e.g., posterior 
embryotoxon)
Skeletal anomalies (butterfly vertebrae, increased 
lower extremity fracture risk)
Dysmorphic facies (prominent forehead, deep-set 
eyes, pointed chin)
Congenital kidney and genitourinary tract 
anomalies
Pancreatic insufficiency
Growth impariment, neurodevelopmental delay
Craniosynostosis
Extra digital flexion crease
Cerebrovascular anomalies, increased risk of 
cerebrovascular accident
Yes
Hepatologic evaluation: liver biopsy to 
assess for bile duct paucity; liver function 
tests to assess for cholestasis
Cardiac exam and imaging 
Musculoskeletal imaging, with skeletal 
radiography
Opthalmologic exam
Detailed physical exam to assess for 
characteristic dysmorphic facies
No access to clinical 
information
Gastroenterological/hepatological evaluation, including liver function, 
bile acid, and clotting factor studies, fat soluble vitamin levels, and 
hepatic ultrasound +/- cholescintigraphy and liver biopsy; regularly 
monitor hepatobiliary function and consider dietary 
therapy/supplementation if needed 
Cardiac exam and imaging
Chest radiography to assess for butterfly vertebrae
Opthalmologic exam
Nephrologic evaluation, including renal function tests and imaging
Neurodevelopmental evaluation
Head CT/MRI to assess for cerebrovascular anomalies; heightened 
surveillance for cerebrovascular accident 
132 ID_129 PKD1 Heterozygote Standard Yes Congenital.or.developmental p.G1166S 2.30E-04 1 DM 11012875 . . VUS Polycystic kidney disease 1 173900 Dominant No
Bilaterally enlarged, cystic kidneys, 
hypertension, progressive CKD
Cysts in other organs (liver, pancreas, seminal 
vesicles, arachnoid membrane)
Cerebrovascular disease (esp. intracranial 
aneurysm)
Cardiac valvular disease (aortic root dilation, 




Detailed history to assess for positive 
family history of disease manifestations; 
Nephrologic evaluation, including 
abdominal ultrasound to detect cysts and 
assessment for positive family history for 
cystic renal disease
No access to clinical 
information
Tight blood pressure management, consider ACE-i/ARB therapy; 
routine renal function tests (serum BUN and creatinine, urinalysis) and 
abdominal imaging to monitor cystic disease progression
Neurologic evaluation, with neuroimaging 
Cardiac exam and imaging
Gastrointestinal evaluation
Hepatological evaluation 
Avoidance of nephrotoxic agents, caffeine, and estrogens (if liver 
involvment)




PKD1 Heterozygote Standard Yes Congenital.or.developmental p.R3277C 3.40E-04 2 DM 19165178
Pathogeni
c
1.5E+08 Likely Benign Polycystic kidney disease 1 173900 Dominant No
Bilaterally enlarged, cystic kidneys, 
hypertension, progressive CKD
Cysts in other organs (liver, pancreas, seminal 
vesicles, arachnoid membrane)
Cerebrovascular disease (esp. intracranial 
aneurysm)
Cardiac valvular disease (aortic root dilation, 
aortic dissection, mitral valve prolapse)
Abdominal wall hernias
Colonic diverticular disease
No None based on internal classification
No access to clinical 
information




PKD2 Heterozygote Standard Yes Congenital.or.developmental p.F482V 3.70E-04 2 DM 22034641 . . VUS Polycystic kidney disease 2 613095 Dominant No
Bilaterally enlarged, cystic kidneys, 
hypertension, progressive CKD
Cysts in other organs (liver, pancreas, seminal 
vesicles, arachnoid membrane)
Cerebrovascular disease (esp. intracranial 
aneurysm)
Cardiac valvular disease (aortic root dilation, 




Detailed history and physical exam to 
assess for personal and/or family history of 
characteristic disease manifestions, 
Nephrologic evaluation, including 
abdominal ultrasound to detect cysts and 
assessment for positive family history for 
cystic renal disease
Information for 1/2 
individuals: Passed 
away at the age of 95 
years old, Mitral valve 
disease, cerebrovascular 
attack (TIA, seizure)
Tight blood pressure management, consider ACE-i/ARB therapy; 
routine renal function tests (serum BUN and creatinine, urinalysis) and 
abdominal imaging to monitor cystic disease progression
Neurologic evaluation, with neuroimaging 
Cardiac exam and imaging
Gastrointestinal evaluation
Hepatological evaluation 
Avoidance of nephrotoxic agents, caffeine, and estrogens (if liver 
involvment)
Consider enrollment into trials for novel therapies (e.g., Tolvaptan) 
135 ID_132 PKD2 Heterozygote Standard Yes Congenital.or.developmental
p.L736_N737
delLN
1.80E-04 1 DM 14993477 . . VUS Polycystic kidney disease 2 613095 Dominant No
Bilaterally enlarged, cystic kidneys, 
hypertension, progressive CKD
Cysts in other organs (liver, pancreas, seminal 
vesicles, arachnoid membrane)
Cerebrovascular disease (esp. intracranial 
aneurysm)
Cardiac valvular disease (aortic root dilation, 




Detailed history and physical exam to 
assess for personal and/or family history of 
characteristic disease manifestions, 
Nephrologic evaluation, including 
abdominal ultrasound to detect cysts and 
assessment for positive family history for 
cystic renal disease
No access to clinical 
information
Tight blood pressure management, consider ACE-i/ARB therapy; 
routine renal function tests (serum BUN and creatinine, urinalysis) and 
abdominal imaging to monitor cystic disease progression
Neurologic evaluation, with neuroimaging 
Cardiac exam and imaging
Gastrointestinal evaluation
Hepatological evaluation 
Avoidance of nephrotoxic agents, caffeine, and estrogens (if liver 
involvment)
Consider enrollment into trials for novel therapies (e.g., Tolvaptan) 
136 ID_133 ROBO2 Heterozygote Standard Yes Congenital.or.developmental p.R797Q 1.30E-04 1 DM 18235093 . . VUS Vesicoureteral reflux 2 610878 Dominant No
Retrograde urinary flow, +/- congenital kidney 
and genitourinary tract anomalies
Yes
Nephrological/urological evaluation, 
including renal function tests and imaging 
and voiding studies (e.g., voiding 
cystourethrogram)
No access to clinical 
information
Regular nephrologic evaluation, including blood pressure monitoring, 
renal function tests, urinalysis, imaging +/- voiding studies 
Heightened surveillance for urinary tract infection






Ear anomalies and hearing impairment
Branchial cleft anomalies (fistulae, cysts)
Congenital kidney and genitourinary tract 
anomalies
Lacrimal duct aplasia
Craniofacial anomalies (cleft palate, 
retrognathia)
Euthyroid goiter
Neurologic anomalies (facial nerve palsy, 
gustatory lacrimation)
No None based on internal classification
No access to clinical 
information




SIX2 Heterozygote Standard Yes Congenital.or.developmental p.V287M 5.80E-04 2 DM 24429398 . . VUS Renal hypodysplasia NA Dominant No
Congenital kidney and/or genitourinary 
anomalies
Yes
Detailed history to assess for positive 
family history of disease manifestations, 
Renal imaging
No access to clinical 
information
Nephrologic evaluation; monitor renal function (blood, urine studies)




SIX5 Heterozygote Standard Yes Congenital.or.developmental p.A158T 2.20E-04 4 DM 17357085
Pathogeni
c
8E+07 VUS Branchio-oto-renal syndrome 2 610896 Dominant No
Ear anomalies and hearing impairment
Branchial cleft anomalies (fistulae, cysts)
Congenital kidney and genitourinary tract 
anomalies
Lacrimal duct aplasia
Craniofacial anomalies (cleft palate, 
retrognathia)
Euthyroid goiter
Neurologic anomalies (facial nerve palsy, 
gustatory lacrimation)
Yes
Detailed physical exam to assess for 
presence of branchial arch and ear 
anomalies and/or hearing impairment
Renal imaging to screen for congenital 
kidney and genitourinary tract anomalies
98 years old, 
Sensorineural hearing 
loss
Detailed examination of cervical region for fistulae; neck CT scan for 
masses
Audiologic evaluation and CT scan of temporal bone for hearing 
impairment; routine audiologic testing to monitor hearing function
Routine nephrologic evaluation, with renal function testing
Endocrinologic evaluation if evidence of euthyroid goiter




SLIT2 Heterozygote Standard Yes Congenital.or.developmental p.S562N 1.50E-04 2 DM 26026792 . . VUS
Congenital anomalies of the 
kidney and urinary tract
NA Dominant No
Congenital kidney and/or genitourinary 
anomalies
Yes
Detailed history to assess for positive 





Nephrologic evaluation; monitor renal function (blood, urine studies)
Consider ACE-i/ARB therapy to delay renal disease progression
141 ID_138 SOX17 Heterozygote Standard Yes Congenital.or.developmental p.G178C 1.10E-04 1 . .
Pathogeni
c
2.7E+08 VUS Vesicoureteral Reflux 3 613674 Dominant No
Retrograde urinary flow, +/- congenital kidney 
and genitourinary tract anomalies
Yes
Nephrological/urological evaluation, 
including renal function tests and imaging 
and voiding studies (e.g., voiding 
cystourethrogram)
No access to clinical 
information
Regular nephrologic evaluation, including blood pressure monitoring, 
renal function tests, urinalysis, imaging +/- voiding studies 

















Choanal atresia or stenosis





Genitourinary anomalies (renal and/or genital)
Endocrine dysfunction (growth hormone 
deficiency, parathyroid hypoplasia, 
hypogonadism, hypothyroidism) 
Tracheoesophageal fistula 
Craniofacial anomalies (dysmorphic facies, 
orofacial clefting)
Thymic hypoplasia or aplasia, immunodeficiency
Musculoskeletal anomalies (hand, vertebral)
Yes
Detailed history to assess for positive 
family history of disease manifestations, 
Opthalmologic exam
Gastrointestinal evaluation and imaging
Detailed neurologic exam, including cranial 
nerve function testing
Detailed physical exam to assess for 
characteristic cranofacial and ear anomalies 
and other associated dysmorphologies
No access to clinical 
information
Regular opthalmologic evaluation to monitor visual function
Cardiac exam and imaging 
Otolaryngologic evaluation, including CT of temporal bones to detect 
middle and inner ear anomalies; routine audiologic function testing 
Abdominal ultrasound, renal function tests 
Detailed neurodevelopmental assessment 
Endocrinological evaluation, including hormone testing
Immunologic evaluation, including CBC and thymic imaging
Orthopedic evaluation and imaging


















Hepatobiliary anomalies (bile duct paucity, 
cholestasis, progressive liver disease)
Cardiac anomalies (e.g., pulmonic stenosis, 
tetralogy of Fallot)
Opthalmologic anomalies (e.g., posterior 
embryotoxon)
Skeletal anomalies (butterfly vertebrae, increased 
lower extremity fracture risk)
Dysmorphic facies (prominent forehead, deep-set 
eyes, pointed chin)
Congenital kidney and genitourinary tract 
anomalies
Pancreatic insufficiency
Growth impariment, neurodevelopmental delay
Craniosynostosis
Extra digital flexion crease
Cerebrovascular anomalies, increased risk of 
cerebrovascular accident
Yes
Hepatologic evaluation: liver biopsy to 
assess for bile duct paucity; liver function 
tests to assess for cholestasis
Cardiac exam and imaging 
Musculoskeletal imaging, with skeletal 
radiography
Opthalmologic exam
Detailed physical exam to assess for 
characteristic dysmorphic facies
No access to clinical 
information
Gastroenterological/hepatological evaluation, including liver function, 
bile acid, and clotting factor studies, fat soluble vitamin levels, and 
hepatic ultrasound +/- cholescintigraphy and liver biopsy; regularly 
monitor hepatobiliary function and consider dietary 
therapy/supplementation if needed 
Cardiac exam and imaging
Chest radiography to assess for butterfly vertebrae
Opthalmologic exam
Nephrologic evaluation, including renal function tests and imaging
Neurodevelopmental evaluation
Head CT/MRI to assess for cerebrovascular anomalies; heightened 




ROBO2 Heterozygote Standard Yes Congenital.or.developmental p.D1222N 4.00E-05 2 DM 24429398 . . VUS Vesicoureteral reflux 2 610878 Dominant No
Retrograde urinary flow, +/- congenital kidney 
and genitourinary tract anomalies
Yes
Nephrological/urological evaluation, 
including renal function tests and imaging 
and voiding studies (e.g., voiding 
cystourethrogram)
No access to clinical 
information
Regular nephrologic evaluation, including blood pressure monitoring, 
renal function tests, urinalysis, imaging +/- voiding studies 








 107480 Dominant No
Imperforate anus
Ear anomalies, hearing impairment
Thumb anomalies
Kidney and genitourinary anomalies
Structural cardiac anomalies 
Foot anomalies
Developmental delay, intellectual disability
CNS anomalies (cranial nerve dysfunction, 
Duane anomaly, brain malformations)
Skeletal anomalies (ribs, vertebrae)
Ocular anomalies 
Growth retardation, congenital hypothyroidism
Yes
Detailed history to assess for positive 
family history of disease manifestations; 
Detailed physical exam to assess for 
characteristic triad of imperforate anus, ear 
anomalies, and thumb anomalies
Access for 2/4 
individuals: one passed 
away at the age of 86 
years old, the second 
one passed away at the 
age of 83 years old. No 
relevant clinical 
features for both of 
them
Otolaryngologic evaluation, including hearing tests; routine 
monitoring of hearing function
Nephrologic evaluation, including renal function tests (serum BUN 
and creatinine, urinalysis) and imaging; routine monitoring of renal 
function
Cardiac exam and imaging
Neurodevelopmental evaluation +/- neuroimaging 
Orthopedic evaluation and imaging
Opthalmologic exam
Endocrine evaluation, with hormone studies if indicated
Avoidance of oto- and/or nephrotoxic agents














Endocrinologic anomalies (hyperparathyroidism, 
hypothyroidism, growth hormone deficiency, 
hypogonadotropic hypogonadism)
Facial anomalies (round face, full cheeks, short 
neck, low nasal bridge)
Opthalmologic anomalies (cataract, nystagmus)
Dental anomalies 
Obesity
Intellectual disability, developmental delay 
Musculoskeletal anomalies (subcutaneous 
ossifications, brachydactyly) 
Yes
Endocrine evaluation, with parathyroid 
hormone and calcium studies +/- Gsα 
protein functional assays
Musculoskeletal exam +/- imaging
No access to clinical 
information
Comprehensive endocrinologic evaluation and monitoring, including 
of parathyroid hormone, serum and urine calcium, phosphate, thryoid 
hormone, and Vitamin D levels
Calcium and vitamin D supplementation to maintain high-normal 




Regular musculoskeletal exams and imaging to monitor height and 
ossifications; surgical removal of ossifications if indicated


















Endocrinologic anomalies (hyperparathyroidism, 
hypothyroidism, growth hormone deficiency, 
hypogonadotropic hypogonadism)
Facial anomalies (round face, full cheeks, short 
neck, low nasal bridge)
Opthalmologic anomalies (cataract, nystagmus)
Dental anomalies 
Obesity
Intellectual disability, developmental delay 
Musculoskeletal anomalies (subcutaneous 
ossifications, brachydactyly) 
Yes
Endocrine evaluation, with parathyroid 
hormone and calcium studies +/- Gsα 
protein functional assays
Musculoskeletal exam +/- imaging
No access to clinical 
information
Comprehensive endocrinologic evaluation and monitoring, including 
of parathyroid hormone, serum and urine calcium, phosphate, thryoid 
hormone, and Vitamin D levels
Calcium and vitamin D supplementation to maintain high-normal 




Regular musculoskeletal exams and imaging to monitor height and 
ossifications; surgical removal of ossifications if indicated
Nutritional and lifestyle counseling if obesity 






0.00E+00 1 NA NA NA NA Likely Pathogenic
Renal Cysts and Diabetes 
Syndrome
 137920 Dominant No
Renal anomalies, tubulointerstitial renal disease, 
CKD
Hyperuricemia, gout
Abnormal liver function tests 
Diabetes mellitus 
Pancreatic hypoplasia, exocrine pancreatic 
dysfunction
Genital tract anomalies (uterine, vaginal) 
Neuropsychiatric disease, intellectual disability, 
CNS anomalies
Yes
Detailed history and physical exam to 
assess for personal and/or family history of 
characteristic disease manifestions
No access to clinical 
information
Nephrologic evaluation, including renal function tests (BUN, 
creatinine, electrolytes) and imaging 
Fasting glucose and glucose tolerance tests
Gastrointestinal and hepatologic evaluation, including liver function 
tests 
Gynecological evaluation
Neurodevelopmental assessment; consider neuroimaging and EEG






0.00E+00 1 NA NA NA NA Likely Pathogenic
Renal Cysts and Diabetes 
Syndrome
 137920 Dominant No
Renal anomalies, tubulointerstitial renal disease, 
CKD
Hyperuricemia, gout
Abnormal liver function tests 
Diabetes mellitus 
Pancreatic hypoplasia, exocrine pancreatic 
dysfunction
Genital tract anomalies (uterine, vaginal) 
Neuropsychiatric disease, intellectual disability, 
CNS anomalies
Yes
Detailed history and physical exam to 
assess for personal and/or family history of 
characteristic disease manifestions
No access to clinical 
information
Nephrologic evaluation, including renal function tests (BUN, 
creatinine, electrolytes) and imaging 
Fasting glucose and glucose tolerance tests
Gastrointestinal and hepatologic evaluation, including liver function 
tests 
Gynecological evaluation
Neurodevelopmental assessment; consider neuroimaging and EEG































Detailed physical exam to assess for 
characteristic craniofacial and 
musculoskeletal anomalies
Urologic/gynecological evaluation to assess 
for genital anomalies
No access to clinical 
information
Comprehensive musculoskeletal exam and imaging
Comprehensive neurodevelopmental exam, with imaging 
Gastroenterological evaluation
Cardiac exam and imaging 
Opthamologic evaluation
Otolaryngologic evaluation, with hearing function tests
Endocrinologic evaluation, with thyroid function tests
Nephrologic evaluation, with renal function tests and imaging



















Electrolyte anomalies (hyponatremia, 
hyperkalemia, metabolic acidosis)
Endocrinologic anomalies (hyperaldosteronism, 
hypereninemia)
No None based on internal classification
No access to clinical 
information
None based on internal classification















Electrolyte anomalies (hyponatremia, 
hyperkalemia, metabolic acidosis)
Endocrinologic anomalies (hyperaldosteronism, 
hypereninemia)
No None based on internal classification
No access to clinical 
information
None based on internal classification
153 ID_150 NR3C2 Heterozygote
Standard 
(indel)









Electrolyte anomalies (hyponatremia, 
hyperkalemia, metabolic acidosis)
Endocrinologic anomalies (hyperaldosteronism, 
hypereninemia)
No None based on internal classification
No access to clinical 
information
None based on internal classification






0.00E+00 1 NA NA NA NA Likely Pathogenic






Elevated liver enzymes (AST and/or ALT)
Glomerulopathy, ESRD
Yes
Detailed history to assess for positive 
family history of disease manifestations; 
Hematologic evaluation, including CBC 
and peripheral blood smear with 
microscopic and immunofluorescence 
analysis
No access to clinical 
information
Routine hematologic evaluation, monitor for thrombocytopenia and 
anemia (secondary to bleeding diathesis)
Otolaryngologic evaluation, including hearing tests
Opthalmologic exam
Hepatologic evaluation, including liver function tests 
Nephrologic evaluation, including renal function tests (serum BUN 
and creatinine, urinalysis); consider ACE-i/ARB therapy to slow renal 
disease progression
Heightened surveillance to prevent bleeding secondary to surgical 
procedures, with prophalyctic agents (e.g., platelet transfusion, 
despromessin)
Avoid anti-platelet and anti-coagulant agents (e.g., aspirin) and high-
risk activities (e.g., contact sports)
Cautious use of ototoxic, hepatotoxic and/or nephrotoxic agents







0.00E+00 1 NA NA NA NA Likely Pathogenic Cornelia de Lange syndrome 122470 Dominant No
Craniofacial anomalies (synophrys, highly 
arched eyebrows, long eyelashes, short nose with 
anteverted nostrils, small widely spaced teeth, 
microcephaly) 
Hirsuitism
Upper limb anomalies (including reduced or 
absent forearms and/or digits, small hands, 
clinodactyly); lower limb anomalies (rarer; small 
feet, syndactyly)
Growth retardation
Intellectual disability, developmental delay, 
seizures
Cardiac anomalies 
Gastrointestinal dysfunction (reflux, pyloric 
stenosis, intestinal malrotation, diaphragmatic 
hernia)
Opthalmologic anomalies and visual impairment
Hearing loss 
Kidney and genitourinary anomalies
Immunodeficiency
Yes
Detailed physical exam to assess for 
characteristic craniofacial and limb 
anomalies and hirsutism
No access to clinical 
information
Gastrointestinal evaluation, including endoscopy 
Comprehensive neurodevelopmental assessment, with imaging and 
EEG
Endocrinologic evaluation
Musculoskeletal exam and imaging; physical therapy if indicated 
Otolaryngologic evaluation, with hearing function tests
Opthamologic evaluation
Cardiac exam and imaging
Nephrologic evaluation, with renal function tests and imaging +/- 
voiding cystourethrogram 
Urologic/gynecologic evaluation
Hematologic evaluation, including complete blood count and 
immunoglobulin, B-cell, and T-cell studies






0.00E+00 1 NA NA NA NA Likely Pathogenic
Alagille syndrome 2, Hajdu-




Hepatobiliary anomalies (bile duct paucity, 
cholestasis, progressive liver disease)
Cardiac anomalies (e.g., pulmonic stenosis, 
tetralogy of Fallot)
Opthalmologic anomalies (e.g., posterior 
embryotoxon)
Skeletal anomalies (butterfly vertebrae, increased 
lower extremity fracture risk)
Dysmorphic facies (prominent forehead, deep-set 
eyes, pointed chin)
Congenital kidney and genitourinary tract 
anomalies
Pancreatic insufficiency
Growth impariment, neurodevelopmental delay
Craniosynostosis
Extra digital flexion crease
Cerebrovascular anomalies, increased risk of 
cerebrovascular accident
Yes
Hepatologic evaluation: liver biopsy to 
assess for bile duct paucity; liver function 
tests to assess for cholestasis
Cardiac exam and imaging 
Musculoskeletal imaging, with skeletal 
radiography
Opthalmologic exam
Detailed physical exam to assess for 
characteristic dysmorphic facies
No access to clinical 
information
Gastroenterological/hepatological evaluation, including liver function, 
bile acid, and clotting factor studies, fat soluble vitamin levels, and 
hepatic ultrasound +/- cholescintigraphy and liver biopsy; regularly 
monitor hepatobiliary function and consider dietary 
therapy/supplementation if needed 
Cardiac exam and imaging
Chest radiography to assess for butterfly vertebrae
Opthalmologic exam
Nephrologic evaluation, including renal function tests and imaging
Neurodevelopmental evaluation
Head CT/MRI to assess for cerebrovascular anomalies; heightened 









Yes Glomerular p.R1410C 8.00E-05 2 DM 8651296
Pathogeni
c
1E+08 VUS Alport syndrome 301050 Dominant No
Glomerulonephritis, with microscopic hematuria; 
ESRD
Hearing loss
Opthalmologic anomalies (anterior lenticonus, 
maculopathy, corneal dystrophy)
Aortic aneuryms (males, rare)
Yes
Nephrological evaluation, including 
assessment for personal and/or family 
history of disease manifestation and 
urinalysis +/- renal biopsy
No access to clinical 
information
Audiologic evaluation, with hearing function testing
Opthalmologic exam
Cardiac evaluation and imaging (males, to screen for aortic aneurysm)
Nephrologic evaluation and monitoring of renal function; ACE-i/ARB 
therapy to slow renal disease progression
158 ID_155 CFHR5 Heterozygote
Standard 
(indel)
No Glomerular p.D409Mfs*5 7.17E-05 1 NA NA NA NA VUS
Nephropathy due to CFHR5 
deficiency
 614809 Dominant No
Glomerulonephritis, ESRD
Hypocomplementemia (low CFHR5 levels)
Yes
Detailed history to assess for positive 
family history of disease manifestations; 





Laboratory studies for complement factors/function
Serology to measure complement-associated autoantibodies
Renal function tests; regular nephrologic monitoring; consider ACE-
i/ARB and lipid-lowering therapy to help delay renal disease 
progression
Consider anti-complement inhibitor therapy (e.g., Eculizumab)
High risk of recurrence and allograft failure post-renal transplant
159 ID_156 CFHR5 Heterozygote
Standard 
(indel)
No Glomerular p.N299Kfs*2 0.00E+00 1 NA NA NA NA VUS
Nephropathy due to CFHR5 
deficiency
 614809 Dominant No
Glomerulonephritis, ESRD
Hypocomplementemia (low CFHR5 levels)
Yes
Detailed history to assess for positive 
family history of disease manifestations;  
Renal biopsy, with immunofluorescence 
and electron microscopy
No access to clinical 
information
Laboratory studies for complement factors/function
Serology to measure complement-associated autoantibodies
Renal function tests; regular nephrologic monitoring; consider ACE-
i/ARB and lipid-lowering therapy to help delay renal disease 
progression
Consider anti-complement inhibitor therapy (e.g., Eculizumab)
High risk of recurrence and allograft failure post-renal transplant






0.00E+00 1 NA NA NA NA Likely Pathogenic
Alagille syndrome 2, Hajdu-




Hepatobiliary anomalies (bile duct paucity, 
cholestasis, progressive liver disease)
Cardiac anomalies (e.g., pulmonic stenosis, 
tetralogy of Fallot)
Opthalmologic anomalies (e.g., posterior 
embryotoxon)
Skeletal anomalies (butterfly vertebrae, increased 
lower extremity fracture risk)
Dysmorphic facies (prominent forehead, deep-set 
eyes, pointed chin)
Congenital kidney and genitourinary tract 
anomalies
Pancreatic insufficiency
Growth impariment, neurodevelopmental delay
Craniosynostosis
Extra digital flexion crease
Cerebrovascular anomalies, increased risk of 
cerebrovascular accident
Yes
Hepatologic evaluation: liver biopsy to 
assess for bile duct paucity; liver function 
tests to assess for cholestasis
Cardiac exam and imaging 
Musculoskeletal imaging, with skeletal 
radiography
Opthalmologic exam
Detailed physical exam to assess for 
characteristic dysmorphic facies
No access to clinical 
information
Gastroenterological/hepatological evaluation, including liver function, 
bile acid, and clotting factor studies, fat soluble vitamin levels, and 
hepatic ultrasound +/- cholescintigraphy and liver biopsy; regularly 
monitor hepatobiliary function and consider dietary 
therapy/supplementation if needed 
Cardiac exam and imaging
Chest radiography to assess for butterfly vertebrae
Opthalmologic exam
Nephrologic evaluation, including renal function tests and imaging
Neurodevelopmental evaluation
Head CT/MRI to assess for cerebrovascular anomalies; heightened 
surveillance for cerebrovascular accident 






0.00E+00 1 NA NA NA NA Likely Pathogenic Lateral meningocele syndrome 130720 Dominant No





Developmental delay, intellectual disability
Musculoskeletal anomalies (hypotonia, 
hyperextensibility, scoliosis, vertebral fusion)
Structural cardiac anomalies




Detailed history to assess for positive 
family history of disease manifestations; 
Detailed physical exam to assess for 
craniofacial anomalies 
Neurologic evaluation, including imaging 
(spine MRI) for spinal meningoceles 
No access to clinical 
information
Neurodevelopmental assessment, with neuroimaging to assess for 
CNS anomalies; neurosurgical intervention if indicated
Opthalmologic exam 
Otolaryngologic evaluation, including hearing tests
Orthopedic exam and imaging 
Cardiac exam and imaging 
Gastrointestinal evaluation and imaging 
Nephrologic/urologic evaluation, including imaging to assess for 









COL4A5 Heterozygote Standard Yes Glomerular p.R1422C 7.30E-04 5 DM 7706490
Pathogeni
c
1.4E+08 VUS Alport syndrome 301050 Dominant No
Glomerulonephritis, with microscopic hematuria; 
ESRD
Hearing loss
Opthalmologic anomalies (anterior lenticonus, 
maculopathy, corneal dystrophy)
Aortic aneuryms (males, rare)
Yes
Nephrological evaluation, including 
assessment for personal and/or family 
history of disease manifestation and 
urinalysis +/- renal biopsy
No access to clinical 
information
Audiologic evaluation, with hearing function testing
Opthalmologic exam
Cardiac evaluation and imaging (males, to screen for aortic aneurysm)
Nephrologic evaluation and monitoring of renal function; ACE-i/ARB 
therapy to slow renal disease progression
163 ID_160 COL4A5 Heterozygote Standard Yes Glomerular p.P1517T 6.10E-04 1 DM 8406498
Pathogeni
c
2E+08 VUS Alport syndrome 301050 Dominant No
Glomerulonephritis, with microscopic hematuria; 
ESRD
Hearing loss
Opthalmologic anomalies (anterior lenticonus, 
maculopathy, corneal dystrophy)
Aortic aneuryms (males, rare)
Yes
Nephrological evaluation, including 
assessment for personal and/or family 
history of disease manifestation and 




Audiologic evaluation, with hearing function testing
Opthalmologic exam
Cardiac evaluation and imaging (males, to screen for aortic aneurysm)
Nephrologic evaluation and monitoring of renal function; ACE-i/ARB 
therapy to slow renal disease progression
125 ID_122 NSD1 Heterozygote
Standard 
(indel)
No Congenital.or.developmental p.L116*fs*1. 0.00E+00 1 NA NA NA NA Likely Pathogenic
Beckwith-Wiedemann 







Developmental delay, intellectual disability
Overgrowth (macrocephaly, height)





Musculoskeletal anomalies (joint laxity, pes 
planus, scoliosis)
Kidney and genitourinary anomalies 
Malignancies, including acute lymphoblastic 
leukemia (rare)
Yes
Detailed physical exam to assess for 
craniofacial anomalies and signs of 
overgrowth
31 years old, no 
relevant clinical 
features
Neurodevelopmental evaluation, with neuroimaging and EEG if 
indicated
Otolaryngologic evaluation, including hearing function tests
Cardiac exam and imaging 
Orthopedic exam and imaging
Nephrologic evaluation, including renal function tests (serum BUN 










603965 Dominant No Focal segmental glomerulosclerosis, ESRD No None based on internal classification
No access to clinical 
information











Nephrotic syndrome, type 4 , 
Wilms tumor, type 1, Denys-
Drash syndrome, Frasier 







Nephropathy (focal segmental 
glomerulosclerosis, ESRD)
Renal and genitourinary tract tumors 
(nephroblastoma, gonadoblastoma)
Genital anomalies (ambiguous genitalia, gonadal 
dysgenesis) 
Diaphragmatic hernia (rare) 
Yes
Nephrologic evaluation, including renal 
function tests and abdominal imaging to 
assess for renal tumors
No access to clinical 
information
Oncologic evaluation and routine monitoring for tumors; prophylactic 
bilateral nephrectomy and/or gonadectomy may be performed 
Regular nephrologic evaluation; ACE-i/ARB therapy to slow renal 
disease progression
Favorable prognosis post-renal transplantation
Endocrine evaluation
167 ID_164 CFHR5 Heterozygote Standard No Glomerular p.Q399X 1.63E-04 1 NA NA NA NA VUS
Nephropathy due to CFHR5 
deficiency
 614809 Dominant No
Glomerulonephritis, ESRD
Hypocomplementemia (low CFHR5 levels)
Yes
Detailed history to assess for positive 
family history of disease manifestations; 
Renal biopsy, with immunofluorescence 
and electron microscopy
No access to clinical 
information
Laboratory studies for complement factors/function
Serology to measure complement-associated autoantibodies
Renal function tests; regular nephrologic monitoring; consider ACE-
i/ARB and lipid-lowering therapy to help delay renal disease 
progression
Consider anti-complement inhibitor therapy (e.g., Eculizumab)
High risk of recurrence and allograft failure post-renal transplant
168 ID_165 CFHR5 Heterozygote Standard No Glomerular c.1331T2A>G 1.96E-04 1 NA NA NA NA VUS
Nephropathy due to CFHR5 
deficiency
 614809 Dominant No
Glomerulonephritis, ESRD
Hypocomplementemia (low CFHR5 levels)
Yes
Detailed history to assess for positive 
family history of disease manifestations; 
Renal biopsy, with immunofluorescence 
and electron microscopy
No access to clinical 
information
Laboratory studies for complement factors/function
Serology to measure complement-associated autoantibodies
Renal function tests; regular nephrologic monitoring; consider ACE-
i/ARB and lipid-lowering therapy to help delay renal disease 
progression
Consider anti-complement inhibitor therapy (e.g., Eculizumab)




CACNA1S Heterozygote Standard No Secondary.Renal p.R1702X 6.09E-04 3 . . . . VUS
Hypokalemic periodic paralysis 
type 1; Malignant hyperthermia 
susceptibility 5, Thyrotoxic 











Episodic attacks of muscular weakness and 
paralysis, accompanied by hypokalemia
Myopathy (variable, generally later-onset)
Malignant hyperthermia (increased 
susceptibility)
No None based on current ACMG59 guidelines
No access to clinical 
information
None based on current ACMG59 guidelines






8.93E-05 1 . . . . VUS
Hypokalemic periodic paralysis 
type 1; Malignant hyperthermia 
susceptibility 5, Thyrotoxic 











Episodic attacks of muscular weakness and 
paralysis, accompanied by hypokalemia
Myopathy (variable, generally later-onset)
Malignant hyperthermia (increased 
susceptibility)
No None based on current ACMG59 guidelines
No access to clinical 
information
None based on current ACMG59 guidelines




Craniofacial anomalies (including high 
protruding forehead, coarse facies, midface 
retraction, and hypertrichosis)
CNS anomalies, seizures, developmental 
delay/intellectual disability




Kidney and genitourinary tract anomalies 
(including hydronephrosis and vesicourethral 
reflux and hypoplastic genitalia)
Yes
Detailed history to assess for positive 
family history of disease manifestations; 
Detailed physical exam to assess for 
characteristic craniofacial anomalies 
Neurodevelopmental evaluation for 
developmental delay/intellectual disability
Orthopedic exam and imaging for skeletal 
anomalies
Nephrologic/urologic evaluation, including 
imaging, for hydronephrosis
No access to clinical 
information
Neurologic evaluation, with imaging












Opthalmologic anomalies (juvenile cataract, 
microcornea)
Increased renal guanidinoacetate excretion
Yes
Opthalmologic exam
Nephrologic evaluation, with urinalysis to 
assess guanidinoacetate excretion
No access to clinical 
information
Routine opthalmologic evaluation
Regular nephrologic evaluation to monitor guanidinoacetate excretion






0.00E+00 1 NA NA NA NA Likely Pathogenic
Glomerulosclerosis focal 
segmental
603965 Dominant No Focal segmental glomerulosclerosis, ESRD Yes
Detailed history to assess for positive 
family history of disease manifestations 
Nephrologic evaluation, with urinalysis 
No access to clinical 
information
Nephrologic evaluation and monitoring of renal function; ACE-i/ARB 
therapy to slow renal disease progression




TSC2 Heterozygote Standard No Cancer c.4570T1G>A 1.02E-04 2 NA NA NA NA Likely Pathogenic Tuberous sclerosis-2  613254 Dominant Yes
Skin lesions (hypomelanotic macules, facial 
angiofibromas, shagreen patches, cephalic 
plaques, ungual fibromas)
CNS tumors (cortical dysplasias, subependymal 
nodules, and subependymal giant cell 
astrocytomas)
Seizures, developmental delay and intellectual 
disability, neuropsychiatric disease
Cardiac rhabdomyomas, cardiac arrhythmias
Lymphangioleiomyomatosis
Renal angiomyolipomas, renal cysts, renal cell 
carcinoma
Retinal hamartomas





Detailed physical exam to assess for 
characteristic skin lesions
CNS, cardiac, and abdominal imaging for 
tumors
No access to clinical 
information
Neurodevelopmental evaluation, with neuroimaging and EEG
Dermatologic evaluation
Opthalmologic exam
Cardiac exam and imaging
Pulmonary function testing
Nephrologic evaluation, including renal function tests (serum BUN 
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Section  S1.  Cohort  information  
  
  
Cohorts.    We  performed  proband-­only  exome  sequencing  and  diagnostic  analysis  among  3,315  
individuals  representing  two  independent  cohorts  of  patients  with  kidney  disease.  1,128  individuals  were  
drawn  from  the  AURORA  study  and  2,187  individuals  were  drawn  from  patients  seen  at  Columbia  
University  Medical  Center  (CUMC).  The  study  was  approved  by  the  Columbia  University  Institutional  
Review  Board  and  local  ethics  committees  and  performed  in  accordance  with  the  policy  on  bioethics  and  
human  biologic  samples  of  the  AURORA  study  sponsor,  AstraZeneca.  
  
AURORA    
The  AURORA  study  and  its  inclusion  and  exclusion  criteria  have  been  previously  described(119-­121).  
The  AURORA  study  recruited  males  and  females  from  280  centers  in  25  countries,  with  the  majority  of  
individuals  from  the  United  Kingdom  and  European  Union(119).  Inclusion  criteria  were:  1)  age  between  
50  and  80  years;;  and  2)  all-­cause  end-­stage  renal  disease  (ESRD)  undergoing  hemodialysis  for  at  least  3  
months.  The  study  did  not  select  for  or  exclude  patients  based  on  the  primary  cause  of  ESRD.  The  
exclusion  criteria  were:  1)  having  received  statin  therapy  within  the  past  6  months  or  having  a  clear  
indication  or  contraindication  for  use  of  a  lipid-­altering  drug;;  2)  expected  kidney  transplantation  within  one  
year;;  3)  major  hematological,  neoplastic,  metabolic  (excluding  diabetes),  gastrointestinal,  or  infectious  
disease  predicted  to  limit  life  expectancy  to  less  than  one  year;;  4)  history  of  malignancy;;  5)  active  liver  
disease  (as  indicated  by  an  alanine  aminotransferase  level  more  than  three  times  the  upper  limit  of  
normal  range);;  6)  history  of  statin-­induced  myopathy;;  7)  uncontrolled  hypothyroidism;;  8)  unexplained  
creatine  kinase  more  than  three  times  the  upper  limit  of  the  normal  range;;  and  9)  serious  hypersensitivity  
to  statins.    
The  AURORA  study  participants  consented  to  genetic  research;;  the  consent  defined  that  results  
would  not  be  provided  back  to  patients.  As  of  May  2018,  Global  Data  Protection  Regulation  (GDPR)  in  
the  European  Union  provides  study  participants  with  the  right  to  request  data.  
Table  S2  shows  the  clinical  features  of  the  exome  sequenced  AURORA  participants  versus  all  




Columbia  University  Medical  Center  (CUMC)  Genetic  Studies  of  Chronic  Kidney  Disease  (CKD)    
Columbia  University  Medical  Center  (CUMC)  is  a  tertiary  care  medical  center  with  a  Nephrology  Division  
providing  care  for  all  aspects  of  kidney  disease,  including  both  inherited  and  acquired  forms  of  chronic  
kidney  disease  (CKD),  hypertension  and  renovascular  disease,  and  ESRD  (dialysis  and  transplantation).  
Among  the  Division’s  areas  of  specialty  care  are  glomerulopathies  and  inherited  kidney  diseases.    
The  CUMC  Genetic  Studies  of  Chronic  Kidney  Disease  (IRB  #AAAC7385)  is  a  genetic  research  
and  biobanking  protocol  recruiting  patients  seen  by  the  CUMC  Nephrology  Division  for  the  evaluation  and  
management  of  kidney  disease,  with  the  aim  of  elucidating  the  genetic  basis  of  CKD.  Inclusion  criteria  are  
a  clinical  diagnosis  of  CKD,  the  criteria  for  which  include:  the  presence  of  renal  failure  requiring  dialysis  or  
transplantation;;  creatinine  >1.5  mg/dL  in  men  or  >1.3  mg/dL  in  women  with  or  without  proteinuria;;  and/or  
the  presence  of  significant  proteinuria  or  hematuria  indicative  of  active  glomerular  disease.  All  patients  
with  a  clinical  diagnosis  of  CKD  are  eligible,  irrespective  of  age,  sex/gender,  and/or  race/ethnicity.    
Patients  are  recruited  mainly  through  office  visits;;  additional  entry  points  include  perinatal  care  
(e.g.,  detection  of  congenital  anomalies  of  the  kidney  and  urinary  tract  on  prenatal  imaging  and  
enrollment  of  the  neonate  after  birth)  and  events  held  by  nonprofit  organizations  for  patients  with  various  
forms  of  CKD  (e.g.,  National  Kidney  Foundation,  IGA  Nephropathy  Foundation,  NephCure  Kidney  
International).  Recruitment  tools  include  an  informational  brochure,  flyer,  and  consent  forms,  all  of  which  
are  available  in  both  English  and  Spanish  and  have  been  approved  by  the  Columbia  Institutional  Review  
Board.  Recruitment  rate  is  approximately  80%.    
Enrollment  is  achieved  using  a  team  of  bilingual  study  coordinators  who  are  in  close  contact  with  
physicians.  The  physicians  introduce  the  study  to  the  participants.  Once  the  potential  participant  indicates  
willingness  to  consider  enrollment,  then  a  study  coordinator  meets  with  the  potential  participant,  reviews  
eligibility,  explains  the  study  in  clear,  easy-­to-­understand  language,  and  provides  a  copy  of  the  consent  
form  for  the  participant  to  read.  The  study  coordinator  answers  any  questions  from  a  participant  regarding  
the  study.    
All  individuals  provide  informed  consent.  For  enrollment  of  minors,  the  signature  of  the  
parent/guardian  is  required.  Minors  6  and  under  are  explained  the  study  in  age-­appropriate  language  but  
no  assent  is  required.  Minors  between  the  ages  of  7-­11  with  decision-­making  capability  are  explained  the  
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study  in  age-­appropriate  language,  and  verbal  assent  is  obtained.  Minors  12  and  older  with  decision-­
making  capability  are  explained  the  study  in  age-­appropriate  language,  and  written  assent  is  documented  
on  the  consent  form.  At  each  step,  individuals  are  reminded  that  their  responses  are  confidential  and  that  
they  may  refuse  to  participate  in  the  project  or  withdraw  at  any  time  without  explanation,  and  further,  that  
such  an  action  will  in  no  way  affect  their  future  interactions  with  their  health  care  provider,  or  by  CUMC.  
The  consent  includes:  usage  of  the  biosamples  collected  for  genetic  studies,  including  microarray  and  
exome  sequencing;;  and  the  request  to  be  re-­contacted  if  a  clinically  actionable  finding  is  identified,  which  
as  a  research-­level  finding  is  first  validated  using  a  second  sample  collected  from  the  individual  at  the  
time  of  re-­contact  in  a  clinically  certified  (CLIA)  laboratory  environment  prior  to  being  formally  returned.  
The  associated  risks  of  CLIA  validation  are  discussed  with  the  individual,  enabling  he  or  she  to  make  an  
informed  choice  regarding  validation  of  the  genetic  findings.  
Following  the  above  consent  process  to  participate  in  the  study,  individuals  provide  a  single  
venous  blood  sample  or  buccal  swab,  from  which  DNA  is  extracted  using  standard  protocols.  As  noted  
above,  the  DNA  is  used  for  genetic  studies  including  microarray  and  exome  sequencing.  In  the  case  of  
neonates,  samples  are  obtained  from  umbilical  cord  blood,  residual  blood  from  clinical  samples,  buccal  
swabs,  or  from  a  single  venous  blood  sample,  in  that  order  of  preference.  All  data  collected  is  stored  in  a  
secure  computerized  database,  and  all  patient  samples  are  stored  using  a  unique,  anonymized  numerical  
identifier,  with  the  relation  of  this  identifier  to  patient  names  maintained  in  the  locked  computer  file  in  the  
centralized  database.  Electronic  data  complies  with  all  HIPAA  and  other  privacy  and  security  regulations,  
and  resides  on  a  firewall  server  maintained  by  the  CUMC  IT  department.    
The  2,187  probands  in  the  present  study  were  selected  as  broadly  representative  subset  of  the  
3,122  patients  recruited  between  October  2013  and  September  2017  for  the  Genetic  Studies  of  CKD  
protocol  (Table  S2).  Importantly,  the  major  clinical  diagnostic  categories  seen  in  the  general  patient  
population  seen  by  the  CUMC  Nephrology  Division  (Table  S3)  are  represented  among  both  the  2,187  
exome-­sequenced  individuals  and  the  3,122  individuals  recruited  for  the  Genetic  Studies  of  CKD.
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Section  S2.  Clinical  characteristics  of  the  patients  with  diagnostic  PKD1  and  PKD2  variants  
  
  
In  total,  we  detected  diagnostic  variants  for  autosomal  dominant  polycystic  kidney  disease  (ADPKD)  in  97  
cases:  75  patients  harbored  variants  in  PKD1,  and  22  patients  had  variants  in  PKD2  (see  Figure  5  and  
Table  S8  and  Table  S9).  Review  of  the  available  clinical  data  supports  that  single-­gene  testing  of  PKD1  
and  PKD2  would  have  been  a  viable  option  for  the  majority  of  these  patients,  but  it  is  important  to  
recognize  that  for  a  minority,  the  primary  cause  of  disease  was  uncertain  based  on  clinical  findings  alone,  
favoring  broader  genetic  workup.  Moreover,  recent  of  discoveries  of  additional  genes  producing  ADPKD-­
spectrum  phenotypes,  such  as  GANAB  (49)  and  DNAJB11(148)  suggest  that  such  that  genome-­wide  
testing  may  still  be  useful,  e.g.,  for  cases  with  such  phenotypes  null  for  diagnostic  variants  in  PKD1  or  
PKD2.  We  did  not  detect  diagnostic  variants  in  such  newly  discovered  genes  among  the  cases  in  our  
cohort,  which  may  reflect  that,  as  noted  in  reviews  of  the  studies  to  date  of  large  ADPKD  cohorts,  the  
overwhelming  majority  of  ADPKD  patients  have  variants  in  PKD1  (~78%)  and  PKD2  (~15%)(178,  185).  
The  patients  with  diagnostic  genetic  findings  in  PKD1  and  PKD2  overwhelmingly  consisted  of  
individuals  clinically  diagnosed  with  “congenital  or  cystic  renal  disease”  (94/97;;  96.9%).  The  5  CUMC  
cases  within  this  clinical  diagnostic  category  had  a  specific  diagnosis  of  the  associated  disease,  
autosomal  dominant  polycystic  kidney  disease  (ADPKD).  The  89  AURORA  cases  with  PKD1  and  PKD2  
alterations  all  had  clinical  diagnoses  of  “congenital  or  cystic  renal  disease”  and  strongly  supportive  
features  based  on  the  available  clinical  data,  such  as  a  history  of  polycystic  liver  disease,  prior  
nephrectomy,  and/or  prior  cerebrovascular  accident.    
The  remaining  3/97  cases  (3.1%)  in  whom  PKD1/2  alterations  were  found  harbored  clinical  
diagnoses  of  nephropathy  “of  unknown  etiology.”  As  these  patients  were  from  CUMC,  we  were  able  to  
review  their  electronic  health  records.  These  individuals  showed  more  atypical  presentations  (e.g.,  age  
over  40  years  at  presentation,  asymmetric  or  focal  PKD  on  renal  imaging,  no  reported  family  history  of  
renal  disease)  such  that  the  primary  cause  of  disease  was  deemed  to  be  uncertain  by  the  referring  
clinician  (i.e.,  a  clinical  diagnosis  of  nephropathy  “of  unknown  etiology”).  Genetic  analysis  has  been  
recommended  to  resolve  such  atypical  cases,  as  mutations  in  other  genes  can  yield  overlapping  clinical  
phenotypes(178,  186).  Hence,  broader  genetic  testing  approaches,  such  as  an  expanded  renal  cystic  
disease  gene  panel  or  exome  sequencing,  may  still  be  useful  in  this  subset  of  individuals.
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Figure  S1.  Allele  frequency  distribution  of  the  343  diagnostic  variants  
  
The  frequency  distribution  of  the  343  diagnostic  variants  is  shown  above.  The  x-­axis  shows  the  frequency  of  the  
variant  (minor  allele  frequency;;  MAF)  in  the  Genome  Aggregation  Database  (gnomAD),  a  database  including  exome  
sequence  data  from  123,136  unrelated  population  controls,  using  the  following  frequency  thresholds:  zero  (absent  in  
gnomAD),  <0.001%,  <0.01%,  <0.1%,  <1%,  and  <5%.  The  y-­axis  shows  the  percent  of  diagnostic  variants  for  a  given  
inheritance  mode  –  autosomal  dominant  (AD);;  autosomal  recessive  (AR);;  or  X-­linked  (XL)  –  within  this  frequency  bin.  
The  frequencies  of  the  diagnostic  variants  largely  fell  well  below  1%,  a  commonly  used  threshold  for  “rare  variants,”  
with  66%  of  variants  altogether  absent  in  gnomAD.  The  maximum  MAF  observed  across  all  variants  and  inheritance  
modes  was  3.1%,  corresponding  to  the  NPHS2  p.R229Q  allele,  a  common  variant  causal  for  steroid-­resistant  
nephrotic  syndrome  when  found  in  trans  with  certain  variants  in  the  more  distal  exons,  including  the  p.A284V  and  
p.R291W  alleles  (also  observed  here)(124,  125).  Excluding  the  NPHS2  p.R229Q  allele,  the  maximum  MAF  observed,  
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Table  S1.  Clinical  features  of  the  exome  sequenced  AURORA  participants  versus  all  AURORA  
study  participants  
  
Cohort   Exome  sequenced   All  participants  
No.  of  Patients   1,128   2,773  
Characteristic   N   %   N   %  
Age  at  time  of  study  entry  (yr)a  
<50   1   0.1   3   0.1  
50-­59   387   34.3   968   34.9  
60-­69   367   32.5   899   32.4  
70+   373   33.1   903   32.6  
Sex  
Female   427   37.9   1050   37.9  
Male   701   62.1   1723   62.1  
Race/Ethnicity  
White  European   1023   90.7   2354   84.9  
Hispanic   50   4.4   113   4.1  
Black/African  American   18   1.6   98   3.5  
Asian   20   1.8   139   5.0  
Other/Unspecified   17   1.5   69   2.5  
Clinical  diagnosis  
Congenital  or  cystic  renal  disease   159   14.1   356   12.8  
Glomerulopathy   231   20.5   512   18.5  
Diabetic  nephropathy   184   16.3   535   19.3  
Hypertensive  nephropathy   193   17.1   554   20.0  
Tubulointerstitial  disease   212   18.8   399   14.4  
Other   50   4.4   129   4.7  
Nephropathy  "of  unknown  etiology"     99   8.8   288   10.4  
a  For  the  full  AURORA  cohort,  only  the  age  categories  above  were  available;;  thus,  the  ages  of  the  AURORA  patients  
exome  sequenced  were  binned  into  these  categories,  to  facilitate  direct  comparison  between  them  and  all  
participants.    
Per  the  AURORA  study  design  (see  Section  S1,  Cohorts),  all  patients  included  had  reached  end-­stage  renal  
disease  and  were  on  dialysis.    
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Table  S2.  Clinical  features  of  the  exome  sequenced  Columbia  University  Medical  Center  (CUMC)  
Genetic  Studies  of  Chronic  Kidney  Disease  (CKD)  participants  versus  all  Genetic  Studies  of  CKD  
study  participants  
  
Cohort   Exome  sequenced   All  participants  
No.  of  Patients   2,187   3,122  
Characteristic   N   %   N   %  
Age  at  time  of  study  entry  (yr)  
0-­21   278   12.7   460   14.7  
22-­44   713   32.6   953   30.5  
45-­64   800   36.6   1034   33.1  
65+   396   18.1   675   21.6  
Sex  
Female   945   43.2   1355   43.4  
Male   1242   56.8   1767   56.6  
Race/Ethnicity  
White  European   1113   50.9   1752   56.1  
Hispanic   435   19.9   538   17.2  
Black/African  American   330   15.1   430   13.8  
Asian   224   10.2   286   9.2  
Other/Unspecified   85   3.9   116   3.7  
Clinical  diagnosis  
Congenital  or  cystic  renal  disease   372   17.0   678   21.7  
Glomerulopathy   1180   54.0   1592   51.0  
Diabetic  nephropathy   186   8.5   199   6.4  
Hypertensive  nephropathy   126   5.8   157   5.0  
Tubulointerstitial  disease   32   1.5   38   1.2  
Other   109   5.0   127   4.1  
Nephropathy  "of  unknown  etiology"     182   8.3   331   10.6  
Reached  ESRD   1016   46.5   1167   37.4  
Positive  family  history  for  kidney  disease   619   28.3   1032   33.1  
ESRD:  End-­stage  renal  disease  (includes  both  patients  on  dialysis  and  renal  transplant  recipients).    
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Table  S3. Clinical  diagnostic  composition  of  the  Columbia  University  Medical  Center  (CUMC)  
Nephrology  outpatient  population  versus  the  Genetic  Studies  of  Chronic  Kidney  Disease  (CKD)  
patients  
  




CUMC  Genetic  Studies  of  CKD  
Exome  sequenced   All  recruited  
Total  no.  of  patients     5,819   2,187   3,122  
Clinical  Diagnosis   N   %   N   %   N   %  
Congenital  or  cystic  renal  disease   256   4.4   372   17.0   678   21.7  
Glomerulopathy   739   12.7   1180   54.0   1592   51.0  
Diabetic  nephropathy   659   11.3   186   8.5   199   6.4  
Hypertensive  nephropathy   2220   38.2   126   5.8   157   5.0  
Tubulointerstitial  disease   38   0.7   32   1.5   38   1.2  
Other     590   10.1   109   5.0   127   4.1  
Nephropathy  "of  unknown  etiology"   1317   22.6   182   8.3   331   10.6  
CKD:  Chronic  kidney  disease;;  CUMC:  Columbia  University  Medical  Center.  
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Table  S4.  Key  resources  used  for  variant  annotation  
  
Purpose   Resource   URL  
Predict  effect  of  DNA  
sequence  variant  on  
function  of  the  encoded  
protein  
ANNOVAR   http://annovar.openbioinformatics.org/  
SnpEff   http://snpeff.sourceforge.net/  
Assess  variant  frequency  
(minor  allele  frequency;;  








dbSNP   https://www.ncbi.nlm.nih.gov/SNP/  
1000  Genomes  Project   http://www.internationalgenome.org/  
DiscovEHR   http://www.discovehrshare.com/  
In-­silico  prediction  of  
deleteriousness  of  variant  
dbNSFP  (version  3.3a)   https://sites.google.com/site/jpopgen/dbNSFP  
Identify  prior  reports  of  
variant  in  disease  cases  
Human  Gene  Mutation  
Database    















Table  S5.  Manually  curated  Mendelian  kidney  and  genitourinary  gene  set  and  observed  exome  
capture    
Gene    
No.  of  exons  not  targeted  by    
exome  sequencing  capture  kit  
Roche   IDT   Both  
ABCC6   0   0   0  
ABCD4   0   0   0  
ACE   0   0   0  
ACP5   0   0   0  
ACTA2   0   0   0  
ACTB   0   0   0  
ACTG2   0   0   0  
ACTN4   0   0   0  
ACVRL1   0   0   0  
ADAMTS13   0   0   0  
AFF4   0   0   0  
AGPAT2   0   0   0  
AGT   0   0   0  
AGTR1   0   0   0  
AGXT   0   0   0  
AHI1   0   0   0  
ALG8   0   0   0  
ALG9   0   0   0  
ALMS1   0   1   0  
ALPL   0   0   0  
AMER1   0   0   0  
AMN   0   0   0  
ANKS6   0   0   0  
ANLN   0   0   0  
ANOS1   0   0   0  
AP2S1   0   0   0  
APC2   0   0   0  
APOA1   0   0   0  
APOPT1   0   0   0  
APRT   0   0   0  
AQP2   0   0   0  
ARHGDIA   0   0   0  
ARID1A   0   0   0  
ARID1B   0   0   0  
ARL13B   0   0   0  
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ARL6   0   0   0  
ARMC5   0   0   0  
ARNT2   0   0   0  
ARX   0   0   0  
ASXL1   0   0   0  
ATP6V0A4   0   0   0  
ATP6V1B1   0   0   0  
ATP7A   0   0   0  
ATP7B   0   0   0  
AUH   0   0   0  
AVP   0   0   0  
AVPR2   0   0   0  
B2M   0   0   0  
B3GLCT   0   0   0  
B4GAT1   0   0   0  
B9D1   0   0   0  
B9D2   0   0   0  
BBIP1   0   0   0  
BBS1   0   0   0  
BBS10   0   0   0  
BBS12   0   0   0  
BBS2   0   0   0  
BBS4   0   0   0  
BBS5   0   0   0  
BBS7   0   0   0  
BBS9   0   0   0  
BCOR   0   0   0  
BCS1L   0   0   0  
BMP4   0   0   0  
BMPER   0   0   0  
BRAF   0   1   0  
BRIP1   0   0   0  
BSCL2   0   0   0  
BSND   0   0   0  
BUB1B   0   0   0  
C1QA   0   0   0  
C1QB   0   0   0  
C1QC   0   0   0  
C2   0   0   0  
C3   0   0   0  
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C4A   0   0   0  
C5orf42   0   0   0  
CA2   0   0   0  
CACNA1S   0   0   0  
CAD   0   0   0  
CASP10   0   0   0  
CASR   0   0   0  
CC2D2A   0   0   0  
CCBE1   0   0   0  
CCDC22   0   0   0  
CD151   0   0   0  
CD19   0   0   0  
CD81   0   0   0  
CD96   0   0   0  
CDC5L   0   0   0  
CDC73   0   0   0  
CDKN1B   0   0   0  
CDKN1C   0   0   0  
CECR1   0   0   0  
CENPF   0   0   0  
CEP104   0   0   0  
CEP120   0   0   0  
CEP164   0   0   0  
CEP290   0   0   0  
CEP41   0   0   0  
CEP83   0   0   0  
CFH   0   0   0  
CFHR5   0   0   0  
CFI   0   0   0  
CHD7   0   0   0  
CHRM3   0   0   0  
CHST14   0   0   0  
CISD2   0   0   0  
CLCN5   0   0   0  
CLCNKA   0   0   0  
CLCNKB   0   0   0  
CLDN16   0   0   0  
CLDN19   0   0   0  
CNNM2   0   0   0  
COL18A1   0   0   0  
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COL4A1   0   0   0  
COL4A3   0   0   0  
COL4A4   0   0   0  
COL4A5   0   0   0  
COL5A1   0   0   0  
COPA   0   0   0  
COQ2   0   0   0  
COQ6   0   0   0  
COQ7   0   0   0  
COQ8B   0   0   0  
COQ9   0   0   0  
COX10   0   0   0  
COX14   0   0   0  
COX20   0   0   0  
COX6B1   0   0   0  
COX7B   0   0   0  
COX8A   0   0   0  
CPT1A   0   0   0  
CPT2   0   0   0  
CRB2   0   0   0  
CREBBP   0   0   0  
CRTAP   0   0   0  
CSPP1   0   0   0  
CTC1   0   0   0  
CTNS   0   0   0  
CUBN   0   0   0  
CUL3   0   0   0  
CYP11A1   0   0   0  
CYP11B1   0   0   0  
CYP17A1   0   0   0  
CYP21A2   0   0   0  
CYP24A1   0   0   0  
DCDC2   0   0   0  
DCHS1   0   0   0  
DDX59   0   0   0  
DGKE   0   0   0  
DHCR7   0   0   0  
DIS3L2   0   0   0  
DKC1   0   0   0  
DLG3   0   0   0  
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DLL3   0   0   0  
DLL4   0   0   0  
DLX4   0   0   0  
DMP1   0   0   0  
DNA2   0   0   0  
DNAAF1   0   0   0  
DNASE1L3   0   0   0  
DNMT3B   0   0   0  
DPH1   0   0   0  
DSTYK   0   0   0  
DYNC2H1   0   0   0  
EBP   0   0   0  
EDNRA   0   0   0  
EFEMP2   0   0   0  
EGF   0   0   0  
EHHADH   0   0   0  
EIF2AK3   0   0   0  
EIF2B4   0   0   0  
EMP2   0   0   0  
ENG   0   0   0  
ENPP1   0   0   0  
EPG5   0   0   0  
ERBB3   0   0   0  
ERCC4   0   0   0  
ERCC6   0   0   0  
ERCC8   0   0   0  
ESCO2   0   0   0  
ETFA   0   0   0  
ETFB   0   0   0  
ETFDH   0   0   0  
EVC   0   0   0  
EVC2   0   0   0  
EYA1   0   0   0  
FAH   0   0   0  
FAM20A   0   0   0  
FAM20C   0   0   0  
FAM58A   0   0   0  
FAN1   0   0   0  
FANCA   0   0   0  
FANCB   0   0   0  
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FANCC   0   0   0  
FANCD2   0   0   0  
FANCE   0   0   0  
FANCF   0   0   0  
FANCG   0   0   0  
FANCI   0   0   0  
FANCL   0   0   0  
FANCM   0   0   0  
FASTKD2   0   0   0  
FAT4   0   0   0  
FBLN5   0   0   0  
FBXL4   0   0   0  
FGA   0   0   0  
FGF10   0   0   0  
FGF20   0   0   0  
FGF23   0   0   0  
FGFR1   0   0   0  
FGFR2   0   0   0  
FGFR3   0   0   0  
FKBP14   0   0   0  
FLCN   0   0   0  
FLNA   0   0   0  
FLNB   0   0   0  
FLT4   0   0   0  
FN1   0   0   0  
FOXC1   0   0   0  
FOXC2   0   0   0  
FOXF1   0   0   0  
FRAS1   0   0   0  
FREM1   0   0   0  
FREM2   0   0   0  
FUZ   0   0   0  
FXYD2   0   0   0  
G6PC   0   0   0  
GALNT3   0   0   0  
GATA3   0   0   0  
GATA6   0   0   0  
GBA   0   0   0  
GCDH   0   0   0  
GCM2   0   0   0  
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GDF2   0   1   0  
GDNF   0   0   0  
GLA   0   0   0  
GLB1   0   0   0  
GLI3   0   1   0  
GLIS2   0   0   0  
GLIS3   0   0   0  
GNA11   0   0   0  
GNAS   0   0   0  
GNAS-­AS1   1   All   1  
GNB1   0   0   0  
GPC3   0   0   0  
GRHPR   0   0   0  
GRIP1   0   0   0  
GSN   0   0   0  
HBB   0   0   0  
HDAC8   0   0   0  
HES7   0   0   0  
HGD   0   0   0  
HNF1A   0   0   0  
HNF1B   0   0   0  
HNF4A   0   0   0  
HOGA1   0   0   0  
HOXA13   0   0   0  
HOXD13   0   0   0  
HPRT1   0   0   0  
HPS1   0   0   0  
HPSE2   0   0   0  
HRAS   0   0   0  
HSD11B2   0   0   0  
HSD17B3   0   0   0  
HSD17B4   0   0   0  
HSD3B2   0   0   0  
HSPA9   0   0   0  
HSPG2   0   0   0  
HYLS1   0   0   0  
ICK   0   0   0  
IFT122   0   0   0  
IFT140   0   0   0  
IFT172   0   0   0  
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IFT27   0   0   0  
IFT43   0   0   0  
IFT80   0   1   0  
IKBKAP   0   0   0  
INF2   0   0   0  
INPP5E   0   0   0  
INPPL1   0   0   0  
INSR   0   0   0  
INVS   0   0   0  
IQCB1   0   0   0  
IRF6   0   0   0  
ITGA3   0   0   0  
ITGA6   0   0   0  
ITGA8   0   0   0  
ITGB4   0   0   0  
JAG1   0   0   0  
JAM3   0   0   0  
KANK1   0   0   0  
KANK2   0   0   0  
KANK4   0   0   0  
KANSL1   0   0   0  
KAT6B   0   0   0  
KCNA1   0   0   0  
KCNH1   0   0   0  
KCNJ1   0   0   0  
KCNJ10   0   0   0  
KCNJ5   0   0   0  
KCTD1   0   0   0  
KDM1A   0   0   0  
KDM6A   0   0   0  
KIF14   0   0   0  
KIF7   0   0   0  
KL   0   0   0  
KLHL3   0   0   0  
KMT2D   0   0   0  
KRAS   0   0   0  
KYNU   0   0   0  
LAMB2   0   0   0  
LAMB3   0   0   0  
LAMC2   0   0   0  
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LARS   0   0   0  
LCAT   0   1   0  
LDHA   0   0   0  
LFNG   0   0   0  
LMBRD1   0   0   0  
LMNA   0   0   0  
LMX1B   0   0   0  
LONP1   0   0   0  
LPIN1   0   0   0  
LRIG2   0   0   0  
LRP2   0   1   0  
LRP4   0   0   0  
LTBP4   0   0   0  
LYZ   0   0   0  
LZTFL1   0   0   0  
MAFB   0   0   0  
MAGED2   0   0   0  
MAP2K1   0   0   0  
MAP2K2   0   0   0  
MAPRE2   0   0   0  
MBTPS2   0   0   0  
MEFV   0   0   0  
MESP2   0   0   0  
MIR17HG   2   All   2  
MKKS   0   0   0  
MKS1   0   0   0  
MLH1   0   0   0  
MMACHC   0   0   0  
MNX1   0   0   0  
MRPS22   0   0   0  
MSH2   0   0   0  
MSH6   0   0   0  
MTM1   0   0   0  
MUC1   0   0   0  
MUT   0   0   0  
MVK   0   0   0  
MYCN   0   0   0  
MYH9   0   0   0  
MYO1E   0   0   0  
NAA10   0   0   0  
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NARS2   0   0   0  
NBN   0   0   0  
NECTIN1   0   0   0  
NEK1   0   0   0  
NEK8   0   0   0  
NEXMIF   0   0   0  
NF1   0   0   0  
NHP2   0   0   0  
NIPBL   0   0   0  
NLRP3   0   0   0  
NOTCH2   0   0   0  
NOTCH3   0   0   0  
NPHP1   0   0   0  
NPHP3   0   0   0  
NPHP4   0   0   0  
NPHS1   0   0   0  
NPHS2   0   0   0  
NR0B1   0   0   0  
NR3C2   0   0   0  
NSD1   0   0   0  
NSDHL   0   0   0  
NUP107   0   0   0  
NUP205   0   0   0  
NUP93      0   0  
OCLN   0   0   0  
OCRL   0   0   0  
OFD1   0   0   0  
OPLAH   0   0   0  
PAF1   0   0   0  
PALB2   0   0   0  
PAX2   0   0   0  
PC   0   0   0  
PDE6D   0   0   0  
PDSS1   0   0   0  
PDSS2   0   0   0  
PET100   0   0   0  
PEX1   0   0   0  
PEX10   0   0   0  
PEX11B   0   0   0  
PEX12   0   0   0  
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PEX13   0   0   0  
PEX14   0   0   0  
PEX16   0   0   0  
PEX19   0   0   0  
PEX2   0   0   0  
PEX26   0   0   0  
PEX3   0   0   0  
PEX5   0   0   0  
PEX6   0   0   0  
PGK1   0   0   0  
PGM3   0   0   0  
PHEX   0   0   0  
PHGDH   0   0   0  
PIEZO2   0   0   0  
PIGA   0   0   0  
PIGL   0   0   0  
PIGN   0   0   0  
PIGT   0   0   0  
PIK3CA   0   0   0  
PIK3R2   0   0   0  
PITX2   0   0   0  
PKD1   0   0   0  
PKD2   0   0   0  
PKHD1   0   0   0  
PLCE1   0   0   0  
PLG   0   0   0  
PLOD1   0   0   0  
PMM2   0   0   0  
PNPLA6   0   0   0  
POMC   0   0   0  
POMT1   0   0   0  
POR   0   0   0  
PORCN   0   0   0  
PPP1R15B   0   0   0  
PQBP1   0   0   0  
PRKCD   0   0   0  
PRODH   0   0   0  
PROKR2   0   0   0  
PRPS1   0   0   0  
PSAP   0   0   0  
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PTEN   0   0   0  
PTH   0   0   0  
PTH1R   0   0   0  
PTPN11   0   0   0  
PTPRO   0   0   0  
PUF60   0   0   0  
PYGM   0   0   0  
RAB18   0   0   0  
RAB23   0   0   0  
RAB3GAP1   0   0   0  
RAB3GAP2   0   0   0  
RAD51C   0   0   0  
RAI1   0   0   0  
RAP1A   0   0   0  
RAP1B   0   0   0  
RBBP8   0   0   0  
RBM10   0   0   0  
RBM8A   0   0   0  
RECQL4   0   0   0  
REN   0   0   0  
RERE   0   0   0  
RET   0   0   0  
RIN2   0   0   0  
RIPK4   0   0   0  
RIPPLY2   0   0   0  
RMND1   0   0   0  
RNU4ATAC   All   All   All  
ROBO2   0   0   0  
ROR2   0   0   0  
RPGRIP1L   0   0   0  
RPL11   0   0   0  
RPL26   0   0   0  
RPL35A   0   0   0  
RPL5   0   0   0  
RPS10   0   0   0  
RPS17   0   0   0  
RPS19   0   0   0  
RPS24   0   0   0  
RPS26   0   0   0  
RPS28   0   0   0  
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RPS29   0   0   0  
RPS7   0   0   0  
RRM2B   0   0   0  
RTTN   0   0   0  
SALL1   0   0   0  
SALL4   0   0   0  
SARS2   0   0   0  
SBDS   0   0   0  
SC5D   0   0   0  
SCARB2   0   0   0  
SCN4A   0   0   0  
SCNN1A   0   0   0  
SCNN1B   0   0   0  
SCNN1G   0   0   0  
SCO1   0   0   0  
SDCCAG8   0   0   0  
SDHB   0   0   0  
SDHC   0   0   0  
SDHD   0   0   0  
SEMA3E   0   0   0  
SERPINH1   0   0   0  
SETBP1   0   0   0  
SF3B4   0   0   0  
SHH   0   0   0  
SI   0   0   0  
SIX1   0   0   0  
SIX2   0   0   0  
SIX5   0   0   0  
SLC12A1   0   0   0  
SLC12A3   0   0   0  
SLC16A12   0   0   0  
SLC1A1   0   0   0  
SLC22A12   0   0   0  
SLC25A1   0   0   0  
SLC26A4   0   0   0  
SLC2A10   0   0   0  
SLC2A2   0   0   0  
SLC2A9   0   0   0  
SLC34A1   0   0   0  
SLC34A3   0   0   0  
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SLC36A2   0   0   0  
SLC37A4   0   0   0  
SLC3A1   0   0   0  
SLC4A1   0   0   0  
SLC4A4   0   0   0  
SLC5A2   0   0   0  
SLC6A19   0   0   0  
SLC6A20   0   0   0  
SLC7A7   0   0   0  
SLC7A9   0   0   0  
SLC9A3R1   0   0   0  
SLIT2   0   0   0  
SLX4   0   0   0  
SMAD3   0   0   0  
SMARCAL1   0   0   0  
SMARCE1   0   1   0  
SMC1A   0   0   0  
SMOC1   0   0   0  
SNRPB   0   0   0  
SOX11   0   0   0  
SOX17   0   0   0  
SOX18   0   0   0  
SOX9   0   0   0  
SPECC1L   0   0   0  
SPINT2   0   0   0  
SRCAP   0   0   0  
STAR   0   0   0  
STK11   0   0   0  
STRA6   0   0   0  
STRADA   0   0   0  
STUB1   0   0   0  
STX16   0   0   0  
SUCLA2   0   0   0  
SUGCT   0   0   0  
TACO1   0   0   0  
TAPT1   0   0   0  
TBC1D20   0   0   0  
TBC1D24   0   0   0  
TBCE   0   0   0  
TBX18   0   0   0  
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TCTN2   0   0   0  
TCTN3   0   0   0  
TERC   0   All   0  
TFAP2A   0   0   0  
THOC6   0   0   0  
TMCO1   0   0   0  
TMEM138   0   0   0  
TMEM216   0   0   0  
TMEM231   0   0   0  
TMEM237   0   0   0  
TMEM67   0   0   0  
TMEM70   0   0   0  
TNFRSF1A   0   0   0  
TNXB   0   0   0  
TP63   0   0   0  
TRAF3IP1   0   0   0  
TRAIP   0   0   0  
TRAP1   0   0   0  
TREX1   0   0   0  
TRIM32   0   0   0  
TRMT5   0   0   0  
TRNT1   0   0   0  
TRPC6   0   0   0  
TRPM6   0   0   0  
TSC1   0   0   0  
TSC2   0   0   0  
TSR2   0   0   0  
TTC21B   0   0   0  
TTC37   0   0   0  
TTC8   0   0   0  
TTR   0   0   0  
TWIST2   0   0   0  
TXNL4A   0   0   0  
UBE2T   0   0   0  
UBR1   0   0   0  
UMOD   0   0   0  
UMPS   0   0   0  
UPB1   0   0   0  
UPK3A   0   0   0  
UQCC2   0   0   0  
 
  147  
USP9X   0   0   0  
VANGL1   0   0   0  
VHL   0   0   0  
VIPAS39   0   0   0  
VPS33B   0   0   0  
WAS   0   0   0  
WDPCP   0   0   0  
WDR19   0   0   0  
WDR34   0   0   0  
WDR35   0   0   0  
WDR60   0   0   0  
WDR73   0   0   0  
WFS1   0   0   0  
WNK1   0   0   0  
WNK4   0   0   0  
WNT3   0   0   0  
WNT4   0   0   0  
WNT5A   0   0   0  
WNT7A   0   0   0  
WT1   0   0   0  
XDH   0   0   0  
XPNPEP3   0   0   0  
XRCC4   0   0   0  
XYLT2   0   0   0  
YAP1   0   0   0  
ZAP70   0   0   0  
ZIC3   0   0   0  
ZMPSTE24   0   0   0  
ZNF423   0   0   0  
ZNF687   0   0   0  
  
a  The  list  was  established  May  2016;;  thus,  we  encourage  readers  to  also  examine  gene-­disease  databases  such  as  Online  
Mendelian  Inheritance  in  Man  (OMIM;;  see  Table  S4)  to  incorporate  more  recently  identified  Mendelian  genitourinary-­












































































































































































































































































































































































































































































































































































































































































































































































































































































































Table  S7.  Stringently  filtered  variants  of  uncertain  significance  (VUS)  in  the  625  genes  associated  
with  Mendelian  forms  of  kidney  and  genitourinary  disease.  
  
  





Clinical'Diagnosis Model Gene Variant Zygosity Associated'Disease MAF CADD'Score MetaSVM'Prediction
M4CAP'
Prediction REVEL'Score
CKD03 AURORA * * * * Glomerulopathy Dominant CFH p.C839* Het Complement>factor>h>deficiency 0 35 . . .
CKD05 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant BUB1B p.K402del Het Mosaic>variegated>aneuploidy>syndrome>1 0 . . . .
CKD09 AURORA * * * *
Nephropathy>"of>
unknown>etiology"
Dominant FLNB p.R1587C Het Spondylocarpotarsal>synostosis>syndrome 0 35 D D 0.792
CKD09 AURORA * * * *
Nephropathy>"of>
unknown>etiology"
Dominant OCLN p.D426fs Het
Band*like>calcification>with>simplified>gyration>and>
polymicogyria
0 . . . .
CKD09 AURORA * * * *
Nephropathy>"of>
unknown>etiology"
Dominant FREM1 p.Q1551fs Het
Bifid>nose>with>or>without>anorectal>and>renal>
anomalies
0 . . . .
CKD111 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant TNFRSF1A p.R397C Het Autosomal>dominant>periodic>fever>syndrome 0 34 D D 0.773
CKD112 AURORA * * * *
Tubulointerstitial>
disease
Dominant CLCNKA p.A445F Het Bartter's>Syndrome>Type>4b,>Neonatal 0 . . . .
CKD112 AURORA * * * *
Tubulointerstitial>
disease
Dominant SI p.I424N Het Sucrase*isomaltase>deficiency,>congenital 0 28.6 D D 0.889
CKD112 AURORA * * * *
Tubulointerstitial>
disease
Dominant UPK3A p.W182* Het Renal>hypodysplasia,>urogenital>dysplasia 0 39 . . .
CKD115 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant ARX p.Q339H Het Proud>syndrome 0 24.2 D D 0.923
CKD120 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant SLC12A1 c.1942+1G>T Het Bartter>syndrome,>type>1,>antenatal 0 26.4 . . .
CKD122 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant SLC4A4 p.T750I Het
Renal>tubular>acidosis,>proximal,>with>ocular>
abnormalities>and>mental>retardation
0 33 D D 0.842
CKD123 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant SLC6A19 p.S323F Het Hartnup>Disorder>Hyperglycinuria 0 26.4 D D 0.876
CKD125 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant FANCM p.Q657* Het Fanconi>anemia 0 35 . . .
CKD127 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant PKD1 p.F2446del Het Polycystic>kidney>disease>1 0 . . . .
CKD128 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant MAP2K2 p.P236L Het Cardiofaciocutaneous>syndrome 0 31 D D 0.964
CKD135 AURORA * * * *
Nephropathy>"of>
unknown>etiology"
Dominant SLC5A2 p.S437P Het Renal>glucosuria 0 27.8 D D 0.78
CKD18 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant AHI1 p.N1146fs Het Joubert>Syndrome>3 0 . . . .
CKD20 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant SCNN1A p.A47L Het Pseudohypoaldosteronism,>Type>I 0 . . . .
CKD22 AURORA * * * * Glomerulopathy Dominant FANCL p.C359fs Het Fanconi>anemia,>complementation>group>L 0 . . . .
CKD22 AURORA * * * * Glomerulopathy Dominant IFT27 p.G40R Het Bardet*Biedl>syndrome>19 0 31 D D 0.845
CKD30 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant COL18A1 c.2464*1G>C Het Knobloch>syndrome 0 22.8 . . .
CKD31 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant KANK1 p.S440fs Het Nephroticsyndrome 0 . . . .
CKD310 AURORA * * * *
Tubulointerstitial>
disease
Dominant PEX6 p.G820del Het Zellweger>syndrome 0 . . . .
CKD317 AURORA * * * *
Tubulointerstitial>
disease
Dominant ATP7B p.M1191V Het Wilson>Disease 0 23.4 D D 0.754
CKD318 AURORA * * * *
Tubulointerstitial>
disease
Dominant LRP4 p.S1504F Het Cenani*lenz>syndactyly>syndrome 0 32 D D 0.775
CKD320 AURORA * * * * Glomerulopathy Dominant STRA6 p.W639* Het Microphthalmia,>syndromic>9,>mcops9 0 45 . . .
CKD34 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant TSC2 p.N1681S Het Tuberous>sclerosis*2 0 26.3 D D 0.87
CKD371 AURORA * * * * Diabetic>nephropathy Dominant MLH1 p.Y684H Het Muir*Torre>syndrome 0 29.3 D D 0.946
CKD372 AURORA * * * *
Tubulointerstitial>
disease
Dominant SI p.Q450del Het Sucrase*isomaltase>deficiency,>congenital 0 . . . .
CKD373 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant WFS1 p.S855P Het Wolfram>syndrome>type>1 0 . . . .




0 . . . .
CKD375 AURORA * * * * Glomerulopathy Dominant DIS3L2 p.RP11RT Het
Perlman's>syndrome>(nephroblastomatosis,>
gigantism)
0 . . . .






Het pseudohypoparathyroidism,>type>1B 0 . . . .
CKD377 AURORA * * * *
Nephropathy>"of>
unknown>etiology"
Dominant KMT2D p.PT697PM Het Kabuki>syndrome>1 0 . . . .
CKD378 AURORA * * * * Glomerulopathy Dominant CEP164 p.K116fs Het Senior*Loken>syndrome,>Nephronopthisis>15 0 . . . .
CKD379 AURORA * * * * Diabetic>nephropathy Dominant NOTCH2 p.N2466del Het
Acroosteolysis>dominant>type,>Alagille>syndrome>2,>
Hajdu*Cheney>Syndrome
0 . . . .
CKD380 AURORA * * * *
Hypertensive>
nephropathy
Dominant CECR1 p.R131fs Het
Sneddon>syndrome>Polyarteritis>nodosa,>childhood*
onset
0 . . . .
CKD381 AURORA * * * * Diabetic>nephropathy Dominant PEX6 p.K866Q Het Zellweger>syndrome 0 31 D D 0.814
CKD382 AURORA * * * *
Hypertensive>
nephropathy




0 . . . .
CKD383 AURORA * * * * Diabetic>nephropathy Dominant CACNA1S p.S555C Het Hypokalemic>periodic>paralysis,>hokpp 0 27.1 D D 0.935
CKD384 AURORA * * * * Diabetic>nephropathy Dominant ARMC5 p.A310N Het
Cushing>syndrome>due>to>macronodular>adrenal>
hyperplasia
0 . . . .
CKD385 AURORA * * * * Diabetic>nephropathy Dominant GLIS2 p.K251* Het Nephronophthisis>7 0 40 . . .
CKD386 AURORA * * * *
Tubulointerstitial>
disease
Dominant APOPT1 p.G186fs Het Mitochondrial>Complex>4>deficiency 0 . . . .
CKD387 AURORA * * * * Glomerulopathy Dominant LAMB2 p.VQ1607VK Het
Nephrotic>syndrome,>type>5,>with>or>without>ocular>
abnormalities>Pierson>Syndrome
0 . . . .
CKD388 AURORA * * * *
Tubulointerstitial>
disease





0 25.1 D D 0.814
CKD389 AURORA * * * * Glomerulopathy Dominant SLC16A12 p.W49G Het Cataract,>juvenile,>with>microcornea>and>glucosuria 0 27 D D 0.78
CKD390 AURORA * * * *
Hypertensive>
nephropathy
Dominant LRIG2 p.P696H Het Ochoa>syndrome,>Urofacial>Syndrome>2 0 32 D D 0.898
CKD391 AURORA * * * * Glomerulopathy Dominant GCDH p.M191V Het Glutaricaciduria,>type>I 0 22.6 D D 0.863
CKD392 AURORA * * * * Glomerulopathy Dominant NPHS2 p.P341fs Het Nephrotic>syndrome>type>2 0 . . . .
CKD393 AURORA * * * * Glomerulopathy Dominant ATP7B p.A1227D Het Wilson>Disease 0 34 D D 0.979
CKD394 AURORA * * * *
Nephropathy>"of>
unknown>etiology"
Dominant CFH p.C320R Het Complement>factor>h>deficiency 0 24.7 D D 0.908
CKD394 AURORA * * * *
Nephropathy>"of>
unknown>etiology"
Dominant FGFR2 p.P72L Het
Pfeiffer>syndrome>type>3,>Antley*Bixler>syndrome,>
Apert>syndrome,>LADD>syndrome
0 23.8 D D 0.815
CKD395 AURORA * * * * Diabetic>nephropathy Dominant RPGRIP1L p.I1062fs Het
Meckel>syndrome>5,>Joubert>syndrome>7,>COACH>
syndrome
0 . . . .
CKD396 AURORA * * * *
Hypertensive>
nephropathy
Dominant AGT p.L134P Het Renal>tubular>dysgenesis 0 23.7 D D 0.775
CKD397 AURORA * * * * Glomerulopathy Dominant KIF7 c.3518*1G>C Het Acrocallosal>syndrome 0 24.2 . . .
CKD398 AURORA * * * *
Tubulointerstitial>
disease
Dominant ALPL p.D458G Het Hypophosphatasia,>infantile 0 . . . .
CKD399 AURORA * * * * Diabetic>nephropathy Dominant COQ2 p.R126fs Het Coenzyme>q10>deficiency 0 . . . .
CKD400 AURORA * * * *
Tubulointerstitial>
disease
Dominant PNPLA6 p.R102fs Het Laurence*Moon>syndrome 0 . . . .
CKD401 AURORA * * * *
Tubulointerstitial>
disease
Dominant SI p.Y176* Het Sucrase*isomaltase>deficiency,>congenital 0 34 . . .









0 . . . .
CKD402 AURORA * * * *
Hypertensive>
nephropathy
Dominant CACNA1S p.P172T Het Hypokalemic>periodic>paralysis,>hokpp 0 27.4 D D 0.891
CKD403 AURORA * * * * Glomerulopathy Dominant SETBP1 p.P1526fs Het Schinzel*Giedion>Midface>Retraction>Syndrome 0 . . . .
CKD404 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant INPP5E p.S148fs Het
Joubert>syndrome>with>hepatic>defectJoubert>
Syndrome>1
0 . . . .
CKD405 AURORA * * * *
Hypertensive>
nephropathy
Dominant CACNA1S p.P172T Het Hypokalemic>periodic>paralysis,>hokpp 0 27.4 D D 0.891
CKD406 AURORA * * * * Diabetic>nephropathy Dominant WNK4 c.1742*1G>A Het Pseudohypoaldosteronism,>type>2b 0 24.6 . . .
CKD407 AURORA * * * * Diabetic>nephropathy Dominant IFT140 p.Q1138L Het
Short>rib*polydactyly>syndrome>(Jeune's>syndrome)>
type>9
0 . . . .




0 25.1 . . .
CKD409 AURORA * * * * Glomerulopathy Dominant PPP1R15B p.S131D Het
Microcephaly,>short>stature,>and>impaired>glucose>
metabolism>2
0 . . . .






Het Orofaciodigital>syndrome>6 0 . . . .
CKD41 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant BCOR p.F145fs Het
Microphthalmia,>Lenz>type,>Microphthalmia,>
syndromic>2
0 . . . .
CKD41 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant ALG8 p.T47dup Het
Polycystic>liver>disease>3>with>or>without>kidney>
cysts
0 . . . .










0 . . . .
CKD411 AURORA * * * *
Hypertensive>
nephropathy
Dominant GRIP1 p.T535K Het Fraser>syndrome 0 . . . .
CKD412 AURORA * * * *
Hypertensive>
nephropathy
Dominant ARID1A p.A43del Het Coffin*Siris>syndrome 0 . . . .
CKD413 AURORA * * * *
Hypertensive>
nephropathy




CKD414 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant FKBP14 p.N70fs Het
Ehlers*Danlos>syndrome>with>progressive>
kyphoscoliosis,>myopathy,>and>hearing>loss
0 . . . .






Het Polycystic>kidney>disease>1 0 . . . .
CKD415 AURORA * * * * Glomerulopathy Dominant ANKS6 c.1618*1G>C Het Nephronophthisis>16 0 24.7 . . .
CKD416 AURORA * * * *
Hypertensive>
nephropathy
Dominant FREM2 p.A514G Het Fraser>syndrome 0 . . . .
CKD417 AURORA * * * * Glomerulopathy Dominant C5orf42 p.L1788del Het Orofaciodigital>syndrome>6 0 . . . .
CKD418 AURORA * * * * Glomerulopathy Dominant CACNA1S p.R1318S Het Hypokalemic>periodic>paralysis,>hokpp 0 25 D . 0.764
CKD419 AURORA * * * * Glomerulopathy Dominant BUB1B c.2851*1G>C Het Mosaic>variegated>aneuploidy>syndrome>1 0 25.1 . . .
CKD419 AURORA * * * * Glomerulopathy Dominant FGFR2 p.R462W Het
Pfeiffer>syndrome>type>3,>Antley*Bixler>syndrome,>
Apert>syndrome,>LADD>syndrome
0 35 D D 0.902
CKD420 AURORA * * * *
Hypertensive>
nephropathy
Dominant RPGRIP1L p.K195* Het
Meckel>syndrome>5,>Joubert>syndrome>7,>COACH>
syndrome
0 35 . . .
CKD421 AURORA * * * * Glomerulopathy Dominant ETFB c.376*2A>G Het Glutaric>acidemia>2b 0 23.4 . . .
CKD421 AURORA * * * * Glomerulopathy Dominant PEX14
p.E329_D331d
up
Het Zellweger>syndrome 0 . . . .
CKD422 AURORA * * * *
Hypertensive>
nephropathy
Dominant LPIN1 p.Y223* Het Myoglobinuria,>acute>recurrent 0 25.6 . . .
CKD423 AURORA * * * * Diabetic>nephropathy Dominant SLC7A9
p.N166_V170d
el
Het Cystinuria 0 . . . .
CKD424 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant PKD1 p.V2549del Het Polycystic>kidney>disease>1 0 . . . .
CKD425 AURORA * * * * Glomerulopathy Dominant ACTN4 p.DV800DM Het Focal>Segmental>Glomerulosclerosis>1 0 . . . .
CKD426 AURORA * * * * Glomerulopathy Dominant CRB2 p.G349D Het FSGS>9>Ventriculomegaly>with>cystic>kidney>disease 0 24.3 D D 0.845
CKD427 AURORA * * * * Diabetic>nephropathy Dominant ERCC4 p.I518fs Het
Fanconi>anemia,>Xeroderma>pigmentosum,>type>f,>
Cockayne>syndrome
0 . . . .
CKD428 AURORA * * * *
Hypertensive>
nephropathy
Dominant SMARCAL1 c.2428*1G>C Het
Schimke>immuno*osseous>dysplasiaSchimke's>
immunoosseous>dystrophy
0 25.6 . . .
CKD429 AURORA * * * * Glomerulopathy Dominant FLNB p.A1391V Het Spondylocarpotarsal>synostosis>syndrome 0 . . . .
CKD429 AURORA * * * * Glomerulopathy Dominant FANCE p.A248fs Het Fanconi>anemia,>complementation>group>e 0 . . . .
CKD430 AURORA * * * * Glomerulopathy Dominant KMT2D
p.A623_E649d
el
Het Kabuki>syndrome>1 0 . . . .
CKD431 AURORA * * * *
Tubulointerstitial>
disease
Dominant FLNB p.F825S Het Spondylocarpotarsal>synostosis>syndrome 0 29.5 D D 0.915
CKD432 AURORA * * * *
Hypertensive>
nephropathy
Dominant WT1 p.NA198NE Het
Denys*Drash>syndrome,>Frasier>syndrome,>Nephrotic>
syndrome>type>4,>Wilms>tumor>type>1
0 . . . .
CKD433 AURORA * * * *
Tubulointerstitial>
disease
Dominant ARID1B p.G355fs Het Coffin*Siris>syndrome 0 . . . .
CKD434 AURORA * * * *
Hypertensive>
nephropathy
Dominant HSPG2 p.P2639fs Het Schwartz*Jampel>syndrome 0 . . . .
CKD434 AURORA * * * *
Hypertensive>
nephropathy
Dominant RPL5 p.T101S Het Blackfan*Diamond>anemia 0 24.6 D D 0.799
CKD435 AURORA * * * *
Hypertensive>
nephropathy
Dominant SCARB2 p.N317fs Het
Epilepsy,>Progressive>Myoclonic,>4>with>or>without>
Renal>Failure
0 . . . .
CKD436 AURORA * * * * Glomerulopathy Dominant FANCD2
p.R119_L120d
el
Het Fanconi>anemia,>Complementation>group>d2 0 . . . .
CKD437 AURORA * * * *
Hypertensive>
nephropathy
Dominant SLIT2 p.D1445fs Het
Congenital>Anomalies>of>the>Kidney>and>the>Urinary>
Tract
0 . . . .
CKD438 AURORA * * * * Diabetic>nephropathy Dominant FUZ p.R284fs Het Caudal>regression>sequence 0 . . . .
CKD438 AURORA * * * * Diabetic>nephropathy Dominant ITGB4 p.Y296S Het
Epidermolysis>bullosa,>junctional,>with>pyloric>
atresia
0 26.5 D D 0.967
CKD439 AURORA * * * *
Tubulointerstitial>
disease
Dominant ITGB4 p.PQ103PE Het
Epidermolysis>bullosa,>junctional,>with>pyloric>
atresia
0 . . . .
CKD44 AURORA * * * * Glomerulopathy Dominant COL18A1 p.Q812* Het Knobloch>syndrome 0 38 . . .
CKD440 AURORA * * * *
Hypertensive>
nephropathy
Dominant SOX17 p.PM269PL Het Vesicoureteral>Reflux>3 0 . . . .






Het Pancreatic>agenesis>and>congenital>heart>defects 0 . . . .
CKD442 AURORA * * * *
Tubulointerstitial>
disease
Dominant TMEM67 p.C62Y Het
Nephronophtisis>11,>Meckel>Syndrome>3,>Joubert>
syndrome>6,>COACH>syndrome
0 25.3 D D 0.792
CKD443 AURORA * * * *
Tubulointerstitial>
disease
Dominant EPG5 p.N2435fs Het Vici>syndrome 0 . . . .
CKD444 AURORA * * * *
Tubulointerstitial>
disease
Dominant FUZ c.234*2A>G Het Caudal>regression>sequence 0 24.5 . . .









0 . . . .
CKD445 AURORA * * * *
Tubulointerstitial>
disease
Dominant KCNA1 p.T268K Het Hypomagnesemia>associated>with>myokymia 0 31 D D 0.953
CKD446 AURORA * * * * Other Dominant SLC34A3 p.G315fs Het
Hypophosphatemic>rickets>with>hypercalciuria,>
hereditary
0 . . . .
CKD447 AURORA * * * * Diabetic>nephropathy Dominant CAD p.P247T Het Congenital>disorder>of>glycosylation,>type>Iz 0 28.5 D D 0.953
CKD448 AURORA * * * *
Tubulointerstitial>
disease
Dominant PEX13 p.A20_G23dup Het Zellweger>syndrome 0 . . . .
CKD449 AURORA * * * *
Tubulointerstitial>
disease
Dominant FANCM p.G549fs Het Fanconi>anemia 0 . . . .
CKD450 AURORA * * * *
Hypertensive>
nephropathy
Dominant PNPLA6 c.808*1G>A Het Laurence*Moon>syndrome 0 24.9 . . .
CKD451 AURORA * * * * Other Dominant CAD p.Y271C Het Congenital>disorder>of>glycosylation,>type>Iz 0 26.6 D D 0.884
CKD451 AURORA * * * * Other Dominant TRPM6 p.VP771Va Het Hypomagnesemia>1,>intestinal 0 . . . .
CKD452 AURORA * * * * Glomerulopathy Dominant TTC21B p.T1133fs Het Nephronophthisis>12 0 . . . .
CKD453 AURORA * * * * Diabetic>nephropathy Dominant PKHD1 p.S3187fs Het
autosomal>recessive>polycystic>kidney>disease,>
Polycystic>and>hepatic>disease
0 . . . .






Het Hand*foot*uterus>syndrome 0 . . . .
CKD455 AURORA * * * * Diabetic>nephropathy Dominant LRIG2 p.I826fs Het Ochoa>syndrome,>Urofacial>Syndrome>2 0 . . . .
CKD456 AURORA * * * *
Tubulointerstitial>
disease
Dominant GATA6 p.G352R Het Pancreatic>agenesis>and>congenital>heart>defects 0 29 D D 0.843
CKD457 AURORA * * * * Diabetic>nephropathy Dominant BSND p.Q138del Het Bartter>Syndrome,>Type>4a,>neonatal 0 . . . .






Het Polycystic>kidney>disease>1 0 . . . .
CKD459 AURORA * * * *
Nephropathy>"of>
unknown>etiology"
Dominant PTEN p.A86V Het
Cowden>syndrome,>VATER>association>with>
macrocephaly>and>ventriculomegaly
0 23.1 D D 0.789
CKD460 AURORA * * * * Other Dominant TMEM67 p.C72F Het
Nephronophtisis>11,>Meckel>Syndrome>3,>Joubert>
syndrome>6,>COACH>syndrome
0 26.6 D D 0.883
CKD461 AURORA * * * *
Nephropathy>"of>
unknown>etiology"
Dominant UMPS p.M1? Het Hereditary>orotic>aciduria 0 23.6 T D 0.336
CKD462 AURORA * * * * Glomerulopathy Dominant KANK4 p.E226* Het Nephrotic>syndrome 0 36 . . .
CKD462 AURORA * * * * Glomerulopathy Dominant SOX17 p.PM269PL Het Vesicoureteral>Reflux>3 0 . . . .
CKD463 AURORA * * * *
Hypertensive>
nephropathy
Recessive CLCN5 p.D391A Hemi
Dent>disease>nephrolithiasis>type>1>
hypophosphatemic>Rickets
0 23.5 D D 0.808
CKD463 AURORA * * * *
Hypertensive>
nephropathy
Dominant AGTR1 p.P95fs Het Renal>tubular>dysgenesis 0 . . . .
CKD464 AURORA * * * * Glomerulopathy Dominant SETBP1 p.L1522fs Het Schinzel*Giedion>Midface>Retraction>Syndrome 0 . . . .
CKD465 AURORA * * * *
Hypertensive>
nephropathy




0 28.4 . . .
CKD466 AURORA * * * *
Tubulointerstitial>
disease
Dominant SETBP1 p.P1525fs Het Schinzel*Giedion>Midface>Retraction>Syndrome 0 . . . .
CKD466 AURORA * * * *
Tubulointerstitial>
disease
Dominant ATP7B p.V997M Het Wilson>Disease 0 28.9 D D 0.883
CKD467 AURORA * * * * Glomerulopathy Dominant CFH p.P438del Het Complement>factor>h>deficiency 0 . . . .
CKD467 AURORA * * * * Glomerulopathy Dominant GCDH p.S186T Het Glutaricaciduria,>type>I 0 26.9 D D 0.954
CKD468 AURORA * * * *
Tubulointerstitial>
disease
Dominant SCNN1A p.N24fs Het Pseudohypoaldosteronism,>Type>I 0 . . . .
CKD469 AURORA * * * *
Tubulointerstitial>
disease
Dominant ACTB p.E361K Het Baraitser*Winter>syndrome>1 0 32 D D 0.938
CKD47 AURORA * * * *
Congenital>or>cystic>
renal>disease
Recessive COL4A5 p.I1386del Hemi Alport>syndrome 0 . . . .
CKD470 AURORA * * * * Diabetic>nephropathy Dominant CREBBP p.A1782T Het Rubinstein>Taybi>syndrome>type>1 0 25 D D 0.902
CKD471 AURORA * * * *
Nephropathy>"of>
unknown>etiology"
Dominant CENPF p.Q2711* Het Stromme>syndrome 0 41 . . .









0 . . . .
CKD472 AURORA * * * * Other Dominant AGPAT2 p.L16_L17dup Het Lipodystrophy>congenital>generalized,>type>1 0 . . . .
CKD473 AURORA * * * * Diabetic>nephropathy Dominant CUBN p.V2670fs Het Megaloblastic>anemia>1*finnish>type 0 . . . .
CKD474 AURORA * * * *
Tubulointerstitial>
disease
Dominant CSPP1 p.I336fs Het Meckel>syndrome,>Joubert>syndrome>21 0 . . . .
CKD475 AURORA * * * *
Hypertensive>
nephropathy
Dominant AGPAT2 p.L16_L17dup Het Lipodystrophy>congenital>generalized,>type>1 0 . . . .









0 . . . .




0 40 . . .
CKD477 AURORA * * * *
Tubulointerstitial>
disease
Dominant TCTN3 c.627+1G>A Het Joubert>syndrome>18,>Orofaciodigital>syndrome>4 0 24.6 . . .
CKD477 AURORA * * * *
Tubulointerstitial>
disease
Dominant UPB1 p.Q224fs Het Beta*ureidopropionase>deficiency 0 . . . .
CKD478 AURORA * * * * Glomerulopathy Dominant BBS1 p.A580T Het Bardet*biedl>syndrome>1 0 32 D D 0.821
CKD478 AURORA * * * * Glomerulopathy Dominant TBCE p.Q281* Het
Hypoparathyroidism*retardation*dysmorphism>
syndrome;>Kenny*Caffey>syndrome,>type>1
0 38 . . .
CKD479 AURORA * * * *
Hypertensive>
nephropathy
Dominant NPHS1 p.E783del Het Congenital>nephrotic>syndrome,>Finnish>type 0 . . . .
CKD480 AURORA * * * * Glomerulopathy Dominant INPP5E p.S399C Het
Joubert>syndrome>with>hepatic>defectJoubert>
Syndrome>1




CKD481 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant PKD2 p.D354G Het Polycystic>kidney>disease>2 0 29.4 D D 0.852
CKD482 AURORA * * * *
Tubulointerstitial>
disease
Dominant BCS1L p.S238C Het Mitochondrial>complex>3>deficiency,>nuclear>type>1 0 27.4 D D 0.942
CKD483 AURORA * * * *
Nephropathy>"of>
unknown>etiology"
Dominant ARID1A p.P20_P21dup Het Coffin*Siris>syndrome 0 . . . .
CKD484 AURORA * * * *
Tubulointerstitial>
disease
Dominant AGPAT2 p.M220T Het Lipodystrophy>congenital>generalized,>type>1 0 26.1 D D 0.95
CKD485 AURORA * * * *
Tubulointerstitial>
disease
Dominant SALL1 p.F85_S86del Het Townes*Brocks>Branchiootorenal*like>Syndrome 0 . . . .
CKD486 AURORA * * * *
Tubulointerstitial>
disease




0 29.7 D D 0.957
CKD486 AURORA * * * *
Tubulointerstitial>
disease
Dominant MESP2 p.L320fs Het Autosomal>recessive>spondylocostal>dysostosis 0 . . . .
CKD487 AURORA * * * *
Nephropathy>"of>
unknown>etiology"
Dominant ACTN4 p.K166R Het Focal>Segmental>Glomerulosclerosis>1 0 25.3 D D 0.808
CKD488 AURORA * * * * Diabetic>nephropathy Dominant CHD7 p.C1816S Het CHARGE>syndrome 0 27.4 D D 0.832
CKD489 AURORA * * * * Diabetic>nephropathy Dominant ETFDH p.Y282C Het Glutaric>acidemia>2c 0 27.7 D D 0.902
CKD490 AURORA * * * * Glomerulopathy Dominant LRP2 p.C3491Y Het Donnai*barrow>syndrome 0 31 D D 0.767
CKD491 AURORA * * * * Diabetic>nephropathy Dominant SLC4A1 p.E77K Het Renal>tubular>acidosis,>distal 0 29.8 D D 0.863




0 26.2 D D 0.91
CKD492 AURORA * * * *
Tubulointerstitial>
disease
Dominant SETBP1 p.P1525fs Het Schinzel*Giedion>Midface>Retraction>Syndrome 0 . . . .
CKD493 AURORA * * * *
Tubulointerstitial>
disease
Dominant TRPC6 p.W493S Het Focal>Segmental>Glomerulosclerosis>2 0 31 D D 0.863
CKD494 AURORA * * * *
Tubulointerstitial>
disease
Dominant FREM1 p.S314fs Het
Bifid>nose>with>or>without>anorectal>and>renal>
anomalies
0 . . . .
CKD495 AURORA * * * * Glomerulopathy Dominant SOX11
p.G156_A157i
nsGAGG
Het Mental>retardation,>autosomal>dominant,>27 0 . . . .
CKD495 AURORA * * * * Glomerulopathy Dominant TRPM6 p.F1069fs Het Hypomagnesemia>1,>intestinal 0 . . . .
CKD496 AURORA * * * *
Hypertensive>
nephropathy
Dominant SETBP1 p.P1525fs Het Schinzel*Giedion>Midface>Retraction>Syndrome 0 . . . .
CKD497 AURORA * * * * Glomerulopathy Dominant CYP24A1 c.259*2A>G Het Hypercalcemia>infantile,>1 0 23.8 . . .
CKD498 AURORA * * * * Glomerulopathy Dominant DLX4 p.QR134HS Het Orofacial>cleft>15 0 . . . .
CKD499 AURORA * * * * Glomerulopathy Dominant TRPC6 p.G517S Het Focal>Segmental>Glomerulosclerosis>2 0 28.5 D D 0.901
CKD50 AURORA * * * *
Hypertensive>
nephropathy





0 25.9 D D 0.776
CKD500 AURORA * * * * Glomerulopathy Dominant ARID1A p.E23* Het Coffin*Siris>syndrome 0 35 . . .
CKD501 AURORA * * * * Glomerulopathy Dominant ASXL1 p.E790fs Het Bohring*Opitz>syndrome 0 . . . .






0 . . . .
CKD503 AURORA * * * *
Tubulointerstitial>
disease
Dominant CLDN16 p.L23del Het Hypomagnesemia>3,>renal 0 . . . .
CKD504 AURORA * * * *
Tubulointerstitial>
disease
Dominant SLC1A1 p.G31R Het Dicarboylic>aminoaciduria 0 32 D . 0.905
CKD505 AURORA * * * *
Tubulointerstitial>
disease
Dominant BBS1 c.1110+2T>G Het Bardet*biedl>syndrome>1 0 23.7 . . .
CKD505 AURORA * * * *
Tubulointerstitial>
disease
Dominant COL4A1 p.G1011* Het
Hereditary>angiopathy>with>nephropathy,>
aneurysms>and>Msucle>cramps>(HANAC)
0 41 . . .






Het Schinzel*Giedion>Midface>Retraction>Syndrome 0 . . . .
CKD507 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant SCN4A p.A1595V Het Hypokalemic>periodic>paralysis,>hokpp>type2 0 24.5 D D 0.904
CKD507 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant ERBB3 p.L74R Het Lethal>congenital>contracture>syndrome>2 0 29.2 D D 0.862
CKD508 AURORA * * * * Glomerulopathy Dominant ATP6V0A4 p.I725V Het Renal>tubular>acidosis,>distal 0 27.8 D D 0.804
CKD508 AURORA * * * * Glomerulopathy Dominant EHHADH p.L692Q Het Fanconi>renotubular>syndrome>3 0 26.6 D D 0.857
CKD509 AURORA * * * *
Tubulointerstitial>
disease
Dominant ARMC5 p.M641fs Het
Cushing>syndrome>due>to>macronodular>adrenal>
hyperplasia
0 . . . .
CKD51 AURORA * * * *
Nephropathy>"of>
unknown>etiology"
Dominant ITGB4 p.C598R Het
Epidermolysis>bullosa,>junctional,>with>pyloric>
atresia
0 26.8 D D 0.863
CKD510 AURORA * * * * Other Dominant SMAD3 p.G82R Het Loeys*Dietz>syndrome>3 0 33 D D 0.821
CKD510 AURORA * * * * Other Recessive INPPL1 p.LL631LI Hom Opsismodysplasia 0 . . . .
CKD511 AURORA * * * * Diabetic>nephropathy Dominant GRHPR c.287+2T>C Het Hyperoxaluria,>primary,>type>2 0 24.6 . . .
CKD511 AURORA * * * * Diabetic>nephropathy Dominant TMEM67 p.Q274* Het
Nephronophtisis>11,>Meckel>Syndrome>3,>Joubert>
syndrome>6,>COACH>syndrome
0 41 . . .
CKD512 AURORA * * * *
Tubulointerstitial>
disease
Dominant LONP1 p.N616T Het CODAS>syndrome 0 27.5 D D 0.867
CKD513 AURORA * * * * Glomerulopathy Dominant FRAS1 p.I3835fs Het Fraser>syndrome 0 . . . .
CKD514 AURORA * * * *
Nephropathy>"of>
unknown>etiology"
Dominant C4A p.E847* Het Complement>component>4A>deficiency 0 36 . . .
CKD515 AURORA * * * *
Hypertensive>
nephropathy
Dominant MUT p.D646fs Het
Vitamin>B12*unresponsive>methylmalonic>acidemia>
type>mut0
0 . . . .
CKD516 AURORA * * * *
Hypertensive>
nephropathy
Dominant PKHD1 p.V3868fs Het
autosomal>recessive>polycystic>kidney>disease,>
Polycystic>and>hepatic>disease
0 . . . .
CKD517 AURORA * * * *
Tubulointerstitial>
disease
Dominant BBS9 p.Y186* Het Bardet*biedl>syndrome>9 0 36 . . .
CKD518 AURORA * * * * Diabetic>nephropathy Dominant ZNF423 c.3709+1G>A Het Nephronophthisis*14>Joubert>syndrome>16 0 27 . . .
CKD519 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant SCN4A p.K90fs Het Hypokalemic>periodic>paralysis,>hokpp>type2 0 . . . .
CKD519 AURORA * * * *
Congenital>or>cystic>
renal>disease
Recessive COL4A5 p.W1654R Hemi Alport>syndrome 0 28.1 D D 0.945
CKD520 AURORA * * * * Glomerulopathy Dominant ALG8 p.C277S Het
Polycystic>liver>disease>3>with>or>without>kidney>
cysts
0 . . . .
CKD521 AURORA * * * * Diabetic>nephropathy Dominant CFH p.W858* Het Complement>factor>h>deficiency 0 37 . . .
CKD523 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant WDPCP c.1916*2A>G Het Bardet*Biedl>syndrome 0 23.3 . . .
CKD523 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant PLCE1 p.E1922fs Het Nephrotic>syndrome>type>3 0 . . . .
CKD524 AURORA * * * * Glomerulopathy Dominant INVS c.2276+2T>C Het
Senior*Loken>syndrome,>Nephronophthisis>2,>
infantile
0 24.2 . . .
CKD524 AURORA * * * * Glomerulopathy Dominant DCDC2 p.H394fs Het Nephronophthisis>19 0 . . . .
CKD525 AURORA * * * * Other Dominant CRB2 p.Q12fs Het FSGS>9>Ventriculomegaly>with>cystic>kidney>disease 0 . . . .
CKD525 AURORA * * * * Other Dominant SLC5A2 p.I297T Het Renal>glucosuria 0 25.4 D D 0.926
CKD526 AURORA * * * *
Nephropathy>"of>
unknown>etiology"
Dominant TRAIP p.E77* Het Seckel>syndrome>9 0 40 . . .
CKD527 AURORA * * * *
Nephropathy>"of>
unknown>etiology"
Dominant FAT4 p.Y1281C Het
Van>Maldergem>Syndrome>2>Hennekam>
lymphangiectasia*lymphedema>syndrome>2
0 25.2 D D 0.779
CKD528 AURORA * * * * Glomerulopathy Dominant SMAD3 p.N345K Het Loeys*Dietz>syndrome>3 0 27.6 D D 0.85
CKD529 AURORA * * * *
Tubulointerstitial>
disease
Dominant AVP p.R31K Het Diabetes>insipidus,>neurohypophyseal 0 31 D D 0.784
CKD529 AURORA * * * *
Tubulointerstitial>
disease
Dominant ABCC6 p.L1417V Het
Pseudoxanthoma>elasticum>arterial>calcification,>
generalized,>of>infancy,>2
0 28.6 D D 0.827
CKD530 AURORA * * * *
Hypertensive>
nephropathy
Dominant XDH p.T1037fs Het Xanthinuria,>type>i 0 . . . .
CKD531 AURORA * * * * Glomerulopathy Dominant APC2 p.R1249H Het Sotos>syndrome 0 29.2 D D 0.772
CKD532 AURORA * * * * Diabetic>nephropathy Dominant HNF1B p.E260K Het Renal>Cysts>and>Diabetes>Syndrome 0 27 D D 0.835






Het Alport>syndrome 0 . . . .
CKD534 AURORA * * * *
Tubulointerstitial>
disease
Dominant VPS33B p.H344N Het
Arthrogryposis,>renal>dysfunction,>and>cholestasis>1;>
arcs1
0 32 D D 0.873
CKD535 AURORA * * * *
Nephropathy>"of>
unknown>etiology"
Dominant RAB3GAP1 c.831*1G>A Het Micro>syndrome 0 26 . . .






0 . . . .
CKD537 AURORA * * * *
Hypertensive>
nephropathy




0 24 . . .






Het Proud>syndrome 0 . . . .
CKD539 AURORA * * * *
Tubulointerstitial>
disease
Dominant SETBP1 p.L1530fs Het Schinzel*Giedion>Midface>Retraction>Syndrome 0 . . . .
CKD540 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant ALPL p.D458G Het Hypophosphatasia,>infantile 0 29.6 D D 0.988
CKD541 AURORA * * * *
Tubulointerstitial>
disease




0 . . . .
CKD542 AURORA * * * * Diabetic>nephropathy Dominant PHGDH p.N82S Het Neu*Laxova>syndrome>1 0 27 D D 0.784
CKD543 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant CYP24A1 p.Y125* Het Hypercalcemia>infantile,>1 0 35 . . .
CKD544 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant WNT7A p.R222Q Het
Ulna>and>fibula,>absense>of,>with>severe>limb>
deficiency
0 33 D D 0.779
CKD545 AURORA * * * *
Tubulointerstitial>
disease
Dominant CUL3 p.I749T Het Pseudohypoaldosteronism,>type>2e 0 25.8 D D 0.953
CKD546 AURORA * * * *
Tubulointerstitial>
disease
Dominant TSC2 p.M740V Het Tuberous>sclerosis*2 0 21 D D 0.825
CKD547 AURORA * * * *
Hypertensive>
nephropathy
Dominant CLCNKB p.A206S Het Bartter>syndrome,>type>3>and>type>4b 0 24.5 D D 0.757
CKD548 AURORA * * * *
Hypertensive>
nephropathy














Het Axenfeld*Rieger>syndrome,>Type>3 0 . . . .
CKD549 AURORA * * * * Diabetic>nephropathy Dominant CHD7 p.K1800T Het CHARGE>syndrome 0 25.5 D D 0.897
CKD550 AURORA * * * * Glomerulopathy Dominant FGA p.T718N Het Amyloidosis,>familial>visceral,>hereditary>renal 0 26.3 D D 0.826
CKD551 AURORA * * * *
Tubulointerstitial>
disease
Dominant BBS1 p.A266fs Het Bardet*biedl>syndrome>1 0 . . . .
CKD551 AURORA * * * *
Tubulointerstitial>
disease
Dominant LRP2 p.P2035L Het Donnai*barrow>syndrome 0 33 D D 0.751
CKD552 AURORA * * * * Diabetic>nephropathy Dominant SERPINH1 p.F146L Het Osteogenesis>imperfecta,>type>X 0 27 D D 0.904
CKD553 AURORA * * * * Diabetic>nephropathy Dominant SLC7A7 p.Q145R Het Lysinuric>protein>intolerance 0 25.8 D D 0.862
CKD554 AURORA * * * *
Hypertensive>
nephropathy




0 27.7 . . .
CKD555 AURORA * * * * Diabetic>nephropathy Dominant PIGT p.P70L Het
Multiple>congenital>anomalies*hypotonia*seizures>
syndrome>3
0 33 D D 0.869
CKD556 AURORA * * * * Diabetic>nephropathy Dominant CRB2 p.A968dup Het FSGS>9>Ventriculomegaly>with>cystic>kidney>disease 0 . . . .
CKD557 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant SLC5A2 p.V63fs Het Renal>glucosuria 0 . . . .
CKD558 AURORA * * * * Glomerulopathy Dominant HSPG2 p.R3906* Het Schwartz*Jampel>syndrome 0 55 . . .






Het Knobloch>syndrome 0 . . . .
CKD560 AURORA * * * *
Nephropathy>"of>
unknown>etiology"
Dominant OCLN c.*68*2A>G Het
Band*like>calcification>with>simplified>gyration>and>
polymicogyria
0 . . . .
CKD561 AURORA * * * *
Tubulointerstitial>
disease
Dominant AGPAT2 p.K186T Het Lipodystrophy>congenital>generalized,>type>1 0 25.3 D D 0.804
CKD562 AURORA * * * *
Tubulointerstitial>
disease
Dominant KIF7 p.LP432LT Het Acrocallosal>syndrome 0 . . . .
CKD563 AURORA * * * *
Hypertensive>
nephropathy
Dominant DNMT3B p.G238E Het
Immunodeficiency*centromeric>instability,>facial>
anomalies>syndrome>1,>icf1
0 32 D D 0.89
CKD563 AURORA * * * *
Hypertensive>
nephropathy
Dominant VANGL1 p.W463G Het Caudal>regression>syndrome 0 29 D D 0.961
CKD564 AURORA * * * * Glomerulopathy Dominant HSPG2 p.L1762del Het Schwartz*Jampel>syndrome 0 . . . .
CKD565 AURORA * * * * Diabetic>nephropathy Dominant SETBP1 p.L1530fs Het Schinzel*Giedion>Midface>Retraction>Syndrome 0 . . . .
CKD566 AURORA * * * * Diabetic>nephropathy Dominant AGT p.C171fs Het Renal>tubular>dysgenesis 0 . . . .
CKD567 AURORA * * * *
Hypertensive>
nephropathy
Dominant G6PC p.L230P Het Glycogen>storage>disease>Ia 0 25.7 D D 0.769
CKD568 AURORA * * * *
Hypertensive>
nephropathy
Dominant KCNJ1 p.Y208C Het Bartter's>syndrome,>type>2 0 23.7 D D 0.892
CKD569 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant RTTN c.2789*1G>C Het
Microsephaly,>short>stature,>and>polymicogyria>with>
or>without>seizures
0 23.5 . . .
CKD569 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant ANKS6 p.Q825* Het Nephronophthisis>16 0 45 . . 0.728
CKD570 AURORA * * * * Glomerulopathy Dominant LRP2 p.M543L Het Donnai*barrow>syndrome 0 27.1 D D 0.831
CKD571 AURORA * * * *
Tubulointerstitial>
disease




0 26 D D 0.785
CKD571 AURORA * * * *
Tubulointerstitial>
disease
Dominant KIF7 p.L280P Het Acrocallosal>syndrome 0 26.9 D D 0.868
CKD572 AURORA * * * *
Hypertensive>
nephropathy
Dominant SLX4 p.S1608* Het Fanconi>anemia,>complementation>group>P 0 43 . . .
CKD573 AURORA * * * *
Tubulointerstitial>
disease
Dominant CTC1 p.L466fs Het Dyskeratosis>congenita 0 . . . .
CKD574 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant CAD p.E123L Het Congenital>disorder>of>glycosylation,>type>Iz 0 . . . .
CKD575 AURORA * * * *
Hypertensive>
nephropathy




0 . . . .
CKD575 AURORA * * * *
Hypertensive>
nephropathy
Dominant C2 p.W420* Het C2>Deficiency 0 40 . . 0.505
CKD576 AURORA * * * *
Hypertensive>
nephropathy
Dominant PRODH p.TM203TV Het Hyperprolinemia,>type>I 0 . . . .






Het Medullary>cystic>kidney>disease>1 0 . . . .
CKD578 AURORA * * * * Diabetic>nephropathy Dominant KIF7 p.P328H Het Acrocallosal>syndrome 0 23.4 D D 0.835
CKD579 AURORA * * * *
Hypertensive>
nephropathy




0 . . . .
CKD579 AURORA * * * *
Hypertensive>
nephropathy
Dominant AMN p.E450fs Het Megaloblasticanemia1*norwegian_type 0 . . . .
CKD580 AURORA * * * * Diabetic>nephropathy Dominant PYGM p.D770A Het McArdle>Disease 0 24 D D 0.974
CKD581 AURORA * * * *
Tubulointerstitial>
disease
Dominant INSR c.101*1G>A Het Rabson*Mendenhall>syndrome 0 23.6 . . .






Het Sotos>syndrome 0 . . . .
CKD583 AURORA * * * * Glomerulopathy Dominant CDKN1C p.R3fs Het Beckwith*wiedemann>syndrome>IMAGE>syndrome 0 . . . .
CKD584 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant GALNT3 p.S227R Het
Tumoral>calcinosis,>hyperphosphatemic,>familial,>
hftc
0 24.8 D D 0.829
CKD585 AURORA * * * *
Nephropathy>"of>
unknown>etiology"
Dominant FAT4 p.K4548del Het
Van>Maldergem>Syndrome>2>Hennekam>
lymphangiectasia*lymphedema>syndrome>2
0 . . . .
CKD586 AURORA * * * *
Hypertensive>
nephropathy
Dominant NPHP4 p.W662* Het Nephronophthisis>4>Senior*Loken>syndrome>4 0 42 . . .
CKD587 AURORA * * * * Glomerulopathy Dominant RIPK4 p.A577G Het Popliteal>pterygium>syndrome,>Bartsocas*Papas>type 0 24.6 D D 0.819
CKD588 AURORA * * * *
Hypertensive>
nephropathy
Dominant AHI1 p.N790fs Het Joubert>Syndrome>3 0 . . . .
CKD589 AURORA * * * *
Hypertensive>
nephropathy
Dominant ANLN c.2476+2T>A Het Focal>Segmental>Glomerulosclerosis>8 0 24.6 . . .
CKD589 AURORA * * * *
Hypertensive>
nephropathy
Dominant DNASE1L3 p.I49S Het Systemic>Lupus>Erythematosus>16 0 25.7 D D 0.854
CKD59 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant LAMC2 c.3328+1G>A Het
Epidermolysis>bullosa,>junctional,>Herlitz>type;>
Epidermolysis>bullosa,>junctional,>non*Herlitz>type
0 24.5 T D 0.158






Het Polycystic>kidney>disease>1 0 . . . .
CKD591 AURORA * * * * Glomerulopathy Dominant ERCC6 p.I907K Het Cockayne>syndrome,>type>B 0 24.4 D D 0.868
CKD592 AURORA * * * *
Hypertensive>
nephropathy
Dominant ATP6V1B1 p.Q91* Het Renal>tubular>acidosis>with>deafness 0 38 . . .
CKD593 AURORA * * * * Glomerulopathy Recessive HDAC8 p.P135fs Hemi Cornelia>de>Lange>syndrome 7.07E*05 . . . .
CKD594 AURORA * * * *
Hypertensive>
nephropathy
Dominant PTPN11 p.P454L Het
Noonan>syndrome>with>multiple>lentiginesLeopard>
syndrome>1
0 34 D D 0.95
CKD595 AURORA * * * * Glomerulopathy Dominant HSD17B4 p.I302fs Het D*bifunctional>protein>deficiency 0 . . . .
CKD596 AURORA * * * *
Hypertensive>
nephropathy
Dominant DLL3 p.R177fs Het Autosomal>recessive>spondylocostal>dysostosis 0 . . . .
CKD597 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant PKD1 p.K102del Het Polycystic>kidney>disease>1 0 . . . .
CKD598 AURORA * * * * Glomerulopathy Dominant SLC16A12 p.D341G Het Cataract,>juvenile,>with>microcornea>and>glucosuria 0 24.9 D D 0.826
CKD599 AURORA * * * *
Hypertensive>
nephropathy
Dominant SIX5 p.A131P Het Branchio*oto*renal>syndrome>2 0 23.3 D D 0.797
CKD599 AURORA * * * *
Hypertensive>
nephropathy
Dominant ROR2 p.S471F Het Robinow>syndrome 0 26.3 D D 0.794
CKD600 AURORA * * * *
Hypertensive>
nephropathy
Dominant SLC22A12 p.V121fs Het Hypouricemia,>renal,>1,>rhuc1 0 . . . .
CKD601 AURORA * * * * Glomerulopathy Dominant SLC26A4 p.A434D Het Pendred>syndrome 0 33 D D 0.837
CKD602 AURORA * * * * Glomerulopathy Dominant PC p.H506P Het Pyruvate>carboxylase>deficiency 0 23.1 D D 0.847
CKD603 AURORA * * * * Diabetic>nephropathy Dominant TCTN3 p.I214F Het Joubert>syndrome>18,>Orofaciodigital>syndrome>4 0 29.4 D D 0.791
CKD603 AURORA * * * * Diabetic>nephropathy Dominant CPT2 p.F552L Het
Lethal>neonatal>carnitine>palmitoyltransferase>2>
deficiency
0 28.4 D D 0.788
CKD604 AURORA * * * *
Tubulointerstitial>
disease
Dominant VPS33B p.R398C Het
Arthrogryposis,>renal>dysfunction,>and>cholestasis>1;>
arcs1
0 35 D D 0.874
CKD604 AURORA * * * *
Tubulointerstitial>
disease
Dominant CUBN p.S2702fs Het Megaloblastic>anemia>1*finnish>type 0 . . . .
CKD605 AURORA * * * *
Nephropathy>"of>
unknown>etiology"
Dominant LRP2 c.13800+2T>C Het Donnai*barrow>syndrome 0 25 . . .
CKD606 AURORA * * * * Glomerulopathy Dominant SLC1A1 p.K468del Het Dicarboylic>aminoaciduria 0 . . . .









0 . . . .
CKD608 AURORA * * * *
Tubulointerstitial>
disease
Dominant AQP2 p.W205R Het Diabetes>insipidus,>nephrogenic 0 28.2 D D 0.87
CKD609 AURORA * * * * Glomerulopathy Dominant CAD p.E1120V Het Congenital>disorder>of>glycosylation,>type>Iz 0 29.6 D D 0.896
CKD610 AURORA * * * *
Nephropathy>"of>
unknown>etiology"
Dominant SLC4A1 p.L765P Het Renal>tubular>acidosis,>distal 0 29.2 D D 0.9
CKD611 AURORA * * * * Glomerulopathy Dominant SETBP1 p.P1533fs Het Schinzel*Giedion>Midface>Retraction>Syndrome 0 . . . .
CKD612 AURORA * * * * Diabetic>nephropathy Dominant GLB1 p.I398fs Het GM1*gangliosidosis,>type>1,>type>2 0 . . . .
CKD613 AURORA * * * *
Tubulointerstitial>
disease
Dominant ARID1B p.Q122fs Het Coffin*Siris>syndrome 0 . . . .
CKD614 AURORA * * * * Glomerulopathy Dominant FANCB c.*70*1G>C Het Fanconi>anemia,>complementation>group>b 0 . . . .
CKD615 AURORA * * * * Diabetic>nephropathy Dominant ABCD4 p.M571fs Het
Methylmalonic>aciduria>and>homocystinuria,>cblJ>
type
0 . . . .
CKD616 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant PKD1 p.S1440del Het Polycystic>kidney>disease>1 0 . . . .







0 . . . .
CKD618 AURORA * * * *
Hypertensive>
nephropathy
Dominant COL4A3 p.DH450ER Het Alport>syndrome 0 . . . .
CKD619 AURORA * * * *
Tubulointerstitial>
disease




CKD620 AURORA * * * *
Nephropathy>"of>
unknown>etiology"
Dominant CECR1 p.Y130H Het
Sneddon>syndrome>Polyarteritis>nodosa,>childhood*
onset
0 24.6 D D 0.875
CKD621 AURORA * * * *
Hypertensive>
nephropathy
Dominant XPNPEP3 p.S21* Het Nephronophthisis*like>nephropathy>1 0 35 . . .
CKD622 AURORA * * * *
Tubulointerstitial>
disease




0 25.5 D D 0.872
CKD623 AURORA * * * *
Hypertensive>
nephropathy
Dominant TMEM67 p.T883A Het
Nephronophtisis>11,>Meckel>Syndrome>3,>Joubert>
syndrome>6,>COACH>syndrome
0 28.8 D D 0.963
CKD624 AURORA * * * *
Nephropathy>"of>
unknown>etiology"
Dominant HOXD13 p.F192del Het Vacterl>association>with>hydrocephalus 0 . . . .
CKD624 AURORA * * * *
Nephropathy>"of>
unknown>etiology"
Dominant SI p.P758H Het Sucrase*isomaltase>deficiency,>congenital 0 26.1 D D 0.908
CKD625 AURORA * * * * Glomerulopathy Dominant HPSE2 p.L457S Het Ochoa>syndromeUrofacial>syndrome>1 0 29.9 D D 0.816
CKD626 AURORA * * * *
Tubulointerstitial>
disease
Dominant NUP107 c.1175*2A>G Het Nephrotic>syndrome,>type>11 0 24.2 . . .
CKD627 AURORA * * * *
Hypertensive>
nephropathy
Dominant TRIM32 p.V583M Het Bardet*biedl>syndrome>11 0 26.7 D D 0.812
CKD628 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant TRAP1 p.S107* Het
Congenital>Anomalies>of>the>Kidney>and>the>Urinary>
Tract
0 39 . . .
CKD629 AURORA * * * *
Hypertensive>
nephropathy
Dominant MAP2K1 p.D16fs Het Cardiofaciocutaneous>syndrome 0 . . . .
CKD629 AURORA * * * *
Hypertensive>
nephropathy




0 31 D D 0.829
CKD63 AURORA * * * *
Nephropathy>"of>
unknown>etiology"
Dominant HOXA13 p.R320S Het Hand*foot*uterus>syndrome 0 32 D D 0.776
CKD630 AURORA * * * *
Nephropathy>"of>
unknown>etiology"
Dominant NPHS1 p.C920S Het Congenital>nephrotic>syndrome,>Finnish>type 0 24.4 D D 0.877
CKD630 AURORA * * * *
Nephropathy>"of>
unknown>etiology"
Dominant COL4A4 p.H1471P Het Alport>syndrome;>nephrotic>syndrome>(FSGS>1) 0 24.3 D D 0.881
CKD631 AURORA * * * * Glomerulopathy Dominant FUZ
p.T239_P242d
el
Het Caudal>regression>sequence 0 . . . .
CKD632 AURORA * * * * Diabetic>nephropathy Dominant DLX4 p.LW204HR Het Orofacial>cleft>15 0 . . . .
CKD633 AURORA * * * * Glomerulopathy Dominant HGD p.E235A Het Alkaptonuria 0 27.8 D D 0.962
CKD633 AURORA * * * * Glomerulopathy Dominant EVC p.S835* Het Ellis>Van>Creveld>syndrome 0 35 . . .
CKD634 AURORA * * * *
Hypertensive>
nephropathy
Dominant ALMS1 p.E23_E24insK Het Alstrom>syndrome 0 . . . .




0 23.2 . . .
CKD635 AURORA * * * * Glomerulopathy Dominant SLC5A2 p.G59fs Het Renal>glucosuria 0 . . . .
CKD636 AURORA * * * * Glomerulopathy Dominant WNK4 p.G1098fs Het Pseudohypoaldosteronism,>type>2b 0 . . . .






Het Polycystic>kidney>disease>1 0 . . . .
CKD72 AURORA * * * * Diabetic>nephropathy Dominant CSPP1 c.3206*2A>G Het Meckel>syndrome,>Joubert>syndrome>21 0 23.6 . . .






Het Blackfan*Diamond>anemia 0 . . . .
CKD77 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant TMEM67 p.S802P Het
Nephronophtisis>11,>Meckel>Syndrome>3,>Joubert>
syndrome>6,>COACH>syndrome
0 29.1 D D 0.951






Het Nephroticsyndrome 0 . . . .
CKD88 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant MYH9 p.R1785L Het Fechtner>syndrome;>Epstein>Syndrome 0 35 D D 0.787
CKD88 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant COL5A1 p.G1456S Het Ehlers*Danlos>syndrome,>classic>type 0 26 D D 0.983
CKD89 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant SARS2 p.E466fs Het
Hyperuricemia,>pulmonary>hypertension,>renal>
failure>and>alkalosis
0 . . . .
CKD91 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant SI p.D785H Het Sucrase*isomaltase>deficiency,>congenital 0 25.1 D D 0.755
CKD92 AURORA * * * *
Hypertensive>
nephropathy




0 24.9 . . .
CKD92 AURORA * * * *
Hypertensive>
nephropathy
Dominant KCNH1 p.L225F Het Zimmermann*Laband>syndrome>1 0 24.9 D D 0.822
CKD95 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant LRP4 p.S177Y Het Cenani*lenz>syndactyly>syndrome 0 30 D D 0.912
CKD99 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant BRIP1 p.C442fs Het Fanconi>anemia 0 . . . .
CKD99 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant HSD17B4 p.P529S Het D*bifunctional>protein>deficiency 0 31 D D 0.95
CKD99 AURORA * * * *
Congenital>or>cystic>
renal>disease
Dominant HSPG2 p.Y1459* Het Schwartz*Jampel>syndrome 0 36 . . .
CKD143 CUMC M 44 White>European Yes Glomerulopathy Dominant ENG p.D248fs Het Hereditary>hemorrhagic>telangiectasia 0 . . . .






Dominant NR0B1 p.I452F Het
Adrenal>hypoplasia,>congenital,>with>
hypogonadotropic>hypogonadism
0 26.9 D D 0.8






Dominant TTC21B p.V972fs Het Nephronophthisis>12 0 . . . .
CKD149 CUMC M 57 White>European Yes Other Dominant COL5A1 p.G1456V Het Ehlers*Danlos>syndrome,>classic>type 0 25.3 D D 0.988
CKD151 CUMC F 55 White>European Yes Glomerulopathy Dominant CASP10 p.D202fs Het Autoimmune>Lymhoproliferative>syndrome>type>2A 0 . . . .
CKD153 CUMC M 31 White>European No
Tubulointerstitial>
disease
Dominant CENPF p.E115* Het Stromme>syndrome 0 39 . . .
CKD153 CUMC M 31 White>European No
Tubulointerstitial>
disease
Dominant PNPLA6 p.T868fs Het Laurence*Moon>syndrome 0 . . . .
CKD154 CUMC F 34 White>European No
Tubulointerstitial>
disease
Dominant KIF7 p.K913W Het Acrocallosal>syndrome 0 . . . .
CKD154 CUMC F 34 White>European No
Tubulointerstitial>
disease
Dominant SLC26A4 p.F683V Het Pendred>syndrome 0 33 D D 0.857
CKD155 CUMC M 51 White>European Yes
Nephropathy>"of>
unknown>etiology"
Dominant PALB2 p.K422dup Het Fanconi>Anemia,>Complementation>Group>N 0 . . . .
CKD156 CUMC M 9 Hispanic Yes Glomerulopathy Dominant WNK1 p.EY53DC Het Pseudohypoaldosteronism,>type>2c 0 . . . .
CKD160 CUMC F 27 White>European Yes Glomerulopathy Dominant SLC6A20 p.L278fs Het Hyperglycinuria 0 . . . .
CKD165 CUMC F 28 White>European No
Tubulointerstitial>
disease
Dominant RMND1 p.W237* Het Combined>oxidative>phosphorylation>deficiency>11 0 42 . . .
CKD175 CUMC F 23 White>European Yes Glomerulopathy Dominant IFT27 c.231+1G>A Het Bardet*Biedl>syndrome>19 0 26.9 . . .
CKD176 CUMC F 46
Other/Unspecifi
ed
Yes Glomerulopathy Dominant KMT2D p.QQ3281* Het Kabuki>syndrome>1 0 . . . .
CKD179 CUMC M 42 Hispanic No
Nephropathy>"of>
unknown>etiology"
Dominant SLC7A7 p.G399S Het Lysinuric>protein>intolerance 0 31 D D 0.76









0 . . . .









Het Congenital>nephrotic>syndrome,>Finnish>type 0 . . . .
CKD191 CUMC F 25 White>European Yes
Nephropathy>"of>
unknown>etiology"




0 26.3 D D 0.938
CKD197 CUMC M 44 Hispanic No Diabetic>nephropathy Dominant KMT2D
p.Q3742_Q374
5del
Het Kabuki>syndrome>1 0 . . . .
CKD198 CUMC M 70 Asian Yes Diabetic>nephropathy Dominant ETFDH p.Y282C Het Glutaric>acidemia>2c 0 27.7 D D 0.902
CKD204 CUMC M 39 Hispanic Yes Glomerulopathy Dominant CAD p.R1295H Het Congenital>disorder>of>glycosylation,>type>Iz 0 24.7 D D 0.799
CKD207 CUMC F 24 White>European No Glomerulopathy Dominant NR0B1 p.R198Q Het
Adrenal>hypoplasia,>congenital,>with>
hypogonadotropic>hypogonadism
0 . . . .
CKD211 CUMC F 72 White>European No Glomerulopathy Dominant CACNA1S p.A1053T Het Hypokalemic>periodic>paralysis,>hokpp 0 33 D D 0.792
CKD212 CUMC M 36 White>European No Glomerulopathy Dominant SDHB p.R46fs Het
Cowden>Syndrome>2,>Pheochormocytoma>
Paragangliomas>4
0 . . . .
CKD216 CUMC M 53 White>European Yes Glomerulopathy Dominant DCHS1 p.R999* Het Van>Maldergem>syndrome>1 0 35 . . .
CKD216 CUMC M 53 White>European Yes Glomerulopathy Dominant ITGA8 p.W135* Het Renal>hypodysplasia*aplasia>1 0 37 . . .






Dominant FAN1 p.P227fs Het Interstitial>nephritis,>karyomegalic 0 . . . .
CKD231 CUMC F 0 Hispanic No
Congenital>or>cystic>
renal>disease
Dominant TTC37 p.P234R Het Trichohepatonenteric>syndrome>1 0 25.8 D D 0.837
CKD232 CUMC F 25 Hispanic No
Congenital>or>cystic>
renal>disease
Dominant TBC1D24 p.Q559* Het DOOR>syndrome 0 35 . . .
CKD238 CUMC M 34 White>European Yes
Tubulointerstitial>
disease
Recessive LFNG p.A66V Het Autosomal>recessive>spondylocostal>dysostosis 0 . . . .
CKD238 CUMC M 34 White>European Yes
Tubulointerstitial>
disease
Recessive LFNG p.E56fs Het Autosomal>recessive>spondylocostal>dysostosis 0 . . . .
CKD249 CUMC F 51
Black/African>
American
Yes Glomerulopathy Recessive COL4A1 p.G130R Het
Hereditary>angiopathy>with>nephropathy,>
aneurysms>and>Msucle>cramps>(HANAC)
0 24.3 D . 0.965
CKD249 CUMC F 51
Black/African>
American
Yes Glomerulopathy Recessive COL4A1 p.G185A Het
Hereditary>angiopathy>with>nephropathy,>
aneurysms>and>Msucle>cramps>(HANAC)
0 22.5 D D 0.778
CKD251 CUMC F 48 Asian Yes
Tubulointerstitial>
disease
Dominant HOXD13 p.A187G Het Vacterl>association>with>hydrocephalus 0 25.4 D D 0.789
CKD251 CUMC F 48 Asian Yes
Tubulointerstitial>
disease
Dominant PC p.A744V Het Pyruvate>carboxylase>deficiency 0 27.9 D D 0.874
CKD253 CUMC M 40 White>European Yes Glomerulopathy Dominant ITGA3 p.Q626* Het
Interstitial>lung>disease,>nephrotic>syndrome,>and>
epidermolysis>bullosa,>congenital
0 38 . . 0.022






Dominant CUBN p.S3090dup Het Megaloblastic>anemia>1*finnish>type 0 . . . .
CKD262 CUMC M 24 White>European Yes Glomerulopathy Dominant CREBBP p.Q2203del Het Rubinstein>Taybi>syndrome>type>1 0 . . . .
CKD263 CUMC F 66 Hispanic No
Nephropathy>"of>
unknown>etiology"
Dominant BBS12 p.S384fs Het Bardet*biedl>syndrome>12 0 . . . .
CKD264 CUMC M 54 White>European Yes Other Dominant WFS1 p.G728D Het Wolfram>syndrome>type>1 0 24.1 D D 0.933










CKD269 CUMC M 53 White>European Yes
Nephropathy>"of>
unknown>etiology"
Dominant BSCL2 p.P295L Het Lipodystrophy>congenital>generalized,>type>2 0 34 D D 0.774
CKD270 CUMC M 50 Asian Yes Glomerulopathy Dominant MUT c.912*1G>A Het
Vitamin>B12*unresponsive>methylmalonic>acidemia>
type>mut0
0 26.1 . . .
CKD275 CUMC M 61 Hispanic No Glomerulopathy Dominant SLC5A2 p.H525fs Het Renal>glucosuria 0 . . . .






Dominant LRIG2 p.R1044fs Het Ochoa>syndrome,>Urofacial>Syndrome>2 0 . . . .






Dominant INVS p.W783* Het
Senior*Loken>syndrome,>Nephronophthisis>2,>
infantile
0 37 . . .
CKD286 CUMC M 37 White>European No Glomerulopathy Dominant FAN1 p.V962M Het Interstitial>nephritis,>karyomegalic 0 32 D D 0.772
CKD298 CUMC F 59 Asian Yes
Nephropathy>"of>
unknown>etiology"
Dominant GATA3 p.V18G Het
Hypoparathyroidism,>deafness,>renal>disease>
syndrome
0 27.3 D D 0.812
CKD300 CUMC F 42 White>European No
Nephropathy>"of>
unknown>etiology"
Dominant CPT2 p.L559V Het
Lethal>neonatal>carnitine>palmitoyltransferase>2>
deficiency
0 25.7 D D 0.855
CKD300 CUMC F 42 White>European No
Nephropathy>"of>
unknown>etiology"
Dominant NARS2 p.Y130* Het Combined>oxidative>phosphorylation>deficiency>24 0 37 . . .
CKD300 CUMC F 42 White>European No
Nephropathy>"of>
unknown>etiology"
Dominant SLC3A1 p.Y65C Het Cystinuria 0 24.8 D D 0.819
CKD303 CUMC M 27 Hispanic Yes Glomerulopathy Dominant ZMPSTE24 p.G192R Het Restrictive>Dermopathy,>Lethal 0 32 D D 0.859
CKD327 CUMC M 54 White>European No Glomerulopathy Dominant CFH p.W134C Het Complement>factor>h>deficiency 0 29.6 D D 0.939
CKD328 CUMC M 66 Asian No Glomerulopathy Dominant PIGN c.2620*2A>T Het
Multiple>congenital>anomalies*hypotonia*seizures>
syndrome>1
0 25.9 . . .
CKD330 CUMC F 35 Hispanic No Glomerulopathy Dominant LDHA p.W227fs Het Glycogen>storage>disease>XI 0 . . . .






Dominant MYH9 p.E1232K Het Fechtner>syndrome;>Epstein>Syndrome 0 35 D D 0.844
CKD336 CUMC F 56 White>European No Diabetic>nephropathy Dominant ITGB4 p.P125S Het
Epidermolysis>bullosa,>junctional,>with>pyloric>
atresia
0 28.6 D D 0.815






Dominant PNPLA6 p.L1003S Het Laurence*Moon>syndrome 0 24.6 D D 0.834






Dominant KIF14 p.L576fs Het Meckel>syndrome>12 0 . . . .






Dominant LARS p.W530R Het Infantile>liver>failure>syndrome>1 0 27.8 D D 0.877
CKD339 CUMC F 51 Hispanic Yes Diabetic>nephropathy Dominant SLC2A9 c.1114*1G>C Het Hypouricemia,>renal,>2 0 24.6 . . .
CKD339 CUMC F 51 Hispanic Yes Diabetic>nephropathy Dominant RIN2 p.R359fs Het Macrocephaly,>alopecia,>cutis>laxa,>and>scoliosis 0 . . . .
CKD339 CUMC F 51 Hispanic Yes Diabetic>nephropathy Dominant RIN2 p.S355fs Het Macrocephaly,>alopecia,>cutis>laxa,>and>scoliosis 0 . . . .




0 . . . .






Dominant MUC1 p.A135fs Het Medullary>cystic>kidney>disease>1 0 . . . .









Het Proud>syndrome 0 . . . .
CKD348 CUMC F 35 Asian No Diabetic>nephropathy Dominant SOX9 p.P238fs Het Campomelic>dysplasia 0 . . . .




1.68E*05 27.3 D D 0.807
CKD353 CUMC M 52
Other/Unspecifi
ed
No Glomerulopathy Dominant MEFV p.GA138GKer Het Familial>Mediterranean>fever 0 . . . .
CKD355 CUMC M 60
Black/African>
American
No Glomerulopathy Dominant GATA3 p.P87R Het
Hypoparathyroidism,>deafness,>renal>disease>
syndrome
0 28.6 D D 0.922
CKD355 CUMC M 60
Black/African>
American
No Glomerulopathy Dominant SOX17 p.Y408fs Het Vesicoureteral>Reflux>3 0 . . . .
CKD357 CUMC F 24
Black/African>
American
No Glomerulopathy Dominant ZAP70 p.V548G Het
Autoimmune>Disease,>multisystem,>infantile*onset,>
2
0 26.2 D D 0.896






Het Hypomagnesemia>4,>renal 0 . . . .
CKD361 CUMC M 70 White>European Yes Glomerulopathy Dominant WNK4 p.ML365IL Het Pseudohypoaldosteronism,>type>2b 0 . . . .






Dominant ETFDH p.I234F Het Glutaric>acidemia>2c 0 29.3 D D 0.907
CKD370 CUMC M 26 Asian Yes Other Dominant CTNS p.F349C Het
Cystinosis,>nephropathic>cystinosis,>late*onset>
juvenile>or>adolescent>nephropathic
0 26.7 D D 0.978
CKD637 CUMC F 60
Black/African>
American
No Glomerulopathy Dominant PALB2 p.Q348del Het Fanconi>Anemia,>Complementation>Group>N 0 . . . .
CKD638 CUMC F 33 White>European No Glomerulopathy Dominant NR0B1 p.P103L Het
Adrenal>hypoplasia,>congenital,>with>
hypogonadotropic>hypogonadism
0 . . . .
CKD639 CUMC F 33 White>European No Glomerulopathy Dominant PC p.L985fs Het Pyruvate>carboxylase>deficiency 0 . . . .
CKD639 CUMC F 33 White>European No Glomerulopathy Dominant CENPF p.S1493D Het Stromme>syndrome 0 . . . .




0 . . . .
CKD641 CUMC F 70 White>European No Glomerulopathy Dominant SRCAP p.R709Q Het Floating*Harbor>syndrome 0 23.4 D D 0.803
CKD642 CUMC F 56 White>European No Glomerulopathy Dominant IFT122 p.S72fs Het Cranioectodermal>dysplasia>type>1 0 . . . .
CKD643 CUMC F 21 White>European Yes Glomerulopathy Dominant CASR p.G487R Het
Neonatal>severe>primary>hyperparathyroidism,>
Hypocalcemia>with>bartter>syndrome
0 31 D D 0.836
CKD644 CUMC F 22
Other/Unspecifi
ed
No Glomerulopathy Dominant FN1 p.QC15LG Het Glomerulopathy>with>fibronectin>deposits>2 0 . . . .
CKD644 CUMC F 22
Other/Unspecifi
ed
No Glomerulopathy Dominant SRCAP
p.P575_G579d
el
Het Floating*Harbor>syndrome 0 . . . .
CKD645 CUMC F 27 White>European No Glomerulopathy Dominant TNXB p.A67fs Het
Vesicoureteral>Reflux>8>Ehlers*Danlos>syndrome>due>
to>tenascin*X>deficiency
0 . . . .
CKD646 CUMC F 63 White>European Yes
Congenital>or>cystic>
renal>disease
Dominant PIK3R2 c.*1827*1G>A Het
Megalencephaly*polymicogyria*polydactyly*
hyodrcephalus>syndrome>1
0 23.3 . . .
CKD646 CUMC F 63 White>European Yes
Congenital>or>cystic>
renal>disease
Dominant ROBO2 p.S1273del Het Vesicoureteral>reflux>2 0 . . . .
CKD647 CUMC M 45 White>European No
Nephropathy>"of>
unknown>etiology"
Dominant NOTCH2 p.I261S Het
Acroosteolysis>dominant>type,>Alagille>syndrome>2,>
Hajdu*Cheney>Syndrome
0 24.8 D D 0.8
CKD648 CUMC M 55 White>European No
Congenital>or>cystic>
renal>disease
Dominant DIS3L2 p.H542fs Het
Perlman's>syndrome>(nephroblastomatosis,>
gigantism)
0 . . . .
CKD649 CUMC M 21 White>European No
Tubulointerstitial>
disease
Dominant CPT1A p.V335fs Het Carnitine>palmitoyl>transferase>1A>deficiency 0 . . . .






Dominant SLC12A1 p.P1083R Het Bartter>syndrome,>type>1,>antenatal 0 32 D D 0.877
CKD651 CUMC F 29 Asian Yes
Congenital>or>cystic>
renal>disease
Recessive INPPL1 p.LL631LI Hom Opsismodysplasia 0 . . . .
CKD651 CUMC F 29 Asian Yes
Congenital>or>cystic>
renal>disease
Dominant INPPL1 p.V336M Het Opsismodysplasia 0 26.7 D D 0.768
CKD652 CUMC F 86 White>European Yes
Nephropathy>"of>
unknown>etiology"
Dominant FANCI p.C650* Het Fanconi>anemia,>complementation>group>I 0 36 . . .
CKD653 CUMC M 61 Asian Yes Glomerulopathy Dominant NPHP4 p.G1028L Het Nephronophthisis>4>Senior*Loken>syndrome>4 0 . . . .
CKD654 CUMC F 39 Asian No Other Dominant WNK1 p.AHS1526ART Het Pseudohypoaldosteronism,>type>2c 0 . . . .
CKD655 CUMC F 50 White>European Yes
Nephropathy>"of>
unknown>etiology"
Dominant ADAMTS13 p.G647fs Het Thrombotic>thrombocytopenic>purpura,>familial 0 . . . .






Het Megaloblasticanemia1*norwegian_type 0 . . . .
CKD656 CUMC M 83 Hispanic No
Hypertensive>
nephropathy
Dominant ABCD4 p.G426C Het
Methylmalonic>aciduria>and>homocystinuria,>cblJ>
type
0 34 D D 0.976
CKD656 CUMC M 83 Hispanic No
Hypertensive>
nephropathy
Dominant ZAP70 p.M1? Het
Autoimmune>Disease,>multisystem,>infantile*onset,>
2
0 21.8 T D 0.403
CKD657 CUMC F 37 Hispanic Yes
Hypertensive>
nephropathy
Dominant VPS33B p.R398C Het
Arthrogryposis,>renal>dysfunction,>and>cholestasis>1;>
arcs1
0 35 D D 0.874
CKD659 CUMC M 23 White>European Yes
Congenital>or>cystic>
renal>disease
Dominant CACNA1S p.I272fs Het Hypokalemic>periodic>paralysis,>hokpp 0 . . . .
CKD660 CUMC F 41 White>European No Other Dominant TTC37 p.L437V Het Trichohepatonenteric>syndrome>1 0 . . . .






Dominant ACE p.A157V Het Renal>tubular>dysgenesis 0 . . . .
CKD662 CUMC M 66 White>European No Glomerulopathy Dominant AMN
p.Ter454Rext*
?
Het Megaloblasticanemia1*norwegian_type 0 21.4 . . .
CKD663 CUMC F 30
Black/African>
American
No Glomerulopathy Dominant FANCM p.Q2006* Het Fanconi>anemia 0 41 . . 0.005
CKD664 CUMC F 56
Black/African>
American
Yes Glomerulopathy Dominant SLX4 c.5153+1G>A Het Fanconi>anemia,>complementation>group>P 0 24.1 . . .
CKD665 CUMC F 28 Asian No Glomerulopathy Dominant AHI1 p.Y639H Het Joubert>Syndrome>3 0 28.2 D D 0.798
CKD665 CUMC F 28 Asian No Glomerulopathy Dominant CUBN p.V3478fs Het Megaloblastic>anemia>1*finnish>type 0 . . . .
CKD666 CUMC F 27 White>European No Glomerulopathy Dominant COL18A1 p.E1005fs Het Knobloch>syndrome 0 . . . .
CKD667 CUMC F 50 White>European No
Nephropathy>"of>
unknown>etiology"




0 . . . .
CKD668 CUMC M 23 White>European Yes Glomerulopathy Dominant PYGM p.L132fs Het McArdle>Disease 0 . . . .
CKD669 CUMC F 23 White>European Yes Other Dominant HPS1 p.Q397* Het Hermansky*Pudlak>syndrome>1 0 35 . . .
CKD670 CUMC F 45 Hispanic Yes Glomerulopathy Dominant SLIT2 p.R51G Het
Congenital>Anomalies>of>the>Kidney>and>the>Urinary>
Tract
0 25.3 D D 0.756
CKD670 CUMC F 45 Hispanic Yes Glomerulopathy Dominant ATP6V0A4 p.S559C Het Renal>tubular>acidosis,>distal 0 26.9 D D 0.834
CKD671 CUMC F 38 Asian No Other Dominant HNF1A p.F81S Het
Diabetes>mellitus,>insulin*dependent,>20;>MODY,>
type>3;>Renal>cell>carcinoma
0 25.6 D D 0.851
CKD672 CUMC F 35 White>European Yes
Tubulointerstitial>
disease
Dominant EHHADH p.R187fs Het Fanconi>renotubular>syndrome>3 0 . . . .
CKD672 CUMC F 35 White>European Yes
Tubulointerstitial>
disease
Dominant ABCC6 p.H589fs Het
Pseudoxanthoma>elasticum>arterial>calcification,>
generalized,>of>infancy,>2
0 . . . .
CKD673 CUMC M 23
Black/African>
American
No Glomerulopathy Dominant STK11 p.E130G Het Peutz*Jeghers>syndrome 0 32 D D 0.851
CKD674 CUMC F 41 White>European No Glomerulopathy Dominant APC2 p.E1409T Het Sotos>syndrome 0 . . . .
CKD675 CUMC M 12 White>European Yes Glomerulopathy Dominant RAB3GAP1 p.L829* Het Micro>syndrome 0 41 . . .
CKD676 CUMC F 39 Hispanic No
Congenital>or>cystic>
renal>disease
Dominant KDM1A p.Y120* Het
Cleft>palate,>psychomotor>retardation,>and>
distinctive>facial>features










Dominant KIF7 p.D52K Het Acrocallosal>syndrome 0 . . . .






Dominant GCDH p.P151S Het Glutaricaciduria,>type>I 0 27.9 D D 0.883
CKD679 CUMC M 28 White>European Yes
Nephropathy>"of>
unknown>etiology"
Dominant KIF14 p.G885S Het Meckel>syndrome>12 0 28.6 D . 0.789
CKD680 CUMC M 63 White>European Yes Other Dominant FANCA p.L1256P Het Fanconi>anemia,>complementation>group>a 0 25 D D 0.79
CKD681 CUMC M 20 Hispanic Yes
Nephropathy>"of>
unknown>etiology"
Dominant NSD1 p.G1267V Het
Sotos>syndrome>1;>Beckwith*Wiedemann>syndrome,>
BWS
0 28.7 D D 0.772
CKD682 CUMC F 56 White>European No Other Dominant BMP4 p.G66E Het Microphthalmia,>syndromic>6 0 32 D D 0.75









Het Coffin*Siris>syndrome 0 . . . .
CKD684 CUMC F 73 Asian No Glomerulopathy Dominant PEX1 p.R745I Het Zellweger>syndrome 0 33 D D 0.764
CKD685 CUMC M 51 Hispanic Yes
Nephropathy>"of>
unknown>etiology"
Dominant CAD p.Y916* Het Congenital>disorder>of>glycosylation,>type>Iz 0 35 . . .
CKD686 CUMC F 31 White>European No Glomerulopathy Dominant ATP6V1B1 c.367+1G>A Het Renal>tubular>acidosis>with>deafness 0 26.6 . . .
CKD686 CUMC F 31 White>European No Glomerulopathy Dominant WNK1 p.K191* Het Pseudohypoaldosteronism,>type>2c 0 26 . . .






Dominant INSR p.F103L Het Rabson*Mendenhall>syndrome 0 28.9 D D 0.935






Dominant FANCC p.I276fs Het Fanconi>anemia,>complementation>group>c 0 . . . .
CKD689 CUMC M 57 White>European No
Nephropathy>"of>
unknown>etiology"
Dominant PIGN p.R45del Het
Multiple>congenital>anomalies*hypotonia*seizures>
syndrome>1
0 . . . .
CKD690 CUMC M 58
Black/African>
American
No Diabetic>nephropathy Dominant ADAMTS13 p.C508R Het Thrombotic>thrombocytopenic>purpura,>familial 0 26.7 D D 0.868
CKD690 CUMC M 58
Black/African>
American
No Diabetic>nephropathy Dominant NUP205 p.MG427IC Het Nephrotic>syndrome,>type>13 0 . . . .
CKD690 CUMC M 58
Black/African>
American






0 . . . .
CKD691 CUMC M 66 Asian No
Nephropathy>"of>
unknown>etiology"
Dominant ALPL p.W270* Het Hypophosphatasia,>infantile 0 43 . . .
CKD692 CUMC M 77 Hispanic No Glomerulopathy Dominant BBS10 p.L97R Het Bardet*biedl>syndrome>10 0 25.4 D D 0.845
CKD693 CUMC M 43 White>European No Other Dominant RBBP8
p.Ter898Qext*
?
Het Seckel>Syndrome>2 0 21.7 . . .
CKD694 CUMC F 29 Asian No Diabetic>nephropathy Dominant ERCC6 p.F765L Het Cockayne>syndrome,>type>B 0 32 D D 0.781
CKD695 CUMC F 37 Asian No Other Dominant EIF2AK3 p.L518del Het Wolcott*Rallison>Syndrome 0 . . . .
CKD696 CUMC M 63
Black/African>
American
No Other Dominant SCO1 p.W95* Het Mitochondrial>Complex>4>deficiency 0 43 . . .
CKD697 CUMC F 36 Hispanic No Diabetic>nephropathy Dominant SCN4A p.T207A Het Hypokalemic>periodic>paralysis,>hokpp>type2 0 23.2 D D 0.834
CKD698 CUMC M 60 White>European No Diabetic>nephropathy Dominant SCNN1A c.*55+2T>C Het Pseudohypoaldosteronism,>Type>I 0 . . . .
CKD699 CUMC F 82 Hispanic No Diabetic>nephropathy Dominant FREM2 p.L2871P Het Fraser>syndrome 0 29.2 D D 0.795
CKD700 CUMC M 61 Hispanic No Diabetic>nephropathy Dominant APOA1
p.R175_A178d
up
Het Amyloidosis,>familial>visceral,>3>or>more>types 0 . . . .
CKD701 CUMC M 86 White>European Yes Diabetic>nephropathy Dominant ARID1B
p.Q127_Q129d
el
Het Coffin*Siris>syndrome 0 . . . .
CKD702 CUMC F 52 Hispanic No Diabetic>nephropathy Dominant LRP4 p.C83F Het Cenani*lenz>syndactyly>syndrome 0 33 D D 0.982
CKD702 CUMC F 52 Hispanic No Diabetic>nephropathy Dominant FANCI p.Y778fs Het Fanconi>anemia,>complementation>group>I 0 . . . .
CKD703 CUMC M 54 Asian No Diabetic>nephropathy Dominant ARID1B
p.A329_A331d
el
Het Coffin*Siris>syndrome 0 . . . .
CKD704 CUMC M 64 White>European No Diabetic>nephropathy Dominant PIK3R2 p.P261del Het
Megalencephaly*polymicogyria*polydactyly*
hyodrcephalus>syndrome>1
0 . . . .
CKD705 CUMC F 68 White>European No Diabetic>nephropathy Dominant KCNJ1 p.C102Y Het Bartter's>syndrome,>type>2 0 26.6 D D 0.95
CKD705 CUMC F 68 White>European No Diabetic>nephropathy Dominant FANCF p.W294* Het Fanconi>anemia 0 43 . . .
CKD706 CUMC F 75 Hispanic No Diabetic>nephropathy Dominant SLC7A9 p.A231V Het Cystinuria 0 33 D D 0.882
CKD706 CUMC F 75 Hispanic No Diabetic>nephropathy Dominant CACNA1S p.L1277F Het Hypokalemic>periodic>paralysis,>hokpp 0 29.1 D D 0.847
CKD707 CUMC F 53 Hispanic No Diabetic>nephropathy Dominant SLC6A19 p.T243fs Het Hartnup>Disorder>Hyperglycinuria 0 . . . .
CKD708 CUMC M 64 White>European No Diabetic>nephropathy Dominant LARS p.H709P Het Infantile>liver>failure>syndrome>1 0 29.2 D D 0.852
CKD709 CUMC M 54 White>European Yes Diabetic>nephropathy Dominant DSTYK p.R46fs Het
Congenital>Anomalies>of>the>Kidney>and>the>Urinary>
Tract
0 . . . .
CKD710 CUMC M 47 Hispanic No Diabetic>nephropathy Dominant ANKS6 p.E44fs Het Nephronophthisis>16 0 . . . .
CKD710 CUMC M 47 Hispanic No Diabetic>nephropathy Dominant EVC2 p.G157fs Het Ellis>Van>Creveld>syndrome 0 . . . .





0 35 . . .
CKD712 CUMC M 70
Black/African>
American
Yes Diabetic>nephropathy Dominant NUP107 p.Q726* Het Nephrotic>syndrome,>type>11 0 40 . . .
CKD713 CUMC M 53
Other/Unspecifi
ed
No Diabetic>nephropathy Recessive EBP p.F140C Hemi Chondrodysplasia>punctata 0 29.3 D D 0.874




Het pseudohypoparathyroidism,>type>1B 0 . . . .
CKD715 CUMC M 43 Hispanic Yes Diabetic>nephropathy Dominant ACE p.Q582fs Het Renal>tubular>dysgenesis 0 . . . .
CKD715 CUMC M 43 Hispanic Yes Diabetic>nephropathy Dominant PTH1R p.G9V Het Metaphyseal>chondrodysplasia,>Murk>Jansen>type 0 . . . .
CKD716 CUMC M 66 Hispanic No Diabetic>nephropathy Dominant CAD p.G957V Het Congenital>disorder>of>glycosylation,>type>Iz 0 29.7 D D 0.893






0 . . . .
CKD718 CUMC M 60
Black/African>
American




0 . . . .
CKD719 CUMC F 71 Hispanic No Diabetic>nephropathy Recessive FGFR1 p.A3fs Hom
Encephalocraniocutaneous>Lipomatosis,>Kallmann>
syndrome>2,>kal2
7.71E*05 . . . .
CKD720 CUMC M 71 Hispanic Yes Diabetic>nephropathy Dominant TSC2 p.L575P Het Tuberous>sclerosis*2 0 28.7 D D 0.92
CKD721 CUMC F 60 White>European No Diabetic>nephropathy Dominant DCHS1 p.G2030V Het Van>Maldergem>syndrome>1 0 . . . .
CKD722 CUMC M 93 White>European No Diabetic>nephropathy Dominant NOTCH2 p.P1312S Het
Acroosteolysis>dominant>type,>Alagille>syndrome>2,>
Hajdu*Cheney>Syndrome
0 26.4 D D 0.762
CKD723 CUMC M 48 Asian No Diabetic>nephropathy Dominant MNX1 p.A134del Het Currarino>syndrome 0 . . . .
CKD723 CUMC M 48 Asian No Diabetic>nephropathy Dominant RPGRIP1L p.G23fs Het
Meckel>syndrome>5,>Joubert>syndrome>7,>COACH>
syndrome
0 . . . .
CKD723 CUMC M 48 Asian No Diabetic>nephropathy Recessive TNXB p.TQ278TK Hom
Vesicoureteral>Reflux>8>Ehlers*Danlos>syndrome>due>
to>tenascin*X>deficiency
0 . . . .
CKD724 CUMC M 60
Black/African>
American
Yes Diabetic>nephropathy Dominant PALB2 p.L1110del Het Fanconi>Anemia,>Complementation>Group>N 0 . . . .
CKD725 CUMC F 42 Hispanic No Diabetic>nephropathy Dominant KIF14 p.E1502fs Het Meckel>syndrome>12 0 . . . .
CKD725 CUMC F 42 Hispanic No Diabetic>nephropathy Dominant KIF14 p.L1504fs Het Meckel>syndrome>12 0 . . . .




0 25.8 D D 0.896
CKD726 CUMC M 64 Hispanic No Diabetic>nephropathy Dominant SLC3A1 p.K306N Het Cystinuria 0 24.9 D D 0.823
CKD727 CUMC F 60
Black/African>
American
No Diabetic>nephropathy Dominant GNAS c.*3+1G>T Het pseudohypoparathyroidism,>type>1B 0 . . . .
CKD728 CUMC F 58 Hispanic No Diabetic>nephropathy Dominant PGM3 p.T404P Het Immunodeficiency>23 0 26 D D 0.768
CKD728 CUMC F 58 Hispanic No Diabetic>nephropathy Dominant SCN4A p.V253M Het Hypokalemic>periodic>paralysis,>hokpp>type2 0 31 D D 0.905
CKD729 CUMC M 69 Asian No Diabetic>nephropathy Dominant MNX1
p.A133_A134d
el
Het Currarino>syndrome 0 . . . .
CKD729 CUMC M 69 Asian No Diabetic>nephropathy Dominant NOTCH2 p.A7fs Het
Acroosteolysis>dominant>type,>Alagille>syndrome>2,>
Hajdu*Cheney>Syndrome
0 . . . .
CKD730 CUMC M 49 Hispanic No Diabetic>nephropathy Dominant UPB1 c.364+1G>A Het Beta*ureidopropionase>deficiency 0 26 . . .
CKD730 CUMC M 49 Hispanic No Diabetic>nephropathy Dominant PUF60 p.E363del Het Verheij>syndrome 0 . . . .
CKD731 CUMC F 63 Hispanic Yes Diabetic>nephropathy Dominant COL4A5 p.A1633V Het Alport>syndrome 0 33 D D 0.778
CKD732 CUMC F 69 Hispanic Yes Diabetic>nephropathy Dominant SLC4A1 p.R514H Het Renal>tubular>acidosis,>distal 0 32 D D 0.769
CKD733 CUMC F 57 White>European No Diabetic>nephropathy Dominant TTC37 p.Y63C Het Trichohepatonenteric>syndrome>1 0 26.9 D D 0.807
CKD734 CUMC M 58 Asian No Diabetic>nephropathy Recessive PGK1 p.R39K Hemi Phosphoglycerate>kinase>1>deficiency 0 28.1 D . 0.936
CKD735 CUMC M 59 White>European No Diabetic>nephropathy Dominant RTTN p.M1? Het
Microsephaly,>short>stature,>and>polymicogyria>with>
or>without>seizures
0 24.2 T D 0.266
CKD736 CUMC F 54 Hispanic No Diabetic>nephropathy Dominant CFI p.C259Y Het Complement>factor>I>deficiency 0 25.8 D D 0.887
CKD737 CUMC F 70 Hispanic No Diabetic>nephropathy Dominant PEX1 p.S241fs Het Zellweger>syndrome 0 . . . .
CKD738 CUMC M 55 Asian No Diabetic>nephropathy Dominant ESCO2 p.Q52del Het Roberts>syndrome 0 . . . .
CKD739 CUMC M 51 Hispanic No Diabetic>nephropathy Dominant SCN4A p.F392fs Het Hypokalemic>periodic>paralysis,>hokpp>type2 0 . . . .
CKD740 CUMC F 33 White>European No Diabetic>nephropathy Dominant TBC1D24 p.F130del Het DOOR>syndrome 0 . . . .
CKD741 CUMC M 62 Asian Yes Diabetic>nephropathy Dominant EHHADH p.L692Q Het Fanconi>renotubular>syndrome>3 0 26.6 D D 0.857
CKD742 CUMC M 27 Asian No Diabetic>nephropathy Dominant ALMS1 p.E2930fs Het Alstrom>syndrome 0 . . . .
CKD742 CUMC M 27 Asian No Diabetic>nephropathy Dominant UPK3A p.T39A Het Renal>hypodysplasia,>urogenital>dysplasia 0 26.1 D D 0.838
CKD743 CUMC M 60 White>European No Diabetic>nephropathy Dominant CEP120 p.L351* Het
Short*rib>thoracic>dysplasia>13>with>or>without>
polydactyly
0 39 . . .





0 28.2 D D 0.883
CKD745 CUMC M 35 White>European Yes Diabetic>nephropathy Dominant LPIN1 p.H710R Het Myoglobinuria,>acute>recurrent 0 27.2 D D 0.838
CKD746 CUMC F 43
Black/African>
American
No Diabetic>nephropathy Dominant CD96 p.QT137QI Het C>syndrome 0 . . . .
CKD747 CUMC M 61 Hispanic No Diabetic>nephropathy Dominant BBIP1 p.Y97* Het Bardet*biedl>syndrome>18 0 42 T . 0.075
CKD748 CUMC M 35
Black/African>
American
Yes Diabetic>nephropathy Dominant ADAMTS13 p.R180S Het Thrombotic>thrombocytopenic>purpura,>familial 0 24.5 D D 0.85
CKD749 CUMC M 60 White>European No Diabetic>nephropathy Dominant PLCE1 p.FT2027FA Het Nephrotic>syndrome>type>3 0 . . . .
CKD750 CUMC F 53 White>European No Glomerulopathy Dominant TRAP1 p.K577fs Het
Congenital>Anomalies>of>the>Kidney>and>the>Urinary>
Tract
0 . . . .
CKD751 CUMC F 65 White>European No Glomerulopathy Dominant COL4A5 p.E49G Het Alport>syndrome 0 23.3 D D 0.763
CKD752 CUMC F 70 White>European No Glomerulopathy Dominant CUBN p.SG1952SA Het Megaloblastic>anemia>1*finnish>type 0 . . . .
CKD753 CUMC M 56
Black/African>
American
No Glomerulopathy Dominant ERCC6 p.G270fs Het Cockayne>syndrome,>type>B 0 . . . .
CKD754 CUMC M 45 Hispanic No Glomerulopathy Dominant HOXA13
p.A120_A132d
el
Het Hand*foot*uterus>syndrome 0 . . . .




CKD756 CUMC M 64 White>European Yes Glomerulopathy Dominant KDM1A p.L582P Het
Cleft>palate,>psychomotor>retardation,>and>
distinctive>facial>features
0 32 D D 0.939
CKD757 CUMC M 68
Other/Unspecifi
ed
No Glomerulopathy Dominant UMPS c.983*2A>G Het Hereditary>orotic>aciduria 0 26 . . .
CKD757 CUMC M 68
Other/Unspecifi
ed
No Glomerulopathy Dominant BCOR p.E769fs Het
Microphthalmia,>Lenz>type,>Microphthalmia,>
syndromic>2
0 . . . .
CKD757 CUMC M 68
Other/Unspecifi
ed




0 26.9 D D 0.841
CKD758 CUMC M 43
Black/African>
American
No Glomerulopathy Dominant FGA p.C812R Het Amyloidosis,>familial>visceral,>hereditary>renal 0 26.2 D D 0.986
CKD759 CUMC M 51 White>European No Glomerulopathy Dominant NLRP3 p.Q45* Het
Muckle*wells>syndrome>Familial>cold*induced>
inflammatory>syndrome>1
0 35 . . .
CKD760 CUMC F 32 Hispanic No Glomerulopathy Dominant HSPG2 p.H1025fs Het Schwartz*Jampel>syndrome 0 . . . .
CKD761 CUMC M 56 White>European No Glomerulopathy Dominant SI p.N1161fs Het Sucrase*isomaltase>deficiency,>congenital 0 . . . .
CKD762 CUMC M 41
Black/African>
American
No Glomerulopathy Dominant PLCE1 p.E2007del Het Nephrotic>syndrome>type>3 0 . . . .
CKD763 CUMC F 47 White>European No Glomerulopathy Recessive CEP41 p.E317fs Het Joubert's>syndrome>type>15 2.03E*05 . . . .
CKD763 CUMC F 47 White>European No Glomerulopathy Recessive CEP41 p.P359fs Het Joubert's>syndrome>type>15 0 . . . .
CKD764 CUMC M 85 Asian No Glomerulopathy Dominant CAD p.Q15* Het Congenital>disorder>of>glycosylation,>type>Iz 0 36 . . .
CKD765 CUMC M 52
Black/African>
American
Yes Glomerulopathy Dominant PEX1 p.T1039fs Het Zellweger>syndrome 0 . . . .
CKD766 CUMC M 49 Hispanic Yes Glomerulopathy Dominant FLNB p.QK192QQ Het Spondylocarpotarsal>synostosis>syndrome 0 . . . .
CKD767 CUMC F 26
Black/African>
American
Yes Glomerulopathy Dominant NEK8 p.V671A Het
Nephronophthisis>9>Renal*heaptic*pancreatic>
dysplasia>2
0 27.3 D D 0.812




0 39 . . .
CKD769 CUMC M 61 White>European Yes Glomerulopathy Dominant EIF2B4 p.N455K Het
Ovarioleukodystrophy,>leukoencelpaly>with>
vanishing>white>matter
0 25.4 D D 0.785
CKD770 CUMC F 30
Black/African>
American
Yes Glomerulopathy Dominant MYH9 p.E498K Het Fechtner>syndrome;>Epstein>Syndrome 0 32 D D 0.846
CKD771 CUMC F 28
Black/African>
American
No Glomerulopathy Dominant AQP2 p.L21P Het Diabetes>insipidus,>nephrogenic 0 23.5 D D 0.762
CKD772 CUMC M 36 Hispanic No Glomerulopathy Dominant ATP7B p.F1094fs Het Wilson>Disease 0 . . . .
CKD773 CUMC M 48 White>European No Glomerulopathy Dominant FBLN5 p.M1fs Het Cutis>laxa>type>IA 0 . . . .
CKD773 CUMC M 48 White>European No Glomerulopathy Dominant ATP6V0A4 p.F477C Het Renal>tubular>acidosis,>distal 0 28 D D 0.945
CKD774 CUMC F 70
Black/African>
American
No Glomerulopathy Dominant SCN4A p.I649T Het Hypokalemic>periodic>paralysis,>hokpp>type2 0 27.6 D D 0.982
CKD775 CUMC M 49 White>European No Glomerulopathy Dominant ETFDH p.Y506C Het Glutaric>acidemia>2c 0 24.3 D D 0.848
CKD776 CUMC F 25 White>European Yes Glomerulopathy Dominant HOXA13
p.A118_A126d
el
Het Hand*foot*uterus>syndrome 0 . . . .
CKD777 CUMC F 32 Hispanic Yes Glomerulopathy Dominant PTEN p.P169A Het
Cowden>syndrome,>VATER>association>with>
macrocephaly>and>ventriculomegaly
0 26 D D 0.96
CKD778 CUMC F 46
Black/African>
American
Yes Glomerulopathy Dominant WDPCP p.K93* Het Bardet*Biedl>syndrome 0 35 . . .
CKD779 CUMC F 34 White>European No Glomerulopathy Dominant ALPL p.I204V Het Hypophosphatasia,>infantile 0 23.7 D D 0.783
CKD780 CUMC M 42 White>European No Glomerulopathy Dominant HES7
p.P130_K134d
el
Het Autosomal>recessive>spondylocostal>dysostosis 0 . . . .
CKD781 CUMC F 10 White>European No
Congenital>or>cystic>
renal>disease
Dominant LRP2 p.Q716* Het Donnai*barrow>syndrome 0 26.9 . . .
CKD781 CUMC F 10 White>European No
Congenital>or>cystic>
renal>disease
Dominant SLC26A4 p.L471P Het Pendred>syndrome 0 28.8 D D 0.981
CKD782 CUMC F 20 Hispanic Yes Glomerulopathy Dominant ACE p.P606V Het Renal>tubular>dysgenesis 0 . . . .
CKD783 CUMC M 50 White>European Yes Glomerulopathy Dominant ACTA2 p.E318G Het Multisystemic>smooth>muscle>dysfunction>syndrome 0 24.4 D D 0.944
CKD784 CUMC M 44 White>European No Glomerulopathy Dominant STK11 p.E120G Het Peutz*Jeghers>syndrome 0 29 D D 0.754
CKD784 CUMC M 44 White>European No Glomerulopathy Dominant ETFDH p.G416D Het Glutaric>acidemia>2c 0 32 D D 0.942
CKD785 CUMC M 46 White>European No Glomerulopathy Dominant APC2 p.TL294TV Het Sotos>syndrome 0 . . . .
CKD786 CUMC M 41 White>European No Glomerulopathy Dominant RPGRIP1L p.K577* Het
Meckel>syndrome>5,>Joubert>syndrome>7,>COACH>
syndrome
0 37 . . .
CKD787 CUMC F 29 White>European No Glomerulopathy Dominant LRIG2 p.Q553* Het Ochoa>syndrome,>Urofacial>Syndrome>2 0 39 . . .
CKD788 CUMC M 41 White>European No Glomerulopathy Dominant ANLN
p.C819_V822d
el
Het Focal>Segmental>Glomerulosclerosis>8 0 . . . .
CKD789 CUMC M 49 White>European No Glomerulopathy Dominant SLIT2 p.D1204Y Het
Congenital>Anomalies>of>the>Kidney>and>the>Urinary>
Tract
0 30 D D 0.764
CKD790 CUMC M 42
Black/African>
American
No Glomerulopathy Dominant LONP1 p.ML23IV Het CODAS>syndrome 0 . . . .
CKD791 CUMC F 40 Asian No Glomerulopathy Recessive TNXB p.TQ278TK Hom
Vesicoureteral>Reflux>8>Ehlers*Danlos>syndrome>due>
to>tenascin*X>deficiency
0 . . . .
CKD792 CUMC M 44 White>European Yes Glomerulopathy Dominant HOGA1 p.P41fs Het Primary>hyperoxaluria>type>3 0 . . . .
CKD793 CUMC F 56 Asian Yes Glomerulopathy Dominant TRMT5 p.F90fs Het Combined>oxidative>phosphorylation>deficiency>26 0 . . . .






0 . . . .
CKD795 CUMC F 77 Asian No Glomerulopathy Dominant FREM1 p.T1490fs Het
Bifid>nose>with>or>without>anorectal>and>renal>
anomalies
0 . . . .
CKD796 CUMC F 54 Asian No Glomerulopathy Dominant HNF1B p.G20R Het Renal>Cysts>and>Diabetes>Syndrome 0 33 D D 0.873
CKD797 CUMC M 42 White>European No Glomerulopathy Dominant PEX12 p.L179fs Het Zellweger>syndrome 0 . . . .
CKD798 CUMC F 43 Hispanic No Glomerulopathy Dominant GRIP1 p.T484I Het Fraser>syndrome 0 28.6 D D 0.951




Het Kabuki>syndrome>1 0 . . . .
CKD800 CUMC M 47 White>European Yes Glomerulopathy Dominant RPGRIP1L p.T631I Het
Meckel>syndrome>5,>Joubert>syndrome>7,>COACH>
syndrome
0 25 D D 0.774
CKD801 CUMC M 44 White>European No Glomerulopathy Dominant FOXC1 p.L13R Het Axenfeld*Rieger>syndrome,>Type>3 0 26.6 D D 0.752
CKD801 CUMC M 44 White>European No Glomerulopathy Dominant STK11 p.K423fs Het Peutz*Jeghers>syndrome 0 . . . .
CKD802 CUMC F 33 White>European No Glomerulopathy Dominant NUP107 p.T205fs Het Nephrotic>syndrome,>type>11 0 . . . .
CKD803 CUMC M 58 White>European No Glomerulopathy Dominant CRB2 p.G178D Het FSGS>9>Ventriculomegaly>with>cystic>kidney>disease 0 24.1 D D 0.932
CKD803 CUMC M 58 White>European No Glomerulopathy Dominant SLC5A2 p.G450fs Het Renal>glucosuria 0 . . . .
CKD804 CUMC M 56
Black/African>
American
No Glomerulopathy Dominant TRAP1 p.E167K Het
Congenital>Anomalies>of>the>Kidney>and>the>Urinary>
Tract
0 34 D D 0.89
CKD805 CUMC F 47 White>European No Glomerulopathy Dominant TRAF3IP1 p.KN295NT Het Senior*Loken>syndrome>9 0 . . . .
CKD805 CUMC F 47 White>European No Glomerulopathy Dominant COL4A1 p.P211fs Het
Hereditary>angiopathy>with>nephropathy,>
aneurysms>and>Msucle>cramps>(HANAC)
0 . . . .
CKD806 CUMC M 71 White>European No Glomerulopathy Dominant PEX3 p.V182fs Het Zellweger>syndrome 0 . . . .
CKD807 CUMC F 61
Other/Unspecifi
ed
No Glomerulopathy Dominant GNA11
c.735+1_735+2
insGA
Het Hypocalciuric>hypercalcemia,>type>2 0 . . . .
CKD808 CUMC M 50 White>European No Glomerulopathy Dominant SLC12A1 p.L925F Het Bartter>syndrome,>type>1,>antenatal 0 32 D D 0.753
CKD809 CUMC F 38 White>European No Glomerulopathy Dominant COL4A1 p.P1377S Het
Hereditary>angiopathy>with>nephropathy,>
aneurysms>and>Msucle>cramps>(HANAC)
0 23.9 D D 0.762
CKD810 CUMC F 38 White>European No Glomerulopathy Dominant CNNM2 p.P724fs Het
Hypomagnesemia>type>6>Hypomagnesemia,>
seizures,>and>mental>retardation
0 . . . .
CKD811 CUMC F 73 White>European No Glomerulopathy Dominant FANCI c.3007*2A>T Het Fanconi>anemia,>complementation>group>I 0 24.3 . . .




0 . . . .
CKD813 CUMC M 65 White>European No Glomerulopathy Dominant ALG8 p.N284S Het
Polycystic>liver>disease>3>with>or>without>kidney>
cysts
0 25.7 D D 0.871
CKD814 CUMC F 54 White>European No Glomerulopathy Dominant EFEMP2 p.L81P Het Cutis>laxa>type>1 0 29.5 D D 0.822
CKD815 CUMC M 40 Hispanic Yes Glomerulopathy Dominant POMT1 p.W300C Het Muscular>dystrophy*dystroglycanopathy,>type>A,>1 0 32 D D 0.921
CKD816 CUMC F 29 White>European No Glomerulopathy Dominant AFF4 p.T588fs Het CHOPS>syndrome 0 . . . .
CKD817 CUMC M 73 White>European No Glomerulopathy Dominant SLC4A4 p.G816R Het
Renal>tubular>acidosis,>proximal,>with>ocular>
abnormalities>and>mental>retardation
0 33 D D 0.866
CKD818 CUMC M 30 White>European No Glomerulopathy Dominant WDPCP p.Y63del Het Bardet*Biedl>syndrome 0 . . . .
CKD819 CUMC M 50 Asian No Glomerulopathy Dominant STRA6 p.N506K Het Microphthalmia,>syndromic>9,>mcops9 0 28.6 D D 0.806
CKD819 CUMC M 50 Asian No Glomerulopathy Dominant PYGM p.I566S Het McArdle>Disease 0 24.7 D D 0.802
CKD820 CUMC M 44 White>European Yes Glomerulopathy Dominant PEX5 p.G43fs Het Zellweger>syndrome 0 . . . .
CKD821 CUMC M 57 Asian No Glomerulopathy Dominant TTC21B p.A570V Het Nephronophthisis>12 0 33 D D 0.815
CKD821 CUMC M 57 Asian No Glomerulopathy Dominant APC2 p.S108L Het Sotos>syndrome 0 . . . .
CKD822 CUMC M 46 Asian No Glomerulopathy Dominant NPHP4 p.V349G Het Nephronophthisis>4>Senior*Loken>syndrome>4 0 25.4 D D 0.79
CKD823 CUMC M 33 White>European Yes Glomerulopathy Dominant RERE p.W438R Het
Neurodevelopmental>disorder>with>or>without>
anomalies>of>the>brain,>eye,>or>heart
0 28.4 D D 0.865
CKD824 CUMC F 35 Asian No Glomerulopathy Dominant SLC4A4 p.L886P Het
Renal>tubular>acidosis,>proximal,>with>ocular>
abnormalities>and>mental>retardation
0 31 D D 0.946
CKD825 CUMC F 35
Other/Unspecifi
ed
No Glomerulopathy Dominant SALL1
p.S156_S159d
up
Het Townes*Brocks>Branchiootorenal*like>Syndrome 0 . . . .
CKD826 CUMC F 69 White>European No Glomerulopathy Dominant SLC6A19 p.E569* Het Hartnup>Disorder>Hyperglycinuria 0 40 . . .
CKD827 CUMC M 46
Other/Unspecifi
ed
No Glomerulopathy Dominant HOGA1 p.T174A Het Primary>hyperoxaluria>type>3 0 26.4 D D 0.955
CKD828 CUMC M 38 Asian No Glomerulopathy Dominant PDSS2 p.I165T Het Coenzyme>q10>deficiency,>primary,>3 0 25.7 D D 0.853
CKD829 CUMC M 25 White>European No Glomerulopathy Dominant RAB3GAP2 c.304+1G>C Het Micro>syndrome 0 27.2 . . .
CKD830 CUMC F 67 White>European No Glomerulopathy Dominant NPHS1 p.Q154fs Het Congenital>nephrotic>syndrome,>Finnish>type 0 . . . .
CKD831 CUMC M 71 Asian No Glomerulopathy Dominant KANK1 p.E963* Het Nephroticsyndrome 0 55 . . .
CKD832 CUMC M 28 White>European No Glomerulopathy Dominant KANK1 p.E880* Het Nephroticsyndrome 0 42 . . .
CKD833 CUMC M 49 White>European No Glomerulopathy Dominant C5orf42 p.E2722F Het Orofaciodigital>syndrome>6 0 . . . .
CKD834 CUMC M 30 Asian No Glomerulopathy Dominant SLC1A1 p.R39* Het Dicarboylic>aminoaciduria 0 40 . . .
CKD835 CUMC F 62 White>European Yes Glomerulopathy Recessive OCLN p.E339fs Hom
Band*like>calcification>with>simplified>gyration>and>
polymicogyria
2.98E*05 . . . .
CKD836 CUMC F 31 Asian No Glomerulopathy Dominant COQ6 p.A49fs Het Coenzyme>Q10>deficiency,>primary,>6 0 . . . .
CKD837 CUMC M 55
Black/African>
American
No Glomerulopathy Dominant FOXC1
p.G450_G454d
up
Het Axenfeld*Rieger>syndrome,>Type>3 0 . . . .
CKD838 CUMC M 50 White>European No Glomerulopathy Dominant GDF2 p.A148G Het Hereditary>hemorrhagic>telangiectasia 0 . . . 0.828
CKD839 CUMC M 59 White>European Yes Glomerulopathy Dominant SDCCAG8 p.E67* Het
Senior>loken>syndrome>type>7,>Bardet*Biedl>
Syndrome>16
0 36 . . .








1.72E*05 28.4 D D 0.976
CKD840 CUMC M 44 White>European No Glomerulopathy Dominant STRADA p.G348V Het
Polyhydramnios,>megalencephaly,>and>symptomatic>
epilepsy
0 . . . .
CKD841 CUMC F 47 White>European Yes Glomerulopathy Dominant ARX p.E250* Het Proud>syndrome 0 36 . . .
CKD841 CUMC F 47 White>European Yes Glomerulopathy Dominant TRAF3IP1 p.M1? Het Senior*Loken>syndrome>9 0 21.9 T D 0.317
CKD842 CUMC F 40 Asian No Glomerulopathy Dominant TTC8 p.D402V Het Bardet*Biedl>Syndrome>8 0 28.5 D D 0.751
CKD843 CUMC M 74 Asian No Glomerulopathy Dominant INF2 p.Q1249fs Het
Focal>Segmental>Glomerulosclerosis>5>Charcot*Marie*
Tooth>disease>E
0 . . . .
CKD844 CUMC F 11 White>European No Glomerulopathy Dominant SLC7A9 p.L111P Het Cystinuria 0 28.1 D D 0.96
CKD844 CUMC F 11 White>European No Glomerulopathy Dominant DLL3 p.P361S Het Autosomal>recessive>spondylocostal>dysostosis 0 29.6 D D 0.882
CKD845 CUMC M 60 White>European No Glomerulopathy Dominant SERPINH1 p.G183C Het Osteogenesis>imperfecta,>type>X 0 32 D D 0.832
CKD846 CUMC M 51 Hispanic No Glomerulopathy Dominant CASP10 p.L310fs Het Autoimmune>Lymhoproliferative>syndrome>type>2A 0 . . . .
CKD847 CUMC M 41 White>European Yes Glomerulopathy Dominant GSN p.E464Y Het
Amyloidosis,>finnish>type>cerebral>amyloid>
angiopathy,>gsn*related
0 . . . .
CKD848 CUMC M 48 Asian No Glomerulopathy Dominant ARID1B
p.S320_G327d
up
Het Coffin*Siris>syndrome 0 . . . .
CKD849 CUMC M 32 White>European No Glomerulopathy Dominant SCARB2 p.P57L Het
Epilepsy,>Progressive>Myoclonic,>4>with>or>without>
Renal>Failure
0 31 D D 0.841
CKD849 CUMC M 32 White>European No Glomerulopathy Dominant SLC12A1 p.S609C Het Bartter>syndrome,>type>1,>antenatal 0 29.3 D D 0.861
CKD850 CUMC F 52 White>European No Glomerulopathy Dominant PAF1 p.Q10* Het Zellweger>syndrome>3 0 39 . . .





0 28.2 D D 0.883
CKD852 CUMC M 43 White>European No Glomerulopathy Dominant PHGDH p.T147P Het Neu*Laxova>syndrome>1 0 27.1 D D 0.841
CKD853 CUMC M 55 White>European No Glomerulopathy Dominant MYO1E
p.K1048_P105
1del
Het Glomerulosclerosis,>focal>segmental,>6 0 . . . .
CKD854 CUMC M 55 White>European Yes Glomerulopathy Dominant SOX18 p.SR255SW Het
Hypotrichosis*lymphedema*telangiectasia*renal>
defect>syndrome
0 . . . .
CKD855 CUMC M 58 Asian No Glomerulopathy Dominant ARID1B
p.Q124_Q131d
el
Het Coffin*Siris>syndrome 0 . . . .
CKD855 CUMC M 58 Asian No Glomerulopathy Dominant TMEM67 p.L820R Het
Nephronophtisis>11,>Meckel>Syndrome>3,>Joubert>
syndrome>6,>COACH>syndrome
0 29.3 D D 0.883




0 28.9 D D 0.931
CKD856 CUMC F 55 Asian Yes Glomerulopathy Dominant ATP7A p.Y1365F Het Occipital>horn>syndrome 0 27.1 D D 0.886
CKD857 CUMC M 71 White>European Yes Glomerulopathy Dominant TTC21B p.K410fs Het Nephronophthisis>12 0 . . . .
CKD858 CUMC F 50 Hispanic Yes Glomerulopathy Dominant ACE p.Q582fs Het Renal>tubular>dysgenesis 0 . . . .
CKD859 CUMC M 71 Asian Yes Glomerulopathy Dominant GSN p.H4fs Het
Amyloidosis,>finnish>type>cerebral>amyloid>
angiopathy,>gsn*related
0 . . . .




0 26.1 D D 0.877
CKD861 CUMC M 31 Hispanic No Glomerulopathy Dominant SIX2 p.R113C Het Renal>hypodysplasia 0 34 D D 0.86
CKD862 CUMC M 52 White>European Yes Glomerulopathy Dominant SOX18 p.A47_A49del Het
Hypotrichosis*lymphedema*telangiectasia*renal>
defect>syndrome
0 . . . .
CKD863 CUMC M 57 White>European Yes Glomerulopathy Dominant HOXA13
p.A120_A131d
el
Het Hand*foot*uterus>syndrome 0 . . . .
CKD864 CUMC F 43 Hispanic Yes Glomerulopathy Dominant ERCC4 p.G508del Het
Fanconi>anemia,>Xeroderma>pigmentosum,>type>f,>
Cockayne>syndrome
0 . . . .
CKD864 CUMC F 43 Hispanic Yes Glomerulopathy Dominant HGD p.L430I Het Alkaptonuria 0 24.9 D D 0.773
CKD864 CUMC F 43 Hispanic Yes Glomerulopathy Dominant SLC26A4 p.M461I Het Pendred>syndrome 0 31 D D 0.902
CKD864 CUMC F 43 Hispanic Yes Glomerulopathy Dominant FAH p.F272L Het tyrosinemia,>type>1 0 23.5 D D 0.783
CKD865 CUMC F 44 Asian Yes Glomerulopathy Dominant FOXC1
p.G378_G380d
up
Het Axenfeld*Rieger>syndrome,>Type>3 0 . . . .
CKD866 CUMC M 54 White>European Yes Glomerulopathy Dominant PKHD1 p.I3243fs Het
autosomal>recessive>polycystic>kidney>disease,>
Polycystic>and>hepatic>disease
0 . . . .
CKD867 CUMC F 53 Asian Yes Glomerulopathy Dominant CHD7 p.Y1333C Het CHARGE>syndrome 0 26.2 D D 0.866
CKD868 CUMC F 26 White>European Yes Glomerulopathy Dominant STRADA p.G348V Het
Polyhydramnios,>megalencephaly,>and>symptomatic>
epilepsy
0 . . . .
CKD868 CUMC F 26 White>European Yes Glomerulopathy Dominant ACTG2 p.S61R Het
Megacystis*microcolon*intestinal>hypoperistalsis>
syndrome,>Visceral>myopathy
0 24.1 D D 0.865
CKD869 CUMC M 54 White>European Yes Glomerulopathy Dominant MYH9 p.K1248E Het Fechtner>syndrome;>Epstein>Syndrome 0 31 D D 0.875
CKD870 CUMC M 23 White>European No Glomerulopathy Dominant SI p.D885fs Het Sucrase*isomaltase>deficiency,>congenital 0 . . . .
CKD871 CUMC M 36
Black/African>
American
No Glomerulopathy Dominant XDH p.P1300A Het Xanthinuria,>type>i 0 27.2 D D 0.83
CKD872 CUMC F 58 Asian Yes Glomerulopathy Dominant KANK1 p.M368fs Het Nephroticsyndrome 0 . . . .
CKD873 CUMC F 36 Hispanic Yes Glomerulopathy Dominant PEX26 p.A177T Het Zellweger>syndrome 0 27.6 D D 0.873
CKD874 CUMC M 31 White>European Yes Glomerulopathy Dominant TRPM6 p.L1146fs Het Hypomagnesemia>1,>intestinal 0 . . . .
CKD875 CUMC F 56 Hispanic Yes Glomerulopathy Dominant LRP2 p.D1906Y Het Donnai*barrow>syndrome 0 32 D D 0.932
CKD876 CUMC F 48 White>European Yes Glomerulopathy Dominant CPT2 p.L573R Het
Lethal>neonatal>carnitine>palmitoyltransferase>2>
deficiency
0 25.1 D D 0.801
CKD877 CUMC F 37 White>European No Glomerulopathy Dominant STRADA p.I11fs Het
Polyhydramnios,>megalencephaly,>and>symptomatic>
epilepsy
0 . . . .




0 23.2 D D 0.856
CKD878 CUMC M 49 White>European Yes Glomerulopathy Dominant TCTN3 p.I591fs Het Joubert>syndrome>18,>Orofaciodigital>syndrome>4 0 . . . .
CKD879 CUMC F 29
Other/Unspecifi
ed
No Glomerulopathy Dominant GLI3 p.GA1336ES Het Pallister*Hall>syndrome 0 . . . .
CKD880 CUMC F 42 White>European No Glomerulopathy Dominant MVK p.N205S Het Mevalonic>aciduria 0 27.1 D D 0.785
CKD881 CUMC F 35
Other/Unspecifi
ed
No Glomerulopathy Dominant MKKS p.C376F Het
Bardet*biedl>syndrome>6,>McKusick*Kaufman>
syndrome
0 33 D D 0.773
CKD882 CUMC F 34
Black/African>
American
No Glomerulopathy Dominant FREM2 p.E2335fs Het Fraser>syndrome 0 . . . .
CKD883 CUMC F 54
Black/African>
American
No Glomerulopathy Dominant CACNA1S p.F1690fs Het Hypokalemic>periodic>paralysis,>hokpp 0 . . . .
CKD884 CUMC F 41
Black/African>
American
No Glomerulopathy Dominant SLC25A1 p.L304dup Het Combined>D*2*>and>L*2*hydroxyglutaric>aciduria 0 . . . .
CKD885 CUMC F 32 White>European No Glomerulopathy Dominant SPECC1L p.T1109M Het Opitz>GBBB>syndrome,>type>2 0 34 D D 0.822
CKD886 CUMC F 30 Asian No Glomerulopathy Dominant DLG3 p.P89K Het Mental>retardation,>x*linked>90 0 . . . .
CKD887 CUMC F 31 White>European Yes Glomerulopathy Dominant CUBN p.C366S Het Megaloblastic>anemia>1*finnish>type 0 25.1 D D 0.846
CKD888 CUMC F 30 Hispanic No Glomerulopathy Dominant SLX4 p.E993* Het Fanconi>anemia,>complementation>group>P 0 35 . . .
CKD889 CUMC M 24
Black/African>
American
Yes Glomerulopathy Dominant CAD p.N611fs Het Congenital>disorder>of>glycosylation,>type>Iz 0 . . . .
CKD890 CUMC F 24
Black/African>
American
No Glomerulopathy Dominant WNT4 p.S116P Het
SERKAL>syndrome>Mullerian>aplasia>and>
hyperandrogenism
0 29.7 D D 0.906
CKD891 CUMC F 70 White>European Yes Glomerulopathy Dominant PYGM c.856*2A>C Het McArdle>Disease 0 23.6 . . .
CKD892 CUMC F 32 White>European No Glomerulopathy Dominant SCN4A p.L752F Het Hypokalemic>periodic>paralysis,>hokpp>type2 0 26.7 D D 0.957
CKD892 CUMC F 32 White>European No Glomerulopathy Dominant GRIP1 p.F838del Het Fraser>syndrome 0 . . . .
CKD893 CUMC F 33
Black/African>
American
No Glomerulopathy Dominant ARID1B p.A491K Het Coffin*Siris>syndrome 0 . . . .
CKD893 CUMC F 33
Black/African>
American
No Glomerulopathy Dominant COL4A1 p.K288fs Het
Hereditary>angiopathy>with>nephropathy,>
aneurysms>and>Msucle>cramps>(HANAC)
0 . . . .
CKD894 CUMC F 34 White>European Yes Glomerulopathy Dominant CSPP1 p.S1186dup Het Meckel>syndrome,>Joubert>syndrome>21 0 . . . .
CKD895 CUMC F 54
Other/Unspecifi
ed
No Glomerulopathy Dominant SCN4A p.W548R Het Hypokalemic>periodic>paralysis,>hokpp>type2 0 29.1 D D 0.856
CKD896 CUMC F 25 Hispanic No Glomerulopathy Dominant SPECC1L c.2561*1delG Het Opitz>GBBB>syndrome,>type>2 0 . . . .
CKD897 CUMC F 46
Black/African>
American
No Glomerulopathy Dominant ALMS1 p.S3694fs Het Alstrom>syndrome 0 . . . .
CKD897 CUMC F 46
Black/African>
American
No Glomerulopathy Dominant DLL4
p.T503_F504d
elinsI
Het Adams*Oliver>syndrome>6 0 . . . .
CKD898 CUMC F 64 Hispanic No Glomerulopathy Dominant DLL3 p.Q23fs Het Autosomal>recessive>spondylocostal>dysostosis 0 . . . .
CKD899 CUMC F 23
Black/African>
American
No Glomerulopathy Dominant RPGRIP1L p.L358fs Het
Meckel>syndrome>5,>Joubert>syndrome>7,>COACH>
syndrome
0 . . . .
CKD899 CUMC F 23
Black/African>
American
No Glomerulopathy Dominant LRIG2 p.M1? Het Ochoa>syndrome,>Urofacial>Syndrome>2 0 28.4 T D 0.254
CKD900 CUMC F 43 Hispanic No Glomerulopathy Dominant CEP41 p.Y50H Het Joubert's>syndrome>type>15 0 27.4 D D 0.924
CKD901 CUMC F 50
Other/Unspecifi
ed
No Glomerulopathy Dominant SLC1A1 p.R356* Het Dicarboylic>aminoaciduria 0 35 . . 0.19
CKD902 CUMC F 21
Black/African>
American
No Glomerulopathy Dominant FANCF p.AA106AP Het Fanconi>anemia 0 . . . .
CKD902 CUMC F 21
Black/African>
American
No Glomerulopathy Dominant C5orf42 p.G299* Het Orofaciodigital>syndrome>6 0 37 . . .
CKD902 CUMC F 21
Black/African>
American
No Glomerulopathy Dominant PKHD1 p.L2373P Het
autosomal>recessive>polycystic>kidney>disease,>
Polycystic>and>hepatic>disease
0 32 D D 0.882
CKD903 CUMC F 38 White>European No Glomerulopathy Dominant STRA6 p.R532G Het Microphthalmia,>syndromic>9,>mcops9 0 28.2 D D 0.755




0 45 . . .




0 . . . .
CKD905 CUMC F 26 White>European No Glomerulopathy Dominant ASXL1 p.A498fs Het Bohring*Opitz>syndrome 0 . . . .
CKD906 CUMC M 31 Hispanic No Glomerulopathy Dominant SALL1 p.L970S Het Townes*Brocks>Branchiootorenal*like>Syndrome 0 24.4 D D 0.755
CKD907 CUMC F 60 White>European No Glomerulopathy Dominant COL5A1 p.G1652A Het Ehlers*Danlos>syndrome,>classic>type 0 24.2 D D 0.89
CKD908 CUMC M 10 White>European Yes
Congenital>or>cystic>
renal>disease
Dominant INPP5E p.R596T Het
Joubert>syndrome>with>hepatic>defectJoubert>
Syndrome>1
0 29.4 D D 0.786
CKD909 CUMC F 29 White>European No
Congenital>or>cystic>
renal>disease
Dominant DNAAF1 p.M1? Het Ciliary>dyskinesia,>primary,>13 0 23.9 T D 0.304
CKD910 CUMC M 3 White>European No
Congenital>or>cystic>
renal>disease




CKD910 CUMC M 3 White>European No
Congenital>or>cystic>
renal>disease
Dominant SI p.G1289R Het Sucrase*isomaltase>deficiency,>congenital 0 33 D D 0.965
CKD911 CUMC M 1 Hispanic No
Congenital>or>cystic>
renal>disease
Dominant ITGA8 p.C713W Het Renal>hypodysplasia*aplasia>1 0 26.8 D D 0.852






Dominant IFT140 p.W186* Het
Short>rib*polydactyly>syndrome>(Jeune's>syndrome)>
type>9
0 39 . . .
CKD913 CUMC M 2 Hispanic No
Congenital>or>cystic>
renal>disease
Dominant SI p.N922fs Het Sucrase*isomaltase>deficiency,>congenital 0 . . . .














Het Hypocalciuric>hypercalcemia,>type>2 0 . . . .






Dominant KMT2D p.E802R Het Kabuki>syndrome>1 0 . . . .
CKD915 CUMC F 3 White>European No
Congenital>or>cystic>
renal>disease
Dominant SPECC1L p.E915fs Het Opitz>GBBB>syndrome,>type>2 0 . . . .
CKD915 CUMC F 3 White>European No
Congenital>or>cystic>
renal>disease
Dominant BRAF p.I710fs Het
Noonan>syndrome>with>multiple>lentigines,>
Cardiofaciocutaneous>syndrome
0 . . . .
CKD915 CUMC F 3 White>European No
Congenital>or>cystic>
renal>disease
Dominant REN p.S107L Het
Renal>tubular>dysgenesis>hyperuricemic>
nephropathy,>familial>juvenile>2
0 34 D D 0.9
CKD916 CUMC M 18 White>European No
Congenital>or>cystic>
renal>disease
Dominant CEP164 p.D89fs Het Senior*Loken>syndrome,>Nephronopthisis>15 0 . . . .






Dominant LONP1 p.E808* Het CODAS>syndrome 0 44 . . .






Dominant COX20 p.G37S Het Mitochondrial>Complex>4>deficiency 0 33 D D 0.788






Dominant INF2 p.P428del Het
Focal>Segmental>Glomerulosclerosis>5>Charcot*Marie*
Tooth>disease>E
0 . . . .
CKD918 CUMC F 9 White>European No
Congenital>or>cystic>
renal>disease
Dominant LFNG p.W53fs Het Autosomal>recessive>spondylocostal>dysostosis 0 . . . .






Dominant EPG5 p.E1399* Het Vici>syndrome 0 41 . . .
CKD920 CUMC F 21 White>European No
Congenital>or>cystic>
renal>disease
Dominant VANGL1 p.T52fs Het Caudal>regression>syndrome 0 . . . .






Het Axenfeld*Rieger>syndrome,>Type>3 0 . . . .
CKD921 CUMC F 9 Asian No
Congenital>or>cystic>
renal>disease




0 . . . .






Het Hand*foot*uterus>syndrome 0 . . . .
CKD922 CUMC M 10 White>European No
Congenital>or>cystic>
renal>disease
Dominant HSD17B4 p.N186I Het D*bifunctional>protein>deficiency 0 31 D D 0.871






Het CHARGE>syndrome 0 . . . .
CKD923 CUMC F 15 Asian No
Congenital>or>cystic>
renal>disease
Dominant COX20 p.P7_E11dup Het Mitochondrial>Complex>4>deficiency 0 . . . .
CKD924 CUMC M 18 White>European No
Congenital>or>cystic>
renal>disease
Dominant LFNG p.W53fs Het Autosomal>recessive>spondylocostal>dysostosis 0 . . . .







Het pseudohypoparathyroidism,>type>1B 0 . . . .
CKD926 CUMC F 11 White>European No
Congenital>or>cystic>
renal>disease
Dominant CA2 p.T192I Het Osteopetrosis>>with>renal>tubular>acidosis 0 28.7 D D 0.857






Dominant C5orf42 p.I980fs Het Orofaciodigital>syndrome>6 0 . . . .






Dominant SLC6A19 p.L101fs Het Hartnup>Disorder>Hyperglycinuria 0 . . . .






Het Coffin*Siris>syndrome 0 . . . .
CKD929 CUMC M 14 White>European No
Congenital>or>cystic>
renal>disease
Dominant GPC3 c.338*1G>T Het Simpson>golabi>behmel>syndrome>type>1 0 24 . . .






Dominant ETFB p.P94fs Het Glutaric>acidemia>2b 0 . . . .
CKD931 CUMC F 14 White>European No
Congenital>or>cystic>
renal>disease
Dominant FUZ p.S211fs Het Caudal>regression>sequence 0 . . . .
CKD932 CUMC F 10 White>European No
Congenital>or>cystic>
renal>disease
Dominant XRCC4 p.E297fs Het
Short>stature,>microcephaly,>and>endocrine>
dysfunction
0 . . . .









0 . . . .
CKD934 CUMC M 21 Hispanic No
Congenital>or>cystic>
renal>disease
Dominant PGK1 p.V303fs Het Phosphoglycerate>kinase>1>deficiency 0 . . . .






Dominant PGM3 p.R197* Het Immunodeficiency>23 0 37 . . .






Dominant SCN4A p.C1730R Het Hypokalemic>periodic>paralysis,>hokpp>type2 0 24 D D 0.783






Het Hand*foot*uterus>syndrome 0 . . . .
CKD938 CUMC M 3 Hispanic No
Congenital>or>cystic>
renal>disease




0 27.7 D D 0.806






Dominant COL4A3 p.P1501S Het Alport>syndrome 0 25.6 D D 0.85
CKD940 CUMC F 16 White>European No
Congenital>or>cystic>
renal>disease
Dominant INSR p.P797fs Het Rabson*Mendenhall>syndrome 0 . . . .






Dominant BBS5 p.L62fs Het Bardet*Biedl>Syndrome>5 0 . . . .
CKD942 CUMC M 7 Hispanic No
Congenital>or>cystic>
renal>disease
Dominant ARID1B p.A460dup Het Coffin*Siris>syndrome 0 . . . .
CKD943 CUMC M 22 Hispanic No
Congenital>or>cystic>
renal>disease




5.63E*06 24.3 D D 0.896
CKD944 CUMC M 3 White>European No
Congenital>or>cystic>
renal>disease
Dominant COL5A1 p.P1533L Het Ehlers*Danlos>syndrome,>classic>type 0 26 D D 0.808






Het Knobloch>syndrome 0 . . . .






Dominant TSC2 p.L1744F Het Tuberous>sclerosis*2 0 28.6 D D 0.887
CKD947 CUMC F 70 White>European Yes
Congenital>or>cystic>
renal>disease




0 24.5 . . .









Het Hand*foot*uterus>syndrome 0 . . . .
CKD949 CUMC M 3 Asian No
Congenital>or>cystic>
renal>disease
Dominant HSPG2 p.C3596Y Het Schwartz*Jampel>syndrome 0 32 D D 0.915






Het Coffin*Siris>syndrome 0 . . . .
CKD949 CUMC M 3 Asian No
Congenital>or>cystic>
renal>disease
Dominant PLOD1 p.K36fs Het Ehlers*Danlos>syndrome,>type>6 0 . . . .






Het Ellis>Van>Creveld>syndrome 0 . . . .
CKD950 CUMC F 18 Hispanic No
Congenital>or>cystic>
renal>disease
Dominant PRODH p.W146* Het Hyperprolinemia,>type>I 0 39 . . 0.068
CKD951 CUMC F 4 White>European No
Congenital>or>cystic>
renal>disease
Dominant HSD17B3 c.385+1G>A Het
46,XY>disorder>of>sex>development>due>to>17*beta*
hydroxysteroid>dehydrogenase>3>deficiency
0 25.5 . . .
CKD951 CUMC F 4 White>European No
Congenital>or>cystic>
renal>disease
Dominant MMACHC p.R230P Het
Methylmalonic>aciduria>and>homocystinuria,>cblc>
type
0 28.6 D D 0.92
CKD951 CUMC F 4 White>European No
Congenital>or>cystic>
renal>disease
Dominant IFT140 p.E1262fs Het
Short>rib*polydactyly>syndrome>(Jeune's>syndrome)>
type>9
0 . . . .
CKD952 CUMC F 3 White>European No
Congenital>or>cystic>
renal>disease
Dominant COL18A1 p.G769R Het Knobloch>syndrome 0 26.1 D D 0.88






Dominant FAM20C p.T472M Het Raine>syndrome 0 32 D D 0.793






Het Coffin*Siris>syndrome 0 . . . .
CKD954 CUMC F 5 White>European No
Congenital>or>cystic>
renal>disease
Dominant TBX18 p.I155T Het
Congenital>hydronephrosisCongenital>anomalies>of>
Kidney>and>Urinary>Tract>2
0 32 D D 0.826
CKD955 CUMC F 37 Hispanic No
Congenital>or>cystic>
renal>disease
Dominant BUB1B c.1567+2T>A Het Mosaic>variegated>aneuploidy>syndrome>1 0 23.5 . . .
CKD956 CUMC M 6 White>European No
Congenital>or>cystic>
renal>disease
Dominant VPS33B c.96+1G>T Het
Arthrogryposis,>renal>dysfunction,>and>cholestasis>1;>
arcs1
0 27.8 . . .
CKD957 CUMC F 7 White>European Yes
Congenital>or>cystic>
renal>disease
Dominant NPHS1 p.C863F Het Congenital>nephrotic>syndrome,>Finnish>type 0 32 D D 0.874
CKD957 CUMC F 7 White>European Yes
Congenital>or>cystic>
renal>disease
Dominant OFD1 p.S76F Het
Joubert>syndrome>type>10,>Orofaciodigital>syndrome>
I,>Golabi*Behmel>syndrome,>type>2
0 21.7 D D 0.774
CKD958 CUMC M 25 White>European Yes
Congenital>or>cystic>
renal>disease
Dominant FREM2 p.LL35LF Het Fraser>syndrome 0 . . . .
CKD959 CUMC F 65 White>European No
Congenital>or>cystic>
renal>disease
Dominant INVS p.A263fs Het
Senior*Loken>syndrome,>Nephronophthisis>2,>
infantile
0 . . . .




















Dominant ABCD4 p.C593fs Het
Methylmalonic>aciduria>and>homocystinuria,>cblJ>
type
0 . . . .






Dominant ETFB p.Q125E Het Glutaric>acidemia>2b 0 26.2 D D 0.803
CKD962 CUMC F 13 Hispanic No
Congenital>or>cystic>
renal>disease
Dominant WNK1 p.S2365fs Het Pseudohypoaldosteronism,>type>2c 0 . . . .
CKD963 CUMC F 12 Hispanic No
Congenital>or>cystic>
renal>disease
Dominant FANCL p.D208Y Het Fanconi>anemia,>complementation>group>L 0 35 D D 0.823
CKD964 CUMC F 18 White>European Yes
Congenital>or>cystic>
renal>disease
Dominant GRHPR c.598+1G>T Het Hyperoxaluria,>primary,>type>2 0 26.6 . . .
CKD965 CUMC M 21 White>European No
Congenital>or>cystic>
renal>disease
Dominant CACNA1S p.F1361L Het Hypokalemic>periodic>paralysis,>hokpp 0 30 D D 0.967
CKD966 CUMC M 37 Asian No Glomerulopathy Dominant EMP2 c.78+1G>A Het Nephrotic>syndrome>type>10 0 23.9 . . .
CKD967 CUMC M 42 White>European No Glomerulopathy Dominant ERCC4 p.F851del Het
Fanconi>anemia,>Xeroderma>pigmentosum,>type>f,>
Cockayne>syndrome
0 . . . .
CKD968 CUMC F 66 White>European No Glomerulopathy Dominant FRAS1 p.C857fs Het Fraser>syndrome 0 . . . .
CKD969 CUMC F 63 White>European Yes Glomerulopathy Dominant CREBBP p.Q2203del Het Rubinstein>Taybi>syndrome>type>1 0 . . . .
CKD970 CUMC F 51 Asian No Glomerulopathy Dominant CLCNKB p.G120R Het Bartter>syndrome,>type>3>and>type>4b 0 25.8 D D 0.971
CKD971 CUMC M 78 White>European No Glomerulopathy Dominant CACNA1S p.M1165K Het Hypokalemic>periodic>paralysis,>hokpp 0 27.8 D D 0.943
CKD972 CUMC M 46
Other/Unspecifi
ed
Yes Glomerulopathy Dominant CLCNKA p.S584fs Het Bartter's>Syndrome>Type>4b,>Neonatal 0 . . . .
CKD973 CUMC M 45 Hispanic No Glomerulopathy Dominant SMARCE1 c.156+1G>A Het Coffin*Siris>syndrome 0 25.7 . D .
CKD973 CUMC M 45 Hispanic No Glomerulopathy Dominant HSD17B3 p.D3fs Het
46,XY>disorder>of>sex>development>due>to>17*beta*
hydroxysteroid>dehydrogenase>3>deficiency
0 . . . .
CKD974 CUMC M 77
Black/African>
American
No Glomerulopathy Dominant FUZ c.387+2T>G Het Caudal>regression>sequence 0 23.6 . . .
CKD975 CUMC M 56 White>European No Glomerulopathy Dominant TRAIP p.E379* Het Seckel>syndrome>9 0 40 . . .
CKD976 CUMC F 73 Asian No Glomerulopathy Dominant APC2 p.S108L Het Sotos>syndrome 0 . . . .
CKD977 CUMC M 27 White>European No Glomerulopathy Dominant FANCA p.E1196* Het Fanconi>anemia,>complementation>group>a 0 35 . . .
CKD978 CUMC F 79 White>European No Glomerulopathy Dominant CENPF c.4986+1G>T Het Stromme>syndrome 0 23.1 . . .
CKD978 CUMC F 79 White>European No Glomerulopathy Dominant TSC2 p.S1336fs Het Tuberous>sclerosis*2 0 . . . .
CKD978 CUMC F 79 White>European No Glomerulopathy Dominant CACNA1S p.*1874R Het Hypokalemic>periodic>paralysis,>hokpp 0 23.4 . . .
CKD979 CUMC M 72 White>European No Glomerulopathy Dominant TRAP1 p.W231R Het
Congenital>Anomalies>of>the>Kidney>and>the>Urinary>
Tract
0 24.8 D D 0.806




0 41 . . .
CKD980 CUMC M 67 White>European No Glomerulopathy Dominant CASP10 p.S59W Het Autoimmune>Lymhoproliferative>syndrome>type>2A 0 . . . .
CKD981 CUMC M 68 Asian No Glomerulopathy Dominant EGF p.G446R Het Hypomagnesemia>4,>renal 0 31 D D 0.752




2.24E*05 29.4 D D 0.882
CKD982 CUMC M 41 White>European No Glomerulopathy Dominant ATP7B p.V1364L Het Wilson>Disease 0 25.3 D D 0.783
CKD983 CUMC F 37
Black/African>
American
No Glomerulopathy Dominant BBS1 p.G57R Het Bardet*biedl>syndrome>1 0 27.5 D D 0.884
CKD984 CUMC M 53 White>European Yes Glomerulopathy Dominant EVC2 p.I87fs Het Ellis>Van>Creveld>syndrome 0 . . . .




0 32 D D 0.798
CKD986 CUMC M 51 White>European No Glomerulopathy Dominant ALMS1 p.L1725fs Het Alstrom>syndrome 0 . . . .
CKD987 CUMC F 63 Asian No Glomerulopathy Dominant SMARCE1 c.*45*2A>T Het Coffin*Siris>syndrome 0 . . . .
CKD987 CUMC F 63 Asian No Glomerulopathy Dominant SCO1 p.E148* Het Mitochondrial>Complex>4>deficiency 0 37 . . .
CKD988 CUMC F 37 Asian No Glomerulopathy Dominant TXNL4A p.L8R Het Burn*McKeown>syndrome 0 25.6 D D 0.932
CKD989 CUMC M 68 White>European No Glomerulopathy Dominant EVC p.R85fs Het Ellis>Van>Creveld>syndrome 0 . . . .
CKD990 CUMC F 38 Asian No Glomerulopathy Dominant GRHPR p.N250Y Het Hyperoxaluria,>primary,>type>2 0 25.8 D D 0.796
CKD991 CUMC M 55
Black/African>
American
No Glomerulopathy Dominant PDSS1 p.P138L Het Coenzyme>Q10>deficiency,>primary,>2 0 26 D D 0.834
CKD992 CUMC F 84 White>European No Glomerulopathy Dominant FLNB p.P441S Het Spondylocarpotarsal>synostosis>syndrome 0 29 D D 0.968
CKD992 CUMC F 84 White>European No Glomerulopathy Dominant EVC p.S974fs Het Ellis>Van>Creveld>syndrome 0 . . . .
CKD992 CUMC F 84 White>European No Glomerulopathy Dominant NSDHL p.Y301H Het CHILD>syndrome 0 26.6 D D 0.808





0 . . . .
CKD994 CUMC F 52 White>European Yes Glomerulopathy Dominant HOXD13 p.A59_A61dup Het Vacterl>association>with>hydrocephalus 0 . . . .
CKD994 CUMC F 52 White>European Yes Glomerulopathy Dominant GDF2 p.W341* Het Hereditary>hemorrhagic>telangiectasia 0 . . . .
CKD995 CUMC M 52 White>European Yes Glomerulopathy Dominant LRP2 p.W1518C Het Donnai*barrow>syndrome 0 35 D D 0.927
CKD996 CUMC M 74 White>European No Glomerulopathy Dominant ASXL1 p.D832fs Het Bohring*Opitz>syndrome 0 . . . .
CKD997 CUMC F 62 Hispanic No Glomerulopathy Dominant SCNN1A p.A334T Het Pseudohypoaldosteronism,>Type>I 0 . . . .
CKD998 CUMC M 89 White>European No Glomerulopathy Dominant KDM6A p.R1111P Het Kabuki>syndrome 0 34 D D 0.821
CKD999 CUMC M 70 White>European No Glomerulopathy Dominant MUT p.R613S Het
Vitamin>B12*unresponsive>methylmalonic>acidemia>
type>mut0
0 34 D D 0.865
CKD1000 CUMC M 34 Hispanic No Glomerulopathy Dominant UPB1 p.D170G Het Beta*ureidopropionase>deficiency 0 27 D D 0.805
CKD1000 CUMC M 34 Hispanic No Glomerulopathy Dominant APC2 p.LK89LE Het Sotos>syndrome 0 . . . .
CKD1001 CUMC M 50 White>European No Glomerulopathy Dominant KAT6B p.E1092del Het Genitopatellar>syndrome 0 . . . .
CKD1001 CUMC M 50 White>European No Glomerulopathy Dominant CPT1A p.K665E Het Carnitine>palmitoyl>transferase>1A>deficiency 0 23.6 D D 0.795




0 23.4 T D 0.416
CKD1003 CUMC M 76 White>European No Glomerulopathy Dominant ACE p.Y20* Het Renal>tubular>dysgenesis 0 35 . . .
CKD1004 CUMC M 53 White>European Yes Glomerulopathy Dominant C2 p.R368* Het C2>Deficiency 0 39 . . .
CKD1005 CUMC M 10
Other/Unspecifi
ed




8.96E*05 31 D D 0.921
CKD1005 CUMC M 10
Other/Unspecifi
ed
Yes Glomerulopathy Dominant PKD1
p.L675_P676in
sGL
Het Polycystic>kidney>disease>1 0 . . . .
CKD1006 CUMC M 62 White>European No Glomerulopathy Dominant PRKCD p.C509R Het Autoimmune>lymphoproliferative>syndrome,>type>2 0 28.5 D D 0.793
CKD1007 CUMC M 29 Asian Yes
Nephropathy>"of>
unknown>etiology"
Dominant IFT140 c.903*1G>A Het
Short>rib*polydactyly>syndrome>(Jeune's>syndrome)>
type>9
0 24.6 . . .
CKD1007 CUMC M 29 Asian Yes
Nephropathy>"of>
unknown>etiology"





0 23.2 D D 0.85






Dominant TRAP1 p.E192fs Het
Congenital>Anomalies>of>the>Kidney>and>the>Urinary>
Tract
0 . . . .
CKD1009 CUMC M 13 Asian Yes
Congenital>or>cystic>
renal>disease
Dominant PEX1 p.T1043I Het Zellweger>syndrome 0 26.7 D D 0.921






Dominant TMCO1 p.L61fs Het
Craniofacial>dysmorphism,>skeletal>anomalies,>and>
mental>retardation>syndrome
0 . . . .
CKD1011 CUMC M 14 Hispanic No
Congenital>or>cystic>
renal>disease
Dominant BBS5 p.L320fs Het Bardet*Biedl>Syndrome>5 0 . . . .
CKD1012 CUMC M 70 White>European No
Congenital>or>cystic>
renal>disease
Dominant PKD1 p.G1250D Het Polycystic>kidney>disease>1 0 27.8 D D 0.838









0 . . . .
CKD1012 CUMC M 70 White>European No
Congenital>or>cystic>
renal>disease
Dominant RAB3GAP2 p.S650fs Het Micro>syndrome 0 . . . .
CKD1013 CUMC M 29 Asian No
Congenital>or>cystic>
renal>disease
Dominant SLC9A3R1 p.E68del Het Nephrolithiasis,osteoporosis,>hypophosphatemic,>2 0 . . . .
CKD1014 CUMC F 44 Hispanic Yes
Tubulointerstitial>
disease
Dominant IFT172 p.E665M Het
Bardet*Biedl>syndrome,>Short>rib*polydactyly>
syndrome>(Jeune's>syndrome)>type>10
0 . . . .
CKD1015 CUMC F 76 Hispanic No Glomerulopathy Dominant PYGM p.P477T Het McArdle>Disease 0 27.9 D D 0.91
CKD1016 CUMC F 71 Asian No Glomerulopathy Dominant FUZ
p.L418_Ter419
delinsR
Het Caudal>regression>sequence 0 . . . .
CKD1017 CUMC F 64
Black/African>
American
No Glomerulopathy Dominant KMT2D p.E1750del Het Kabuki>syndrome>1 0 . . . .
CKD1018 CUMC M 39 White>European Yes Glomerulopathy Dominant EVC2 p.Q1040* Het Ellis>Van>Creveld>syndrome 0 40 . . .
CKD1019 CUMC F 51 Hispanic No Glomerulopathy Dominant ATP7B p.C271R Het Wilson>Disease 0 24.9 D D 0.964
CKD1019 CUMC F 51 Hispanic No Glomerulopathy Dominant ARMC5 p.S533fs Het
Cushing>syndrome>due>to>macronodular>adrenal>
hyperplasia
0 . . . .
CKD1020 CUMC M 49 White>European No Glomerulopathy Dominant MYH9 p.R393C Het Fechtner>syndrome;>Epstein>Syndrome 0 34 D D 0.873
CKD1021 CUMC F 70 White>European No Glomerulopathy Dominant FRAS1 p.C623R Het Fraser>syndrome 0 24.6 D D 0.854




0 29.6 D D 0.755
CKD1022 CUMC F 56 White>European No Glomerulopathy Dominant COL5A1 p.G1540V Het Ehlers*Danlos>syndrome,>classic>type 0 25.5 D D 0.944
CKD1022 CUMC F 56 White>European No Glomerulopathy Dominant RERE p.W438L Het
Neurodevelopmental>disorder>with>or>without>
anomalies>of>the>brain,>eye,>or>heart
0 34 D D 0.842




0 32 D D 0.812
CKD1024 CUMC F 65 Hispanic No Glomerulopathy Dominant DDX59 p.Q379fs Het Orofaciodigital>syndrome>V 0 . . . .
CKD1025 CUMC M 56 Asian Yes Glomerulopathy Recessive PKD1 p.N2395Y Het Polycystic>kidney>disease>1 5.40E*06 25 D D 0.824
CKD1025 CUMC M 56 Asian Yes Glomerulopathy Recessive PKD1 p.V1376A Het Polycystic>kidney>disease>1 4.09E*06 25.5 D D 0.75
CKD1026 CUMC M 60 Hispanic No Glomerulopathy Dominant KMT2D p.E1750del Het Kabuki>syndrome>1 0 . . . .
CKD1027 CUMC M 44 White>European No Glomerulopathy Dominant CENPF
p.K1231_E123
2del
Het Stromme>syndrome 0 . . . .
CKD1028 CUMC M 33 White>European No Glomerulopathy Dominant CTNS p.A256L Het
Cystinosis,>nephropathic>cystinosis,>late*onset>
juvenile>or>adolescent>nephropathic
0 . . . .
CKD1029 CUMC F 52 White>European No Glomerulopathy Dominant C1QA p.S202L Het C1q>Deficiency 0 32 D D 0.825
CKD1030 CUMC M 46 White>European No Glomerulopathy Dominant TMEM67 p.T478I Het
Nephronophtisis>11,>Meckel>Syndrome>3,>Joubert>
syndrome>6,>COACH>syndrome
0 25.3 D D 0.853
CKD1031 CUMC M 33 White>European No Glomerulopathy Dominant AFF4
p.E172_H173in
sQ
Het CHOPS>syndrome 0 . . . .
CKD1031 CUMC M 33 White>European No Glomerulopathy Dominant TRAF3IP1 p.S362* Het Senior*Loken>syndrome>9 0 37 . . .




CKD1033 CUMC M 35 White>European No Glomerulopathy Recessive EIF2B4 c.1191+2T>C Hom
Ovarioleukodystrophy,>leukoencelpaly>with>
vanishing>white>matter
8.12E*06 24.1 . . .




0 27.5 D D 0.845
CKD1035 CUMC M 25 White>European No Glomerulopathy Dominant GATA6 p.V391M Het Pancreatic>agenesis>and>congenital>heart>defects 0 32 D D 0.76






Dominant NEK1 p.A433fs Het
Short>rib*polydactyly>syndrome>(Jeune's>syndrome)>
type>6
0 . . . .
CKD1037 CUMC M 27
Black/African>
American
No Glomerulopathy Dominant COQ9 p.AA2VT Het Coenzyme>Q10>deficiency,>primary,>5 0 . . . .
CKD1038 CUMC F 46 White>European Yes Glomerulopathy Dominant TSC2 p.P1046L Het Tuberous>sclerosis*2 0 28.4 D D 0.76
CKD1039 CUMC F 42
Black/African>
American
No Glomerulopathy Dominant FANCC p.H165fs Het Fanconi>anemia,>complementation>group>c 0 . . . .
CKD1040 CUMC M 71 White>European No Glomerulopathy Dominant KAT6B p.S604del Het Genitopatellar>syndrome 0 . . . .
CKD1041 CUMC F 36 Hispanic No Glomerulopathy Dominant SLC26A4 c.1708*1G>A Het Pendred>syndrome 0 26.3 . . .
CKD1042 CUMC F 38 Hispanic No
Congenital>or>cystic>
renal>disease
Dominant RIN2 p.P358fs Het Macrocephaly,>alopecia,>cutis>laxa,>and>scoliosis 0 . . . .
CKD1043 CUMC F 29 Hispanic No Glomerulopathy Dominant TRNT1 p.M158fs Het
Sideroblastic>anemia>with>B*cell>immunodeficiency,>
periodic>fevers,>and>developmental>delay
0 . . . .
CKD1044 CUMC F 32 Hispanic No Glomerulopathy Dominant COL4A5 p.A1633V Het Alport>syndrome 0 33 D D 0.778
CKD1045 CUMC F 43 White>European No
Congenital>or>cystic>
renal>disease
Dominant WFS1 p.E301K Het Wolfram>syndrome>type>1 0 24.1 D D 0.871
CKD1046 CUMC F 53 White>European No Other Dominant NPHP4 p.Q953fs Het Nephronophthisis>4>Senior*Loken>syndrome>4 0 . . . .
CKD1046 CUMC F 53 White>European No Other Dominant DLL3 p.E130* Het Autosomal>recessive>spondylocostal>dysostosis 0 36 . . .
CKD1046 CUMC F 53 White>European No Other Dominant FANCE p.G175fs Het Fanconi>anemia,>complementation>group>e 0 . . . .
CKD1046 CUMC F 53 White>European No Other Dominant CEP104 p.Y284* Het Joubert>syndrome>25 0 34 . . .
CKD1047 CUMC F 48 Hispanic Yes Glomerulopathy Dominant PYGM p.D629G Het McArdle>Disease 0 25.3 D D 0.789
CKD1048 CUMC M 56 White>European Yes
Nephropathy>"of>
unknown>etiology"
Recessive WFS1 p.T665P Hom Wolfram>syndrome>type>1 8.14E*05 24.5 D D 0.907
CKD1049 CUMC M 56 White>European No
Nephropathy>"of>
unknown>etiology"
Dominant RERE p.G540C Het
Neurodevelopmental>disorder>with>or>without>
anomalies>of>the>brain,>eye,>or>heart
0 35 D D 0.956
CKD1050 CUMC M 42 Asian No
Nephropathy>"of>
unknown>etiology"
Dominant NEK1 p.K505fs Het
Short>rib*polydactyly>syndrome>(Jeune's>syndrome)>
type>6
0 . . . .
CKD1051 CUMC F 31 White>European No Glomerulopathy Dominant DIS3L2 c.2496+1G>T Het
Perlman's>syndrome>(nephroblastomatosis,>
gigantism)
0 23.9 . . .
CKD1052 CUMC F 59 White>European No Glomerulopathy Dominant PUF60 p.S383* Het Verheij>syndrome 0 43 . . .
CKD1053 CUMC M 57 White>European No
Nephropathy>"of>
unknown>etiology"
Dominant SCARB2 p.G253R Het
Epilepsy,>Progressive>Myoclonic,>4>with>or>without>
Renal>Failure
0 34 D D 0.924
CKD1054 CUMC M 57 Hispanic Yes Glomerulopathy Dominant PYGM p.D629G Het McArdle>Disease 0 25.3 D D 0.789
CKD1055 CUMC M 83
Black/African>
American
No Glomerulopathy Dominant FGA p.P65T Het Amyloidosis,>familial>visceral,>hereditary>renal 0 27.1 D D 0.953






Dominant COL4A1 p.G287fs Het
Hereditary>angiopathy>with>nephropathy,>
aneurysms>and>Msucle>cramps>(HANAC)
0 . . . .
CKD1057 CUMC M 73 Asian No Glomerulopathy Dominant VPS33B c.1170+2T>C Het
Arthrogryposis,>renal>dysfunction,>and>cholestasis>1;>
arcs1
0 23.6 . . .
CKD1058 CUMC F 70 White>European No
Hypertensive>
nephropathy
Dominant SALL4 p.R864L Het
Acro*renal*ocular>syndrome,>Duane*Radial>Ray>
Syndrome>IVIC>Syndrome
0 . . . .
CKD1059 CUMC F 40 Hispanic No Glomerulopathy Dominant HSPG2 p.W143* Het Schwartz*Jampel>syndrome 0 38 T . 0.153
CKD1059 CUMC F 40 Hispanic No Glomerulopathy Dominant TRPC6 p.Y277C Het Focal>Segmental>Glomerulosclerosis>2 0 25.8 D D 0.882
CKD1060 CUMC M 41 Hispanic No
Nephropathy>"of>
unknown>etiology"
Dominant SCN4A p.L236V Het Hypokalemic>periodic>paralysis,>hokpp>type2 0 23.3 D D 0.83
CKD1061 CUMC F 79 Hispanic Yes
Nephropathy>"of>
unknown>etiology"
Dominant TBX18 p.G60del Het
Congenital>hydronephrosisCongenital>anomalies>of>
Kidney>and>Urinary>Tract>2
0 . . . .
CKD1062 CUMC F 66 Asian No
Hypertensive>
nephropathy
Dominant MUT p.A278V Het
Vitamin>B12*unresponsive>methylmalonic>acidemia>
type>mut0
0 32 D D 0.969
CKD1062 CUMC F 66 Asian No
Hypertensive>
nephropathy
Dominant CACNA1S p.R1560L Het Hypokalemic>periodic>paralysis,>hokpp 0 34 D D 0.841
CKD1062 CUMC F 66 Asian No
Hypertensive>
nephropathy
Dominant TRMT5 p.F90fs Het Combined>oxidative>phosphorylation>deficiency>26 0 . . . .
CKD1063 CUMC M 38 White>European No
Congenital>or>cystic>
renal>disease
Dominant KCNJ1 p.P334S Het Bartter's>syndrome,>type>2 0 25.8 D D 0.797
CKD1064 CUMC M 60 Asian No
Hypertensive>
nephropathy
Dominant HSD17B4 p.G378E Het D*bifunctional>protein>deficiency 0 28.1 D D 0.862
CKD1065 CUMC F 55 Asian No
Nephropathy>"of>
unknown>etiology"
Dominant PNPLA6 p.L974S Het Laurence*Moon>syndrome 0 24.5 D D 0.869
CKD1066 CUMC M 75 White>European Yes
Hypertensive>
nephropathy
Dominant WNT7A p.R245C Het
Ulna>and>fibula,>absense>of,>with>severe>limb>
deficiency
0 28.4 D D 0.804










0 . . . .
CKD1068 CUMC M 70
Black/African>
American
No Glomerulopathy Dominant TTC21B p.K693fs Het Nephronophthisis>12 0 . . . .
CKD1069 CUMC M 58
Other/Unspecifi
ed
No Glomerulopathy Dominant ETFDH c.1328*1G>T Het Glutaric>acidemia>2c 0 26.4 . . .
CKD1069 CUMC M 58
Other/Unspecifi
ed
No Glomerulopathy Dominant SLX4 p.N1111fs Het Fanconi>anemia,>complementation>group>P 0 . . . .
CKD1070 CUMC F 65 White>European No Glomerulopathy Dominant MAFB p.R210L Het
Multicentric>carpo*tarsal>osteolysis>with>or>without>
nephropathy
0 27.4 D D 0.87




0 . . . .
CKD1071 CUMC M 80 White>European No
Nephropathy>"of>
unknown>etiology"
Dominant NIPBL p.K2166del Het Cornelia>de>lange>syndrome>type>1 0 . . . .




0 27 D D 0.789
CKD1073 CUMC M 78 Hispanic No Other Dominant PNPLA6 p.V737fs Het Laurence*Moon>syndrome 0 . . . .






Dominant CFH p.G676E Het Complement>factor>h>deficiency 0 26.4 D D 0.754






Recessive PGK1 p.K246E Hemi Phosphoglycerate>kinase>1>deficiency 1.68E*05 27.4 D D 0.943
CKD1075 CUMC M 69 Hispanic No
Congenital>or>cystic>
renal>disease
Recessive LRP2 p.N2158T Het Donnai*barrow>syndrome 0.000486 24.3 D D 0.812
CKD1075 CUMC M 69 Hispanic No
Congenital>or>cystic>
renal>disease
Dominant CLCNKA p.L653fs Het Bartter's>Syndrome>Type>4b,>Neonatal 0 . . . .
CKD1075 CUMC M 69 Hispanic No
Congenital>or>cystic>
renal>disease
Recessive LRP2 p.P2361T Het Donnai*barrow>syndrome 2.44E*05 24.4 D D 0.755
CKD1076 CUMC F 59 Hispanic No
Tubulointerstitial>
disease
Dominant DCHS1 p.R2070fs Het Van>Maldergem>syndrome>1 0 . . . .
CKD1077 CUMC M 70 White>European No Other Dominant FANCM p.Y445* Het Fanconi>anemia 0 35 . . .
CKD1078 CUMC M 62 Hispanic Yes
Hypertensive>
nephropathy





0 35 . . .
CKD1079 CUMC M 76 Hispanic No
Congenital>or>cystic>
renal>disease
Dominant COL18A1 p.G760V Het Knobloch>syndrome 0 23.8 D D 0.88
CKD1080 CUMC M 60 White>European No
Hypertensive>
nephropathy
Dominant GATA3 p.N351fs Het
Hypoparathyroidism,>deafness,>renal>disease>
syndrome
0 . . . .
CKD1080 CUMC M 60 White>European No
Hypertensive>
nephropathy
Dominant CAD p.L577P Het Congenital>disorder>of>glycosylation,>type>Iz 0 25.4 D D 0.911
CKD1081 CUMC F 52
Black/African>
American
No Glomerulopathy Dominant SI p.T617fs Het Sucrase*isomaltase>deficiency,>congenital 0 . . . .
CKD1082 CUMC M 35 Hispanic No
Hypertensive>
nephropathy
Dominant CPT2 p.D328E Het
Lethal>neonatal>carnitine>palmitoyltransferase>2>
deficiency
0 24.8 D D 0.843






Dominant RERE p.D18_R21dup Het
Neurodevelopmental>disorder>with>or>without>
anomalies>of>the>brain,>eye,>or>heart
0 . . . .






Dominant FLNB p.I2547T Het Spondylocarpotarsal>synostosis>syndrome 0 24.6 D D 0.796
CKD1084 CUMC F 72 Hispanic No
Hypertensive>
nephropathy
Dominant PEX26 p.A177T Het Zellweger>syndrome 0 27.6 D D 0.873










0 . . . .
CKD1086 CUMC F 49 White>European No
Hypertensive>
nephropathy
Dominant INPP5E p.V393A Het
Joubert>syndrome>with>hepatic>defectJoubert>
Syndrome>1
0 26.8 D D 0.8
CKD1087 CUMC F 62 Asian Yes Glomerulopathy Dominant DLL4 p.P370R Het Adams*Oliver>syndrome>6 0 28.8 D D 0.915
CKD1088 CUMC F 61 White>European No
Nephropathy>"of>
unknown>etiology"
Dominant BBS4 p.E412fs Het Bardet*Biedl>Syndrome>4 0 . . . .






0 . . . .
CKD1090 CUMC F 54 White>European No
Hypertensive>
nephropathy
Dominant CLCNKB p.G295A Het Bartter>syndrome,>type>3>and>type>4b 0 23.3 D D 0.76
CKD1090 CUMC F 54 White>European No
Hypertensive>
nephropathy
Dominant VANGL1 p.I423F Het Caudal>regression>syndrome 0 29.3 D D 0.924
CKD1091 CUMC M 35 Hispanic No
Nephropathy>"of>
unknown>etiology"
Dominant EMP2 p.Y141C Het Nephrotic>syndrome>type>10 0 25.7 D D 0.83
CKD1092 CUMC M 67 White>European No
Tubulointerstitial>
disease
Dominant INPP5E p.Y293D Het
Joubert>syndrome>with>hepatic>defectJoubert>
Syndrome>1
0 25.4 D D 0.867
CKD1093 CUMC M 50 Hispanic No Other Dominant SCO1 p.K116E Het Mitochondrial>Complex>4>deficiency 0 25.1 D D 0.752
CKD1094 CUMC F 54 Asian No Glomerulopathy Dominant ENPP1 p.G379V Het Hypophosphataemicrickets 0 29.3 D D 0.901
CKD1095 CUMC F 81 Hispanic No Glomerulopathy Dominant BCOR p.L808H Het
Microphthalmia,>Lenz>type,>Microphthalmia,>
syndromic>2
0 . . . .






Dominant LAMC2 p.S807N Het
Epidermolysis>bullosa,>junctional,>Herlitz>type;>
Epidermolysis>bullosa,>junctional,>non*Herlitz>type
0 . . . .
CKD1097 CUMC M 49 White>European Yes Glomerulopathy Dominant UMOD p.E96* Het
Medullary>cystic>kidney>disease>2>hyperuricemic>
nephropathy>glomerulocystic>kidney>disease




CKD1098 CUMC M 83 White>European No
Hypertensive>
nephropathy
Dominant ROR2 p.E467G Het Robinow>syndrome 0 26.4 D D 0.802
CKD1099 CUMC M 80 White>European Yes
Hypertensive>
nephropathy
Dominant GATA6 p.R403L Het Pancreatic>agenesis>and>congenital>heart>defects 0 26.6 D D 0.899
CKD1100 CUMC F 58 White>European No Glomerulopathy Dominant UPB1 p.T129R Het Beta*ureidopropionase>deficiency 0 33 D D 0.838






Dominant ACE p.S12fs Het Renal>tubular>dysgenesis 0 . . . .
CKD1102 CUMC M 42
Black/African>
American






0 . . . .
CKD1103 CUMC M 67 White>European No Other Dominant FGFR1 p.L466F Het
Encephalocraniocutaneous>Lipomatosis,>Kallmann>
syndrome>2,>kal2
0 25.5 D D 0.756
CKD1104 CUMC F 54 White>European No
Hypertensive>
nephropathy
Dominant SCN4A p.P1331L Het Hypokalemic>periodic>paralysis,>hokpp>type2 0 27.8 D D 0.87
CKD1105 CUMC M 37 White>European No Other Dominant ALMS1 p.K4105fs Het Alstrom>syndrome 0 . . . .
CKD1106 CUMC M 78 White>European No
Hypertensive>
nephropathy
Dominant RIN2 p.P358fs Het Macrocephaly,>alopecia,>cutis>laxa,>and>scoliosis 0 . . . .
CKD1107 CUMC M 75 Hispanic No
Hypertensive>
nephropathy
Dominant ALPL p.E332* Het Hypophosphatasia,>infantile 0 46 . . .
CKD1108 CUMC F 47
Black/African>
American
No Other Dominant CACNA1S p.I1133T Het Hypokalemic>periodic>paralysis,>hokpp 0 24.1 D D 0.779
CKD1108 CUMC F 47
Black/African>
American
No Other Dominant ACE p.S12fs Het Renal>tubular>dysgenesis 0 . . . .
CKD1109 CUMC M 67 Asian No Glomerulopathy Dominant NPHP4 p.Y96C Het Nephronophthisis>4>Senior*Loken>syndrome>4 0 27.1 D D 0.915
CKD1110 CUMC M 82 White>European Yes Other Dominant FREM2 p.D557E Het Fraser>syndrome 0 24.2 D D 0.751
CKD1110 CUMC M 82 White>European Yes Other Dominant MYH9 p.K940del Het Fechtner>syndrome;>Epstein>Syndrome 0 . . . .
CKD1111 CUMC F 55 Asian No Glomerulopathy Dominant TMEM67 p.M1? Het
Nephronophtisis>11,>Meckel>Syndrome>3,>Joubert>
syndrome>6,>COACH>syndrome
0 23 D D 0.511
CKD1111 CUMC F 55 Asian No Glomerulopathy Dominant GCM2 p.P103S Het Hypoparathyroidism,>familial>isolated 0 25.8 D D 0.896






Dominant COQ2 p.R126fs Het Coenzyme>q10>deficiency 0 . . . .
CKD1113 CUMC F 51
Black/African>
American
No Glomerulopathy Dominant MKKS p.A488I Het
Bardet*biedl>syndrome>6,>McKusick*Kaufman>
syndrome
0 . . . .
CKD1114 CUMC M 43 White>European No Glomerulopathy Dominant SI p.N1169D Het Sucrase*isomaltase>deficiency,>congenital 0 27.2 D D 0.828






Dominant FANCA p.S290fs Het Fanconi>anemia,>complementation>group>a 0 . . . .
CKD1116 CUMC F 56 White>European No Glomerulopathy Dominant CECR1 p.H335C Het
Sneddon>syndrome>Polyarteritis>nodosa,>childhood*
onset
0 . . . .






Dominant CEP164 p.P494T Het Senior*Loken>syndrome,>Nephronopthisis>15 0 . . . .
CKD1118 CUMC F 51 White>European No
Tubulointerstitial>
disease
Dominant IFT122 p.K630fs Het Cranioectodermal>dysplasia>type>1 0 . . . .
CKD1119 CUMC F 62 White>European No Glomerulopathy Dominant NF1 p.G1216C Het Neurofibromatosis,>type>I 0 28.6 D D 0.77
CKD1120 CUMC F 43 Asian No Glomerulopathy Dominant FAM20C p.E115fs Het Raine>syndrome 0 . . . .
CKD1120 CUMC F 43 Asian No Glomerulopathy Dominant FAM20C p.P116fs Het Raine>syndrome 0 . . . .
CKD1121 CUMC M 41 Hispanic No Glomerulopathy Dominant ACE p.Q151* Het Renal>tubular>dysgenesis 0 39 . . .
CKD1122 CUMC F 59 White>European No Glomerulopathy Dominant CLCN5 p.D684G Het
Dent>disease>nephrolithiasis>type>1>
hypophosphatemic>Rickets
0 27.4 D D 0.969
CKD1123 CUMC M 56
Black/African>
American
No Glomerulopathy Dominant SC5D p.Q217* Het Lathosterolosis 0 35 . . .
CKD1123 CUMC M 56
Black/African>
American
No Glomerulopathy Dominant TMEM216 p.L23fs Het Joubert>syndrome>2,>Meckel>syndrome 0 . . . .






0 . . . .
CKD1125 CUMC F 62 White>European No Glomerulopathy Dominant IFT172 p.Q826* Het
Bardet*Biedl>syndrome,>Short>rib*polydactyly>
syndrome>(Jeune's>syndrome)>type>10
0 38 . . .
CKD1126 CUMC F 66
Black/African>
American
No Glomerulopathy Dominant BBS2 p.D371fs Het Bardet*biedl>syndrome>2 0 . . . .
CKD1127 CUMC M 53 White>European No Glomerulopathy Dominant MUT p.E360G Het
Vitamin>B12*unresponsive>methylmalonic>acidemia>
type>mut0
0 29 D D 0.949
CKD1128 CUMC M 25 White>European No
Congenital>or>cystic>
renal>disease
Dominant LDHA p.S5fs Het Glycogen>storage>disease>XI 0 . . . .
CKD1129 CUMC M 37 White>European No Glomerulopathy Dominant APC2 p.E899* Het Sotos>syndrome 0 35 . . .
CKD1130 CUMC F 35
Black/African>
American
No Glomerulopathy Dominant STRA6 p.L129P Het Microphthalmia,>syndromic>9,>mcops9 0 . . . .
CKD1131 CUMC F 60 White>European No
Congenital>or>cystic>
renal>disease
Dominant COL4A3 p.C1662Y Het Alport>syndrome 0 24.8 D D 0.959
CKD1132 CUMC M 35 Hispanic No Other Dominant GLB1 p.G94E Het GM1*gangliosidosis,>type>1,>type>2 0 24.1 D D 0.836










0 . . . .
CKD1134 CUMC F 35 Asian No Glomerulopathy Dominant C2 p.R368* Het C2>Deficiency 0 39 . . .
CKD1135 CUMC F 54 Hispanic Yes
Nephropathy>"of>
unknown>etiology"
Dominant PKHD1 p.G2748A Het
autosomal>recessive>polycystic>kidney>disease,>
Polycystic>and>hepatic>disease
0 . . . .
CKD1136 CUMC M 49 White>European No Glomerulopathy Dominant CACNA1S p.Q919* Het Hypokalemic>periodic>paralysis,>hokpp 0 43 . . .
CKD1136 CUMC M 49 White>European No Glomerulopathy Dominant CACNA1S p.V918L Het Hypokalemic>periodic>paralysis,>hokpp 0 33 D D 0.865
CKD1137 CUMC F 35 Hispanic No Glomerulopathy Dominant SCN4A p.M1312I Het Hypokalemic>periodic>paralysis,>hokpp>type2 0 25 D D 0.851
CKD1138 CUMC M 64 White>European No Glomerulopathy Dominant PIGN c.2180+1G>C Het
Multiple>congenital>anomalies*hypotonia*seizures>
syndrome>1
0 26.6 . . .
CKD1139 CUMC M 75 White>European No Glomerulopathy Dominant ZNF687 c.2635*1G>A Het Paget>disease>of>bone>6 0 24.2 . . .
CKD1140 CUMC F 46 Hispanic No Glomerulopathy Dominant FANCM p.Q354* Het Fanconi>anemia 0 39 . . .
CKD1141 CUMC F 46
Black/African>
American
Yes Glomerulopathy Dominant RIPPLY2 c.240*1G>C Het Autosomal>recessive>spondylocostal>dysostosis 0 25 . . .
CKD1142 CUMC M 66 White>European No
Congenital>or>cystic>
renal>disease





0 . . . .
CKD1143 CUMC M 56 White>European No Glomerulopathy Dominant TCTN3 p.E537fs Het Joubert>syndrome>18,>Orofaciodigital>syndrome>4 0 . . . .






Dominant KL p.A749S Het Tumoral>calcinosis,>hyperphosphatemic 0 . . . .






Dominant FANCA p.V551A Het Fanconi>anemia,>complementation>group>a 0 23.3 D D 0.809
CKD1146 CUMC F 66 Hispanic No Glomerulopathy Dominant PLCE1 p.C1725fs Het Nephrotic>syndrome>type>3 0 . . . .
CKD1147 CUMC F 71 White>European No Glomerulopathy Dominant MYO1E p.R557C Het Glomerulosclerosis,>focal>segmental,>6 0 35 D D 0.815
CKD1148 CUMC F 27
Black/African>
American
No Glomerulopathy Dominant NIPBL p.S2460C Het Cornelia>de>lange>syndrome>type>1 0 28.6 D D 0.792
CKD1149 CUMC M 57 White>European No
Nephropathy>"of>
unknown>etiology"




0 28.6 D D 0.88






Het Meckel>syndrome,>Joubert>syndrome>21 0 . . . .










0 24.3 D D 0.923
CKD1153 CUMC M 65 Asian No
Nephropathy>"of>
unknown>etiology"




0 . . . .
CKD1154 CUMC F 49
Black/African>
American
Yes Glomerulopathy Dominant SI p.A1299E Het Sucrase*isomaltase>deficiency,>congenital 0 32 D D 0.961
CKD1155 CUMC M 54 Hispanic No
Nephropathy>"of>
unknown>etiology"
Dominant CREBBP p.A2110D Het Rubinstein>Taybi>syndrome>type>1 0 21.6 D D 0.764
CKD1156 CUMC M 49
Black/African>
American
No Other Dominant CSPP1 p.RY133RF Het Meckel>syndrome,>Joubert>syndrome>21 0 . . . .




0 32 D D 0.831
CKD1157 CUMC M 66 White>European No Other Dominant MRPS22 p.LR14LG Het Combined>oxidative>phosphorylation>deficiency>5 0 . . . .
CKD1158 CUMC M 47 White>European Yes Glomerulopathy Dominant INPPL1 p.V81A Het Opsismodysplasia 0 25.5 D D 0.772
CKD1159 CUMC F 47 White>European No Other Dominant FGF20 p.P34T Het Renal>hypodysplasiaaplasia>2 0 . . . .






Dominant TMEM67 p.Y293* Het
Nephronophtisis>11,>Meckel>Syndrome>3,>Joubert>
syndrome>6,>COACH>syndrome
0 35 . . .






Dominant CRB2 p.L1234fs Het FSGS>9>Ventriculomegaly>with>cystic>kidney>disease 0 . . . .
CKD1162 CUMC F 30
Black/African>
American
No Glomerulopathy Dominant TTC21B p.A164fs Het Nephronophthisis>12 0 . . . .






0 . . . .
CKD1163 CUMC F 66 White>European No Other Dominant PHGDH p.M169V Het Neu*Laxova>syndrome>1 0 24.6 D D 0.905






Dominant UPK3A p.S183L Het Renal>hypodysplasia,>urogenital>dysplasia 0 . . . .
CKD1165 CUMC M 22 White>European No
Congenital>or>cystic>
renal>disease
Dominant C5orf42 p.V3181del Het Orofaciodigital>syndrome>6 0 . . . .
CKD1166 CUMC F 23 Hispanic Yes Glomerulopathy Dominant ACTA2 p.V47M Het Multisystemic>smooth>muscle>dysfunction>syndrome 0 26.2 D D 0.796
CKD1167 CUMC M 64 Asian No
Hypertensive>
nephropathy
Dominant CAD c.5394+2T>C Het Congenital>disorder>of>glycosylation,>type>Iz 0 23.2 . . .
CKD1168 CUMC M 64 Asian No
Hypertensive>
nephropathy
Dominant RIN2 p.T36fs Het Macrocephaly,>alopecia,>cutis>laxa,>and>scoliosis 0 . . . .
CKD1169 CUMC F 49 Asian No Glomerulopathy Dominant PIGN p.Y895* Het
Multiple>congenital>anomalies*hypotonia*seizures>
syndrome>1
0 38 . . .
CKD1170 CUMC F 61
Black/African>
American
Yes Glomerulopathy Dominant CENPF
p.K1088_T111
5del
Het Stromme>syndrome 0 . . . .
CKD1170 CUMC F 61
Black/African>
American
Yes Glomerulopathy Dominant LRIG2 p.F331fs Het Ochoa>syndrome,>Urofacial>Syndrome>2 0 . . . .
CKD1171 CUMC M 33 Hispanic No
Nephropathy>"of>
unknown>etiology"




Models  and  associated  filtering  parameters  are  detailed  in  Chapter  II,  Methods.    
Age  is  age  at  time  of  study  entry  (yr).    
For  AURORA  patients,  study  consent  protocols  permitted  providing  only  the  broad  clinical  diagnosis  for  
patient  information.  
  
Family  history  data  was  available  only  for  CUMC  patients.  
Zygosity:  heterozygous  (Het);;  homozygous  (Hom);;  or  hemizygous  (Hemi).    
MAF:  Minor  allele  frequency.
CKD1172 CUMC M 60 White>European No
Hypertensive>
nephropathy
Dominant GATA6 p.S45del Het Pancreatic>agenesis>and>congenital>heart>defects 0 . . . .






0 . . . .
CKD1174 CUMC F 45 Asian No
Congenital>or>cystic>
renal>disease
Dominant SLC3A1 p.P112S Het Cystinuria 0 28.3 D D 0.844
CKD1175 CUMC F 25
Black/African>
American
No Glomerulopathy Dominant CACNA1S p.D1082G Het Hypokalemic>periodic>paralysis,>hokpp 0 29 D D 0.913




0 37 . . .
CKD1177 CUMC M 31 White>European No Glomerulopathy Dominant EIF2B4 p.A224S Het
Ovarioleukodystrophy,>leukoencelpaly>with>
vanishing>white>matter
0 24.8 D D 0.75
CKD1178 CUMC M 36 White>European Yes Glomerulopathy Dominant CUBN p.D3398fs Het Megaloblastic>anemia>1*finnish>type 0 . . . .
CKD1179 CUMC F 61 White>European No Other Dominant PEX6 p.L914P Het Zellweger>syndrome 0 32 D D 0.963









Het Johanson*Blizzard>syndrome 0 . . . .






Dominant PC p.A307V Het Pyruvate>carboxylase>deficiency 0 33 D D 0.935
CKD1182 CUMC M 31
Black/African>
American
No Glomerulopathy Dominant RMND1 p.L309R Het Combined>oxidative>phosphorylation>deficiency>11 0 29.4 D D 0.88
CKD1183 CUMC M 35 White>European No Glomerulopathy Dominant ITGB4 p.H1472fs Het
Epidermolysis>bullosa,>junctional,>with>pyloric>
atresia
0 . . . .
CKD1184 CUMC M 47 White>European Yes
Hypertensive>
nephropathy
Dominant XYLT2 p.D599del Het Spondylocular>syndrome 0 . . . .
CKD1184 CUMC M 47 White>European Yes
Hypertensive>
nephropathy




0 . . . .
CKD1185 CUMC F 59
Black/African>
American
No Other Dominant COL4A3 p.D1518H Het Alport>syndrome 0 25 D D 0.959
CKD1186 CUMC F 60
Other/Unspecifi
ed
No Other Dominant NUP205 p.S263L Het Nephrotic>syndrome,>type>13 0 . . . .
CKD1187 CUMC M 59 Asian Yes Glomerulopathy Dominant CPT1A p.G555D Het Carnitine>palmitoyl>transferase>1A>deficiency 0 28.4 D D 0.933
CKD1188 CUMC M 35 White>European No Glomerulopathy Dominant WFS1 p.F538S Het Wolfram>syndrome>type>1 0 25.6 D D 0.901






Dominant BBS2 p.G375R Het Bardet*biedl>syndrome>2 0 33 D D 0.787
CKD1190 CUMC F 35
Black/African>
American
No Glomerulopathy Dominant ACE p.D538G Het Renal>tubular>dysgenesis 0 27 D D 0.761
CKD1190 CUMC F 35
Black/African>
American
No Glomerulopathy Dominant MUT p.T106I Het
Vitamin>B12*unresponsive>methylmalonic>acidemia>
type>mut0
0 25.1 D D 0.923
CKD1191 CUMC M 50 Hispanic Yes
Hypertensive>
nephropathy
Dominant TBC1D24 p.Q559* Het DOOR>syndrome 0 35 . . .






Dominant POMT1 p.G240C Het Muscular>dystrophy*dystroglycanopathy,>type>A,>1 0 31 D D 0.896
CKD1193 CUMC F 21 White>European No Other Dominant HOXD13 p.A59_A61dup Het Vacterl>association>with>hydrocephalus 0 . . . .






Dominant ERCC6 p.G270D Het Cockayne>syndrome,>type>B 0 . . . .
CKD1195 CUMC M 60 Asian No Other Dominant CDKN1C p.P25R Het Beckwith*wiedemann>syndrome>IMAGE>syndrome 0 28.1 D D 0.807
CKD1196 CUMC M 40
Black/African>
American
No Glomerulopathy Dominant HOXD13 p.S225C Het Vacterl>association>with>hydrocephalus 0 29.2 D D 0.801
CKD1196 CUMC M 40
Black/African>
American
No Glomerulopathy Dominant SERPINH1
p.T32_A33insA
APGT
Het Osteogenesis>imperfecta,>type>X 0 . . . .
CKD1196 CUMC M 40
Black/African>
American
No Glomerulopathy Dominant SCARB2 p.Y89H Het
Epilepsy,>Progressive>Myoclonic,>4>with>or>without>
Renal>Failure
0 25.5 D D 0.925
CKD1196 CUMC M 40
Black/African>
American
No Glomerulopathy Dominant CREBBP p.V1405M Het Rubinstein>Taybi>syndrome>type>1 0 27.1 D D 0.881
CKD1197 CUMC M 53 Hispanic No Glomerulopathy Recessive MBTPS2
p.S128_S129d
el
Hemi IFAP>Syndrome>with>or>without>Bresheck>Syndrome 0 . . . .





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table  S10.  Summary  of  the  343  diagnostic  variants  found  in  the  307  positive  patients  
All  positive  patients,  N=307  
Inheritance   No.  of  patients   %  
Autosomal  dominant   206   67  
Autosomal  recessive   42   14  
X-­linked     54   18  
Dual   5   2  
  
All  diagnostic  variants,  N=343  
   No.  of  variants   %  
Variant  effect  
Protein-­truncating   167   49  
Frameshift   66   19  
Nonsense   63   18  
Splice-­site   38   11  
Non-­truncating   176   51  
In-­frame  insertion  or  deletion   5   1  
Missense   171   50  
Variant  type  
Previously  reported   202   59  
Novel  a   141   41  
ACMG  Classification  
Pathogenic   169   49  
Likely  Pathogenic   174   51  
a  Novel:  not  present  in  the  clinical  variant  databases  assessed  (see  Methods  and  Table  S4)  at  the  time  of  analysis.    





























































































































































































































Table  S12.  Genetic  and  clinical  heterogeneity  of  diagnostic  genetic  findings  in  the  AURORA,  
CUMC,  and  AURORA-­CUMC  cohorts    
  
Cohort  
No.  of  distinct  
monogenic  
disorders  detected  
No.  of  singleton  
genetic  
diagnoses  
No.  of  recurrent  
genetic  
diagnoses    






AURORA   24   13   11   8  
CUMC   55   35   20   15  
AURORA-­
CUMC   66   39   27   21  
 
  183  
Table  S13.  Comparison  of  diagnostic  yield  between  the  AURORA  and  CUMC  cohorts  
  
In  this  study,  we  aimed  to  evaluate  the  utility  of  exome  sequencing  across  the  different  categories  of  the  
kidney  and  genitourinary  disorders  encountered  in  clinical  practice.  Combined,  the  patients  from  the  
AURORA  and  CUMC  cohorts  represent  the  major  causes  of  kidney  disease  (see  main  text,  Table  7).  
Individually,  the  AURORA  and  CUMC  cohorts  represent  two  distinct  populations  differing  in  their  setting,  
recruitment  goals,  and  clinical  features  (see  Section  S1  and  Tables  S1,  S2,  and  S3).  The  AURORA  
study  recruited  patients  with  end-­stage  renal  disease  (ESRD)  aged  50-­80  years,  predominantly  from  
Europe  and  South  America.  The  CUMC  cohort  represents  a  multiethnic  population  with  chronic  kidney  
disease  (CKD)  or  ESRD  served  at  a  tertiary  care  medical  center  in  New  York  City.  Unsurprisingly,  
comparison  of  diagnostic  yield  between  the  two  cohorts  showed  differences  (see  below,  Table  S12).  The  
overall  diagnostic  yield  was  higher  in  the  AURORA  cohort;;  however,  detailed  examination  revealed  that  
this  was  driven  by  the  enrichment  for  autosomal  dominant  polycystic  kidney  disease  (ADPKD)  cases  in  
AURORA.  The  age  entry  criteria  of  age  >50  years  in  AURORA  may  have  resulted  in  this  enrichment  for  
ADPKD  cases,  owing  to  the  lower  mortality  rate  for  ADPKD  patients  on  dialysis(188).  As  shown  below,  
after  removing  patients  with  ADPKD  (from  both  cohorts),  the  overall  diagnostic  yield  did  not  vary  
significantly  between  the  two  cohorts.  
The  only  other  clinical  category  for  which  the  two  cohorts  significantly  differed  was  among  
patients  with  tubulointerstitial  disease.  This  likely  results  from  the  relatively  small  sample  size  and  
absence  of  patients  with  pyelonephritis,  an  acquired  etiology  of  renal  disease,  among  the  CUMC  
tubulointerstitial  disease  cases.  The  difference  reflects  the  fact  that  the  CUMC  is  a  primary  referral  center  
for  glomerular  disease  and  physicians  are  highly  selective  in  coding  a  diagnosis  of  tubulointerstitial  
disease.  Thus,  patients  with  tubulointerstitial  disease  account  for  a  small  fraction  (generally,  <1%)  of  the  
total  CUMC  outpatient  population  (see  Table  S4),  and  these  few  individuals  are  enriched  for  patients  
referred  for  suspected  hereditary  forms  of  tubulointerstitial  disease.  In  contrast,  the  AURORA  
tubulointerstitial  disease  group  represents  a  broader  sample  of  patients  with  all-­cause  tubulointerstitial  
disease:  in  particular,  nearly  50%  of  cases  have  the  acquired  etiology  of  pyelonephritis  as  cause  of  their  




  Clinical  Diagnosis  








(%)   OR  (95%  CI)   P-­value
a  
Congenital  or  cystic  renal  
disease   96/159   60.4   31/372   8.3   16.6  (10.0,  28.1)   <  2.2  x  10
-­15  
Congenital  or  cystic  renal  
disease,    
excluding  ADPKD  cases  
7/70   10.0   26/365   7.1   1.4  (0.51,  3.62)   1.00  
Glomerulopathy   24/231   10.4   77/1180   6.5   1.7  (0.98,  2.7)   0.50  
Diabetic  nephropathy   1/184   0.5   5/186   2.7   0.19  (0.004,  1.8)   1.00  
Hypertensive  nephropathy   6/193   3.1   2/126   1.6   2.0  (0.35,  20.4)   1.00  
Tubulointerstitial  diseaseb   3/212   1.4   8/32   25   0.04  (0.01,  0.20)   4.7  x  10-­5  
Other   1/50   2.0   5/109   4.6   0.43  (0.01,  4.0)   1.00  
Nephropathy  “of  unknown  
etiology”   9/99   9.1   39/182   21.4   0.37  (0.15,  0.82)   0.08  
Total   140/1128   12.4   167/2187   7.6   1.7  (1.3,  2.2)   1.2  x  10-­4  
Total,  excluding  ADPKD  cases   51/1039   4.9   162/2180   7.4   0.64  (0.46,  0.89)   0.08  
  
a  Bonferroni-­adjusted  p-­value,  for  10  independent  comparisons.    
b  50%  of  the  AURORA  patients  with  tubulointerstitial  disease  have  the  acquired  etiology  of  pyelonephritis.  In  contrast,  
there  were  no  cases  of  pyelonephritis  in  the  CUMC  tubulointerstitial  disease  cohort.    
ADPKD:  Autosomal  Dominant  Polycystic  Kidney  Disease;;  ADPKD  cases  were  individuals  with  diagnostic  PKD1  or  




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Age  is  age  at  time  of  study  entry  (yr).    
  
For  AURORA  patients,  study  consent  protocols  permitted  providing  only  the  broad  clinical  diagnosis  for  
patient  information.  
  
Family  history  data  was  available  only  for  CUMC  patients.  
Zygosity:  heterozygous  (Het);;  homozygous  (Hom);;  or  hemizygous  (Hemi).    
  








American   Hispanic   Total  
N/N  total   %  
N/N  
total   %   N/N  total   %  
Control   173/1219   14   14/511   3   187/1730   11  
All  kidney  disease  cases   100/348   29   36/485   7   136/833   16  
Glomerulopathy   53/159   33   26/204   13   79/363   22  
  Focal  segmental  
glomerulosclerosisa   34/63   54   22/53   42   56/116   48  
Hypertensive  nephropathy   13/47   28   6/34   18   19/81   23  
Diabetic  nephropathy   9/43   21   1/98   1   10/141   7  
Congenital  or  cystic  renal  disease   4/43   9   0/81   0   4/124   3  
Other   5/20   25   0/26   0   5/46   2  
Nephropathy  “of  unknown  etiology”   16/36   44   3/42   7   19/78   24  
N/N  total  =  Number  of  individuals  with  the  APOL1  risk  genotypes  divided  by  the  total  number  of  
individuals  in  the  given  clinical  diagnostic  subgroup    
a  Among  the  patients  clinically  diagnosed  with  glomerulopathy,  no  AURORA  cases  carried  clinical  
diagnostic  codes  for  focal  segmental  glomerulosclerosis,  a  subtype  of  glomerulopathy;;  thus,  the  






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Age  is  age  at  tim















A  study  protocol  did  not  perm
it  analysis  of  genetic  data  for  secondary  findings,  w









  59  genes.  Am





  59  gene  findings  w
ere  detected,  w














”)  and  2)  the  greater  im
plications  of  these  
genetic  findings,  including  the  subspecialty  referrals  and  initial  e valuation  prom








”,  respectively)  and  the  im








    Zygosity:  heterozygous  (H
et);;  hom
ozygous  (H
om
).    
Inheritance:  autosom
al  dom
inant  (AD
);;  autosom
al  recessive  (AR
).  
